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SUMMARY 
This thesis evaluates the ability of (R, S)- and (R, R)-[125I1-QNB, two 
radioiodinated diastereoisomers of the high affinity muscarinic antagonist quinuclidinyl 
benzilate (QNB), to image dynamic changes in cholinergic function in the central nervous 
system using in vivo autoradiography. 
The regional uptake and retention of (R, S)-[125I]-QNB in the rat brain between 2 and 24 
hours after intravenous administration was investigated to assess the utility of this 
technique to image muscarinic receptors in the central nervous system. The regional 
uptake and retention of tracer was compared to that of Sawada et al., (1990b) for (R)- 
[125I]-QNB. Similarly, the uptake and retention of (R, R)-[1251]-QNB was investigated 
between 30 mins and 6 hours after administration using in vivo autoradiography and was 
compared to that of (R, S)-[125I]-QNB. 
Secondly, the sensitivity of (R, S)- and (R, R)-[ 125I]-QNB to dynamic changes in 
cholinergic neurotransmission in vivo, was assessed in conscious rats. The uptake and 
retention of. (R, S)- and (R, R)-[125I]-QNB following a cholinergic challenge produced by 
administration of the long lasting AChE inhibitor heptylphysostigmine, was investigated. 
Regional brain levels of (R, S)- and (R, R)-[125I]-QNB in heptylphysostigmine treated 
animals were compared to levels in saline treated animals by in vivo autoradiography. The 
ability of ACh to displace (R, S)- and (R, R)-[1251]-QNB binding from rat brain sections in 
vitro in the presence of heptylphysostigmine was also investigated. Finally, the effects of 
heptylphysostigmine administration on regional cerebral blood flow were investigated 
using [14C]-IAP autoradiography in conscious rats. 
Uptake and Retention Of (R, S)- and (R, R)-[1251]-QNB 
The in vivo uptake and retention of (R, S)-[125I]-QNB in the brain of conscious rat was 
investigated up to 24 hours after tracer administration. At all time points the uptake of 
tracer was consistent with regional mAChR concentration. Highest levels of radioactivity 
were observed in the cortex and caudate nucleus, with intermediate levels observed in the 
thalamus and low levels observed in the cerebellum. Washout of tracer from brain 
appeared to be dependent upon regional mAChR concentration. Negligible loss of 
radioactivity was observed in the cortex between 2 and 24 hours (10% reduction) -an area 
of high mAChR concentration, while significant washout of activity occcurs from the 
mediodorsal thalamus (40% reduction) -an area of moderate mAChR concentration. These 
observations are consistent with those of Sawada et al., (1990b) for (R)-[1251]-QNB and 
verify the validity of this methodology to image mAChRs in vivo. 
The uptake and retention of (R, R)-[ 125I]-QNB in the brain of conscious rat was 
investigated between 30 mins and 6 hours after administration of tracer. Regional 
distribution of radioactivity was similar to that of (R, S)-[125I]-QNB at all time points and 
x1l 
was consistent with regional mAChR concentration. Retention of 
(R, R)-["'II-QNB in brain is significantly shorter than that of (RS)-['25I]-QNB. 
This is most notable in the thalamus where a proportionally greater amount of 
radioactivity is washed out over a much shorter period of time. i. e. a 70% loss of 
(R, R)-["'I]-QNB over 6 hours compared to a 40% loss of (R, S)-['25I]-QNB over 
24 hours. Preliminary investigations confirmed that the washout of 
(1;, R)-["I]-QNB occurs more rapidly than that of (R, S)-[1251]-QNB from all 
brain regions. 
These observations are consistent with those of a previous study where the in 
vivo dissociation rate of (R, R)-[1251]-QNB (k1=0.0654 min-1) from mAChRs 
was observed to be 13 fold faster than that of (RS)-[125I]-QNB (k10.0049 
min-1) (Gibson, et al., 1989). 
The lower affinity and faster kinetics of binding displayed by (R, R)-['2 I]-QNB 
as determined in vitro in this thesis and in previous in vitro studies (Zeeberg, et 
al., 1991) support the observations made in vivo. It was therefore postulated 
that (RR)-[125I]-QNB would be more sensitive to changes in synaptic ACh 
concentration than (FS)["'I]-QNB and thus a more suitable ligand than 
(R, S)-["'II-QNB for imaging dynamic changes in cholinergic function in vivo. 
Imaging Changes In Cholinergic Function With (RS)- and(R, R)-['251]-QNB 
The ability to measure ACh release in vivo would allow assessment of 
neurotransmitter function in pathological conditions such as Alzheimer's 
disease. Quantification of changes in postsynaptic radioligand binding as a 
result of competition from increased levels of endogenous neurotransmitter 
would provide an indirect measure of synaptic concentration of 
neurotransmitter and a means to assess function. This has been successfully 
demonstrated with the dopaminergic system, where displacement of 
radioligand from dopamine D2 receptors following amphetamine induced 
increases in endogenous dopamine, has been quantified non-invasively in vivo. 
using PET and SPECT. The ability to quantify synaptic neurotransmitter 
concentration in such a manner in the cholinergic system would have 
significant application for imaging neurotransmitter function in disease states. 
To this end the sensitivity of (R, S)- and (R, R)-['25I]-QNB binding, to a 
cholinergic challenge produced by the administration of the long lasting AChE 
inhibitor heptylphysostigmine was assessed with in vivo autoradiography. It 
was postulated that increases in synaptic ACh concentration produced by 
heptylphysostigmine (which does not itself compete directly for mAChRs) 
would displace (R, S)- or (R, R)-['251]-QNB binding which could then be 
quantified. 
Heptylphysostigmine administration (2mg/kg) did not induce displacement of 
(R, S)- or (R, R)-['251]-QNB binding in vivo. Similarly 10'-10-2M ACh failed to 
displace either (RS)- or (RR)-['z I]-QNB binding from rat brain sections in 
vitro in the presence of 10- 
xlv 
6M heptylphysostigmine. Contrary to this, heptylphysostigmine administration 
significantly increased brain levels of (R, S)- and (R, R)-[1251]-QNB in vivo. Increases 
were observed predominantly in the cortex with both (R, S)- and (R, R)-[1251]-QNB, 
although a number of sub-cortical regions were also affected. The most consistent and 
greatest increase with both tracers was observed in the auditory cortex, with an average 
increase across the time points of 66% and 58% observed respectively for (R, S)- and 
(R, R)-[1251]-QNB. 
It was postulated that the increased brain levels of radioactivity measured 
following heptylphysostigmine administration were the consequence of elevated levels of 
cerebral blood flow-a known effect of AChE inhibitor administration (Linville et al., 
1992). An increased blood flow rate would deliver a greater supply of tracer to the brain 
and may account for the increases in radioactivity observed in the cortex of 
heptylphysostigmine treated animals. To this end rCBF was measured in conscious rats by 
[14C]-IAP autoradiography 2 hours after administration of heptylphysostigmine (2mg/kg 
iv). Significant increases in rCBF were measured in a number of cortical regions including 
those which displayed increased levels of (R, S)- or (R, R)-[ 125I]-QNB following 
heptylphysostigmine administration. Hypothetical concentration of radiotracer in the 
cortex of rat was observed to increase in a similar manner to that measured in vivo when 
the rate of blood flow was raised in a3 compartment model of tracer uptake and retention. 
From these observations it was concluded that the increases in regional levels of (R, S)- 
and (R, R)-[1251J-QNB observed following heptylphysostigmine administration are the 
result of elevated cerebral blood flow. 
Three hypotheses were considered to account for the lack of radioligand displacement 
observed following heptylphysostigmine administration.: 
1) Heptylphysostigmine was ineffective in inhibiting AChE and raising synaptic ACh 
levels at the dosage used in this thesis 
2) A small amount of displacement occurred but was masked by the effects of increased 
cerebral blood flow 
3) (R, S)- and (R, R)-[1251]-QNB are of too high affinity for mAChRs to be displaced by 
endogenous neurotransmitter. 
A number of factors suggest that the first hypothesis is unlikely. Semi-quantitative AChE 
histochemistry on sections of rat brain taken from in vivo studies with heptylphysostigmine 
indicate that AChE activity was significantly inhibited in the brain up to 24 hours. In vivo 
microdialysis studies support these results indicating that heptylphysostigmine at the dose 
used in this thesis significantly inhibits brain AChE activity for prolonged periods 
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(Messamore et al., 1993, Cuadra et al., 1994). The increases in cerebral blood flow 
measured following heptylphysostigmine administration-which are known to result from 
the action of excess ACh on the cerebrovasculature (Taylor, 1990), and the behaviour of 
animals receiving heptylphysostigmine (salivation, urination, muscle tremor, hypomobility 
etc) both indicate raised levels of ACh. Additionally, reports in the literature indicate that 
heptylphysostigmine at this dosage is effective in producing significant increases (i. e. 
1000%) in synaptic ACh levels. 
The third hypothesis is viewed as the most plausible. Consideration of the the relative 
affinities of endogenous neurotransmitter and radioligand for mAChRs (KD= 3.3µM and 
<1 nM for ACh and [ 125I]-QNB respectively) together with the resting synaptic 
concentration of ACh in the normal brain. (3-6nM) indicate that a substantial increase in 
synaptic ACh concentration would have been necessary to produce even a modest 
displacement of radioligand binding. It therefore seems unlikely that increasing synaptic 
ACh concentration with AChE inhibitors is an effective means of displacing (R, S) or 
(R, R)-[125I]-QNB binding in vivo. This view is supported by a recent report indicating 
that a binding potential of between 3-10 for a radioligand is optimal for sensitivity to 
neurotrasnmitter changes and produces greatest displacement of ligand (Endres and 
Carson, 1998). Consideration of the binding potential of (R)-[ 125I]-QNB as determined by 
Sawada et al., (1990b) for frontal cortex BP=1 171, parietal cortex BP= 977, caudate 
nucleus BP= 1116, thalamus BP= 247 and cerebellum BP= 51 indicates that both of the 
high affinity diastereoiosmers (R, S) and (R, R) of radioiodinated QNB will be extremely 
insensitive to changes in neurotransmitter concentration. In conclusion, (R, S)- and (R, R)- 
[125I]-QNB are unsuitable ligands for the detection of cholinergic function in vivo. 
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Preface and Declaration 
This thesis reports the evaluation of two radioiodinated stereoisomers [(R, S) and (R, R)] of 
quinuclidinyl benzilate as potential ligands to image dynamic changes in cholinergic 
neurotransmission in the central nervous system in vivo. Results are presented from 
investigations in two broadly defined areas: 
1) The uptake and retention of (R, S)-[1251]-QNB in conscious rat brain compared to 
that of (R, R)-[125I]-QNB and that of (R)-[125I]-QNB described by Sawada et al., 
(1990b). 
2) The ability of (R, S)- and (R, R)-[1251]-QNB to image dynamic changes in 
cholinergic neurotransmission in vivo produced by administration of the 
cholinesterase inhibitor heptylphysostigmine. 
This thesis comprises my own original work and has not been presented previously as a 
thesis in any form. The assistance of J. Owens in performing HPLC analysis of plasma and 
brain homogenate samples in metabolite studies is gratefully acknowledged. 
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CHAPTER 1 
INTRODUCTION 
1.1 ACETYLCHOLINE IN THE CNS 
1.1.1 Cholinergic Pathways In The CNS 
ACh is one of the most ubiquitous transmitters in the mammalian CNS. It is involved 
in the control of a variety of complex functions including learning, memory and modulation 
of behaviour. Cholinergic neurons exist as both projection neurons and interneurons in 
nearly all parts of the forebrain, midbrain and brainstem , although they are relatively 
few in 
number in the cerebellum. Specific cholinergic markers such as AChE, ChAT, mAChRs and 
nAChRs are used to identify neurons as cholinergic. Of these markers only ChAT is located 
pre-synaptically, with the others found both pre- and post-synaptically. 
It is not possible to identify the presence of ACh itself by histochemical means, 
therefore cholinergic pathways in the CNS were originally identified by the presence of the 
of AChE, the catabolic enzyme for ACh by the pioneering work of Kolle and Shute and 
Lewis in the 1950s and 1960s (Shute and Lewis, 1967). 
AChE is present at cholinergic synapses and can thus be used as a means to identify the 
location of cholinergic neurons in the CNS. On the basis of AChE histochemistry, Shute and 
Lewis (1967) identified two major ascending neuronal tracts containing AChE stained fibres. 
The first of these ascends from the brainstem, projecting dorsally into the thalamus, and 
ventrally up to the basal forebrain. The second ascends from the basal forebrain to the 
cerebral cortex (Krnjevic and Silver, 1965). This pattern of AChE distribution and of 
cholinergic innervation has been confirmed and expanded upon with the use of improved 
AChE histochemical assays (Butcher and Woolf, 1984). 
The presence of AChE however, does not guarantee cholinergic innervation of a 
particular brain region. AChE is not exclusively located to cholinergic synapses in the CNS 
and therefore AChE histochemistry cannot be used as the definitive marker for the presence 
of cholinergic neurons. Not until the development of immunohistochemical and in situ 
hybridization techniques for ChAT (Crawford. et al., 1982, Ruggiero et al., 1990, Woolf, 
1991) the synthetic enzyme for ACh, could neurons be unequivocally identified as 
cholinergic. Both of these techniques are highly specific for the identification of cholinergic 
neurons. The presence of ChAT mRNA as verified by in 'situ hybridization is now accepted 
as the definitive technique for the identification of cholinergic neurons (Butcher et al., 1993). 
Comparison of the pattern of cholinergic neurons identified with each of the above 
techniques produces a pleasingly high degree of correlation. The 'results observed with 
AChE histochemistry (Talbot et al., 1988), ChAT in situ hybridization (Woolf, 1991) and 
ChAT immunohistochemistry (Ruggiero et al., 1990) authenticate the observations of Shute 
and Lewis (1967) in identifying two main cholinergic pathways within the mammalian 
brain. These two pathways incorporate eight major cholinergic cell groups which project to a 
variety of CNS structures and are constitutive of the major cholinergic innervation of the 
Fig 1: Schematic representation in the horizontal plane of the major cholinergic systems in 
mammalian brain. Illustration shows 2 major cholinergic projection pathways : the basal 
forebrain cholinergic complex consisting of the medial septum (ms), vertical and 
horizontal limbs of the diaginal band of Broca (td) , substantia 
inominata (si), and nucleus 
basalis (bas) which project to the cortex and hippocampus; and the pontomesencephalo- 
tegmental cholinergic complex consisting of the pedunculopontine (tpp) and laterodorsal 
(dltn) tegemental nuclei which project to the thalamus and descendingly to the pontine and 
medullary reticular reticular (Rt) formations. Additional abbreviations: amyg-amygdala, 
ant cg-anterior cingulate cortex, DeC-deep cerebellar nuclei, CrN-dorsal cranial nerve 
nuclei, diencep-diencephalon, DR-dorsal raphe nucleus, ento-entorhinal cortex, frontal- 
frontal cortex, ICj-Islands of Calleja complex, ins-insular cortex, LC-locus ceruleus, LR- 
lateral reticular nucleus, olfact bulb-olfactory bulb, pir-piriform cortex, PN-pontine nuclei, 
pr-perirhinal cortex, parietal-parietal cortex, SN-substantia nigra, Sp5-spinal nucleus of the 
cranial nerve 5, temporal-temporal cortex, Ve-vestibular nuclei, vis lat-lateral visual 
cortex, visual med-medial visual cortex. 
CNS. The projecting cell groups include cholinergic neurons associated with the basal 
forebrain including the medial septal nucleus (MS), vertical and horizontal limbs of the 
diagonal band of Broca (VDB and HDB), and the'nucleus basalis of Meynert (NBM). The 
other major cholinergic cell groups include the pedunculopontine tegmental nucleus (PPT) 
and the laterodorsal tegmental nucleus (LTD) of the rostral brainstem, the medial habenula 
(MH) and the parabigeminal nucleus (PG) [see Figl]. The majority of these cell groups are 
not restricted to traditional nuclear boundaries and the neurons contained within them are not 
homogenous for ACh (Mesulam, 1988). Most notably GABAergic neurons are present 
within these nuclei (Gulyas et al., 1990). 
With this in mind Mesulam (1988) devised the Chl-Ch8 nomenclature to classify the 
cholinergic neurons within these cell groups -see Table 1 (Mesulam, 1988). When applied, 
this nomenclature refers only to the cholinergic neurons within a traditional neuroanatomical 
region. Tracer experiments in animals have indicated that the Chl and Ch2 cell groups (MS 
and VDB) provide the main cholinergic innervation for the hippocampus, projecting through 
the septo-hippocampal pathway. The neurons synapse mainly on hippocampal pyramidal 
and dentate gyrus granule neurons (Wainer et al., 1993). The 63 (HDB) projects mainly to 
the olfactory bulb, Ch4 (NBM) to the cortex and amygdala, CH5 and Ch6 (PPT and LDT) to 
thalamic nuclei, Ch7 (MH) to interpenduncular nucleus and Ch8 (PG) to the superior 
colliculus (Mesulam, 1990). Despite the identification of multiple cholinergic cell groups, 
the major ascending cholinergic projections conform to the original pattern identified by 
Shute and Lewis (1967) of two major cholinergic pathways. One originating in the 
magnocellular basal forebrain and a second arising from the mesopontine tegmental 
cholinergic cell group in the rostral brainstem. These two ascending cholinergic cell groups 
will now be discussed. 
Basal Forebrain Cholinergic Neurons Chl-Ch4 "'. 
The basal forebrain is made up of a constellation of four groups of cholinergic 
projection neurons (Chl-Ch4) consisting of the MS, VDB, HDB and the NBM which is the 
largest of the cell groups. All of the neurons in Chl-Ch4 stain positively for AChE and 
ChAT, identifying them as cholinergic (Mesulam and Geula, 1988). A significant proportion 
of these neurons are immunoreactive for p75 NGFr, the low affinity nerve growth factor 
receptor (Mesulam et al., 1989). Nerve growth factor (NGF) is a neurotrophin that appears to 
be critical in the development and maintenance of cholinergic neurons (Levi-Montaclini and 
Angeletti, 1968, Kew and Sofroniew, 1997). With the exception of a few striatal 
interneurons, the cholinergic neurons of the basal forebrain are 
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` Table 1 
Nomenclature and Major Projections of Cholinergic Cell Groups in the Brain 
Cholinergic Cell Anatomical Cell Abbreviation Major Projection 
Group Group 
Chl Medial septal MS Hippocampus 
nucleus 
Ch2 Vertical limb of the VDB Hippocampus 
diagonal band of 
Broca 
Ch3 Horizontal limb of HDB Olfactory bulb 
the diagonal band of 
Broca i 
Ch4 Nucleus basalis of NBM Cerebral cortex 
Meynert 
(Magnocellularis) 
Ch5 Pedunculopontine PPT Thalamus 
tegmental nucleus 
Ch6 Lateraldorsal LDT Thalamus 
tegmental nucleus 
Ch7 Medial habenula MH Interpenduncular 
nucleus 
Ch8 Parabigeminal PG Superior colliculus 
nucleus 
Nomenclature and classification of cholinergic cell groups is based upon that of Mesulam, 
(1988) for human brain.. 
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thought to be the main site of action of NGF in the CNS. Several lines of evidence are 
available to support this theory. Immunoreactivity for p75 NGFr co-localises with ChAT, the 
specific cholinergic marker, in neurons in the basal forebrain (Wainer et al., 1993). Injection 
of radiolabelled NGF into cortex or hippocampus results in the retrograde labelling of 
neurons in the basal forebrain (Schwab et al., 1979) and injection of NGF intraventricularly 
into neonate rats produces increased levels of ChAT in basal forebrain neurons (Gnahn et al., 
1983). 
Experimental lesion of neurons arising from the basal forebrain has highlighted the 
degree to which NGF is necessary to sustain the viability of cholinergic neuronal function. 
Studies involving transection of the fimbria-fornix, the pathway through which Chl-Ch2 
(MS and VBD) neurons project to the hippocampus, results in a marked reduction in the 
size and number of neurons in these areas of the basal forebrain (Gage et al., 1986). Injection 
of an immunotoxin specific for p75 NGFr into the hippocampus results in near total 
depletion of hippocampal cholinergic neurons, with a correlated significant decrease in 
cholinergic neurons in the MS and VDB (Ohtake et al., 1997). Destruction of the connection 
between the MS and VDB and the hippocampus in this manner appears to deprive the 
cholinergic neurons in the MS and VDB access to the high levels of NGF found in this 
structure resulting in their degeneration. By providing the neurons with a supply of NGF 
post-lesion via intraventricular injection, the neuronal degeneration normally observed can 
be prevented (Kromer, 1987). The ability of NGF to reverse neurodegeneration has led to its 
proposal as a therapeutic agent in the treatment of neurodegenerative conditions such as 
Alzheimer's disease. In this vein, infusion of NGF has been shown to ameliorate age related 
memory deficits and atrophy of the basal forebrain (Fischer, et al.. 1987). NGF appears to be 
critical for the survival and function of cholinergic neurons in this region. The exact 
mechanism by which NGF exerts its trophic effects has yet to be elucidated, but the presence 
of NGFr is known to be necessary (Hempstead et al., 1989). Cholinergic neurons in the basal 
forebrain synthesise p75 NGFr in their perikaya. The receptor is then transported 
intraxonally into the cortex, where it binds with cortically produced NGF. The NGF-NGFr 
complex is then transported retrogradely back into the cell body of the basal forebrain 
cholinergic neuron where it exerts is trophic effect (Hefti et al., 1986). As the cholinergic 
neurons of the basal forebrain are the only neurons expressing NGFr in large amounts, its 
presence can be used to identify the neuron not only as cholinergic, but as a cholinergic 
neuron originating in the basal forebrain. The reverse case does not hold however, as not all 
cholinergic neurons in the basal forebrain express NGFr and thus its absence does not 
exclude the neuron from being cholinergic. 
Recent investigations, however, have begun to question the role of NGF in maintenance of 
adult cholinergic neurons. In contrast to fimbria-fornix transection of hippocampal neurons, 
destruction of NGF synthesising neurons produced no subsequent degeneration of MS cells. 
This suggests that NGF is not required for the maintenance of adult neurons in this region, 
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that NGF is synthesised in novel sites outside of the hippocampus or that other trophic 
factors may be involved (see-Wainer et al., 1993 for discussion). 
The Ch4 neurons of the basal forebrain provide the major cholinergic 
innervation of the cerebral cortex. The entire cerebral cortex receives a dense cholinergic 
innervation as mapped out by AChE histochemistry (Geula and Mesulam, 1989) ChAT 
immunohistochemistry (Mesulam et al., 1991) and NGFr immunoreactivity (Mesulam et al., 
1992). In neurodegenerative diseases such as Alzheimer's, where there are severe cognitive 
deficits, there is a significant correlation between the loss of pre-synaptic cortical cholinergic 
markers and the loss of cell bodies in the NBM (Ch4) of the basal forebrain (Price, 1986). 
In contrast to the cerebral cortex, cholinergic innervation of the thalamus by basal 
forebrain neurons is minimal, as evinced by NGFr immunoreactivity (Mesulam, 1995). The 
mediodorsal and reticular thalamic nuclei displaying the most dense innervation (Hallanger 
et al., 1987). As with thalamic nuclei, the basal ganglia receive minimal cholinergic input 
from the basal forebrain cholinergic complex, with the striatum displaying greatest NGFr 
immunoreactivity. The basal ganglia does however receive substantial cholinergic 
innervation (displaying intense ChAT staining), the majority of which is intrinsic, arising 
from numerous cholinergic interneurons (Mesulam et al., 1992). 
Mesopontine Tegmental Cholinergic Neurons Ch5-Ch6 
The cholinergic projection neurons of the mesopontine consist of the 
pedunculopontine (PPT) and lateral dorsal (LDT) tegmental nuclei, with both regions 
staining intensely for ChAT (Butcher et al., 1992). The LDT is located slightly more 
caudally than PPT, but as with other cholinergic projection nuclei, there is no confinement to 
traditional neuroanatomical boundaries and thus no precise delineation between the two 
nuclei. The PPT and LDT neurons have been found to express a rich NADPH diaphorase 
(NADPHd) content (Vincent et al., 1983), which is known to be analogous to nitric oxide 
synthase (NOS) (Hope et al., 1991). A combined NOS mRNA in situ hybridization and 
ChAT immunocytochemistry study revealed that these markers are colocalized in the 
majority of PPT and LDT neurons (Sugaya and McKinney, 1994). PPT and LDT neurons 
are also immunoreactive for several neuropeptides including atrial natriuretic peptide (ANP) 
and substance P, although their function in these brain regions has yet to be elucidated 
(Standaert et al., 1986). 
The cholinergic neurons of the Ch5-Ch6 mesopontine tegmentum project to a variety 
of ascending and descending target nuclei. The most substantial ascending projections are to 
the thalamus, which receives its major cholinergic innervation from mesopontine projection 
neurons (Hallanger et al., 1997). Minor projections arising from the mesopontine cholinergic 
complex include those to cortical, extrapyramidal and limbic structures and to the basal 
forebrain (Preda et al., 1993). Descending projections provide innervation of the superior 
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colliculus and pontine and medullary nuclei (Hallanger and Wainer, 1988). The PPT projects 
to virtually all thalamic nuclei, whereas the LDT, projects more selectively to the anterior, 
laterodorsal, central medial and mediodorsal thalamic nuclei which are closely associated 
with the limbic system (Hallanger et al., 1987). The PPT also has limited connections with 
extrapyramidal structures, particularly the SNc (Lee, et al., 1988). Innervation of basal 
forebrain structures is minor, with evidence suggesting that mesopontine projection neurons 
synapse only on non-cholinergic neurons in the NBM (Martinez-Murillo et al., 1990). 
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1.1.2 Functional Aspects Of Cholinergic Neurotransmission 
Synthesis, Storage and Release Of Acetylcholine 
ACh is synthesised from choline and acetylcoenzyme A (acetylCoA) in the terminals 
of cholinergic neurons in a reaction catalysed by the enzyme choline-O-acetyltransferase 
(ChAT) (Tucek, 1985). Newly formed ACh is then transported into cholinergic synaptic 
vesicles in the nerve terminal by an energy dependent active transport mechanism (Parsons, 
S. M. et al., 1993). Depolarisation of the nerve terminal by the invasion of a propagating 
action potential results in release of ACh from vesicles by a calcium dependent exocytotic 
process. Once released, ACh is free to interact with postsynaptic cholinergic receptors 
(nicotinic or muscarinic) to produce a postjunctional response, before it is hydrolysed into 
choline and acetate by acetylcholinesterase (AChE), the degradative enzyme for ACh. 
The most influential factor governing cholinergic neurotransmission is the supply of 
the precursor choline. The supply of choline is the rate limiting step in ACh synthesis and is 
strongly influential on the rate of release . The axoplasm of a cholinergic nerve contains 
only a small supply of choline (Potter, 1970) and the brain cannot synthesise choline de 
novo at a significant rate (Lakher and Wurtman, 1987). Therefore, the majority of choline 
needed for synthesis is supplied in diet and is obtained from the extracellular fluid 
surrounding the neuron . Choline 
is also obtained from the hydrolysis of previously released 
ACh (Potter, 1970 ). 
A sodium dependent high affinity uptake system (SDHACU) present in the pre- 
synaptic membrane of cholinergic neurons exists to transport choline into the nerve terminal 
(Yammmamura, and Snyder, 1973). This transport system is intrinsically linked to ACh 
synthesis, with virtually all choline transported by this means converted into ACh. A low 
affinity carrier facilitated transport mechanism for choline also exists. This system is thought 
to be present in all neurons, however, and is involved in the transport of choline for ,' 
phopholipid synthesis. Transport of choline by the high affinity system is potently inhibited 
by drugs such as hemicholinium-3 (HC-3) and troxypyrrolinium which in turn inhibit ACh 
synthesis and release. 
The rate of choline uptake (and thus ACh synthesis) is accelerated following 
depolarisation of the nerve terminal and release of ACh (Potter, 1970, Collier and Katz, 
1974). In this vein, it has been suggested that prior release of ACh is necessary for choline 
uptake (Murrin et al., 1977) and that the rate of choline transport is inversely proportional to 
the vesicular concentration of ACh in the presynaptic terminal (Yammamura and Snyder, 
1973). Release and synthesis of ACh are thus intrinsically linked, ensuring that the rate of 
synthesis keeps pace with the demand for neurotransmitter (Browning and Schulman, 1968). 
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The activity of the synthesising enzyme ChAT is not a rate limiting factor in ACh 
synthesis(Salvaterra and Vaughn, 1989), Evidence suggests, however, that it may be 
indirectly involved. Two forms of the enzyme exist, cytosolic ChAT (cChAT) and 
membrane bound ChAT (mChAT). Cytosolic ChAT accounts for the majority of the enzyme 
in nerve terminals, with mChAT constituting the remaining 10-20%. Membrane bound 
ChAT forms part of a presynaptic membrane bound complex which is structurally or 
functionally associated with the SDHACU system. Thus mChAT activity may influence the 
rate of ACh synthesis by indirectly affecting choline uptake (Jope et al., 1979). 
ChAT activity is regulated by a number of hormones and growth factors including 
thyroid hormone, oestrogen, interleukin-3, basic fibroblast growth factor, brain derived 
neurotrophic factor and nerve growth factor (Rylett and Schmidt, 1993). In particular, 
enzyme activity is sensitive to ionic conditions in the nerve terminal, the concentration of 
chloride ions having a major effect (Rossier et al., 1977). The enzyme is inhibited by a 
number of naphthylvinylpyridines, monohalogenated AChs and halogenoacetonyl- 
trimethylammonium compounds (Parsons et al., 1993). 
Once synthesised in the cytosol, newly formed ACh is transported into synaptic 
vesicles in the nerve terminal for storage. An energy dependent active transport system 
located in the vesicle membrane exists to transport ACh from the cytosol into vesicles. ACh 
is stored in the vesicle at a concentration approximately 100 fold greater than that in the 
cytosol (Parsons et al., 1993). The vesicular ACh transporter (AChT) consists of two 
macromolecular components. The first is a proton pumping ATPase known as V-Type 
ATPase (Yamagata and Parsons, 1989). This pumps protons into the vesicle acidifying it 
creating a pH gradient across the membrane (Michaelson and Angel, 1980). The production 
of this pH gradient allows the AChT to concentrate ACh within the vesicle. The second 
component consists of the AChT itself, which exchanges vesicular protons for cytosolic 
ACh (Rebois et al., 1980). Storage of ACh in the vesicle can be blocked by the compound 
vesamicol, which in turn also inhibits ACh release (Marshall, 1970). Vesamicol prevents 
storage of ACh in vesicles by non-competitive inhibition of the AChT, binding to a site 
distinct to that of ACh (Bahr and Parsons, 1986). 
ACh is released from cholinergic nerve terminals by a calcium dependent exocytotic 
process that usually occurs at the active zones in the pre-synaptic membrane(Parsons et al., 
1993). Two forms of release exist. The first occurs in quiescent nerves where there is a 
spontaneous release of a single quanta of ACh'that can be detected electrophysiologically as 
a spontaneously occurring miniature end plate potential (mepp). The frequency of this 
release is dependent on the intraterminal Ca2+ concentration (Silinsky, 1985). The second 
form is evoked release of neurotransmitter. Evoked release occurs when a cholinergic nerve 
terminal is invaded by an action potential. Depolarisation of the terminal membrane occurs, 
causing voltage sensitive Ca2+ channels to open, resulting in a transient rise in intraterminal 
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Ca2+ ion concentration. This leads to the synchronous release of a large number of quanta of 
ACh (For review of mechanism of release see Parsons et al., (1993). 
This Ca2+ dependent release of ACh from cholinergic neurons is modulated by a 
number of auto-, homo- and heteroreceptors located pre- and post-synaptically at cholinergic 
synapses (Pepeu et al., 1990). These receptors alter the intraterminal Ca2+ ion concentration 
to either enhance or inhibit transmitter release. In each distinct brain region cholinergic 
neurons are equipped with different sets of these receptors making differential regional 
modulation of ACh release possible (Pepeu et al., 1990). Modulatory receptors include 
mAChRs, nAChRs, dopamine D2, glutamatergic NMDA, cholecystekinin (CCK), opioid, 
GABA, adenosine Al, 5-HT and a2 adrenoceptors (Table 2). 
Although the electrophysiological events resulting in ACh release are well 
understood, there is in contrast, divided opinion as to the mechanism by which transmitter is 
released from the nerve terminal. There are two main hypotheses, the vesicular exocytosis 
hypothesis and the membrane gate hypothesis. According to the former theory, all releasable 
ACh is stored within synaptic vesicles, with the readily releasable fraction of ACh stored in 
the vesicles nearest to the site of release. A larger reserve of transmitter is stored in vesicles 
lying further away from the release sites. Release of ACh occurs when there is a Ca2+ 
dependent fusion of the vesicle membrane and the nerve terminal membrane, resulting in 
the expulsion of the vesicular contents by exocytosis (Silinsky, 1985). 
The membrane gate hypothesis is based upon the supposition that ACh stored within 
vesicles represents transmitter reserve. Quantal release of ACh is produced by the opening 
of Ca 2+ sensitive membrane gates in the pre-synaptic terminal that allow fixed quantities of 
axoplasmic ACh to escape. Thus, according to this hypothesis, axoplasmic ACh represents 
the readily releasable store of transmitter and vesicular ACh represents transmitter reserve 
which can be released into the axoplasm as and when necessary. For a discussion of the 
relative merits of these hypotheses see Bowman, 1990 and Parsons, et al., 1993 (Parsons . et 
al., 1993). 
Once released into the synaptic cleft ACh has a very short period of time in which to 
effect a response before it is hydrolysed by a cholinesterase enzyme. Hydrolysis is extremely 
rapid, one molecule of ACh being broken down by AChE every 80-100J4s (Quinn, 1987). 
Vertebrates possess two cholinesterase enzymes, AChE (acetyl acylhydrolase, 
acetylcholinesterase or true cholinesterase) and pseudo- or butyrylcholinesterase (BuChE). 
These enzymes catalyse the hydrolysis of the ester bond in ACh, producing choline and 
acetate. AChE is highly specific for ACh and will hydrolyse it in favour of other choline 
esters (Massoulie' et al., 1993). BuChE is less specific for ACh, and is thought to regulate 
the synaptic level of ACh only when AChE is saturated. Both enzymes are present pre- and 
post-synaptically, and display a variety of different molecular forms (Massoulie and Bon, 
1982). The catalytic site of an AChE molecule consists of two subsites. The anionic site, 
which attracts and holds the positively charged nitrogen group of ACh and the esteratic site, 
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Table 2 
Pre- and Postsynaptic Receptors Influencing Release of ACh 
Region Receptor Location Effect on release 
Forebrain M1-M5 Presynaptic Decrease 
D2 Postsynaptic Increase 
CCK Postsynaptic Increase or Decrease 
GABA Postsynaptic Decrease 
Opioid Postsynaptic Decrease 
5-HT Postsynaptic Decrease 
Striatum M1, M2 Tresynaptic Decrease 
D2 Postsynaptic Decrease 
NMDA Postsynaptic Increase 
5-HT Presynaptic Decrease 
Al Presynaptic Decrease 
k-opioid Presynaptic Decrease 
Hippocampus M1, M2, M4 Presynaptic Decrease 
GABA Presynaptic Increase 
Al Presynaptic Decrease 
Cortex M1, M2, M4 Presynaptic Decrease 
5-HT1F, 5-HT2 Presynaptic Decrease 
K-opioid, S-opioid Presynaptic Decrease 
Neurokinin-1 Presynaptic Decrease 
a2 Presynaptic Decrease 
GABA Pres na tic Decrease 
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which catalyses hydrolysis. Once a molecule of ACh has bound to the enzyme, the reaction 
occurs in two stages. Firstly choline is split off, leaving an acetylated esteratic site on the 
enzyme, the latter then reacts with water releasing acetate and regenerating the enzyme. The 
activity of the enzyme is saturable and its action is inhibited by a variety of compounds that 
prolong the actions of ACh, such as physostigmine, tacrine, HEP and organophosphates. 
Muscarinic Cholinergic Receptors 
Acetylcholine receptors were originally defined into two classes, muscarinic and 
nicotinic, on the basis of tissue responses to certain agonist and antagonist compounds. The 
presence of muscarinic cholinergic receptors in a tissue can be identified by a response to 
muscarine, an alkaloid derived from the poisonous mushroom Amanita Muscaria , that 
mimics the actions of ACh and which is selectively antagonised by atropine, an alkaloid 
derived from deadly nightshade (Atropa belladonna). Similarly, the presence of nicotinic 
cholinergic receptors in a tissue can be identified by a response to nicotine which is 
antagonised by d-tubocurarine. In 1914 Dale defined the two classes of cholinergic receptor 
on the basis of the tissue responses described above (Dale, 
11914). 
In the periphery muscarinic acetylcholine receptors (mAchRs) mediate a variety of 
well documented actions (for overview see Wess et al., 1990) including reduction of heart 
rate, vasodilatation, constriction of airways, increased secretions from sweat and lacrimal 
glands and constriction of the iris sphincter and ciliary muscles of the eye. Within the central 
nervous system they are present in relatively high densities as heteroreceptors and 
autoreceptors regulating neurotransmitter release. As such they are involved in a large 
number of physiological and psychological functions. These include involvement in sensory 
and motor functions, emotional and stress responses, and regulation of REM sleep. In 
addition they participate in the regulation of higher cognitive functions such as learning an 
memory (Raiteri et al., 1984; Akaike et al., 1988; Vizi et al., 1989, Raiteri et al, 1990 ). 
Muscarinic Receptor Subtypes 
Until the early 1980s and the division of mAChRs into M1 and M2 on the basis of 
the binding properties of the novel ligand pirenzepine, mAChRs were thought to represent a 
fairly homogenous class of receptor. Pharmacological evidence to the contrary however, had 
existed since the 1950s. Gallamine, a neuromuscular blocking agent, used as an adjunct to 
general anaesthesia, was observed to produce sinus tachycardia as a side effect (Walton , 
1950). 
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In isolated heart preparations, gallamine blocked the negative inotropic and chronotropic 
effects produced by the introduction of ACh, but was ineffective in antagonising the 
contractile actions produced by muscarinic agonists in isolated smooth muscle (Riker et al., 
1951). Muscarinic receptors in heart therefore appeared to be different to those located in 
smooth muscle and exocrine glands. 
Verification of multiple receptor subtypes came when the binding properties of the 
novel muscarinic antagonist pirenzepine were first described(Matsuo et al., 1979). 
Pirenzepine was initially used for treatment of gastric ulcers. It inhibited gastric acid and 
pepsinogen production at doses that had no effect on either heart rate or gastrointestinal 
motility; suggesting the presence of at least two subtypes of muscarinic receptor. Pirenzepine 
was subsequently used to define the presence of three subpopulations of muscarinic receptor. 
It binds with high affinity to mAChRs in the CNS and peripheral ganglia (M 1 receptors); 
with intermediate affinity to mAChRs in exocrine glands (M3 receptors); and with low 
affinity to receptors in the heart [M2 receptors] (Hammer et al, 1982). 
The development of additional novel muscarinic antagonist compounds has aided the 
pharmacological classification of mAChRs into the three subtypes described above. The 
muscarinic antagonists 4-diphenylacetoxy-N-methlypiperidine methoiodide (4-DAMP) and 
hexahydrosiladifenidol (HHSiD) were found to antagonise M3 mediated contractions of -- 
intestinal smooth muscle more potently than M2 mediated cardiac responses and were thus 
define as M3 selective (Barlow et al, 1976, Lambrecht et al, 1989). 
However, these compounds are not strictly M3 selective as they exhibit high affinity for M1 
receptors also. It is therefore more accurate to define them as non-M2 antagonists. A group 
of compounds displaying M2 selectivity are also available. These include 11-[2- 
[(diethylamino)-methyl]-1-piperidinyl] acetyl-5,11 dihydro-6H-pyrido-[2,3b] [1,4] 
benzodiazepine-6-one (AF-DX 116), which displays actions converse to those described for 
M3 selective antagonists (Pedder et al 199 1). 
None of the muscarinic antagonists currently available is highly specific for a single 
receptor subtype, with most exhibiting between a2 and 10 fold difference in affinity 
between the subtype for which they are selective and the other subtypes (see Table 3). In this 
regard, there are also no true subtype selective muscarinic agonists available, with only 
McN-A-343 displaying a moderate M1 selectivity (Hu J. and El-Fakahany, 1990). However, 
the recent discovery of neurotoxins (isolated"from snake venom) displaying a high degree of 
selectivity for M1 and M4 receptors provides some optimism for the future development of 
subtype selective muscarinic ligands (Adern and Karlsson, 1997). 
Cloning Of Muscarinic Receptor Genes 
Unequivocal evidence for the heterogeneity of mAChRs came in the late 1980s when 
5 different subtypes were identified using molecular biological techniques 
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Table 3 
Affinity of Muscarinic Antagonists at Five muscarinic Receptor Subtypes 
Antagonist ml m2 m3 m4 m5 
Pirenzepine 6 223 138 37 89 
HHSiD 22 131 15 15 93 
4-DAMP 0.58 3.8 0.52 1.17 1.05 
Methoctrarnine 50 13 213 32 135 
AF-DX 384 31 6 66 10 537 
Table shows Ki (nM) values for 5 muscarinic antagonists for binding to human ml-m5 
mAChRs. Affinity values were derived from [3H]-N methyl scopolamine displacement 
experiments (Dorje et al., 1991). 
HHSiD= hexahydrosiladifenidol, 4-DAMP= 4-diphenylacetoxy-N-methylpiridine 
methoiodide, AF-DX 384= 5,11-dihydro-11-{[(2-{2-[(dipropylamino)methylj-l- 
piperidinyl Jethyl)aminolcarbonyl) -6H-pyrido(2,3-b)(1,4)benzodiazepine-6-one. 
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Bonner et al., 1987a, Kubo et al., 1986a, Kubo et al., 1986b; Peralta et al., 1987). 
Muscarinic m1 and m2 receptors were first cloned from cDNA libraries extracted from 
porcine brain and heart (Kubo et a1., 1986a, Kubo et al, 1986b). Three more muscarinic 
receptors were cloned shortly afterwards (m3, m4, and m5) by screening cDNA and genomic 
libraries under low stringency conditions with oligonucleotide probes corresponding to 
regions of high homology between ml and m2 sequences (Bonner et al, 1987. Peralta et al., 
1987b, Lioa et al., 1990). 
The convention of designation for mAChRs is to use an uppercase "M" or a 
lowercase "m" for receptors identified pharmacologically (M) or by molecular biology (m) 
respectively. On the basis of the pharmacological properties of the expressed recombinant 
receptors and the relative distribution of their mRNA , the m1, m2 and m3 cloned receptors 
appear to correspond to the M1, M2 and M3 receptors identified solely by pharmacological 
means (Maeda et al., 1988). In this thesis, both conventions will be used and should be 
interpreted as being interchangeable. 
Of the cloned receptors m1 is abundantly expressed in the forebrain and sympathetic 
ganglia and exhibits high affinity for pirenzepine ( Ehlert and Tran, 1990; Giraldo et al, 
1987, Hammer et al., 1982; Kashihara et al., 1992; Yasuda et al., 1993). The m2 receptor 
exhibits high affinity for AF-DX 116 and gallamine (Kashihara et al., 1992) and accounts for 
almost the entire mAChR population in the heart. Compared to the mI receptor it is 
expressed in a low uniform density throughout the brain (Ehlert et a 1., 1990, Yasuada et al, 
1993). The m3 receptor displays high affinity for the M3 (non-M2) antagonists HHSiD and 
4-DAMP and is the major mAChR in the exocrine glands (Kashihara et al., 1992, Pedder et 
al., 1991). It is expressed in low levels through out the brain (Yasuda et al., 1993). The m4 
receptor exhibits high affinity for 4-DAMP and himbacine (Kashihara et al., 1992). It is 
abundantly expressed in the forebrain, particularly the corpus striatum and olfactory tubercle 
(Yasuda et al., 1993). The ms receptor also shows high affinity for HHSiD and 4-DAMP 
and is typified by its low affinity for AF-DX 116 (Yasuda et al, 1993). Out of the five cloned 
receptors it is expressed in the lowest density throughout the brain, representing less than 2% 
of the total density of mAChRs (Yasuda et al., 1993). 
Muscarinic Receptor Structure 
Analysis of the primary sequences of mAChRs shows that they are members of the 
superfamily of genes which are G-Protein coupled (Bonner et al., 1987, Kubo et al., 1986). 
This family of receptors is typified by the presence of 7 hydrophobic domains in their 
sequence which span the membrane (Fig 2). The transmembrane (TM) segments of mAChRs 
represent the regions of highest homology between the different subtypes of receptor. There 
is a 63% continuity of identity among the amino acid residues making up the 7 TM regions 
in the human ml-m5 receptors. The main sequence differences between the subtypes exist in 
14 
Fig 2: Structure of a membrane bound G-protein coupled mAChR. 
A shows 7 transmembrane segments typical of G-protein receptors, the cytoplasmic 
carboxy terminus (COOH), the extracellular amino terminus (NH2) and the 4 intracellular 
amino acid loops (il-i4). B is a helical wheel model of depicting the likely orientation of 
the 7 transmembrane segments which from a barrel like structure with a central pore 
containing the binding site for mAChR ligands. 
Muscarinic Receptor Structure 
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Fig 2: Structure of a membrane bound G-protein coupled mAChR. 
the amino acid residues making up the extracellular amino acid termnis, the third 
intracellular loop and the cytoplasmic carboxy terminis of the receptor structure. Of these 
regions the third intracellular loop displays the greatest divergence. This region varies from 
156 (ml) to 239 (m3) amino acid residues in length and accounts for 35-45% of the total 
number of residues in the entire receptor sequence. A comparison sequences shows that ml, 
m3 and m5 receptors show homology with each other, while m2 and m4 constitute a 
separate homologous group. The 7 TM regions are thought to form a barrel like structure in 
the membrane, with a central pore. Acetylcholine and other muscarinic ligands are proposed 
to bind at a site within this pore. Hulme et al., (1990) predict that the most conserved 
residues in the receptor sequence form the inner surface of this pore and have suggested that 
this may be responsible for the lack of highly selective subtype specific muscarinic 
antagonists and agonists available. 
Ligand Binding Site 
The binding site on mAChRs is thought to exist on a highly conserved aspartic acid 
residue, which is anionic in nature, in the third intracellular TM region, (Ehlert et al, 1980). 
The anionic nature of the proposed binding site conforms with knowledge that all effective 
muscarinic antagonists are cationic. Peptide mapping and sequencing studies with [3H] 
propylbenzilycholine mustard ([3H] PrBCM) have provided further evidence to support the 
proposed location of the binding site. Results indicate that [3H] PrBCM covalently binds to 
aspartic acid residues 105 and 111 in human m1 and m4 sequences respectively (Hulme et 
al, 1990). In addition, the chemically reactive aziridinium site on [3H] PrBCM is structurally 
similar to the quaternary ammonium head group of many muscarinic ligands. Further 
evidence supporting the anionic aspartate residue as the ligand binding site comes from site 
mutation studies. Mutation of the aspartate 105 to asparagine in the third TM region in the 
m1 receptor abolishes ligand binding and transduction mechanism activation (Fraser et al., 
1989). Other site mutation studies have shown that threonine and tyrosine residues in the 
fifth TM region are necessary for agonist but not antagonist binding (Wess et al., 1991, Wess 
et al., 1992). 
Allosteric modulation Of mAChRs 
Considerable evidence now exists for the presence of allosteric interactions between 
muscarinic drugs and other agents acting on mAChRs (Birdsall et al., 1987, Hulme et al., 
1990, Mithcleson, 1988; Tucek and Proska, 1995). All five mAChRS are known to be 
sensitive to allosteric modulation (Ellis et al., 1991). The neuromuscular blocking agents 
gallamine, alcuronium and pancuronium all act allosterically at mAChRs. In general these 
compounds have a negative allosteric effect. That is they inhibit the binding of competitive 
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muscarinic ligands to the orthosteric (primary) binding site in a non-competitive manner. 
Gallamine, the most studied allosteric ligand, characteristically slows down both the 
association and dissociation kinetics of ligands binding to the orthosteric site (Stockton et 
al., 1983). In contrast, alcuronium is known to enhance the binding of [3H] NMS to 
mAChRs by increasing the affinity of the binding sites for the radioligand (Tucek et al., 
1990). It should be noted however, that the positive allosteric effect of alcuronium is 
observed only with m2 and m4 receptors (Jakubik and Tucek, 1994). Of the five muscarinic 
receptor subtypes the m2 receptor displays the greatest susceptibility to allosteric 
modulation. In transfection studies with Chinese hamster ovary cells expressing the 
individual mAChR subtypes the affinity of the uncoupled receptors for alcuronium was as 
follows m2> m4> ml> m3> M5 (Jakubik et al., 1996). 
Consideration of the binding kinetics suggests the allosteric binding site on mAChRs 
is located in a position close to the orthosteric binding site but at a more extracellular 
location (Proska and Tucek, 1994; Tucek et al., 1993). Allosteric ligands are generally large 
charged molecules and when bound to the allosteric site are thought to create a steric 
hinderance to competitive muscarinic ligands binding to the orthosteric site. The allosteric 
effects of these compounds are observed in intact cells and tissues, suggesting that the 
allosteric binding site is located on the extra cellular surface of the receptor. Site directed 
mutagenesis studies on the mAChR sequence support this theory (see Tucek and Proska, 
1995 and Wess, 1996). 
Signal Transduction Mechanisms 
Binding of ACh or any other muscarinic agonist to a mAChR stimulates signalling 
by initiating binding of the receptor to a G-protein complex, which provides the specificity 
for coupling to an appropriate receptor. The G-protein consists of a heterotrimer of three 
different proteins, Ga , Gß and Gy , 
in order of molecular weight . Upon 
binding to the 
activated receptor, the a subunit of the G-protein separates from the By subunits and then 
interacts with the appropriate effector protein or ion channel to stimulate or inhibit the 
release of intracellular second messengers. Coupling of the mAChR to the a subunit occurs 
primarily through interaction at the third cytoplasmic loop (bless et al, 1989, Wess et al., 
1990). Recent evidence indicates that the By subunits may also be involved in the activation 
of second messenger systems (Camps et al, 1992). 
Muscarinic receptors can be broadly divided into two categories depending upon the 
effector systems which they employ; those which inhibit adenylate cyclase activity and those 
which stimulate phosphoinositide hydrolysis. Results from transfection studies involving the 
individual receptor genes have demonstrated that m2 and m4 receptor activation produces a 
pertusis toxin sensitive inhibition of adenylate cyclase and ml, m3, and ms receptor 
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activation produce a pertusis toxin insensitive stimulation of phosphoinositide hydrolysis 
(Lai et al, 1988; Peralta et al, 1988, Lai J. et al, 1991, Liao, 1990). However, it should be 
noted that pertusis toxin sensitive ml activation of phosphoinositide hydrolysis has also 
been identified (Mei et al., 1989). 
The effector systems that individual receptors employ is primarily determined by the 
type of G-protein with which it is able to interact. The ml, m3 and ms receptors 
preferentially couple to G-proteins of the Gq/11 family (Berstein et al., 1992, Offermans et 
al., 1994, Wong and Ross, 1994). These G-proteins mediate the activation of various 
isoforms of phospholipase Cß (PLCB), that catalyse phosphoinositide hydrolysis (Peralta et 
al., 1988 Smrcka et al., 1991, Berstein et al., 1992). The m2 and m4 subtypes are selectively 
linked to G-proteins of the Gi/o class which, with the exception of Gz, are inactivated by 
pertusis toxin (Parker et al., 1991, Offermans et al., 1994). It should be noted however, that 
one receptor subtype can couple to both effector systems. Thus, m2 and m4 receptors can 
couple to phosphoinositide hydrolysis, although only weakly and at high receptor levels and 
agonist doses (Ashkenazi et al., 1987). In fact it appears that a single receptor can activate 
multiple effector systems by interaction with different G-proteins. 
The predominant effector systems that interact with mAChRs are briefly described below. 
Adenylate Cyclase 
The negative coupling of m2 and m4 receptors to adenylate cyclase is well 
documented (see Caufield et al, 1993 for review). It is now also recognised that under 
certain conditions ml, m3 and ms receptors may also inhibit enzyme activity (Peralata et 
al., Nature 1988, Lai et al., 1992). In contrast however, mAChR activation has been shown 
to stimulate adenylate cyclase activity in a variety of expression systems, (Baumgold and 
Fishman, 1988; Regunathan et al, 1990; Olianas et a1:, 1992). Several regulatory 
mechanisms are likely to be responsible for muscarinic receptor mediated activation of 
adenylate cyclase including a Ca2+/ protein kinase C (PKC) dependent mechanism (Jansson, 
et al., 1991, Baumgold et al, 1992). Muscarinic receptor activation can also increase (Brandi 
et al., 1987) and decrease (Hughes et al, 1986) levels of cAMP by activation and inhibition 
respectively, of cyclic AMP phosphodiesterase, the catabolic enzyme for cAMP. 
Phospholipase C 
Receptor mediated phospholipase C (PLC) activation is the first step in a cascade of 
events resulting in phosphoinositide hydrolysis. Increased PLC activity is historically 
associated with stimulation of ml, m3 and ms mAChRs. However, as with adenylate 
cyclase, activation of this enzyme is by no means exclusive to these receptors, as the m2 and 
m4 subtypes may also stimulate PLC (Ashkenazi et al, 1987, Peralata et al., 1988). However, 
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PLC activation and hydrolysis of membrane phospholipid is greater following ml , m3 or 
m5 than m2 or m4 receptor activation (Peralta et al, 1988, Ashkenazi et al, 1989). 
Upon activation, PLC hydrolyses the membrane phospholipid phosphatidylinositol 
4,5-bisphosphate (PIP2) into 1,2-diacyl-sn-glycerol (diacylglycerol, DAG) and D-myo- 
inositol 1,4,5-trisphosphate (IP3) (Berridge, 1983, Fisher et al., 1987). DAG then binds to 
and stimulates protein kinase C (PKC) and IP3liberates Ca2+ stored in the endoplasmic 
reticulum by binding to the IP3 receptor, an IP3 sensitive Ca2+ channel. Activated PKC is 
then able to phosphorylate proteins, thereby regulating their functions. 
Phospholipase A2 
Activation of ml, m3 and ms has been shown to stimulate the release of arachidonic 
acid by activating the enzyme phospholipase A2 (Conklin et al., 1988, Felder, et al, 1990). 
Arachidonic acid is released by the action of PLA2 on membrane phospholipid, it can then 
be converted into a number of eicosanoid compounds and activates PKC. Muscarinic m2 and 
m4 receptors do not stimulate PLA2 at physiological levels of expression (Conklin et al, 
1988). 
Phospholipase D 
Phospholipase D (PLD) hydrolyses the membrane phospholipid phosphatidyl choline 
into phosphatidic acid and choline (Chalifour et al., 1980, Exton , 1990). 
Posphatidic acid, 
after interaction with the enzyme phosphotidate phosphohydrolase, produces DAG which is 
then able to activate PKC (Gustavsson et al., 1990). As with PLC, all five mAChR subtypes 
are coupled to PLD with m 1, m3 and ms receptors producing a more robust activation than 
m2 and m4 receptors (Sandmann et al, 1991). The coupling of mAChRs to PLD may be of 
general importance to cholinergic transmission in so far as it results in the production of 
choline, a precursor for ACh. 
'Distribution Of Muscarinic Receptors Within The CNS 
The distribution of mAChRs within the CNS has been mapped out using ''a variety of 
techniques. Binding sites were first visualised in the 1970s with in vitro autoradiography 
studies using [3H] radioligands (Yamamura, et al., 1974; Kuhar and Yamamura, 1975). 
More recently, the development of immunoprecipitation (using subtype selective antibodies) 
and in situ hybridization techniques, has provided unequivocal evidence of the distribution 
of muscarinic sites within the brain. In general, there is excellent agreement between the 
different techniques as to the distribution of mAChRs. 
l 
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Radioligand binding studies have identified a high density of M1 receptors in the 
hippocampus, cortex and striatum (Spencer et al., 1986, Cortes and Palacios, Brain 1986, 
Mash and Potter, 1986; Frey and Howland, 1992). Lower population density is observed in 
the thalamus and hypothalamus and in the brainstem nuclei. This distribution of Ml 
receptors is supported by immunoprecipitation (Levey et al., 1991, Wallet al., 1991) and in 
situ hybridization studies (Buckley et al., 1988, Vilaro et al., 1994). 
M2 receptors show a more widespread distribution with mRNA present in nearly all 
brain regions (Vilaro et al., 1992). Autoradiography studies indicate a low uniform 
distribution throughout the CNS, with M2 receptors placed most predominantly in thalamic 
nuclei, striatum, superior colliculus, pontine nuclei, and brainstem (Regenold et al., 1987; 
Wang et al., 1987; Frey and Howland, 1992). Results of immunoprecipitation studies 
support this distribution (Levey et al., 1991). In general, the distribution of M2 sites is 
similar to that of the cholinergic markers AChE and ChAT, i. e. high density in striatum, 
thalamic nuclei, and superior colliculus (Fibiger, 1982; Quirion and Boska, 1986; Woolf, 
1991). In contrast the distribution of MI sites is very different to that of the cholinergic 
markers. These observations suggest a presynaptic location for M2 receptors and a 
postsynaptic location of MI receptors. Functional evidence has suggested the presence of 
M2 receptors on presynaptic cholinergic terminals where they act as autoreceptors regulating 
the release of ACh (Lapchak et al., 1989; Hoss etal., 1990). Although m2 receptors are 
thought to be the predominant subtype of autoreceptor in areas such as the striatum (Billard 
et al., 1995) evidence exists to suggest that all five subtypes of receptor may have roles as 
presynaptic autoreceptors on projecting cholinergic neurones (Vilaro, et al., 1994, 
Vannucchi et al., 1995; Stillman et al., 1996). 
Distribution of M3 sites within the CNS has been mapped with autoradiography 
(Michael et al., 1989; Michael and Whiting, 1990), immunoprecipitation (Levey, 1993; 
Levey, et al., 1994) and in situ hybridization (Buckley et al., 1988; 8: 4646-4652, Vilaro et 
al., 1994). The pattern observed is similar to that of M1 receptors, with high density in the 
cortex,, striatum and hippocampus and lower density in the thalamic, hypothalamic and 
brainstem nuclei . M3 receptors however, are present in higher density in certain thalamic 
and brainstem nuclei and possibly also in some deeper cortical layers (Quirion et al., 1993). 
The functional role of the M3 receptor in the CNS is yet to be established, although evidence 
exists for their role as autoreceptors (Vilaro'et Al., 1994). 
The visualisation of M4 and M5 receptors has been hampered by the lack of subtype 
selective ligands . However, recent labelling strategies utilising in vitro autoradiography, 
have allowed their distribution in the CNS to be mapped (Ferrari-Dileo et al., 1994, Flynn et 
al., 1997, Reever et al., 1997). M4 receptors are found in greatest density in the caudate 
nucleus, nucleus accumbens, and olfactory tubercle. Areas of lower density are found in the 
cortex, hippocampus and the laterodorsal and pedunculopontine tegmental nuclei (Buckley 
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et al., 1988, Vilaro et al., 1991). The distribution profile of the M5 receptor is distinct from 
the other four subtypes. Of the mAChRs, it is expressed in the lowest density in the CNS, 
although recent evidence suggests its level of expression may be higher and more 
widespread than originally thought (Reever et al., 1997). Brain regions which are relatively 
enriched with M5 receptors include the outer layers of the cerebral cortex, the hippocampus, 
the caudate nucleus, and the nucleus accumbens. As with the M3 and M4 subtypes little is 
known about its physiologic role. 
Nicotinic Cholinergic Receptors 
Nicotinic acetylcholine receptors (nAChRs) are a family of ligand gated cation 
channels belonging to a larger superfamily including 5-HT, GABAA and glycine receptors 
(Ortells and Lunt, 1995). They are comprised of hetero-oligomers consisting of five 
membrane spanning subunits which form a barrel like structure in the membrane around a 
central ion channel (Fig 3) (Cartaud et al., 1973 ). Molecular cloning studies in chick, rat 
and human have identified multiple genes that encode various subtypes of subunit that allow 
assembly of a wide variety of receptor oligomers with different distribution and distinct 
pharmacological profiles (Sargent et al., 1993). Peripheral nAChRs, such as those found at 
the neuromuscular junction or in electric organ tissue, are made up of al, ßl, 7 and S or F 
subunits in the fixed stoichiometry of 2.1.1.1. ( e. g. 2a1, lßl, ly, and 15 or le). Neuronal 
nAChRs differ from those in the periphery in that they have no y, S or c subunits in their 
make up, and consist of various complements of a2-a9 and ß2-ß4 subunits. In mammalian 
brain two major neuronal populations of nAChR can be delineated using radioligand 
binding: those recognising a-bungarotoxin (a-BgT) and neuronal bungarotoxin (n-BgT) 
with high affinity and those that do not (Clarke, et al., 1985 Sugaya et al., 1990). The 
major brain species of nAChR constitutes the receptor population with low affinity for w- 
and -BgT. These receptors are composed of two a4 and three ß2 subunits (Whiting and 
Lindstrom, 1986) and bind [3H]-nicotine and [3H]-ACh with high affinity (Clarke et al., 
1985). Neuronal nAChRs with high affinity for a- and n-BgT do not display the same high 
affinity for nicotine or reflect ACh binding in terms of kinetics, pharmacological profile or 
distribution. Recent evidence suggests that these receptors are composed of homo-oligomers 
consisting predominantly of subunits of the a7 subtype (Breese et al., 1997). Additional 
multiple forms of neuronal nAChR exist, composed of different combinations of both a and 
ß subunits which form a wide variety of functional hetero-oligomers with distinct 
pharmacological and physiological properties. Furthermore, each neuronal subpopulation 
displays a distinct pattern of distribution within the brain as will be described in a later 
section (Sargent et al., 1993 ) 
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Fig 3: Structure of ligand gated nicotinic ion channel-receptor 
Figure shows five membrane spanning subunits (A) which form a barrel like structure in 
the membrane around a central ion channel (B) . The stoichiometry of peripheral and 
neuronal nicotinic receptors is shown in C. Peripheral nAChRs, such as those found at the 
neuromuscular junction or in electric organ tissue, are made up of al, ßl, y and S or c 
subunits in the fixed stoichiometry of 2.1.1.1. ( e. g. 2(x1, lßl, ly, and 18 or le). Neuronal 
nAChRs differ from those in the periphery in that they have no g, d or e subunits in their 
make up, and consist of various complements of a2-a9 and ß2-ß4 subunits. 
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Nicotinic Receptor Structure and Ligand Binding Site 
Analysis of the amino acid sequence of nAChRs reveals significant sequence 
homology between receptor subtypes with similar distribution of hydrophillic and 
hydrophobic regions within their length (Galzi and Changeux, 1995). The receptor 
sequence consists of a large hydrophillic amino terminal domain, a compact hydrophobic 
domain split into three segments of 19-27 amino acids termed M1-M3, a small highly 
variable hydrophillic domain and a hydrophobic C-terminal domain of approximately 20 
amino acids termed M4. It is thought that the large hydrophillic domain is exposed to the 
synaptic cleft and plays some role in the binding of ligands. The small hydrophillic domain 
is exposed to the cytoplasm and the four hydrophobic domains comprise the transmembrane 
segments of the protein, some of which line the ion channel (Galzi and Changeux, 1995). 
From studies on Torpedo electric organ it was elucidated that the nAChR in this 
tissue and that in muscle, carried two ACh binding sites (Reynolds and Karlin, 1978). The 
binding sites were originally thought to reside solely upon the a-subunit but evidence from 
site-directed mutagenesis studies on muscle nAChR has indicated that the ligand binding 
sites exists at the interfaces between the a and ß and a and ä/s subunits. In hetero- 
oligomeric neuronal nAChRs of the ai2ßJ3 type(e. g. a42ß23) the binding sites are formed in 
a similar manner (Alkondon et al., 1993). However, in the homo-oligomeric a7 or a8 
subtypes of nAChR, five identical ACh binding sites are formed due to the identical nature 
of the subunits making up the receptor protein (Sargent et al., 1993). 
The subtype composition of the receptor is very important in determining sensitivity 
to agonists and antagonists. Expression of different subunit combinations in oocytes has 
allowed direct comparison of the binding properties of the receptor subtypes. 
For example, a4ß2 receptors display the greatest sensitivity to ACh and (-) nicotine, with an 
EC50 of 0.7pmol/L for both compounds. The a3ß2 receptor subtype displays' lower affinity 
for ACh and (-) nicotine with an EC50 of 5 pmol/L. Both of these receptor subtypes are 
insensitive to a-BgT. In contrast a7 nAChRs which are blocked by both a- and n-BgT are 
relatively insensitive to ACh and (-) nicotine, with EC50s of 155 pmol/L and 10 pmol/L 
respectively (Court and Perry, 1994). The rank order of potency of the nAChR agonists 
ACh, (-)-cytisine, 1,1 -dimethyl-4-phenylpiperazinium (DMPP) and tetraethylammonium on 
nAChRs formed from ß2 or ß4 subunits combined with a2, a3 or a4 subunits has 
established the importance of both a and ß subunits in defining the binding properties of 
nAChRs (Luetje and Patrick, 1991). Receptors containing the ß4 subunit were most 
sensitive to (-)-cytisine whereas those containing the ß2 subunit were (-)-cytisine insensitive. 
Currently no subtype selective nAChR agonists are available, although development of 
a4ß2 selective compounds is on going as potential therapeutic agents for the treatment of 
Alzheimer's disease (Abreo et al., 1996). The alkaloid epibatidine, a natural product in frog 
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skin , is the most potent nicotinic agonist ligand reported to 
date. It binds with high affinity 
at [3H]-cytisine and [125I]- a-BgT sites and is functionally more potent than nicotine (Qian 
et al., 1993). It also appears to be an excellent ligand for in vitro and in vivo labelling of 
nAChRs (Perry and Kellar, 1995). 
In comparison, several nAChR antagonist compounds are available that allow a 
certain degree of delineation between receptor subtypes. For example, while having no 
effect on a2ß4 and a4ß2 subtypes, n-BgT is a potent inhibitor of a3ß2 nAChRs (Luetje et 
al., 1990 ). In addition, the neurotoxin neosugurotoxin (NSTX), potently blocks a2ß2, a4ß2 
and a3ß2 but not 0 or alßläy/e (muscle) nAChRs subtypes (Martin et al., 1993). 
Furthermore, the nAChR antagonist methylcaconitine (MLA) an inhibitor of [125I]-a-BgT 
binding, blocks the ion channel response at 0 but not a4ß2, a3ß2 or muscle type nAChRs , 
thus making it the only antagonist that can clearly distinguish between neuronal and muscle 
type BgT sensitive nAChRs. 
Alternative Ligand Binding Sites 
Evidence indicates that a number of ligand binding sites distinct from the classical 
ACh binding site may exist which allosterically modulate nAChR ion-channel function. 
Alternative "Channel Activator" sites are thought to be present on the a-subunit of nAChRs . 
Compounds such as the AChE inhibitors physostigmine and galanthamine act at these sites 
in a positive allosteric manner resulting in increased neuronal nAChR ion conductance 
(Pereira et al., 1993). Evidence also indicates that the neurotransmitter 5-HT binds to the 
same site on the a subunit and increases ion conductance by increasing the frequency of 
channel opening (Schrattenholz et al., 1996). 
A number of pharmacologically and chemically diverse compounds such as 
chlorpromazine, phencyclidine, MK801, local anaesthetics, detergents, fatty acids, 
barbiturates and alcohols can produce a negative allosteric effect on nAChR ion channel 
function (Lena and Changeux, 1993). These compounds are non-competitive (negative 
allosteric) channel blockers which are thought to interact with two distinct sites that differ 
from those of competitive blockers. The first high affinity site, which binds ligands in the 
nanomolar range, is thought to be located within the ion channel and is composed of amino 
acid residues of the M2 segment in each of the, five subunits making up the nAChR protein. 
Binding of ligands to this site is facilitated by agonist activation of the receptor and produces 
a rapid reversible channel blockade, with ion conductance blocked simply by steric 
hindrance (Valenzuela et al., 1994). The second binding site binds ligands with low affinity 
and is thought to accelerate desensitisation of the ion-channel receptor. There are thought to 
be numerous (10-20) sites of this type on each nAChR molecule which are postulated to be 
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located at the interface between the lipid membrane and the receptor protein (Lena and 
Changeux, 1993). 
Steroids can inhibit neuronal nAChR function by binding to a receptor site distinct 
from both the classical ACh site and the ion-channel site (Inoue and Kuriyama, 1989). 
Progesterone and testosterone coupled to bovine serum, have been observed inhibit 
neuronal a4ß2 nAChRs in a voltage sensitive manner. In addition, corticosterone 
administration to mice following adrenalectomy, produces a reversible increase in 
sensitivity to (-)-nicotine . Furthermore, 
high steroid concentrations (u molar range) have 
been observed to displace [125I]-a-BgT from rat brain membranes and to reduce the affinity 
of (-)-nicotine for this site (Lena and Changeux, 1993). Calcium ions also appear to have a 
role in modulation of nAChR ion-channel function. Calcium ions produce a negative 
allosteric effect by binding to a large number of sites on the nAChR protein, some of which 
are very likely to be located within the ion channel as suggested by voltage sensitive 
decreases in conductance observed (Fairclough et al., 1986). This binding site is also known 
as the dihydropyridine binding site, as L-type Ca2+ channel blockers of this class of 
compound have been observed to have effect at this site (Lopez et al., 1993). Calcium ion 
may also produce a positive allosteric effect by binding to another category of site carried 
only by neuronal nAChRs, potentiating the response to agonists in a voltage sensitive 
manner (Mulle et al., 1992). 
Transitional States of nAChR 
Nicotinic AChRs follow a "concerted allosteric" scheme in which they can exist in 
any one of four functionally distinct interconvertible transition states at any one time. The 
activation and desensitisation transition states have been analysed in detail 
electrophysiologically in vivo and in vitro (Neidmann and Changeux, 1979). 
The receptor can be in a resting state (R), an activated state (A) where the channel opens on 
a microsecond to millisecond timescale when activated, but has low affinity (1014 M- 1 MM) 
for agonists, or in one of two desensitised closed channel states I and D. In the sensitised 
states the channels are refractory to activation on microsecond and minute timescale 
respectively, but display high affinity (1 nM-1 pM) for agonists (Glaze and Change, 1995). 
Desensitisation of the receptor is characterised by the slow progressive decline in response 
amplitude following a prolonged period of receptor-ion channel activation 
The classical ACh binding site together with the distinct classes of allosteric binding 
site described above, co-operatively modify the equilibrium between the receptor states thus 
affecting the number of receptors existing in any one of the four states at any time. As with 
the ligand binding profile of individual receptor subtypes the subunit composition of each 
receptor has great influence upon the kinetics of activation and desensitisation , with the 
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homo-oligomers (e. g. oc7 and (x8) exhibiting most rapid desensitisation (see Galzi and 
Changeux, 1995). -" 
Distribution of nAChRs in the CNS 
The distribution of nAChRs has been extensively mapped using radioligand binding 
and in situ hybridization techniques in rodent brain. The topographical distribution of 
nAChRs corresponds well with the effects elicited by (-)-nicotine and the known functions 
associated with each brain region. Studies with [3H]-(-)-nicotine have revealed abundant 
high affinity sites in the cerebral cortex (layers III and IV), thalamus, medial habenula, 
superior colliculus and interpenduncular nucleus (Clarke et al., 1985 ). A second class of 
sites revealed by radioligand binding studies with [125I]-(x-BgT display a distribution 
pattern distinct to that of [3H] +)-nicotine, with high a density of binding observed in the 
hippocampus, cortex (layers I and IV), amygdala and certain brainstem nuclei (Clarke et al., 
1985). 
The distribution of nAChR subunit mRNA detected by in situ hybridization generally 
correlates with the distribution of the [3H]-(-)-nicotine and [1251]-a-BgT binding sites. The 
distribution of a4ß2 mRNA generally reflects the pattern of [3H]-(-)-nicotine binding, 
supporting the theory that receptors of this subunit composition compose the majority of the 
high affinity nicotine sites in the CNS (Wada et al., 1989). The. other subunits generally 
display a more circumscribed pattern of distribution. The a3 subunit constitutes the major a 
subunit present in the medial habenula and cortical layer IV. It is also found in the thalamus, 
hypothalamus and brainstem. The a2 subunit is concentrated in certain interpenduncular 
nuclei, the lateral dorsal tegmental nucleus of the brainstem, hippocampus and inferior 
colliculus (Wada et al., 1989). The a5 is present in significant levels in distinct layers of the 
subicular complex, substa. ntia nigra pars compacta, interpenduncular nucleus and dorsal- 
motor nucleus of the vagal nerve (Wada et al., 1990). The distribution of a7 mRNA closely 
resembles the binding pattern of [125I]-a-BgT and is distinct from that of [3H]-(-)-nicotine. 
It is present in highest density in the cerebral cortex (layers I and IV) and in the , hippocampus, particularly he CA4 region. Little or no a7 mRNA is present in the thalamus, 
striatum or substantia nigra (Seguela et al., 1993). Of the ß subunits, ß2 and ß4 are most 
widely distributed in the brain and are present in nearly all areas. The ß3 subunit expression 
is more limited but is present in highest density along with ß4, in the medial habenula 
(Dineley-Miller et al., 1992). 
- Topographical analysis of nAChR distribution in human brain has yet to be 
completed to the same degree as that in rodent brain. However, radioligand binding and in 
situ hybridization studies indicate broad agreement with the distribution of receptors in 
rodent brain. Binding of [3H]-(-)-nicotine was observed to be greatest in the thalamus , 
particularly the lateral geniculate nucleus (Perry et al., 1989). A high density of binding was 
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also observed in the subicular complex, specifically the pre-subiculum with a general low 
level of binding observed in the hippocampus. The exception being the CA2-3 region. 
Human cortex also displays a distinct pattern of nAChR distribution. In somato-sensory and 
occipital visual cortex binding is highest in upper and lower cortical layers while layer IV is 
relatively low in nAChR binding site density (Perry et al., 1992). As in rodent brain, the 
distribution of a7 [125I]-a-BgT sites is distinct to that of receptors with high affinity for (-)- 
nicotine. Binding sites are concentrated in dentate and CAI-3 regions of the hippocampus 
(Court and Perry, 1994). 
Although displaying widespread distribution, the pattern of nAChR expression does 
not correlate to any distinct cholinergic projection pathway within the CNS. However, 
concentrated nAChR binding observed in the thalamus, substantia nigra and superior 
colliculus suggests location of nAChRs immediately postsynaptic to brainstern Ch5-Ch6 
projection neurons where they may act to modify function. Therefore, these nAChRs are 
likely to have a role in arousal, attention and modulation of thalamic sensory control (Court 
and Perry, 1994). The identification of nAChRs in the substantia nigra, together with the 
well known presynaptic modulation of dopamine release by nAChRs, indicates a role for 
these receptors in the modulation of the extrapyramidal motor system (Rapier et al., 1988). 
Considerable evidence exists for modulation of neurotransmitter release by pre- 
synaptic nAChRs (see Wonnacott et al., 1996 for review). They exist as autoreceptors on 
motor, cortical and hippocampal cholinergic neurons where they have been shown to 
increase the release of ACh. The loss of nAChR in these regions (see later section) parallels 
the degeneration of cholinergic terminals in Alzheimer's disease and is consistent with a pre- 
synaptic location of these receptors. Evidence suggests that these autoreceptors are of 
predominantly a4ß2 subtype. Neuronal nAChRs are also present as heteroreceptors where 
they increase the release of a variety of neurotransmitters including dopamine, 
noradrenaline, GABA and excitatory amino acids. Of the heteroreceptor actions of nAChRs, 
the most well characterised is the nicotinic stimulation of striatal dopamine release (Rapier et 
al., 1988). 
In addition to modulatory actions on neurotransmitter release, nAChRs are involved 
in a number of physiological and behavioural functions. In particular nAChRs are 
implicated in learning and memory processes. Administration of nicotine is known to 
enhance learning and memory performance in a variety of cognitive ability tests (Buccafuso 
and Jackson, 1991, Levin, 1992, Gray, 1994 ). Nicotine also reverses deficits in cognitive 
impairment produced by cholinergic lesion, an effect which persists even after the 
withdrawal of nicotine (Levin, 1992). The presence of nAChRs in the subiculum complex of 
the hippocampus, are thought to be associated with the perforant pathway projecting from 
the subiculum to dentate granule cells. Therefore, stimulation of these nAChRs may mediate 
the effects of nicotine on learning and memory. Nicotine administration also produces EEG 
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desynchronisation, indicating that nAChRs have a role to play in arousal and attentional 
processes (Soldatos et al., 1980 ). 
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ACh In The Cerebral Circulation 
There is a considerable body of evidence indicating that ACh mechanisms play a 
significant role in the regulation of cerebral blood flow. Systemic administration of ACh 
increases cerebral blood flow (Aubineau et al., 1977). Application of ACh or ACh agonists 
such as carbachol to isolated perfused cerebral arteries and arterioles produces vasodilatation 
in vessels in a resting state and additionally produces relaxation in pre-contracted vessels 
(Edvinsson et al., 1977, Dacey and Bassett, 1987). Furthermore systemic administration of 
cholinesterase inhibitors such as physostigmine, that increase extracellular levels of ACh, 
have been observed to increase CBF without concomitant metabolic activation (Scremin et 
al., 1982). Anatomic AChE and ChAT studies have identified a network of ACh fibres 
innervating the cerebrovasculature (Arneric et al., 1988). Additionally, high levels of AChE 
and ChAT are preferentially associated with cerebral arteries in comparison to peripheral 
arteries and specific choline uptake and release mechanisms, systems closely associated with 
ACh nerve terminals have been identified in major cerebral arteries (Arneric et al., 1988) . 
These observations indicate that cerebral blood flow is at least in part regulated by ACh 
innervation. A neurogenic basis for ACh regulation of cerebral blood flow is enhanced by 
evidence from studies involving stimulation of cholinergic projection neurons. Electrical 
stimulation of the nucleus basalis in the basal forebrain and the fastigial nucleus of the 
cerebellum increases cerebral blood flow in the cortex of rats in a stimulation dependent 
manner (Arneric et al., 1987). The importance of ACh in regulation of cerebral blood flow 
has recently been confirmed by the observation that ACh neurons provide the major 
innervation of the cortical microvasculature-an important vascular segment for regulation of 
cerebral blood flow (Vaucher and Hamel, 1995). 
The vasodilatory responses of cerebral vessels to cholinomimetic administration or to 
stimulation of ACh neurons can generally be blocked in a competitive and reversible 
manner by the administration of atropine. Responses are therefore elicited through action at 
mAChRS. Under physiological conditions the vasodilatory action of ACh is endothelium 
dependent and is produced by stimulation of mAChRs on the vascular endothelium 
(Furchgott and Zawadzki, 1980). Activation of endothelial mAChRs stimulates synthesis 
and release of an endothelial derived relaxing factor , believed to be nitric oxide which then 
acts to modulate vascular tone (Paler et al., 1987). Nitric oxide is produced from 1-arginine 
by the synthetic enzyme nitric oxide synthase, the action of which can be inhibited by a 
number of 1-arginine analogues such as L-NOARG (More et al., 1990). Administration of 
L-NOARG inhibits cortical vasodilatation following electrical stimulation of the ACh basal 
forebrain, implicating nitric oxide release in ACh mediated vasodilatation (Biesold et al., 
1989). 
Recent evidence has identified the presence of a population of cortical nitric oxide synthase 
containing neurons associated with the vascular bed receiving cholinergic input from the 
basal forebrain (Voucher and Lintel, 1997). This observation indicates that ACh regulation 
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of cerebral blood flow is partly controlled via direct action on mAChRs of the vascular 
endothelium and partly via stimulation of local nitric oxide releasing relay neurons 
associated with the vascular bed. The evidence outlined above indicates a significant role for 
ACh in the control of cerebral blood flow. 
Behavioural Aspects Of Cholinergic Transmission 
ACh and Arousal 
The concept of arousal as a general state of CNS activity is classically related to the 
different stages of sleep and wakefulness (Morass and Meagan, 1949). During the waking 
state, cortical electroencephalogram (EEG) is dominated by a pattern of low voltage, high 
frequency discharge known as EEG de synchrony, which is characteristic of an aroused 
state. The concept of arousal has since been developed into the notion of a state of CNS 
activity that optimises the processing of sensory stimuli in the cerebral cortex. A process 
which is now construed as a form of attentional function (Hebb, 1955). The level of arousal, 
consciousness and the regulation of the sleep waking cycle was originally proposed to be 
under the influence of an ascending reticular activating system controlled by the reticular 
formation (Moruzzi and Magoun, 1949). It is now known that arousal is controlled by a 
diffuse network of cholinergic and monoaminergic (NA, DA and 5-HT) pathways which 
innervate wide areas of the forebrain and cortex (Robbins, 1997). 
The involvement of cholinergic mechanisms in the control of cortical activation 
dates from the well known ability of systemically administered muscarinic antagonists to 
block EEG desynchronisation during normal waking periods (Longo, 1966). This 
observation was tied to the concept of a reticular activating system by the identification of a 
projecting cholinergic cell group (mesopontine cholinergic complex) in the rostral brainstem 
by Shute and Lewis (1967). This system was proposed to mediate the major activating 
effects on cortical EEG, with the observation that cholinergic neurons in this region 
increased their firing rate during periods of EEG desynchronisation. 
The theory of cholinergic mesopontine control of cortical activation was 
consolidated with the confirmation of a major cholinergic pathway connecting the 
mesopontine cholinergic complex and the thalamus, and was enhanced by the observation 
that depolarisation of cholinergic thalamic neurons was associated with EEG 
desynchronisation (McCormick, 1989). The thalamus itself is now known to play an 
important role in cortical activation and information processing (Riekkinen et al., 1991). 
However, control of cortical activation by the mesopontine cholinergic complex was 
discredited to a significant degree with the demonstration that cholinergic neurons of the 
basal forebrain provide the main cortical innervation as well as the major afferent input to 
the reticular nucleus of the thalamus (Levey et al., 1987). Furthermore, a diffuse network of 
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intrinsic cholinergic neurons within the cortex was identified which may also be involved in 
cortical activation. A considerable body of evidence now exists supporting basal forebrain 
regulation of cortical EEG activity. Increased firing of cholinergic neurons of the NBM 
display inverse correlation with the power of cortical slow delta activity (Buzsaki et al., 
1988a). Selective lesioning of NBM cholinergic neurons produces cortical cholinergic 
deafferentiation and slowing of EEG (Buzsaki et al., 1988b) which can be partially alleviated 
by administration of muscarinic agonists or anticholinesterase drugs (Riekkinen et al., 1991). 
These ascending cholinergic projections from the NBM play an important role in 
attentional function. Following lesion of NBM, rats with approximately a 70% loss of 
cortical ChAT activity , display impaired performance 
in a5 choice continuous performance 
test of attention, involving location of randomly presented light flashes. (Muir et al., 1995). 
This behaviour is not thought to be the consequence of the loss of motor or sensory function 
but a direct deficit of attentional performance. The deficit in performance is exacerbated 
when the duration of stimulus is shortened, and is mimicked by pharmacological 
manipulations that reduce cholinergic function (Robbins, 1997). In addition, the effects of 
both lesioning and pharmacological intervention can be reversed by administration of the 
anticholinesterase physostigmine, thus defining the deficit as primarily cholinergic in nature 
(Muir et al., 1995). Impairment of performance in this task has recently been identified as 
functional deficit of the cholinergic frontal cortex (Muir, 1996, ). It is now apparent that 
different regions of the basal forebrain are involved in control of distinct cortical functions. 
Lesion of the VDB produces cholinergic deafferentiation of the parietal cortex and a 
functional impairment associated with conditional discrimination. Furthermore, loss of 
cholinergic input to the hippocampus, produced by lesion of the MS results in impairment of 
performance in working memory tasks (Robbins, 1997). 
Learning and Memory 
There is a large body of evidence to suggest the involvement of central cholinergic 
systems in learning and memory. Different fields of research have provided the empirical 
bases for the cholinergic hypothesis of learning and memory. These are behavioural 
pharmacology- the effects of cholinergic drugs on cognitive performance, behavioural 
neuroscience-the effect of brain lesions on cognitive performance and aging and dementia 
research. The last field providing the most convincing evidence, with a correlation between 
reduced cognitive performance in aging and dementia as observed in Alzheimer's disease, 
and loss of cholinergic markers in the brain (Bartus et al., 1982). 
The amnesiac effect of the cholinergic antagonist scopolamine provided some of the 
first pharmacological evidence of a role for the cholinergic system in learning and memory 
(Drachman and Leavith, 1974). Systemically injected scopolamine was observed to produce 
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amnesia in young healthy adults in a manner comparable to that observed in aged untreated 
adults. The effects could be reversed by the subsequent administration of a cholinesterase 
inhibitor. These results indicated that the cognitive deficit observed was cholinergic in 
nature. In addition, administration of pirenzepine, mecamylamine and hemicholinium all 
produced similar impairments in memory. Many subsequent experiments have been 
performed (often involving scopolamine) showing that cholinergic antagonists mediate 
impaired performance in tasks of learning and memory. More recent studies however, have 
indicated that the cognitive impairment observed with scopolamine does not directly affect 
mnemonic function but produces this deficit by inhibition of sensory, "attentional and motor 
functions. For example, in young healthy monkeys intramuscular administration of 
scopolamine produced a deficit in a delayed matching to sample task (Rupniak et al., 1991). 
The impairment showed a similar profile when the delay was lengthened or irrelevant stimuli 
were presented during the delay interval, and was similar to the performance observed in 
untreated aged rats. Administration of physostigmine enhanced the performance of 
scopolamine treated rats in the standard test but not in the prolonged delay or irrelevant 
stimuli trials. In addition, physostigmine did not enhance the performance of aged rats. 
These results suggest that the cholinergic system does not mediate short term memory in this 
task, or at least that the anti-cholinergic action of scopolamine does not affect short term 
memory. Disruption of attentional processing by scopolamine is a more likely explanation 
for these data. Further evidence is available to support the theory that mnemonic deficits 
observed following systemic administration of scopolamine may not primarily affect the 
learning and memory process but is actually the result of impaired sensory and attentional 
function (Kirk et al., 1988). The cholinergic specificity of scopolamine in producing 
cognitive deficits is also in question. Compounds such as d-amphetamine, fluoxetine and no- 
otropic drugs such as piracetam, aniracetam and diazepam have all been observed to 
attenuate memory impairment produced by scopolamine, indicating the involvement of other 
non-cholinergic neurotransmitter (Smith, 1988). A further problem with the interpretation of 
the studies detailed above concerns the specificity of action of cholinergic compounds 
following systemic injection. Systemic injection of cholinergic drugs produces 
undifferentiated effects -i. e. the entire central cholinergic system will be affected. Individual 
cholinergic pathways control qualitatively different psychological functions and therefore 
any behaviour observed following systemic administration of a cholinergic compound is 
likely to be the result of drug action on a number of different cholinergic pathways. Studies 
involving local infusion or injection of cholinergic drugs into specific brain regions 
circumvent this problem and allow a more controlled analysis of cholinergic involvement in 
learning and memory. 
Several studies have been performed in which local infusion of drugs into the 
hippocampus has been observed to impair performance in learning and memory tasks 
(Blozovski and Hennocq, 1982, Brito et al., 1983, Blokland et al., 1992). These studies 
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however, did not take into account possible impairment of attentional and motor functions 
and should be regarded as far from conclusive evidence with regard to hippocampal 
cholinergic involvement in learning and memory. Further studies involving the bilateral 
injection of scopolamine and pirenzepine into the hippocampus of rats have been performed 
(Messer et al., 1987). Scopolamine was observed to produce accuracy impairment and also 
increase the latency of response in a T-maze alternation task, whereas pirenzepine only 
caused accuracy impairment. These observations lend support to the theory of a more 
specific action of pirenzepine and involvement of the MI receptor in learning and memory. 
Additional support for this theory comes from another study in which a unilateral 
intraventricular infusion of pirenzepine impaired performance in a spatial learning task in 
rats (Hagan et al., 1987). Thus, drugs with more specific cholinergic actions appear to 
produce more specific effects on learning and memory. Further evidence involving 
muscarinic receptors in the control of learning and memory comes from the study of 
Andrews et al., (1994) in which pirenzepine, AF-DX 116 and UH-AH 37 each impaired 
performance in cognitive tasks. 
The non-specificity of systemically administered scopolamine on cholinergic 
pathways was further demonstrated by the observation that injection of scopolamine into 
selective brain regions produced different effects on memory performance. Bilateral 
injections into the hippocampus produced a delay dependent performance in a delayed 
matching to position task, while similar injections into the pre-frontal cortex produce a delay 
independent deficit in the same task. These results suggest a role for the hippocampal 
cholinergic system in short term memory with the pre-frontal cholinergic system appearing 
to affect memory by a non-specific mechanism. In this regard scopolamine appears to have a 
greater effect on working memory than on reference memory (Ingles et al., 1993). 
Intrahippocampal injections of both pirenzepine and methoctramine have been observed to 
produce deficits in working memory without appearing to have any effect on reference 
memory. In a similar study, injections of mecamylamine also produced cognitive 
impairment indicating the involvement of nicotine receptors in working memory (Ohno et 
al., 1993). As in previous studies, however, the non-specific effects of treatment on 
attentional processes, motor function and motivation were not taken into consideration. 
Further studies with scopolamine involving intraventricular infusion in monkeys support the 
theory of cholinergic disruption of attentional function in producing cognitive deficits as 
opposed to a direct effect on working memory. In a continuous performance task 
scopolamine reduced the number of responses noted with no associated decrease in 
accuracy. This effect was exacerbated when stimulus duration was shortened (Callahan et 
al., 1993). 
From the studies outlined above it is apparent that different cholinergic pathways 
within the brain are associated with different psychological functions and that systemic 
administration of cholinergic drugs such as scopolamine provide relatively little evidence to 
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support a specific role for cholinergic systems in learning and memory processes. In 
addition, the mnemonic deficits observed upon systemic administration of cholinergic drugs 
are more likely to be due to disruption of attentional function. Studies involving the 
injection of cholinergic drugs into specific brain sites have much greater value and support a 
less direct role of ACh in learning and memory. 
The hypothesis that cholinergic degeneration of the basal forebrain is responsible for 
geriatric memory dysfunction and dementia in Alzheimer's disease gave rise to studies of the 
involvement of the cholinergic system in mnemonic functions in experimental animals. 
Animal models of Alzheimer's were developed by lesioning brain cholinergic nuclei. As the 
cortical and hippocampal regions receive their major innervation from the cholinergic nuclei 
of the basal forebrain these areas were targeted for lesion studies. 
The majority of studies performed have employed the use of axon sparing neurotoxic 
excitatory amino acids, particularly ibotenic and kainic acid, to produce basal forebrain 
lesions. These compounds produce general cell body destruction in the basal forebrain 
including cholinergic cells of the NBM and are thought to be more selective than electrolytic 
or radiofrequency induced lesions. Kainic or ibotenic acid lesions of the basal forebrain have 
been found to impair memory function in a number of learning and memory tasks including 
passive avoidance including active avoidance , spatial navigation and spatial 
delayed 
matching to sample tasks. For review of these studies see Dunnett et al., (1991). These 
observations have been interpreted as lesions disturbing learning and memory processes and 
as evidence for the involvement of cholinergic systems in these processes. However, the 
cognitive deficits displayed may be the result of disruption of other cognitive or non- 
cognitive processes and may be attributable to the destruction of other non-cholinergic cell 
groups within the basal forebrain. In this regard, ibotenic acid lesions of the basal forebrain 
have been observed to produce a high mortality rate and cause a wide range of 
somatosensory and motor deficits. The location of the lesion also appears to have important 
effects on memory performance. For example, excitotoxic lesion of rat NBM results in 
impairment of reference memory leaving working memory intact while bilateral lesion of 
the hippocampus selectively disrupts working memory leaving reference memory intact. 
Evidence also suggests that the memory deficits observed are more likely to be the result of 
disruption of attentional processes (Robbins. et al., 1989). The specificity of the lesion for 
cholinergic cells has also been brought into question. In basal forebrain lesion studies 
comparing four excitotoxins, N-methyl-D-aspärtate (NMDA), kanic, ibotenic and quisqualic 
acid, all four toxins produced comparable cortical ChAT depletions. However, quisqualate 
produced fewer side effects than the others and showed greater specificity to cholinergic 
neurons. In addition, quisqualic acid produced severe deficits in a passive avoidance test but 
only ibotenic acid produced deficits in a spatial navigation test, a standard test for cognitive 
deficits induced by basal forebrain lesions (Dunnett et al., 1987). In several further studies 
these observations have been repeated(See Dunnett, et al., 1991 for review). Quisqualic acid 
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produces greater destruction of NBM-cortical cholinergic neurons than ibotenic acid as 
assayed by cortical ChAT activity, while producing significantly milder deficits in cognitive 
performance. 
An excitotoxin even more effective in destroying cholinergic NBM neurons, a-amino-3- 
hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA), has also been studied. AMPA can 
produce greater than 70% depletion of cortical ChAT activity while having minimal or no 
effect on cognitive performance. Although AMPA produces a more specific and greater 
cholinergic cell loss than ibotenic acid it should be noted that a significant loss of non- 
cholinergic cells in the basal forebrain still occurs (Page et al., 1995). 
The studies detailed above would appear to indicate that the cholinergic involvement 
in cognitive deficits observed following basal forebrain lesion has been overestimated. As 
the cholinergic specificity of the lesion increases the deficits in learning and memory are 
reduced. Therefore, while AMPA would appear to be the neurotoxin of choice to induce 
cholinergic basal forebrain lesions, a highly selective cholinergic toxin would provide 
further elucidation of the chofinergic involvement in learning and memory. 
Initial developments on a selective cholinergic neurotoxin centred on ethylcholine mustard 
aziridinium (AF64A). This compound was shown to be a selective neurotoxin for septo- 
hippocampal neurons (Fisher et al., 1982). Intraventricular injection of AF64A produced 
destruction of cholinergic neurons and reduced ChAT and ACHE activity in the 
hippocampus (Hanin, 1990). However, AF64A has been discredited as a selective 
cholinergic neurotoxin as it was found to cause gross tissue damage when injected 
intraparenchymally (Jarrard, et al., 1984 ). 
The coupling of 192 IgG, a monoclonal antibody specific for the p75 low affinity 
NGFr, to saporin, a ribosome inactivating factor, provided the first highly selective 
cholinergic neurotoxin (Wiley et al., 1991). Intraventricular infusion of 192 IgG Saporin 
produces high levels of basal forebrain cholinergic cell loss associated with minimal effects 
on monoaminergic and other cholinergic systems. In addition, intracortical injection was 
observed to produce loss of cortical cholinergic neurons as evinced by reduced AChE 
staining, without affecting non-cholinergic systems (Holley et al., 1994). Initial studies 
involving intracortical injection of 192 IgG Saporin produced impaired performance in 
spatial awareness tasks and associated reduction of ChAT activity (Nilssson et al, 1992). 
These observations lend support to cholinergic, involvement in learning and memory. In 
contrast however, specific lesion of the basal forebrain produced a high degree of 
cholinergic cell loss, with minimal non-cholinergic cell loss but no associated deficits in 
memory and learning (Wenket al., 1994). A further study with 192 IgG saporin induced 
lesion of the NBM supports the above observations, with virtually no learning and memory 
deficits shown (Torres et al., 1994). 
From the above data it is apparent that the more specific the lesion is for cholinergic cells, 
the less dramatic the effect is on learning and memory. Extrapolation of these data would 
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suggest that a completely selective cholinergic lesion would have no effect on learning and 
memory. It does however appear that the cholinergic system in the basal forebrain is 
involved in attentional rather than mnemonic processes (see previous section ACh and 
Arousal for details). 
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1.1.3 Cholinergic System In Alzheimer's Disease 
Alterations in cholinergic function, particularly the loss of mAChRs has been 
reported in a number of neurological and psychiatric conditions. These include 
schizophrenia (Tandon et al., 1991), Huntington's disease (Penney et al., 1982), Progressive 
Nuclear Palsy and Parkinson's disease (Palacios et al., 1990). However, the most consistent 
and well documented neuropathological condition associated with cholinergic degeneration 
is Alzheimer's disease. 
Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 
almost 1 in 10 individuals over the age of 65 (Evans, 1989). It accounts for over 50% of the 
senile dementia and the majority of pre-senile dementia cases and is characterised 
progressive deterioration of higher cognitive functions including the loss of memory 
(Octave, 1995). Postmortem AD brains display two distinctive neuropathological features 
which constitute conclusive diagnostic markers for AD: intracellular neurofibrillary tangles 
and extracellular neuritic senile plaques. Intracellular neurofibrillary tangles accumulate in 
neuronal perikarya and consist of paired helical filaments containing the microtubule 
associated protein tau (Delacourte and Defossez, 1986). The presence of tau in neuronal cell 
bodies represents a highly aberrant localisation of the protein, as compared to the axonal 
localisation observed in normal neurons (Kowall et al., 1987). In AD brains, tau is present 
in tangles in a hyperphosphorylated form (Grundke-Iqabal et al., 1986). The amount of 
phosphorylated tau in AD brain is several hundred fold greater to that in normal brains, 
making tau an excellent disease marker (Vandermeeren et al., 1993). 
The neuritic plaques observed extracellularly in AD brains contain amyloid peptide 
fibrils in their core. These fibrils consist of the amyloid ß or A4 (ßA4) 
peptide (Glenner et al., 1984). The ßA4 peptide is derived from a larger precursor peptide 
termed the amyloid precursor peptide/protein (APP) ,a glycosylated transmembrane protein 
with a single membrane spanning domain (Kang et al., 1987). APP is normally cleaved 
within its transmembrane domain yielding a secretory form , the exact physiological role of 
which is not entirely understood. Processing in this manner normally involves cleaving APP 
in the ßA4 domain, which consists of 15 transmembrane and 28 extracellular amino acids. 
However, an alternative processing pathway exists in which APP is cleaved at abnormal 
transmembrane and extracellular sites, generating a soluble form of ßA4 which may then go 
on to form amyloid plaques. 
In addition to these specific neuropathological features AD brains exhibit extensive cellular 
atrophy and cell loss, shrinkage of cortical thickness, enlargement of sulci and ventricles and 
changes in multiple neurochemical systems including ACh, glutamate, GABA and 5-HT. 
However, the most consistent and severe neurochemical abnormality associated with 
AD is the loss of cholinergic innervation of the cerebral cortex and hippocampus (Coyle et 
al., 1983). ChAT activity is significantly reduced in the cortex and hippocampus of AD 
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brains (Reisine et al., 1978). Post-mortem analysis of AD brains reveals that the NBM, the 
major source of cortical and hippocampal cholinergic innervation, is degenerated in AD 
(Whitehouseet al., 1982). In addition, a linear correlation between reduced cortical ChAT 
activity and degree of dementia has been observed (Perry et al., 1978). Observations such as 
these prompted Bartus et al., (1982) to propose the cholinergic hypothesis of AD in 1982, 
which specifically attributed the cognitive deterioration associated with the disease to the 
degeneration of the cholinergic basal forebrain . 
Muscarinic Receptors in Alzheimer's Disease 
The observation that the muscarinic antagonist scopolamine produces cognitive 
deficits in young healthy humans (see ACh in Learning and Memory) promoted interest in 
the expression levels of muscarinic receptors in dementia and AD. Pharmacologically 
defined binding sites have been analysed in detail in both AD and control brains post- 
mortem (see Levey, 1996 for review). Initial results were somewhat conflicting, with 
several groups reporting decreases and other groups reporting no change in receptor density. 
The reason for these discrepancies is not certain, but may be due to the use of non-subtype 
selective radioligands in the performance of the binding assays. More recently, the general 
consensus was that neither the total population of receptors (as detected by N-methyl 
scopolamine or quinuclidinyl benzilate) nor the M1 or M2 subtypes (detected using 
pirenzepine), undergo any marked change in number or affinity in AD (Perry et al., 1990). 
However, several inconsistencies in these results still exist, as these ligands do not have the 
necessary specificity to accurately distinguish between the individual mAChR subtypes or to 
spatially resolve their pre- or post-synaptic location. Several studies indicate that M1 
receptors, which are generally regarded as primarily postsynaptic, undergo no change in AD 
as determined pharmacologically by radioligand binding studies. In contrast, "pre-synaptic" 
M2 receptor levels are reduced in cortex and hippocampus in AD (Mash et al., 1985). 
The recent identification of five distinct molecular mAChR subtypes has made 
interpretation of the above results difficult with regard to the distribution of the molecular 
subtypes within the brain. A recent immunoprecipitation study has provided information on 
the expression of the molecular mAChR subtypes in AD. AA significant reduction in the level 
of mI receptor protein was observed in the cortex and hippocampus of AD brains compared 
to controls, despite unchanged levels of Ml binding sites observed in the same tissues as 
detected by [3H] pirenzepine (Flynn et al., 1995). These observations are in conflict with 
the previous theory which suggests that m1 receptor levels are unchanged in AD. The 
authors suggest that although the number of MI ligand binding sites is unchanged an altered 
form of receptor protein may be present in AD which results in reduced antibody recognition 
and the reduction in mi sites observed. In addition, they propose that the existing receptor- 
binding sites may be non-functional or functionally impaired, as the antibodies bind to the 
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third intracellular loop of the receptor a site which is critical in G-protein interaction. 
Therefore, a specific alteration at this site may have severe consequences on signal 
transduction and signal amplification following receptor activation. 
In agreement with previous ligand binding studies Flynn et al., observed reduced m2 
immunoreactivity in cortex and hippocampus, correlated with reduced M2 ligand binding 
site density. A further observation from this study was a significant increase in m4 
immunoreactivity in cortical regions. This increase in m4 sites may be responsible for the 
findings of previous ligand binding studies in which levels of Mi receptor binding was 
unchanged. The ligand binding specificity for the in 1 and m4 receptors overlap, in that they 
are both "Ml-like" . The opposing 
directions of change in the levels of these receptors in AD 
could therefore feasibly account for the apparent lack of change in Ml receptor numbers in 
ligand binding studies (Levey, 1996). 
Cholinergic Therapy of Alzheimer's Disease 
The cholinergic hypothesis of Alzheimer's disease attributes the cognitive deficits of 
the disease and their severity to the degeneration of the cholinergic pathways from the NBM 
to the cortex and hippocampus. For this reason therapies aimed at the treatment of AD have 
been generally based upon cholinergic replacement, with the aim of alleviating the 
symptoms or to slow down deterioration by attenuating the progression of the disease. 
Initial therapies were based upon the success of L-DOPA in the treatment of Parkinson's, 
with precursor loading of patients with choline or lecithin in an attempt to boost ACh 
synthesis( Wurtman, 1985). This approach was unsuccessful however, possibly due to the 
need to simultaneously increase release and inhibit breakdown of ACh. Thus far, four other 
cholinergic strategies have been investigated, including increasing ACh release, reducing 
breakdown of ACh , activating postsynaptic mAChRs and stimulation of second messengers 
(Lamy, 1994). To date, with the exception of AChE inhibitors, all of these strategies have 
met with no success, although research is on going in the development of CNS penetrative 
subtype specific mAChR agonists (Iverson, 1993). 
Cholinesterase inhibitors such as physostigmine and tacrine have been reported to 
have produced limited improvements in cognition and memory in clinical studies in some 
AD patients (Lamy, 1994). Physostigmine, one of the oldest and most studied AChE 
inhibitors, produces a small improvement in cognition of less severely demented AD 
patients (Stern et al., 1988). However, its short duration of action and common adverse side 
effects preclude its use as a major therapeutic agent for AD. Tacrine has displayed the most 
promising therapeutic effects of all AChE inhibitors studied for the treatment of AD. It has a 
longer duration of action and fewer side effects than physostigmine and produces not only a 
symptomatic improvement in AD but may also slow disease progression (Giacobini, 1994). 
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Compared to physostigmine it is a relatively weak AChE inhibitor. Therefore its ability to 
alleviate symptoms of AD is not simply a result of its ability to inhibit AChE and is due to 
other effects of the drug. Indeed tacrine is known to have multiple actions on mammalian 
brains (Lamy, 1994). A possible mechanism to explain the slower deterioration of AD 
patients resulting from tacrine treatment comes from data indicating that cholinergic agonist 
may regulate the processing and secretion of ßA4 by increasing PKC levels of target cells 
(Nitsch et al., 1992). Increasing the levels of ACh in AD close to those in normal brains may 
activate normal APP processing, thus reducing ßA4 deposition and the neurodegeneration 
associated with it (Giacobini, 1994). In agreement with this hypothesis is the observation 
that chronic treatment with the mAChR antagonist atropine (mimicking cholinergic de- 
nervation in AD) increases ßA4 content in rat cerebral cortex (Beach et al., 1996). From the 
above observations it appears that AChE inhibitors have limited efficacy in the treatment of 
AD, with limited beneficial effect in some patients with mild to moderate symptoms. They 
are however the only viable therapy presently available for the disease. For a review of 
AChE inhibitors in AD see Lamy, (1994). 
Nicotinic Receptors in Alzheimer's Disease 
With the lack of success of previous cholinergic therapies for AD generally aimed at 
increasing mAChR function, research interest turned towards nAChRs. In contrast to 
mAChRs, there is clear evidence from numerous ligand binding studies that there is a 
significant loss of nAChRs from the cortex and hippocampus in AD along with parallel 
reductions in ChAT activity (Whitehouse et al., 1986). For a review on nAChRs in AD see 
Court and Perry, (1994). 
Nicotinic receptors exist as pre-synaptic autoreceptors, activation of which enhances 
ACh release from cholinergic neurons in the cortex and hippocampus, and as such they 
present novel targets for cholinergic therapy in AD (Araujo et al., 1988). Administration of 
nicotine is observed to enhance cognitive performance (Sahakian et al., 1989) and a reduced 
occurrence of AD has been reported in populations of smokers and former smokers as 
compared to non-smoking population. These observations indicate the possible therapeutic 
and neuroprotective actions of nAChR stimulation. Problems exist with the use of nicotine 
as a therapeutic agent itself concerning the prevalent undesirable side effects associated with 
the drug, such as addiction and adverse cardiovascular effects. However, research is on 
going into the development of novel subtype selective therapeutic drugs with action at 
central nAChRs, with particular interest in the a4ß2 nAChR which is thought to represent 
the population of pre-synaptic receptors lost in AD (Abreo et al., 1996). 
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ApoE: Selective Vulnerability of Cholinergic Neurons In Alzheimer's Disease 
Although other neurochemical systems in the brain degenerate in AD, cholinergic 
neurons appear to be the most vulnerable. This selective vulnerability may be due to the 
unique nature of ACh neurons in that they use choline for two purposes: ACh synthesis and 
membrane phosphatidyl choline synthesis. The enzymes involved in both processes are 
dependent upon the concentration of choline as their rate limiting step in the formation of 
phosphatidylcholine and ACh. Therefore, in a situation where choline is in short supply and 
ACh neurons are physiologically active, synthesis of ACh transmitter will take precedence 
over membrane building, in order to sustain neurotransmission (Ulus et al., 1989). If this 
situation persists, phosphatidylcholine will be removed from the membrane to supply 
choline for transmitter synthesis-a process known as "autocannabilism" , which may 
lead to 
cell shrinkage and even death. From postmortem studies it has been found that 
phosphatidylcholine turnover is accelerated and choline availability reduced in AD brains 
(Blusztain et al., 1990). Changes in membrane composition such as this could result in the 
abnormal exposure of the transmembrane domain of APP and could feasibly be the cause of 
its abnormal processing and the production of ßA4 (Wurtman et al., 1992). 
Recently, the role of apolipoprotein E (ApoE) a lipid carrier molecule playing a key 
role in mobilisation and redistribution of cholesterol and phospholipid during membrane 
remodelling associated with synaptic plasticity and CNS injury, has been implicated in the 
pathology of AD (Poirier et al., 1991). Three major isoforms of ApoE exist, E2, E3 and E4. 
These isoforms are expressed from multiple alelles on a single gene and give rise to three 
common homozygous phenotypes c2/s2, E3/s3, c4/E4 and three heterozygous phenotypes 
62/63, s2/E4 and s3/s4 (Poirier et al., 1994). Evidence strongly suggests that possession of 
the Apos4 allele is a pre-disposition to development of AD and an indicator of poorer 
response to cholinergic therapy. The frequency of the Apos4 allele has been shown to be 
markedly increased in AD patients (Poirier et al., 1993). A gene dosage effect has also been 
observed, in that as the age of onset of AD increases, Apos4 allele copy number decreases . 
In addition, ApoE mRNA levels have been shown to be reduced in the cortex and 
hippocampus of AD brains post-mortem, with subjects of Apoc4/e4 genotype expressing 
approximately 50% of the level of ApoE compared to Apoc3/s3 or control brains (Bertrand 
et al., 1995). It is therefore reasonable to assume that ApoE associated lipid transport is 
severely compromised in AD, resulting in inefficient cholesterol and phospholipid transport 
and ultimately loss of synaptic integrity (Poirier, 1994). This loss of function may selectively 
damage the cholinergic system which, as described above, relies heavily upon intact 
phospholipid metabolism. The theory of the selective vulnerability of cholinergic neurons in 
AD is enhanced with the observations that the characteristic reductions in ChAT activity in 
the cortex and hippocampus of AD brains is proportional to the E4 allele copy number, i. e. 
as E4 copy number increases, ChAT activity decreases (Poirier, 1994 ). However, in conflict 
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with the above observations, a recent study has indicated that reductions in ChAT activity 
and nAChR number observed in AD were independent of ApoE genotype (Svensson et al., 
1997). In addition, a study with ApoE knockout mice, no deficit in central cholinergic 
activity (e. g. ChAT activity, receptor number) or cognitive performance was observed 
between knockout and wild type mice (Anderson and Higgins, 1997) despite previous report 
to the contrary (Gordon et al., 1995). 
The evidence described above indicates that the ApoE4 genotype influences the 
integrity and function of the cholinergic system in AD, with E4 carriers being at greater risk 
for the loss of cholinergic neurons and therefore also less capable of responding to 
cholinergic therapies based upon enhancing the function of remaining cholinergic neurons. 
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1.2 IMAGING OF THE CNS IN VIVO 
Techniques for brain imaging can be broadly divided into two categories: structural 
and functional. Structural techniques such as computed tomography (CT) and magnetic 
resonance (MRI) imaging, generally provide purely neuro-anatomical and pathological 
information on the brain, while functional imaging techniques such as positron emission 
tomography (PET) and single photon emission computed tomography (SPECT) allow 
compilation of functional maps reflecting the biochemistry and physiology of the brain. 
1.2.1 Structural Imaging 
Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) 
Computed tomography is a method of x-ray examination of the CNS in which a thin 
slice or planar volume of tissue is examined. In contrast to conventional radiography, the x- 
ray is collimated to a linear beam, allowing measurement of absorbance in a thin slice or 
planar volume of the brain. This decreases the superimposition of tissues and the scatter 
effects of wide-beam x-rays upon the image as in conventional radiography (Orison, 1989). 
The x-ray source coupled with detectors surrounding the head measure the amount of x-ray 
transmission passing through the region of interest, enabling calculation of the attenuation of 
the x-ray beam occurring at specific points within the brain. Digital storage and processing 
using mathematical algorithms is then accomplished with the aid of computers to re- 
construct the radiographic image. In certain instances, where a more detailed image of a 
specific area of interest is needed, the technique of contrast enhanced CT is employed. 
Contrast enhanced CT involves the intravenous injection of a radio-opaque medium that will 
absorb x-rays. The contrast medium is of high electron density and is usually iodine based. 
Contrast enhanced CT is used to increase the contrast between areas of high and low 
absorbance of x-rays on the radiographic image. It can be used to increase the image contrast 
between areas of normal and abnormal tissue that are not well defined prior to contrast 
medium infusion, such as breakdown of the blood brain barrier. 
In contrast to CT, MRI is a relatively new technique with a significantly different 
method of image production. MRI manipulates the physical phenomenon of spinning 
subatomic particles (nucleons) present in the nucleus of any atom. The intrinsic magnetic 
properties of a nucleus of any atom (and also their magnetic resonance parameters ) are 
dependent upon the proton density within the nucleus. Nuclei with even numbers of protons 
and neutrons display no significant magnetic properties as they tend to cancel each other out. 
However unpaired nuclei, with an odd number of protons, such as the hydrogen nucleus 
(single proton) are highly magnetic and also extremely useful for MRI. The hydrogen 
nucleus which is present in natural abundance in biological tissues can be manipulated for 
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MRI. When placed in a magnetic field protons will orient their spin in alignment with the 
magnetic field. Pulsing of the tissue with a radiofrequency wave at the correct frequency, 
excites the spinning protons causing them to move out of alignment with the magnetic field. 
When the radiowave pulse ends, they will revert their spin to a position of equilibrium 
within the magnetic field while simultaneously losing energy which can be detected as a 
radiofrequency or transverse magnetic field signal. This signal is then amplified and 
, 
processed by computer to reconstruct an image. A specific area of tissue emitting a signal 
can be identified by creating gradients within the magnetic field allowing the x, y and z co- 
ordinates of given value to be generated which in turn allows three dimensional 
reconstruction of the image. Images can therefore also be constructed in any plane desired. 
MRI displays several advantages over CT as a method of imaging the CNS. It makes 
use of natural non-radioactive nuclei without the use of ionising radiation to generate 
images. The images themselves are of high resolution with the absence of bone or dental 
artefacts commonly observed with CT (see Chakeres and Schmalbrock, 1992). 
Both CT and MRI are conventionally concerned with the imaging of brain pathology 
and neuroanatomy and are routinely used diagnostically for a number of CNS conditions. 
These include visualisation of cerebral contusions, oedema and haemorrhage following head 
trauma, cerebrovascular infection (e. g. meningitis), cerebral infarction of various types and 
diagnosis of cerebral neoplasms. Additionally they are both used to image the pathology of a 
number of neurodegenerative diseases including Alzheimer's disease (for review see Smith, 
1996). However, relatively recently MRI techniques have been expanded to visualise brain 
function. Using a blood oxygenation level dependent (BOLD) contrast mechanism for MRI, 
cerebral blood flow and oxygen utilisation in rat was measured. The technique is based upon 
the levels of deoxyhaemoglobin (which acts as a natural paramagnetic agent) which are 
altered by oxygen consumption and the metabolic activity of neurons during elevated 
function. Experiments such as these were subsequently repeated in cats (Turner et al., 1991) 
since which time functional MRI (fMRJ) has been successfully used to map functional 
activity in the human brain in numerous studies (for review see Kim and Ugurbil, 1997 ) 
including Alzheimer's disease (Smith, 1996). 
As a functional imaging technique, fMRI offers advantages over the more 
conventional functional imaging techniques of PET and SPECT. Theoretically fMRI offers 
higher resolution both temporally and spatially as well as allowing repeated scanning in a 
single subject without concern for the cumulative effect of multiple doses of ionising 
radiation. Furthermore, fMRI allows highly accurate comparison of functional and 
anatomical maps of the brain as both types of data may be acquired simultaneously during a 
single imaging session. 
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1.2.2 Functional Imaging 
Autoradiography 
In vivo receptor autoradiography involves the selective labelling of CNS receptors by 
the intravenous administration of a radioligand with high affinity and specificity for the 
target receptor. The first studies of in vivo receptor labelling with autoradiography utilised 
radioligands for the mapping of mAChRs with [3H] quinuclidinylbenzilate (QNB) (Kuhar 
and Yammamura, 1975), [311] diprenorphine for opiod receptors (Pert et al., 1975) and [311] 
spiperone for dopamine receptors (Kuhar, et al., 1978). These radioligands have several 
characteristics that allow them to be used for in vivo receptor labelling including rapid 
penetration into the brain from the circulation, high receptor affinity, very slow dissociation 
kinetics, antagonist activity that allows them to label all receptor affinity states high 
specific/non-specific binding ratio and ability to quantifying target by modelling its 
interaction with the radioligand. The high affinity of the ligand for the receptor results in 
retention of ligand at or on receptor molecule, allowing generation of autoradiograms which 
provide information on receptor distribution within the CNS (Kuhar et al., 1986). 
Mapping of neurotransmitter receptors in this manner has a number of important 
applications such as providing insight into mechanism of drug action, and the chemical 
organisation of the brain as well as neuropathological applications. Additionally, in vivo 
autoradiographic studies are essential for the development of PET and SPECT tracers which 
allow non-invasive imaging of CNS function in man. The ability of this technique to 
elucidate mechanisms of drug action can be illustrated by considering the well known effects 
of opiate drugs. Drugs acting at opioid receptors are known to produce a variety of effects 
including analgesia , cough suppression and respiratory 
depression as well as their 
characteristic addictive effects. Investigation of the distribution of opioid receptors among 
central neuronal circuits allows understanding of these drug effects and how they are 
produced. A significant number of autoradiographic studies mapping opioid receptor 
distribution have been performed (see Knapp et al., 1993). Opioid receptors are widely 
distributed throughout the CNS, with differential distribution between the receptor subtypes 
(c3, µ, x) observed. The nucleus tractus solitarius in the brainstem , which is crucial in 
respiratory control, is know to contain high densities of yc and to a lesser extent a opiod 
receptors. Drug action on these receptors is therefore very likely to be responsible for 
respiratory depression associated with opioid drugs. Other regions of high density include 
laminae I and III of the dorsal horn of the spinal cord, regions that are proposed to be 
involve in the analgesic actions produced by opiates (Dubner and Bennet, 1983). 
In vivo receptor mapping also has applications in assessing the neurotoxic action of 
drugs. Amphetamines are routinely used in research in psychiatric disorders, producing their 
beneficial effects by altering monoaminergic neurotransmission. However, over-use or 
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abuse of these drugs results in neurotoxicity. The extent of neurotoxicity can be estimated by 
measurement of the high affinity uptake sites situated on monoaminergic nerve terminals. 
Reduction of uptake binding site density is specifically attributed to the loss of neurons. The 
neurotoxic actions of amphetamines such as fenfluramine and the amphetamine based drugs 
3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymeth-amphetamine 
(MDMA) on monoaminergic (particularly 5-HT) neurons has been investigated in some 
depth using in vivo autoradiographic techniques (Appel et al., 1989, De Souza et al., 1990, 
Battaglia et al., 1991). Repeated administration of MDMA was observed to produce 
profound reductions in [3H]-paroxetine labelled 5-HT uptake sites in 5-HT pathways 
ascending to the cortex, striatum and hippocampus, while having no effect on [3H]-mazindol 
binding, measuring DA uptake sites, thus demonstrating a neurotoxic specificity to 5-HT 
neurons. In addition to opioid and 5-HT receptors several CNS receptor systems have been 
mapped with in vivo autoradiography. These include mAChRs with [3H] and [125I] labelled 
quinuclidinylbenzilate (QNB), nAChRs with [3H] and [125I]-a-bungarotoxin , dopamine 
D2 receptors with [3H]-spiperone, and benzodiazepine receptors with [3H] Ro15-1788 and 
Ro 15-4513 (for review see Kuhar et al., 1986). 
Aside from functional mapping of specific neurotransmitter receptors and elucidation 
of drug action upon these receptors, in vivo autoradiographic techniques can be applied to 
map metabolic activity in the CNS. The [14C]-iodoantipyrine (IAP) and [14C]-2- 
deoxyglucose (2-DG) autoradiographic techniques have made it possible to map regional 
cerebral blood flow and local cerebral glucose utilisation, respectively, within individual 
brain regions (Sokoloff et al., 1977, Sakurada et al., 1978). These techniques demonstrate 
highly localised activity dependent changes in cerebral blood flow and glucose utilisation 
with a high degree of spatial resolution, with coupling of flow and metabolism to relevant 
anatomical structures. 
The conceptual basis for metabolic mapping with [14C]_2_DG is founded upon some 
basic features of brain biochemistry. The brain is dependent almost entirely upon aerobic 
catabolism of glucose for its energy requirements, with function in any brain region directly 
related to the energy consumption within that region. As the brain can store only a very 
limited amount of carbohydrate, and its energy requirement is dependent upon the level of 
function, the energy demands must be met by aerobic catabolism of glucose continuously 
supplied by the cerebral circulation. It follows that increased metabolic activity is often 
accompanied by increased cerebral blood flow, which is necessary to meet the increased 
glucose requirements. The above techniques are therefore extremely useful tools as a 
measure of CNS function. 
Functional mapping with [14C]-2-DG has been applied to numerous areas of 
neuropharmacology, including the functional effects of stimulation or blockade of 
neurotransmitter systems such as glutamate, 5-HT, GABA and ACh. In tune with the theme 
of this thesis, some examples of functional changes induced by modulation of cholinergic 
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transmission will be discussed. Administration of the mAChR antagonist scopolamine 
depresses cerebral glucose utilisation in an anatomically selective manner (Helen and 
London, 1984). In contrast, the effects administration of the mAChR agonist oxotremorine 
produces pronounced increases in glucose metabolism primarily in brain structures 
associated with motor function, e. g. motor cortex, nigrostriatal system, globus pallidus. 
Oxotremorine produces marked tremor in experimental animals , and it appears that the 
increased glucose metabolism in brain motor control regions is associated with this motor 
dysfunction rather than as a result of drug action on cholinergic receptors (Dow-Edwards et 
al., 1981). The cholinergic agonist arecoline produces similar increases in glucose utilisation 
to oxotremorine in motor regions of the brain, but also produces significant increases in the 
hippocampus. The differences in metabolic activation induced by the two compounds are 
suggested to be the result of their differential effects on mAChR subtypes (Sonancrant et al., 
1985). Administration of nicotine also produces significant increases in glucose 
metabolism, with correlation to brain regions such as the subiculum and superior colliculus, 
that display a high density of nAChRs (London et al., 1988). Furthermore, glucose 
metabolism is significantly reduced in the cortex of animals following basal forebrain 
lesions (London et al., 1984). 
The acute and chronic functional consequences of unilateral intracerebral injection of 
excitatory amino acids into the basal forebrain has been mapped using [14C]-2-DG 
autoradiography in conscious rats (Browne et al., 1998). Acute stimulation of NBM neurons 
by injection of AMPA significantly reduced glucose use in 9 cortical regions innervated by 
NBM efferents, including the frontal, sensory-motor and cingulate cortices. Acute 
stimulation of NBM neurons by NMDA injection reduced glucose use in only two cortical 
regions, however, NMDA injection was additionally observed to reduce glucose utilisation 
in a number of cortical regions (including frontal and parietal cortices) contralateral to the 
injection site. In contrast, injection of the GABAA agonist muscimol into the NBM had no 
effect on glucose utilisation in any of the associated cortical regions. Assessment of 
excitotoxic lesions 3 weeks after injection of AMPA, NMDA, ibotenic acid or quisqualic 
acid into the NBM indicated no significant alterations in glucose use, suggesting long term 
compensatory functional adaptation occurs following cortical de-nervation. These 
observations support the view that AMPA receptors are co-localised with basal forebrain 
cholinergic neurons to a greater extent than other glutamatergic receptor subtypes. 
PET and SPECT 
Quantitative imaging of functional and pathological processes in the living 
mammalian brain has recently become feasible through the development of PET and SPELT 
imaging techniques. PET and SPECT are non-invasive tomographic methods for imaging the 
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emitting radionuclides such as [11 C], [13N] and [I 8F] which allows them to be substituted 
into compounds of biological interest without altering their basic pharmacology. This is of 
distinct advantage when using radiotracers to describe the chemistry of a biological process. 
However, these radionuclides have a very short half-life (e. g. [ 13N] t 1/2 = 9.96 mins) 
which necessitates on site cyclotron and radiochemistry facilities to produce the 
radionuclides and synthesise the tracers. PET scanners detect the brain distribution of 
radioactivity by means of externally placed banks of paired detectors that register co- 
incidental energy (in form of 2? rays) from the annihilation of emitted positrons with 
electrons. Tomographic techniques similar to those employed in CT are then used to 
reconstruct an image from the y rays produced. Because of the simultaneous emission of two 
y rays in exactly opposite directions, images of high resolution can be constructed. 
SPECT employs similar principles to those used in PET, with the main difference 
being the nature of the radioisotope used to label tracer compounds. SPECT utilises y or 
photon emitting radioisotopes such as [123I] and [99m Tel in conjunction with a rotating y 
camera or multiple detector rings to register emitted activity. In contrast to PET, the 
synthesis of radioligands is relatively simple as the half life of the compounds is 
considerably longer (e. g. [1231] t 1/2 = approx. 13.2 hours) which also facilitates ease of 
scanning. The radioisotopes are also available commercially making SPECT scanning 
considerably cheaper. However, addition of these large radioisotopes into biological 
compounds may alter the pharmacology and biodistribution kinetics of the labelled ligand. 
Therefore a great deal of effort is employed in the synthesis of chemical structures that are 
lipophilic while retaining pharmacological action. One other disadvantage of SPECT is its 
reduced spatial resolution compared with PET, due to incomplete correction for attenuation 
and scatter of activity signal. With the use of the correct collimator, resolution can be 
improved at the expense of sensitivity, resulting in longer scanning time. Therefore it is 
necessary to obtain a balance between sensitivity and spatial resolution. 
Radioligands for PET and SPECT have to satisfy a number of criteria, very similar 
to those for ligands used in vitro homogenate binding studies, before they are acceptable for 
use in human studies. These include: (1) Saturability of the receptor site of interest by 
radioligand such that increasing doses of unlabelled ligand will displace binding of 
radioligand. (2) Appropriate competition by various radioligands known to bind to the 
receptor of interest. (3) Regional distribution of radioligand consistent with the known 
pattern of neurorceptors. In addition the ligands must be of sufficiently high specific activity 
to aid detection as receptor densities in the CNS are very low. 
A number of ligands for imaging neuroreceptor systems, neurotransmitter 
precursors, neurotransmitter enzymes and transporters are now available for use with both 
PET and SPECT . These techniques have a number of clinical applications including 
measurement of cerebral blood flow, glucose metabolism, neuroreceptor mapping and 
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monitoring of drug treatment, allowing investigation of the physiology and pathophysiology 
of the human brain. 
The use of [11C] N-methylspiperone to label dopaminergic D2 receptors with PET 
was among the first reports of in vivo receptor visualisation in humans (Wagner et al., 1983). 
Subsequent studies, combined with mathematical modelling, in which the experimental 
paradigm involved prior administration of neuroleptic drugs to inhibit radioligand binding, 
followed by a second scan in the control state (no drugs), allowed calculation of receptor 
density and affinity (Wong et al., 1986a , Wong et al., 1986b). Dopamine D2 receptors have 
also been mapped successfully in humans with 123I-(S)-N-(1-ethyl-2-pyrrolidinyl) methyl- 
2-hydroxy-3-iodo-6-methoxy benzamine (123IBZM) and SPECT (Kung et al., 1990). The 
D2 receptor is implicated in a number of neurologic and psychiatric conditions such as 
schizophrenia, manic depression, Parkinson's disease, Huntington's disease, and in drug 
abuse, thus imaging of this receptor is of clinical importance. The clinical utility of 
functional imaging with PET and SPECT has been demonstrated by visualisation of 
dopaminergic transmission in conditions such as schizophrenia and Parkinson's disease. For 
example, clinically effective doses of chemically distinct neuroleptic drugs known to 
produce their beneficial effects at D2 receptors were observed to display 85-90% occupancy 
of D2 receptors in the putamen of schizophrenic patients (Farde et al., 1986). Additionally, 
the loss of D2 receptors in Parkinson's sufferers has been quantified with the use of ['8FJ- 
spiperone (Hantraye et al., 1986). Dopamine synthesis, the dopamine transporter and Dl 
receptors can also be imaged with a variety of radioligands with both PET and SPECT. 
A number of other neuroreceptor systems can be visualised with both PET and 
SPECT. These include 5-HT2 receptors with [11C]- ketanserin and N-1-[11C]-methyl-2-Br- 
LSD ([11C]-MBL) with PET (Baron et al., 1985, Wong et al., 1987). SPECT ligands for 5- 
HT2 receptors are based upon LSD analogues such as [ 1231]-ethyl-LSD which displays high 
levels of specific binding in animal models. These receptors are implicated in 
neuropsychiatric disorders, behavioural dysfunction and drug abuse and are therefore of 
clinical importance. 
PET imaging of opioid receptors was first demonstrated with the use of [ 11 C]- 
carfenatil which is highly selective for they receptor subtypes (Frost et al., 1985). Based on 
animal studies implicating opioid receptors in epilepsy, a PET scanning study on epileptic 
patients with this radioligand revealed increased ligand uptake in cortical sites ipsilateral to 
seizure focus, suggesting that epilepsy could be related to upregulation of opioid receptors 
(Frost et al., 1988). Benzodiazepine receptors have been imaged in primate and man using 
[1231]-iomazenil with SPECT and with PET using [11C]-flunitrazepam and [11C]-Ro-15- 
1788 
. 
Much interest has centred upon imaging of the central cholinergic system and in 
particular mapping of cholinergic receptors, due to the associated degeneration of this 
neurotransmitter system in Alzheimer's disease. Muscarinic cholinergic receptors were first 
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imaged in man with SPECT using [1231] -QNB and a few years later with [11C]- 
scopolamine in PET ( Eckelman et al., 1984a, b, Frey et al., 1987). Distribution of binding 
was consistent with data from autoradiographic studies and the known cholinergic pathways 
within the CNS. Since then a great deal of effort has been applied to the development of 
novel mAChR ligands for use with PET and SPECT, with particular emphasis on the 
development of subtype selective mAChR ligands. Recently however, interest has moved 
towards development of nAChR ligands which have been successfully imaged with [11C]- 
nicotine for PET in animals (Nordberg et al., 1989). Imaging of the cholinergic system will 
be discussed in greater detail in the next section. 
PET and SPECT techniques can also be applied to measure cerebral blood flow and 
glucose utilisation in discrete brain regions within man. Measurement of rCBF with PET and 
SPECT is based upon the same principles as the autoradiographic technique of Sakurada et 
al, (1978) using the freely diffusible tracer [14C]-LAP (see Methods: Theory of rCBF). With 
PET radioactive water H2[150] or [150]-butanol are used to measure blood flow (Fox et 
al., 1984, Berridge, et al., 1991). With SPECT, rCBF may be measured using the [133Xe] 
clearance technique, which involves inhalation of the inert radioactive Xe (Celsis et al., 
1981) or by use of more conventional injectable radioactive tracers such as [1231]-isopropyl- 
p-iodoamphetamine (1IMP), [99mTc]-d-L-Hexamethylpropyleneamine (HMPAO) and 
[99mTc]-Ethylcysteinate Dimer (ECD) (Hill, et al., 1984, Neirinckx et al., 1987, Holman et 
al., 1989). Glucose utilisation has also been mapped in man using ligands such as [18F]- 
fluorodeoxyglucose with PET, which is based upon the same principles as [14C]-2-DG 
(Phelps et al., 1981). These techniques have been applied to mapping of cerebral function in 
a number of physiological and pathological conditions in man including Alzheimer's disease 
(for review see Waldemar, 1995). 
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1.2.3 Imaging Of Cholinergic Neurotransmission In Vivo 
ACh, Acetylcholinesterase and the Vesicular ACh Transporter 
During the past decade considerable effort has been made in the development of 
radiopharmaceuticals for the in vivo study of cholinergic neurotransmission with PET and 
SPECT. The synthesis of more selective and specific radioligands, together with the . 
development of more efficient PET and SPECT cameras have provided new possibilities for 
clinical investigation of cholinergic neurotransmission in the physiology and pathology of 
the human brain (Maziere et al., 1995). Ligands are available or are in development that 
allow in vivo imaging of nearly all aspects of cholinergic neurotransmission from the 
synthesis of endogenous ligand to distribution and activity of the catabolic enzyme AChE. 
Direct labelling and visualisation of ACh itself is not possible due to the high dilution 
that occurs with endogenous unlabelled ligand, however attempts have been made to study 
the ACh synthesis in vivo. PET studies performed in monkeys with the ACh precursor 
choline labelled with [11C] have have been successful to a limited degree. A low uptake of 
radioactivity by brain (less than 1% of injected dose) along with a very rapid metabolism of 
newly synthesised [11C]-ACh was observed. These observations combined with a lack of 
specificity for cholinergic brain regions indicate limited clinical applications for this 
technique. 
Imaging of the distribution and activity of AChE, the catabolic enzyme for ACh, has 
met with greater success. Interest in the localisation and function of this enzyme is based 
upon the dramatic decrease of enzyme activity observed in the brains of patients with 
neurodegenerative diseases such as Huntington's and Alzheimer's. The therapeutic use of 
AChE inhibitors such as tacrine (THA) in AD provides a clinical basis on which 
visualisation of enzyme function is desirable, as this would enable determination of, drug 
efficacy and elucidation of mechanism of action. Autoradiographic studies with [3H] and 
[ 14C] labelled THA demonstrated distinct binding sites of high and low affinity for THA in 
the brain, with neither of these sites co-localised with AChE activity . PET studies in baboon 
using an [I 1C] methylated derivative of THA (MTHA) displayed a similar divergence of 
localisation from that of AChE. High levels of binding were observed in the cortex and basal 
ganglia compared to the cerebellum, with binding inhibited or displaced by administration 
of non-radiolabelled THA (Tavitian et al., 1993). [11C]-MTHA should therefore be useful in 
determining the sites and method of action of THA. An [1 1C] labelled form of the classical 
AChE inhibitor physostigmine has also been developed for imaging of AChE distribution in 
the brain. In a combined AChE histochemistry and autoradiographic study in rat, the 
distribution of [1 'C]-physostigmine was superimposable on the pattern of ACNE staining in 
the same sections (Planas et al., 1994). In PET studies in primates [11C]-physostigmine 
displayed blood flow dependent uptake into the brain followed by redistribution of 
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radioactivity to AChE-rich brain regions (Tavitian et al., 1993). These studies indicate the 
potential of this compound as a marker for alterations in cholinergic transmission observed 
in neuropathological conditions. Activity and distribution of AChE has also been mapped in 
man with [11C] -methylpiperidinyl propionate (PMP) (Frey et al., 1997). 
Cholinergic neurons and specifically cholinergic nerve terminals, can be mapped 
with ligands that selectively radiolabel the vesicular ACh transporter. The vesicular ACh 
transporter removes newly synthesised ACh from the cytoplasm in nerve terminals and 
concentrates it in synaptic vesicles ready for release. This process is inhibited by the 
compound vesamicol. Autoradiographic studies with 2-(4-phenylpiperidino-cyclohexanol 
(AH 5183) have demonstrated vesamicol binding sites highly localised to cholinergic nerve 
terminals (Marien et al., 1987). Ligands for both PET and SPECT based upon the non-toxic 
trozamicol, a pharmacologically inactive precursor of vesamicol have been developed. Two 
SPECT ligands are available [123I1-HIPP and (1231]-m-iodobenzyltrozamicol and one PET 
ligand [18F]-fluorobenzyltrozamicol (Efange et al., 1993a, Efange et al., 1993b , Efange et 
al., 1993c). Results indicate that these radiotracers can be successfully used as markers of 
presynaptic cholinergic innervation (Maziere, 1995). 
Nicotinic Receptors 
Nicotinic receptors are widely distributed in the mammalian brain and fulfil a 
number of physiological roles including pre-synaptic modulation of ACh release and an 
involvement in learning and memory. In addition, loss of nAChR number is implicated in 
the pathology of AD. They can be labelled in vivo with high affinity in mice by injection of 
[3H]-nicotine which displays rapid brain uptake and a pattern of distribution similar to that 
of [3H]-ACh (Brouselle et al., 1989). Nicotine has also been labelled with [11C] for use in 
PET and nAChRs have been visualised in monkeys and in man with this ligand (Nyback et 
al., 1989). In AD patients uptake of [11C]-nicotine is reduced in cortical areas compared to 
the uptake observed in age matched controls (Nordberg et al., 1990). This reduction in 
uptake is thought to be related to the loss of nAChRs observed in AD brains post-mortem. 
Although uptake into the brain is good and distribution is similar to that of [3H]-nicotine 
following intravenous administration, [11C]-nicotine displays high levels of non-specific 
binding, very rapid loss of radioactivity from brain tissues and rapid metabolism (Nyback et 
al., 1994). It is therefore less than ideal for imaging of nAChRs. Considerable effort is 
currently being invested in the development of nAChR ligands suitable for use in PET and 
SPECT which display a greater specific/non-specific binding ratio and a more favourable 
kinetic and metabolic profile. A PET study evaluating the high affinity nAChR agonists N- 
[1ICI-ABT 418 and N-[11C]-methylcytisine was attempted in baboons. However, both 
ligands displayed low levels of uptake into the brain combined with rapid washout of 
radioactivity from brain tissues and rapid metabolism of tracer making visualisation of 
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receptors impossible (Valette et al., 1997). More favourable results were forthcoming with a 
series of [3H] labelled nicotine analogues including [3H]-(R, S)-5-isothiocyanonicotine and 
[3H]-(R, S)-5-aminonicotine, which have been evaluated in vitro and in vivo and appear to 
possess the appropriate attributes for potential PET and SPECT ligands (Kim et al., 1996). A 
lot of interest is currently centred upon developing the high affinity nAChR agonist 
epibatidine, an alkaloid naturally occurring in frog skin, as a ligand for in vivo use with PET 
and SPECT. Epibatidine has been labelled with [3H] and evaluated in vitro where it 
displays very high affinity for nAChRs and extremely low non-specific binding (Perry and 
Kellar, 1995). A [3H] labelled analogue (+)-norchloroepibatidine has also been developed 
and evaluated in vitro and in vivo in mice where it displays similar high specificity and low 
non-specific binding with a similar distribution to [3H]-nicotine in vitro (Scheffel et al., 
1995). [125I] and [ 1231] radiolabelled forms of IPH, an epibatidine analogue, have been 
studied in vivo as a potential SPECT ligand for nAChRs (Musachio et al., 1996). 
Epibatidine and its analogues appear thus far to be the most promising candidate ligands for 
the visualisation of nAChRS in vivo. However, other nAChRs such as [18F]-Exo-2-(2- 
fluoro-5-pyridyl)-7-azabicyclo [2.2.1] Heptane for PET and [125/1231]. (-)-iodonicotine for 
SPECT are additionally available (Horti et al., 1996, Saji et al., 1993). 
Muscarinic Receptors 
Many investigations have pursued the imaging of mAChRs in the brain (for review 
see Maziere, 1995). Potent mAChR antagonists, many of which are ligands commonly used 
for in vitro autoradiographic studies have been labelled as potential tracers for PET and 
SPECT. In particular quinuclidinyl, piperidinyl and tropanyl esters of benzillic acid which 
display high affinity for mAChRs have been used. In man, mAChRs were first visualised by 
external means with the use of [123I]-QNB (Eckelman et al., 1984a). This ligand was 
subsequently used to study mAChRs in AD where a moderate loss of mAChR function was 
reported compared to an age matched control (Holman et al., 1985). 
Since then a number of ligands have been used successfully for both PET and 
SPECT to image mAChRs in the living brain, including [11C] and [18F]-QNB, [11C]_ 
benztropine, [11C]-scopolamine, [11C]-n-methyl-4-piperidinyl benzilate (NMP) and [1231]- 
iododexetimide (Prenant et al., 1989, Wilson et al., 1989, Dewey et al., 1990, Frey et al., 
1992, Mulholland et al., 1995). PET studies with [11C1-QNB in baboon demonstrated 
distribution of tracer in the brain corresponded to the pattern of mAChR localisation as 
evinced from in vitro and in vivo binding studies, with high concentrations of radioactivity 
located in the cortex and striatum and low levels of residual activity, indicative of non- 
specific binding, observed in the cerebellum (Varastet et al., 1992). Additionally, 
administration of mAChR antagonists such as atropine or dexetimide resulted in 
displacement of binding from the cortex and striatum while no changes were observed in the 
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cerebellum. These observations support the utility of this ligand in the accurate imaging 
mAChR distribution within the CNS. 
Quantitative estimation of cerebral mAChRs was investigated in AD with [11C] 
(+)2a-tropanyl benzilate ([11C]-TRP) and PET. Observations suggested a selective loss of 
mAChR in cortex of AD patients. However, the kinetic properties of the ligand, high binding 
rate relative to transport and slow dissociation kinetics make accurate regional estimation of 
mAChR density difficult, limiting the clinical use of this ligand (Koeppe et al., 1994 ). A 
similar problem is seen with [l 1C]-scopolamine (Frey et al., 1992) and with [123I]-QNB 
(Wyper et al., 1993) prompting the search for a ligand with more suitable kinetics which 
would attain equilibrium conditions more rapidly. To this end, [11C]-NMP was developed 
and evaluated as potential ligand for imaging of mAChRs (Mulholland et al., 1995). NMP 
displays greater brain uptake than TRP combined with more favourable kinetic parameters 
for quantifying mAChR number in the brain. 
The potent mAChR antagonist dexetimide and its inactive enantiomer levetimide 
have been radiolabelled for use with both PET and SPECT with [11C] and [123I] 
respectively (Dannals et al., 1988, Wilson et al., 1989). Furthermore, two [18F] labelled 
fluorine analogues, 2-fluoro- and 4-fluoro-dexetimide and a bromine analogue [76Br] 4 
-bromodexetimide, have also been synthesised (Hwang et al., 1991, Kassiou et al., 1995). 
In rats both of the fluorine analogues and the bromine labelled compound displayed high 
specificity for mAChRs in the brain. However, 2-fluoro-dexetimide also displayed rapid de- 
fluorination in vivo making it unsuitable as a PET ligand. In contrast the bromo-compound is 
very stable in the brain. In baboons, [76Br]-4-bromodexetimide shows rapid brain uptake, 
with high retention of tracer in cortical regions compared to a rapid washout of tracer from 
cerebellum during the experimental period. In addition, radioactivity could be displaced 
from cortical regions following intravenous administration of cold dexetimide indicating 
high specificity of the tracer for mAChRs. Evaluation of [1231]-iododexetimide in mice 
indicated its suitability as a mAChR ligand for SPECT including stereospecificity for 
mAChRs (Wilson et al., 1989). An advantage of using [1231]-iododexetimide with SPECT 
to image mAChRs in human brain is that the distribution of the ligand represents almost 
entirely specific binding to mAChRs. In contrast, the distribution of [1231]-iodolevetimide 
the inactive enantiomer, represents non-specific binding. This allows subtraction of data 
from images obtained with levetimide from those obtained with dexetimide permitting an 
extremely accurate measurement of specific binding. This is of obvious benefit when 
attempting to quantify small changes in receptor number such as those apparent in AD. 
The majority of the tracers discussed above, while having good brain penetration and 
retention and distribution consistent with the known pattern of mAChRs in the brain, display 
poor selectivity for the mAChR subtypes. With the loss of M2 receptors observed in AD 
development of tracers with this subtype selectivity are highly desirable as they would be 
likely to provide data useful for the diagnosis and monitoring of this disease. Considerable 
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effort is therefore being channelled into development of M2 selective ligands for use in PET 
and SPECT. The mAChR antagonist QNB although a non-selective ligand has four 
diastereoisomers displaying different affinities and kinetic parameters for binding to 
mAChRs . It has been proposed that with careful protocol design preferential imaging of M2 
mAChRs should be possible with proper manipulation of the kinetics of the diastereoisomers 
(Gibson et al., 1989). However, more direct strategies have been used to develop subtype 
selective mAChR ligands. These include attempts to increase the blood-brain barrier 
permeability for existing subtype selective analogues (Gisler et al., 1992, Doods et al. 1993) 
and modifying more permeable ligands to have higher selectivity (Baumgold et al., 1991). 
Attempts were made to synthesise a series of novel mAChR ligands with subtype selectivity. 
This resulted in a number of 3-(3-substituted-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1- 
methylpyridines (substituted -TZTP) including xanolemine and butylthio-TZTP which 
demonstrated M1 selectivity. These compounds have subsequently been labelled with [11 C] 
and evaluated in monkeys with PET (Farde et al., 1996). Both ligands displayed high uptake 
into brain and localised predominantly in the cortex and striatum. An analogue of QNB, in 
which the phenyl ring has been replaced with an iodopropenyl substituent (IQNP) has also 
been prepared (McPherson et al., 1994) IQNP displays high specificity for M1 mAChRs in 
vitro and in vivo, and is a potentially useful ligand for SPECT. An M2 selective ligand 3-(3- 
(3-[18F] fluoropropyl) thio)-12,2,5 thiadiazol-4-yl)-1,2,5,6-tetrahydro-l-methylpyridine 
([ 18F] FP-TZTP) has been synthesised and evaluated in vitro and in vivo (Kiesewetter et al., 
1995). The ligand displays greater than 3 fold affinity for M2 over M1 receptors and the 
biodistribution of tracer is consistent with that of M2 rather than M1 receptors. [18F] FP- 
TZTP is therefore a very promising ligand for the visualisation of M2 receptors in man with 
PET. 
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1.2.4 3-Quinuclidinyl-4-Iodobenzilate (IQNB) 
Quinuclidinyl benzilate (QNB) is a high affinity mAChR antagonist. In a non- 
radiolabelled form it is non-subtype selective and displays a Ki value of between 0.032nM 
and 0.2nM in vitro with individual receptor preparations [see Table 4]. The iodinated form of 
QNB was originally developed for use as a radioligand for the imaging of myocardial 
mAChRs (Rzeszotarski et al., 1982). In a subsequent competition study with [3H]-QNB, 
iodo-QNB was observed to display high affinity for mAChRs in the caudate of rabbit brain 
as well as for mAChRs in the heart, indicating its potential as a ligand for the imaging of 
central mAChRs (Gibson et al., 1983). Iodo-QNB radiolabelled with [123I] and (125j] was 
successfully synthesised and evaluated. Distribution of radioactivity in rats was confined to 
organs known to have high densities of mAChRs (Rzeszotarski et al., 1982). Subsequent 
studies have provided evidence to suggest receptor-mediated localisation of radioactivity. 
Following intravenous administration in rats [125I]-QNB shows high tracer uptake in the 
cortex and cerebellum with maximum concentration reached after 30 mins. In the caudate no 
washout of radioactivity is observed up to 4 hours after administration, correlating with the 
high density of mAChRs known to exist in this brain region. In contrast greater than 90% of 
radioactivity is lost from the cerebellum by 4 hours, ' consistent with the low level of 
mAChRs present in this region, suggesting initial tracer uptake into this brain region 
corresponds to non-specific binding (Gibson et al., 1984a). Additionally, with in vivo 
competition studies, co-injection of cold tracer or another mAChR ligand, blocks tracer 
localisation in target tissues such as the cortex and caudate (Gibson et al., 1984a, Eckelman 
et al., 1984b). 
Both the non-iodinated parent compound QNB and iodo-QNB exhibit 
stereoisomerism. QNB has one chiral centre about the 3-carbon atom in the quinuclidinyl 
moiety of the compound (Fig 4. ), creating two stereoisomers (R)- and (S)-QNB. The (R) 
isomer displays approximately 100 greater fold affinity for mAChRS than the (S) isomer 
(Meyerhoffer, 1972). Introduction of an iodine to one of the phenyl rings in the QNB 
structure results in a second chiral carbon in the benzillic acid moiety (see Fig 4. ). Therefore, 
iodo-QNB has four diastereomeric forms each of which displays different affinity and 
binding kinetics for mAChRs. The chiral centre on the quinuclidinyl moiety has greatest 
influence on the kinetic parameters of the individual diastereoisomers and is therefore 
always quoted first when assigning stereochemistry to iodo-QNB. As with QNB the (R) 
configuration at the quinuclidinyl centre confers greatest affinity for mAChRs, thus iodo- 
QNB has two high affinity (R, S) and (R, R) and two low affinity (S, S) and (S, R) 
diastereoisomeric forms (Rzesotarski et al., 1988). The binding kinetics and affinities of the 
diastereoisomers (particularly the high affinity (R, S) and (R, R) forms) have been 
characterised in a number of in vitro and in vivo binding studies. In vitro (R, R, S) [1251]- 
QNB (i. e. compound is of undefined/racemic stereochemistry at benzillic chiral centre) 
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Structure Of 3-quinuclidinyl 4-iodobenzilate 
N 
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Fig 4: Structure of four diastereoisomers of IQNB. Each diastereoisomer displays different 
affinity and binding kinetics for mAChRs. (R) configuration at the quinuclidinyl moiety 
confers greatest affinity for mAChRs, therefore IQNB has two high affinty 
diastereoisomers (R, S) and (R, R) and two low affinity diastereoisomers (S, S) and (S, R) 
with the rank order of affinity for mAChRs (R, S)> (R, R)> (S, S)> (S, R). * indicates chiral 
carbon atom. 
Table 4 
Affinity Of QNB Compared To Other Muscarinic Antagonists 
M1 M2 M3 
Antagonist Ki (nM) Ki (nM) Ki (nM) 
R-QNB 0.032 0.13 0.2 
Atropine 0.2 0.7 - 
Pirenzepine 0.37 7.1 2.5 
AF-DX 384 31 6 66 
4-DAMP 0.58 3.8 0.52 
Table shows the affinity constant for a number of mAChR antagonists derived from 
displacement of [3H]-N methyl scopolamine binding to bovine striatal membrane , rat 
myocardium membrane and rat pancreatic membrane preparations (R-QNB, for Ml, M2 and 
M3 receptors and atropine for M1 and M2 receptors) and displacement of [3H]-N methyl 
scopolamine binding to Ml, M2 and M3 receptors expressed in Chinese hamster ovary cells 
(pirenzepine, AF DX 384 and 4-DAMP). Ki values for R-QNB are in the subnanomolar 
range for all mAChR subtypes indicating high affinty for each receptor. 
Ki values are taken from Rzeszotarski et al., (1988) and Dorje et al., (1991). 
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displayed high affinity for mAChRs in membrane receptor preparations of rat and dog 
caudate-putamen and of dog heart (Gibson et al., 1984b). In a combined in vitro and in vivo 
study, the binding parameters and regional distribution of the two high affinity 
diastereoisomers were examined (Gibson et al., 1989). Following intravenous injection into 
rats, distribution of both (R, S) and (R, R) [1251]-QNB was consistent with pattern of 
mAChRs in the CNS, with high uptake of radioactivity in the cortex, hippocampal and 
caudate and low uptake in the cerebellum. In contrast however, (R, R)-IQNB displayed a 
considerably faster washout from brain tissues than (R, S) indicating lower affinity for 
mAChRs. The in vivo behaviour of the ligands was reflected in vitro, with the ligands 
displaying considerably different binding kinetics. Estimation of the in vitro equilibrium 
association constant (Kp) indicates that (R, S)-IQNB has approximately 3 fold higher affinity 
for mAChRs than (R, S), with KA of 8.9 x 109 M-1 and 2.9 x 109 M-1 respectively. This in 
itself is a relatively small difference in affinity, but the estimated rate constants are markedly 
different. The calculated dissociation rate of (R, S) (k_1 _0.0049 min-1) is 13 fold slower 
than that for (R, R) (k_1 = 0.0654 min-1). The calculated association rate of (R, S) (k+1 =1 
1.9 x 10-8 M-1 min-1) 2.5 fold slower than (R, R) (k4. l =4.4 x 107 M-1 min-1). A similar 
study was performed to estimate the binding parameters of (R, S)- and (R, R)-IQNB to 
transfected cell membranes expressing individual mAChR subtypes (Zeeberg et al., 1991). 
In this study the equilibrium dissociation constant (KD) and association (k+l) and 
dissociation (k_ 1) rates were estimated for both diastereoisomers for binding to m 1, m2 and 
m3 receptors. Both ligands displayed a similar degree of high affinity for all receptor 
subtypes and in general k+I and k_ I values for binding to m1 and m3 receptors were similar. 
In contrast however, both ligands displayed faster dissociation rate from m2 receptors, 
indicating a slight specificity for ml type receptors. A further study characterising the in 
vitro and in vivo behaviour of (R, S)-IQNB reported similar results to the study above, with a 
more rapid washout of tracer associated with brain regions expressing M2 receptors. The 
authors suggested that the difference in dissociation kinetics observed may be of use when 
designing imaging protocols to allow selective imaging of M2 receptors (Gibson et al., 
1992). The data outlined above confirm that the (R, S) diastereoisomer of IQNB displays the 
highest affinity for mAChRs. Sawada et al., (1990b) performed a complete kinetic analysis 
of (R, RS) and (S, RS)-[125I]QNB in vivo in rats. Two sets of experiments were performed 
evaluating the washout of ligands from brain following intracarotid injection and brain 
uptake and retention of ligands following intravenous injection. Data was analysed using 4 
compartmental models incorporating blood-brain barrier transport, non-specific binding to 
tissue and high and low affinity binding to mAChRs. Results indicate that (R) and (S) 
ligands have similar transport rates into the brain and therefore IQNB is not subject to 
stereospecific transport. Uptake and retention of (S)-IQNB in brain structures was 
considerably less than that of (R)-IQNB. A fairly low uniform distribution of radioactivity 
was observed throughout the brain indicative of low affinity for mAChRs. Washout of (S)- 
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IQNB from brain structures is also considerably more rapid than that observed with (R)- 
IQNB. (R)-IQNB displays high uptake and retention in brain structures relative to their 
mAChR concentration, with high levels observed in the cortex and caudate, intermediate 
levels in the thalamus and low levels in the cerebellum. The concentration of ligand 
observed in the cerebellum, although considerably lower than in cortex or caudate, was 
higher than that of (S)-IQNB. This observation is consistent with the higher affinity of (R)- 
IQNB for mAChRs and indicates binding to a population of low affinity sites which are 
possibly of the M2 subtype. The intermediate level of binding observed in thalamic regions 
is reflected in the washout out of ligand from this region, which is more rapid than cortex or 
caudate but slower than cerebellum. This is consistent with the presence of a mixed 
population of high and low affinity binding sites within this region. The observations above 
indicate that the stereochemistry of IQNB confers a degree of subtype selectivity for 
mAChRs (i. e. M1 selectivity) as well as influencing the affinity of the ligand for receptors. 
It should be noted at this point that the stereochemical designation employed in this 
thesis and when referring to previous publications is in accordance with the corrected 
stereochemistry for iodo-QNB of Kiesewetter et al., (1996) and Zeeberg et al., (1997). In 
recent years a degree of confusion has existed as to the correct stereochemical assignment of 
the diastereoisomers of iodo-QNB in papers published before 1993. The original 
stereochemical assignment of the benzillic acid centre was incorrect, resulting in (R, S)- 
IQNB being wrongly identified as (R, R)-IQNB. This error has since been identified and the 
stereochemical assignment corrected, based upon x-ray crystallography and the in vivo 
behaviour of the ligands. Thus, the rank order of affinity of the 4 diastereoisomers of IQNB 
for mAChRs is (R, S) > (R, R) > (S, S) > (S, R). 
Since the first report of imaging of mAChRs in man with SPECT the technique has 
been applied in a number of studies attempting to quantify changes in mAChRs in dementia 
(Eckelman et al., 1984a). The first study performed with an AD patient compared regional 
brain uptake of [1231]-QNB and cerebral blood flow measured with [123I]-IMP (Holman et 
al., 1985). In AD reductions in blood flow were observed in the temporal and parietal cortex 
compared to age matched control. The uptake and retention of IQNB in both control and AD 
was consistent with the pattern of mAChR density, with a moderate reduction in activity in 
the temporal-parietal cortex observed in AD brain, suggesting a reduction in mAChR 
binding. The authors reject the theory that tfie, reduction in IQNB retention in this brain 
region is a blood flow mediated event on the basis that the radioactivity observed in the 
cerebellum is considerably lower than in the cortex at this time point, despite the two regions 
having relatively similar rates of blood flow. Data from the scans was obtained up to 15 
hours after intravenous administration of the tracer, with the IQNB content of the brain 
observed to rise slowly over this time. Information on the subtype selectivity of IQNB could 
not be determined as no dissociation from putative M2 receptors could be observed. A 
number of other studies with AD patients have confirmed the focal reduction in IQNB 
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uptake in the temporal-parietal cortex of AD with an associated increase in 
striatum/cerebellum ratio with time (Weinberger et al., 1990a, b). A further study by 
Weinberger et al., (1991) reports similar deficits in IQNB uptake into temporal-parietal 
cortex of AD brain, while control brains display high uptake in the basal ganglia and cortex, 
low uptake in the thalamus and negligible uptake of radioactivity in the cerebellum after 21 
hours. The lack of radioactivity present in the cerebellum at this time is consistent with the 
relatively sparse localisation of mAChRs in this region and re-inforces the receptor-mediated 
theory of tracer retention in the brain. From this study it is uncertain whether IQNB labels 
any mAChR subtype selectively, but the negligible amount of tracer in the cerebellum a 
region which contains mostly M2-like receptors combined with the faster dissociation rate of 
the ligand for this receptor, suggests an M1-like selectivity for the ligand in vivo. However, 
accurate modelling of tracer kinetics with a suitable compartment model will be necessary 
for quantification of mAChR density. In contrast, a similar study of (R, S) [ 1231]-QNB 
uptake into brain was examined at 21 hours in relation to cerebral blood flow (Wyper et al., 
1993). Results from this study indicate that although blood flow deficits are apparent in the 
majority of AD cases, a selective reduction in mAChR density is only apparent in the more 
severely demented patients where disease progression is advanced. These observations 
support the view that alterations in local cerebral blood flow have little impact on IQNB 
concentration in any brain region. 
Further evidence to support this view comes from a combined [ 18F]-FDG PET and IQNB 
SPECT study. This study reports similar reductions in metabolic activity and IQNB uptake 
in AD patients, although abnormalities in IQNB uptake were generally greater (Weinberger 
et al., 1992). 
The studies outlined above provide powerful evidence of the utility of SPECT to 
image mAChRs with [123I]-QNB in man. However, several problems still exist with this 
technique such as the lack of a suitable mathematical model allowing accurate quantification 
of receptor number. Additionally, the lack of subtype selective radioligands is preventing 
visualisation of M2 mAChRs which are the subtype most likely to be lost in AD. However, 
conflicting reports on the loss of mAChR populations combined with the relatively low 
homogeneous distribution of mAChRs in the brain make accurate determination of M2 
receptor number difficult. Additional evidence has recently indicated loss of nAChRs in AD 
resulting in an effort to develop in vivo ligands specific for this receptor. These observations 
indicate that the ability to measure ACh function in vivo (i. e. ACh release) may be of greater 
importance than absolute quantification of receptor number. This view is supported by the 
loss of cholinergic function associated with AD and the current cholinergic replacement 
treatments aimed at the enhancement of ACh transmission (e. g. cholinesterase inhibitors) 
which form the basis of Alzheimer's therapy. The ability to measure ACh release in vivo 
would provide a means of assessing deficits in ACh function in AD and also provide a 
means to assess the efficacy of any replacement therapy. As it is not possible to measure 
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ACh release directly, quantification of changes in postsynaptic receptor-radiotracer binding 
following increased ACh outflow may provide a means to measure in vivo synaptic ACh 
concentration and thus the ability to assess cholinergic function in the brain. 
A number of PET and SPECT studies have indicated that it is possible to measure 
displacement of dopamine D2 receptor ligands from receptors in vivo by increasing synaptic 
concentrations of endogenous neurotransmitter. Amphetamine induced increases in synaptic 
AD levels have been observed to displace [18F]-N-methylspiroperidol, [11C]-raclopride and 
[123I]-IBZM binding from D2 receptors in the striatum of baboons, non-human primates 
and man (Brucke et al., 1991, Logan et al., 1991, Innis et al., 1992, Carson et at., 1997). 
Furthermore, studies in man have indicated that altered dopaminergic function can be 
measured by this technique in pathological conditions such as Parkinson's disease and 
schizophrenia. In un-medicated Parkinsonian patients no change in [123I]-IBZM binding to 
D2 receptors in the striatum was observed compared to controls. However in L-Dopa 
medicated patients a significant reduction in binding was observed., indicating that 
pharmacologically induced changes in dopaminergic function can be detected by 
postsynaptic radioligand binding (Brucke et at., 1991). Amphetamine induced displacement 
of [I 1C]-raclopride is greater in schizophrenic patients than in controls (Breier et at., 1997). 
These observations provide evidence to suggest that altered neurotransmitter function in 
pathological conditions is measurable with radioligands in vivo. At the commencement of 
the investigations constituting this thesis no such studies had been attempted for the 
cholinergic system. The in vivo characteristics of the stereoisomers of IQNB indicate that 
they would be well suited to such studies in the cholinergic system. Quantification of 
changes in postsynaptic receptor-IQNB binding induced by agents that alter ACh release but 
do not themselves bind to cholinergic receptors, would provide an indirect measure of in 
vivo synaptic ACh concentration and thus the ability to assess cholinergic function in a 
particular brain region. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 [1251]-QNB IN VIVO AUTORADIOGRAPHY 
Basic Principles of In Vivo Brain Receptor Imaging 
During the past two decades the study of neuroreceptors and their interactions 
with neurotransmitters and drugs has been of prime interest in the field of 
neuroscience. Important findings on the biochemical and phannacologic aspects of 
these sites and their anatomic distribution has been made through the development of 
potent and selective radioligands, receptor binding assays and autoradiographic 
techniques. In vitro receptor studies are typically performed by incubating radioligands 
with brain tissue homogenate preparations and determining the amount of binding after 
removal of un-bound radioactivity . From the data the number of sites and their affinity 
for a particular ligand can be estimated[see section 2.2]. Quantitative in vitro 
autoradiographic techniques have the added advantage of providing an image of the 
density and distribution of receptors. With the extension of these techniques it is now 
possible to image receptor function in vivo in the living mammalian brain. 
In vivo receptor imaging is based upon the principle that an intravenously injected 
radioligand or inhaled radioactive gas can pass from the blood into the brain and bind 
to target receptors with high specificity and selectivity allowing mapping of 
neuroreceptor distribution and number either by external detection of emitted 
radioactivity as in SPECT and PET or by autoradiographic means in experimental 
animals. With autoradiography, PET and SPECT the anatomical location and time 
course of ligand receptor interactions can be observed and quantitative information on 
regional receptor concentrations can be obtained. A correlation is sought between 
image information and normally occurring processes in the brain or to abnormalities 
that may reveal underlying neurologic or psychiatric diseases. 
Before use as in vivo imaging agents radioligands must satisfy a number of selection 
criteria similar to those for ligands used in vitro .A ligand must display high affinity 
and pharmacologic specificity for receptor, binding to receptors should be saturable 
and reversible and should display appropriate regional distribution. However, 
conditions in vivo are considerably different to those in vitro. Blood flow, 
permeability of ligand to blood brain barrier, ligand metabolism and the presence of 
endogenous neurotransmitter all affect receptor binding in vivo. Furthermore, 
conditions in vitro can be manipulated (e. g. ionic concentration and temperature of 
incubation medium) to maximise binding and reduce non-specific binding (e. g. post 
incubation washing). In contrast, non-specific binding in vivo increases linearly with 
plasma tracer concentration. Therefore to reduce non-specific binding plasma tracer 
concentration must be kept to a minimum. 
An ideal radioligand for use as an in vivo imaging agent would therefore have the 
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following attributes: 
" Freely diffusible across the blood-brain barrier 
" Rapid clearance from the blood following administration 
" High affinity and specificity for target receptor 
" Rapid clearance from non-specific sites in the brain 
" Forms no lipophilic radiolabelled metabolites that may enter the brain 
" May be radiolabelled to high specific activity 
The aim of receptor mapping in vivo with such ligands is to provide evidence 
of receptor-specific accumulation of radioligand and also to gain quantitative 
information on receptor density and affinity (i. e. KD and Bmax). However, absolute 
quantification of KD and Bmax in the same manner as that employed in vitro is not 
appropriate in vivo . Due to the factors described above and to the fact that the free 
ligand pool in the brain cannot be measured directly, the conditions and assumptions 
of the law of mass action do not apply. It is therefore necessary to develop a model 
that permits quantification of receptor density and affinity in vivo. To this end there are 
two types of experimental approach: 
1) Equilibrium Binding Studies 
This technique is a direct extension of in vitro equilibrium binding assays. It is based 
upon relatively few assumptions with regard to mechanisms of ligand distribution and 
produces ligand distribution proportional to regional receptor density. 
Following administration tracer is considered to exist in two major anatomic 
compartments, the intravascular compartment (CB) and the extravascular compartment 
(CE). Tracer in CE may be free (LE), non-specifically bound (NSE) or bound 
specifically to receptors (SE). It is assumed that following introduction of tracer the 
system reaches equilibrium and the concentrations in the non-saturable compartments 
CB, LE and NSE are linearly proportional to one another. 
Thus: LE+NSE= X, Cß 
where ? is a constant representing regional tissue to blood partition coefficient for free 
and non-specifically bound tracer. 
From the above, total tracer concentration (CT) can be defined as: 
C7= CBVB + CEVE (1) 
=CBVB + (LE+NSE+SE)Vß 
Where VB= volume of intravascular compartment 
VE volume of extravascular compartment 
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Assuming that LE, NSE and SE are distributed uniformly in the tissue and 
VB + VE=1 (2) 
Solving for SE: 
SE = 
CT cavB 
- LE - NSE (3) 
Substituting for equation (1): 
SE = 
CT - CBVB 
_A CB (4) VE 
and by elimination of VE using equation (2): 
SE= CT-CBVB-GCB (5) 
(1-VB) 
Equation (5) may be used to determine specific binding from total tissue levels of 
tracer by PET or SPELT when regional values of VB and I are known and CB is 
determined by temporal analysis of tracer content in peripheral arterial blood. 
In practice, an experiment of this kind is initiated by injection of a bolus dose of 
radioligand followed by an infusion protocol previously determined to produce a 
constant arterial concentration of radioligand. Equilibrium in various tissue 
compartments is then inferred from observation of the measured time-activity curves in 
various regions of interest in the brain. A single experiment of this kind determining 
regional radioligand distribution is sufficient to determine regional levels of specifically 
bound ligand when intravascular and non-specific binding corrections are made. 
Additionally, when total tissue ligand concentration reflects predominantly specific 
binding a single equilibrium image will directly yield a regional map of receptor 
density (Frey et al., 1985a, b). 
2) Kinetic Binding Studies 
This method of in vivo receptor quantification is based upon analysis of the 
distribution of radioligand in the blood and tissue (Frey et al., 1984). 
A similar compartment model to the one described for equilibrium binding is 
considered, with tissue compartment consisting of free, non-specifically bound and 
specifically bound radioligand. 
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The exchange rates of tracer between compartments are described by transfer 
coefficients K!, K2, k3, k4, ks and k6. Tracer entry to and exit from tissue are 
determined by regional cerebral blood flow and capillary tracer concentration [see 
section 4.3 for more detail]. Transport constants Kl, K2 describing blood-brain and 
brain-blood transfer of tracer and constants k5 and k6 describing binding and un- 
binding of tracer to non-specific sites within the brain, can be defined as first order rate 
constants since the processes represent simple diffusion and non-saturable binding 
respectively. k3 and k4 describe interaction of free tracer in tissue with the free 
receptor population , that is k4 = dissociation of 
bound ligand from receptor and k3= 
association of free ligand to receptor. 
k3 is related to the concentration of free ligand in tissue and the free receptor 
concentration thus: 
k3= kaR (6) 
Where ka is the association rate constant and R is the free receptor population. 
Under conditions where R is constant k3 becomes a pseudo first order rate constant, 
and an expression describing the relationship between the blood and tissue tracer time 
courses in terms of the model parameters can be derived. For this relationship to hold 
the tracer must not occupy a significant proportion of the free receptors. 
In practice, a tracer kinetic experiment involves a single intravenous bolus 
injection of radioligand with continuous determination of arterial tracer concentration 
and regional tissue tracer concentration for imaging with PET or SPELT; For 
autoradiography in experimental animals, continuous determination of arterial tracer 
concentration is combined with determination of regional tissue concentration at 
multiple time points in multiple animals. Arterial blood and tissue time activity curves 
can then be analysed by non-linear least squares curve fitting procedures to determine 
estimates of the model parameters (Frey et al., 1984). 
An important issue for tracer kinetic modelling is the relationship between receptor 
density and experimental derivation of k3. Free receptor concentration is related to total 
receptor concentration RT, as: RT= R+ SE + LRE (7) 
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Where LRE= receptor bound to endogenous neurotransmitter. Thus, alterations in 
specific binding may reflect changes in total receptor density and also synaptic levels 
of endogenous neurotransmitter. Only when ka is regionally invariant and constant 
between individuals will k3 determination permit inference of changes in receptor 
density (equation 6). Similarly, KD cannot be estimated by this method, instead a 
combined measure of affinity and density, the Binding Potential (BP=k3/k4) for 
receptor populations is employed (Mintun et al., 1984). However, assessment of 
absolute values for KD and Bmax utilising this technique is possible with use of 
complex mathematical models (Gjedde and Wong, 1990). 
2.1.1 Uptake and Retention Of (R, S)- And (R, R)-[1251]. QNB 
In Rat Brain 
Surgical Preparation 
Male sprague dawley rats were placed in a perspex chamber and anaesthetised with 
5% halothane in a nitrous oxide and oxygen mixture (70%/30%). Anaesthesia was 
subsequently maintained by administration of 0.5-1% halothane in the gas mixture via 
a face mask. Right femoral vessels were exposed by blunt dissection through a small 
incision in the skin in the groin of the rat. Polyethylene catheters (Portex, exterior 
diameter 0.96mm, interior diameter 0.58mm) attached to a larger polyethylene catheter 
(Portex, exterior diameter 1.40mm, interior diameter 0.63mm) were inserted 
approximately 2cm into both the femoral artery and vein and tied in place with surgical 
silk. The surgical ties were then secured in place by means of a small amount of 
cyanocrylate glue. 
A hollow stainless steel rod was then passed under the skin, through the 
incision in the groin, along the line of the leg and up out through a small incision in 
the back of the neck. The arterial and venous catheters were then passed up through 
the steel rod and exteriorised through the incision in the neck. The steel rod was then 
removed. Both the wound in the groin and in the back of the neck were then infiltrated 
with antiseptic xylocaine gel (2%) and sutured closed with surgical silk. The catheters 
were then secured in place with a small amount of cyanocrylate glue. Anaesthesia was 
discontinued, and animals were allowed a minimum period of 1 hour of recovery 
before any further manipulations were performed. 
Experimental Procedure 
Male Sprague-Dawley rats weighing 300-350g were used in all experiments. 
Following recovery from anaesthesia animals received an intravenous injection of 
200gCi (0.7mls in 0.9% saline) of either (R, S)- or (R, R)-[125I]-QNB (specific 
activity 1480 MBq/mmol) at a constant rate over 30 seconds. Following administration 
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of tracer timed arterial blood samples (1004l) were collected, with up to 14 samples 
taken over the initial 45 mins of the experiment. The regime for subsequent sampling 
of arterial blood was dependent upon the experimental end point for the individual 
animal as follows: 
Animals sacrificed at 1 hour: further sample collected at 1 hour 
2 hours: further samples collected at 1 and 2 hours 
6 hours: further samples collected at 1,2,4, and 6 hours 
of 12 hours: further samples collected at 1,2,4,8 and 24 hours 
to 24 hours: further samples collected at 1,2,4,8,12, and 24 hours 
All arterial blood samples were immediately centrifuged and 20µ1 plasma samples 
taken to determine [12511 content and glucose concentration by means of liquid 
scintillation analysis and semi-automated glucose oxidase enzyme assay (Beckman) 
respectively. Arterial plasma samples were also taken at predetermined intervals before 
and after isotope administration* for analysis of pCO2, pO2 and pH using a blood gas 
analyser (168 or 288 pHBlood Gas System, CIBA. Corning). In all animals arterial 
blood pressure and core temperature were monitored at predetermined intervals before 
and after isotope administration, by means of a pressure transducer (P231D Gould 
Stratham, Model 2202) connected to the femoral artery catheter and a rectal 
temperature probe respectively. Throughout the duration of the experiment animals had 
free access to food and water. 
At the end of the experimental period animals were sacrificed by an 
intravenous injection of pentobarbitone sodium (Euthatal, 200mg/ml) and decapitated 
at 2,6,12 and 24 hours for (R, S) [125I]-QNB experiments (n=5 for 2 and 24 hrs 
and n=3 for 6 and 12 hrs) and 0.5,1,2 and 6 hours for (R, R) [125I]-QNB 
experiments (n=5 for each time point). Brains were then rapidly removed and frozen in 
isopentane at -4200 for 10 mins. The frozen brains were then mounted onto swivel 
headed microtome chucks with plastic embedding matrix (Lipshaw) over solid C02. 
Preparation Of [1251] Autoradiograms 
Triplicate serial 20. tm coronal sections of frozen brain were cut in a cryostat 
microtome at 200µm intervals throughout the brain and thaw mounted onto glass 
coverslips and then dried rapidly on a hot pate at 600C. The coverslips were then 
glued onto thin card and autoradiograms generated by exposing the brain sections 
along with pre-calibrated [125I] standards (0.66 - 313.02jCi/g tissue equivalents) to 
[12511 sensitive film (Kodak BioMax MR) in light - tight cassettes for 3 days. Films 
were then processed according to the manufacturers instructions. 
Quantification Of Autoradiograms 
[12511 autoradiograms were analysed using a computer based image analysis system 
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(M4 MCID, Imaging Research Inc. ). Films were analysed densitometrically for 
radioisotope content in discrete brain regions by grey level comparison with pre- 
calibrated standards. Images captured by the video camera are digitised into an array of 
image points (pixels), each with a grey level in the range of 0-256. The grey level 
measured is refered to the dynamic range of the sensor and is converted to a relative 
optical density (ROD) value. For example, if an image of grey level 64/256 produces 
a ROD of 0.25, then a grey level of 128/256 would produce a ROD of 0.5. The ROD 
produced has no intrinsic biological value, it is merely the value the video image is 
assigned by the systems internal measurement scale. The system was therefore 
calibrated against [1251] tissue equivalent standards in the range of 0-313.02 pCi/g, 
with a zero value produced by taking a background reading from the film. This 
generates a calibration curve of ROD values versus isotope concentration, allowing 
subsequent quantification of tissue isotope concentrations in discrete brain regions. 
Measurements of isotope concentration were made by placing a measuring frame over 
each anatomical region of interest. The size of the measuring frame was variable but 
was kept constant for anatomical regions of interest between individual studies. For all 
in vivo studies with (R, S)- and (RR)-[1251]-QNB 33 distinct anatomical regions were 
analysed, with bilateral readings taken from 6 consecutive sections for each region of 
interest. Structures in the rat brain were defined anatomically by reference to the 
stereotaxic atlas of Paxinos and Watson (1986). 
Data generated from autoradiograms were expressed as meant S. E. M % Dose per 
I OOg brain normalised to the caudate nucleus to reduce the impact of inter-animal 
variability. 
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2.1.2 Metabolic Fate of (R, S)- and (R, R)-[1251]-QNB In Vivo 
in rat 
The purpose of this study was to analyse rat brain and plasma samples by high 
performance liquid chromatography (HPLC) for the presence of tracer breakdown 
products following intravenous injection of (R, S)- or (RR)-(I25I]-QNB into the 
conscious rat. 
All HPLC work was carried out with the following solvent system Solvent A: 0.1 % 
trifluoroacetic acid in acetonitrile, Solvent B: 0.1% aqueous trifluoroacetic acid. 
Analytical work was carried out using an LKB 2000 series binary pump system with 
an LKB UV spectrophotometer at 230 nm and a Packard Radiomatic 500TR flow 
monitor. A Jones C18 Genesis column (4.6 x 250 mm) with 10 mm guard cartridge 
was used with 50% solvent A, 50% Solvent B at a flow rate of lml/min. Data were 
collected and analysed using Packard FLO-ONE software. The background signal was 
subtracted from each trace and the start and end points of each trace were assigned 
manually. Peak areas were recorded as a percentage of total peak area. 
Surgical Preparation 
Animals were prepared surgically as described in section 2.1.1. 
Experimental Procedure 
Experiments were performed in male Sprague dawley rats (300-350g) injected 
intravenously with 200p. Ci (R, S)- or (R, R)-[125I]-QNB(specific activity 1480 
MBq/mmol) in 0.7 mis 0.9% saline. Arterial blood samples (iml) were taken at time 
intervals ranging from 1 min to 12 hours following tracer administration. The blood 
volume removed at each time was replaced by a slow intravenous injection of saline 
(0.9%). Samples were immediately centrifuged and the plasma removed and stored on 
ice. A 20 µl aliquot of plasma was removed from each sample for liquid scintillation 
counting. 250 µ1 of acetonitrile was added to 250 µl of plasma from each time point. 
The mixture was vortexed then centrifuged at 2000 rpm-for 10 min and the supernatant 
removed. A 150 µL sample of the supernatant was injected on to the analytical HPLC 
system detailed previously. Animals injected with (R, S)-[1251]-QNB were 
decapitated at 2,6,12 and 24 hours after administration of tracer. Animals injected 
with (R, R)-[125I]-QNB were decapitated 30,60,120 and 360 mins after 
administration of tracer. Each brain was rapidly removed and homogenised in lml 
saline (0.9%) using a small hand held glass homogeniser. Equal volumes of 
homogenate and acetonitrile were mixed and centrifuged at 2000 rpm for 10 min to 
give a clear supernatant. The supernatant was injected directly on to the analytical 
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HPLC system detailed previously. 
In addition to investigation of the metabolism of (R, S)- and (R, R)-[1251]_QNB 
in vivo, the degree of degradation occurring following re-constitution of tracer in 
saline was examined. HPLC analysis of an ethanolic solution of [ 125I]-QNB injectate 
removed from the injecting syringe was performed as detailed above for plasma. 
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2.1.3 Effect of Heptylphysostigmine Administration on Uptake 
and Retention of (R, S)-and (R, R)-[1251]-QNB in the Brain 
of Conscious Rat 
Surgical Preparation 
Surgical preparation of animals was performed as described as in 2.1.1. 
Experimental Protocol 
Experiments were carried out in 20 male sprague dawley rats weighing 300-350g as 
described in 2.1.1 with the following alterations. Heptylphysostigmine tartrate 2mg/kg 
(0.7mls in 0.9% saline) or vehicle (0.7mls 0.9% saline) was administered as an 
intravenous infusion at a constant rate over 30 mins, one hour before injection of 
(R, S)- or (RR)-[125I]-QNB (specific activity 1480 MBq/mmol). Animals were 
sacrificed by an intravenous injection of pentobarbitone sodium (Euthatal, 200mg/ml) 
and decapitated at 2 and 24 hours (n= 5 at both time points for heptylphysostigmine 
and vehicle treated animals) following tracer administration for (RS)-[125I]-QNB 
experiments, with 24 hour animals receiving a second intravenous infusion of 2mg/kg 
heptylphysostigmine or vehicle 8 hours following the initiation of the first infusion. In 
(R, R)-[125I]-QNB experiments animals were decapitated 30 mins, and 1,2 and 6 
hours following tracer administration (n=5 for each time point for both 
heptylphysostigmine and vehicle treated animals). Brains were then rapidly removed 
and frozen in isopentane at -42OC for 10 mins. The frozen brains were then mounted 
onto swivel headed microtome chucks with plastic embedding matrix (Lipshaw) over 
solid C02. 
Preparation Of [12511 Autoradiograms 
Autoradiograms were prepared as described in 2.1.1 except that additional 20]4m 
coronal sections were taken and thaw mounted onto glass slides and rapidly dried on a 
hot plate at 600C. Triplicate sections were taken at pre-determined levels of the caudate 
nucleus, dorsolateral hippocampus and cerebellum. These sections then underwent 
histochemical staining for acetylcholinesterase activity as described in section 2.4. 
Quantification of Autoradiograms 
Autoradiograms were analysed as described in section 2.1.1. 
Data Analysis 
At each time point the data from the two experimental groups, heptylphysostigmine 
and vehicle were analysed using a two tailed Student's unpaired t- test. The data were 
expressed as mean t S. E. M. of % Dose per 100g brain normalised to the caudate 
nucleus. I 
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2.2 [1251]-QNB IN VITRO AUTORADIOGRAPHY 
General Principles of In Vitro Ligand Auotradiography 
In vitro ligand binding autoradiography is based upon the principle that radiolabelled 
ligands, which are highly selective for particular recognition sites, emit energy which 
will produce a photographic image when placed in contact with radiation sensitive 
film. The optical density of the image is related to the amount of radioligand bound and 
hence to the density of the binding sites in any given area and can be quantified by 
reference to calibrated radioactive standards. Thus in vitro autoradiography techniques 
allow anatomical mapping of the distribution of ligand binding sites within the CNS 
with a high degree of spatial resolution and sensitive quantification of ligand binding 
densities in discrete brain regions. 
Receptor Theory and Ligand - Receptor Complex Interactions 
As an integral part of the in vivo characterisation of the stereoisomers [125I]-QNB, it 
is necessary to determine their in vitro binding kinetics . 
The behaviour of these 
stereoisomers in vitro provides parameters by which they may be described 
pharmacologically and valuable background information which may be utilised to 
define differences in their performance as in vivo imaging agents. 
In this section the basic principles behind in vitro binding studies will be 
discussed along with a more detailed examination of the theory involved in kinetic and 
equilibrium binding assays from which binding data for a particular ligand and 
receptor can be derived. 
Law Of Mass Action 
Ligand-receptor interactions generally follow kinetics very similar to those of classic 
enzyme-substrate interactions and are based upon the Law of Mass Action: 
Unbound ligand reversibly binds to unbound receptor at a rate dependent upon the 
concentration of the two reactants, and the resultant ligand-receptor complex breaks 
down at a rate proportional to the concentration of the complex. At equilibrium or 
steady state, the rate of association is equal to rate of dissociation, that is, the rate of 
formation of the complex is equal to the rate of its breakdown. 
These rules form the basis for ligand-receptor interactions but are only valid as long as 
the following conditions apply. 
The interaction of the ligand and receptor must be completely reversible. The reactants 
can only exist in one of two states, either completely free or completely bound. 
Measured products do not include elements unavailable for binding(e. g. degraded or 
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non-specific ligand). All receptor sites have unitary affinity and are independent of 
each other. 
Thus, in a simple bimolecular reaction, where the rate limiting step is the collision of 
the ligand with the receptor site: 
k+1 
[L] + [R] [LR) 
k-1 
Where: 
[L] = concentration of free ligand 
[R] = concentration of free receptor 
[LR] = concentration of ligand-receptor complex 
k +i= Association Rate Constant (On rate), and defines the rate at which the ligand 
receptor complex is formed. 
k- i= Dissociation Rate Constant (Off rate), and defines the rate at which the ligand 
receptor complex breaks down. 
Therefore, Association rate= k+ i[L][R] 
and Dissociation rate= k- i[LR] 
and at equilibrium or steady state: k+ i[ L][ R] =k- i[ LR] . 
This can be rearranged to: 
k-i= [L)[R] 
_ KD (1) k+i [LR] 
Where KD is the Equilibrium Dissociation constant and is expressed in moles per litre. 
It is equal to the concentration of ligand which occupies 50% of receptors at 
equilibrium. A low Kn denotes high affinity of the ligand for binding to the receptor. 
Ligand - receptor interactions also show saturability, that is, only a finite number of 
specific receptor sites exist per unit of tissue. This number of specific receptor sites is 
termed Bmax and is usually expressed in pmoles per mg protein. 
Therefore, according to the above: [LRI+, [R] = Bmaz 
Multiply by [L] : [L][LR]+[L][R] = BB[L] 
[LR][L] +f 
[LRI 
[L][R] =B max[L] LRI 
Substituting for equation (1): [LRJ([L]+ Ko) -B 
71 
[LR] = 
Bow[L] 
(2) 
[L]+KD 
This is the classic law of mass action for enzyme-substrate interactions adapted for 
ligand-receptor interactions. If we now define [RL] as bound ligand B and [I; ] as free 
Iigand F: B=B max and BF+ BKD =B maF F+ KD 
Dividing by F: B+E KD =B muF 
B Bnw-B 
(3} 
F Kn 
This is the Scatchard Equation. This equation allows the calculation of the Equilibrium 
Dissociation Constant KD and the maximum number of specific binding sites Bmax, if 
the concentrations of free and bound ligand are known at equilibrium. 
Kinetic Analysis: Ligand Association and Dissociation 
Initial experiments performed in the characterisation of ligand-receptor interaction are 
likely to be exploratory studies of the kinetics of association and dissociation. An 
important aim is to establish the time needed for equilibrium binding to be achieved. 
During kinetic analysis the formation and breakdown of product over time is measured 
and the association or dissociation rate constants for the reaction can be calculated from 
data derived from such experiments. 
The rate of formation of [LR] is described by: 
d LR] 
=k+ i[L][R] -k- S[LR] 
At equilibrium: 
d LR] 
=0 and k+ i[L][R] =k- i[LR] 
Experimental derivation of k+l(the association rate constant) involves measuring the 
formation of [LR] under conditions where [L] is in excess. This is known as an 
Association Time Course Experiment. Binding assays of this type, using membrane 
homogenate preparations requires the addition of radioligand in a single concentration 
to fixed level of receptor protein in a single tube, removing aliquots and filtering at 
time intervals until equilibrium is reached. This methodology is not compatible with in 
vitro autoradiographic analysis. Instead, individual brain sections are incubated in a 
fixed amount of a single concentration of radioligand. The starting times are staggered 
and the assay is then terminated after the appropriate time period by washing of the 
sections in buffer. From this type of assay, the observed association rate or kobs 
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(min-1) can be derived, and from this the more useful association rate constant k+1 
(M-Imin- 1). The association rate is defined by a Second Order rate equation. 
Therefore, the time taken to reach equilibrium depends upon the concentration of the 
two reactants as well as the rate constant. i. e. the lower the concentration of receptor or 
radioligand, the longer before equilibrium is reached. 
Raw data from an illustrative association time course experiment can been seen 
in Fig. 5. This data can be transformed to obtain a linear representation of association, 
from which kobs can be derived. A plot of 1nBe/Be-BT against time, where Be is 
specific binding at equilibrium and BT is specific binding at time T, yields a straight 
line with the observed association rate (kobs) equal to the slope of the line. An 
example of association data transformed in such a manner can be seen in Fig. 6. 
Experimental derivation of k-1(the dissociation rate constant) involves incubating 
receptors with a single concentration of radioligand until equilibrium (when formation 
and breakdown rates are equal) and then initiating dissociation of the ligand receptor 
complex by addition of excess unlabelled competitor to saturate the receptors and 
reduce the on rate to a negligible value. The competitor should preferentially have a 
structure chemically distinct from that of the radioligand. Dissociation of the ligand- 
receptor complex is then halted at increasing time intervals by washing of the sections 
in buffer. The level of dissociation occurring( without rebinding) increases in a manner 
proportional to the period of incubation with the competitor, and hence the amount of 
specifically bound ligand decreases. This type of assay is known as a Dissociation 
Time Course Experiment, raw data from an illustrative example can be seen in Fig. S. 
This data can be transformed to give a linear representation of dissociation from which 
k-1 can be calculated. A plot of In BdBo against time, where BT is specific binding at 
time T and Bo is specific binding at time zero (i. e. at equilibrium before dissociation is 
initiated), yields at straight line with k-1 equal to the slope. An example of dissociation 
data transformed in such a manner can be seen in Fig. 6. 
Association and Dissociation time course experiments yield the on and off rates for a 
k 
radioligand, this data may then be used to determine KD, as: KD = -' k+i 
Equilibrium Studies: Saturation , Analysis 
The equilibrium dissociation constant KD, and the number of receptor sites Bmax may 
also be determined experimentally by Saturation analysis. This involves incubating a 
fixed amount of tissue in increasing concentrations of radioligand until such time as 
equilibrium is achieved. Ideally, a concentration of ten fold below to ten fold above the 
estimated KD value should be used. As the concentrations of ligand used are low 
"noise" produced by non-specific binding can be a problem with this type of assay. 
The level of non-specific binding is therefore determined in the presence of excess cold 
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Raw Data From Theoretical Association 
And Dissociation Time Course Assays 
0 
z 
A z 
U 
Ger 
c) 
W 
C#D 
A: Association Time Course 
30 
20 
10 
0 
B: Dissociation Time Course 
70 
60 
so- 
40- 
30. 
20 
10 
0 
0 2468 
TIME (MINS) 
10 12 
Fig 5: Raw data form theoretical Association (A) and Dissociation (B) assays. 
(A) shows saturation of specific binding sites at equilibrium. (B) shows dissociation of 
ligand from receptor with time in the presence of a saturating concentration o 
non-labelled competitor. 
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Linear Transformation Of Data From 
Theoretical Association And Dissociation Time 
Course Assays 
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Fig 6: Linear transformation of raw data from theoretical Association (A) and 
Dissociation (B) time course assays. Where Be is equilibrium specific binding, 
BT is specific binding at time T, and Bo is specific binding at time zero. On and 
off rates are obtained from the slopes of the respective plots. The equilibrium 
dissociation constant KD is equal to the off rate divided by the on rate. 
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Raw Data From A Theoretical Saturation Assay 
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Fig 7: Typical rectangular hyperbola from a theoretical saturation assay. 
Plot shows specific binding of radioligand to receptors against free radioligand 
concentration. KD and Bmax may be calculated from this curve. 
o KD 2a6s 10 12 
Scatchard Plot 
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Fig 8: Scatchard plot of data from a theoretical saturation asssay. 
Plot shows specifically bound radioligand against ratio of Bound/Free radioligand. 
this produces a straight line the slope of which is equal to -1/KD. The x intercept defines Bmax. 
ligand. This saturates the receptors and effectively eliminates specific binding. Specific 
binding is then calculated by subtracting Non-specific binding from Total binding. 
Fig. 7 shows as typical rectangular hyperbola from a saturation experiment, with 
specific binding plotted against free radioligand concentration. 
The KD value can be estimated from this plot and is defined as the concentration of 
free radioligand at which 50% maximal binding is produced at equilibrium. 
Several arithmetical transformations have been devised to derive linear plots of data 
from saturation assays in an effort to allow more accurate determination of binding 
parameters. The most commonly used of these is the Scatchard Plot, which is based 
upon the Scatchard equation (equation 3 above). This equation was derived by 
Scatchard in 1949 to describe the binding of molecules to proteins which were 
independent of each other with identical KD values. 
Scatchard analysis involves plotting the ratio of bound to free radioligand against 
bound radioligand. This produces a linear plot, the slope of which is equal to -1/KD, 
while the x intercept defines Bmax. (Fig. 8). 
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2.2.1 in Vitro Association Time Course Assay: 
Determination of Observed Association Rate Constants 
for (R, S)- and (R, R)-[125I]. QNB 
Surgical Preparation 
Male Sprague dawley rats (300-400g) were placed in a perspex box and euthanasia by 
an excess of halothane (5%) in a nitrous oxide and oxygen mixture (70% : 30%). 
Death was defined as the point at which there was complete failure of respiration and at 
which no heartbeat could be found. Rats were then decapitated and the whole brain 
carefully dissected out. Excess blood, small bone fragments and any hair adhering to 
the brain was then removed before the brain was rapidly frozen in isopentane at -420C 
for 10 minn. Brains were then mounted onto swivel headed microtome chucks with 
Gurr O. C. T. Compound (BDH) over solid C02 and coated in plastic embedding 
matrix (M1-Lipshaw) to reduce the effects of dehydration during cold storage. Brains 
were then sectioned in a cryostat microtome at -200C with serial 20 gm coronal 
sections of the caudate nucleus, dorsolateral hippocampus and cerebellum identified 
anatomically by reference to the rat brain atlas of Paxinos and Watson (1986) collected 
onto subbed glass microscope slides. Two 20µm coronal sections were collected onto 
each slide. All sections were then placed in a slide box, which was taped shut to 
prevent access of air, and stored in a freezer at -200C overnight before use. This was 
done as freshly cut sections adhere poorly to slides and immediate use can result in 
loss of tissue during the performance of the assay. Storing overnight aids the bonding 
of the tissue section to the slide and improves the resolution of the assay. All sections 
were used within one week of harvest. 
Pre-washing 
Before use in a binding assay, all sections were placed in slide racks and washed in 
50mM phosphate buffered saline containing 10mM EDTA (pH 7.4) at 25°C for 30 
mins. Pre-washing in this solution dissociates endogenous ligand receptor complexes 
and inactivates most proteases ( Potter et al, 1984; Mash et al, 1985). After 30 mins 
washing the sections are removed from the slide racks and laid out in binding trays and 
dried in a cold air stream. 
Preparation Of Incubate Medium 
All in vitro binding assays with either (R, S)- or (R, R)-[1251]-QNB were performed in 
an incubate medium consisting of 50mM phosphate buffered saline (PBS) containing 
1mM ethylene diaminetetraacetic acid (EDTA) and 1mM N-ethylmalemide (NEM). 
The addition of EDTA and NEM to the buffer stabilises the low affinity agonist states 
of muscarinic receptors and facilitates their labelling with QNB (Potter et al, 1984; 
Flynn and Potter, 1985). Mash and Potter (1986) also reported that pre-soaking of un- 
75 
fixed sections of rat brain in buffer containing 10mM EDTA increased the levels of 
specific binding and helped to preserve tissue integrity in their binding assays. For 
these reasons the above incubate medium was chosen for the performance of all in 
vitro binding assays. 
Determination Of Non-Specific Binding 
Non-specific binding in all in vitro assays with either (R, S)- or (R, R)-[1251]-QNB 
was determined by addition of an excess concentration of the non-selective muscarinic 
receptor antagonist atropine. 
Experimental Procedure 
Rat brain sections at the level of the caudate nucleus, dorsolateral hippocampus and 
cerebellum sections were placed in binding trays before being incubated in 0.2 nM 
(R, S)- or (R, R)-[125I]-QNB in 50mM PBS containing 1mM EDTA and 1mM NEM 
(pH 7.4),. for 1,2,5,10,20,40,60,90, and 120 mins at 25°C, to determine Total 
binding. Non-specific binding for each brain region was determined as for Total, with 
the presence of 2µM atropine in the incubate medium. 
Each section was incubated in 400µl of medium applied directly onto the section with 
an adjustable Iml Gilson pipette. After initiation of the assay the binding tray cover 
was fitted to reduce loss of incubate medium from sections by evaporation. 
Triplicate sections from each region were assayed to determine both Total and Non- 
specific binding. 
After the appropriate time period had elapsed, incubation medium was poured off the 
sections before they were briefly dipped in distilled water. Sections were then placed 
in slide racks and washed in 50mM PBS (pH 7.4) for 30 mins at 250C. 
Following washing, sections were removed from the slide racks and dried in a cold air 
stream before processing for [1251] autoradiography as described below. 
Preparation of Autoradiograms 
Autoradiograms were prepared as described in section 2.1.1. 
Quantification Of Autoradiograms 
. 
Autoradiograms for in vitro studies were analysed as described in section 2.1.1. For in 
vitro studies with [1251]-QNB determination of Total, Non-specific and Specific 
binding is necessary. For all in vitro assays, to determine Total and Non-specific 
binding, bilateral readings were taken from the triplicate brain sections pre-designated 
as Total and Non-specific, for each of the three brain regions examined (frontal, 
parietal and cerebellar cortices). A value for specific binding was then derived by 
subtracting Non-specific from Total binding. Binding data expressed as pCi per g 
brain can then be converted to nmoles per g brain through knowledge of the specific 
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activity of the tracer. 
Data Analysis 
The observed association rate (kobs) was derived according to the theory detailed in 
section 2.2, with levels of Total, Non-specific and Specific binding expressed as 
nmoles per g for each region of interest. 
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2.2.2 In Vitro Saturation Analysis: 
Determination of the Equilibrium Dissociation Constant 
for (R, S)- and (R, R)-[1251]-QNB 
Experimental Protocol 
20µm coronal sections of rat brain at the level of the caudate nucleus, dorsolateral 
hippocampus and cerebellum prepared as described in section 2.2.1. 
were placed in binding trays before being incubated in 0.007 nM, 0.01 nM, 0.03 nM, 
0.05 nM, 0.07 nM or 0.1 nM (R, S)- or (R, R)-[1251]-QNB in 50mM PBS containing 
1mM EDTA and 1mM NEM (pH 7.4) for 90 mins at 250C, to determine Total 
binding. Non-specific binding was determined as for Total with 1 µM atropine present 
in the incubation medium. Each section was incubated in 400µl of medium applied 
directly onto the section with an adjustable lml Gilson pipette. After initiation of the 
assay the cover of the binding tray was fitted to prevent loss of incubate medium form 
sections through evaporation. Triplicate sections from each region were assayed to 
determine both Total and Non-specific binding. 
After 60 mins, the binding tray cover was removed and the incubation medium poured 
of the sections before they were briefly dipped in distilled water. Sections were then 
placed in slide racks and washed in 50mM PBS (pH 7.4) for 30 mins at 250C. 
Following washing, sections were removed from slide racks and dried in a cold air 
stream. 
Preparation of Autoradiograms 
Autoradiograms were prepared as described in section 2.1.1. 
Quantification Of Autoradiograms 
Analysis of autoradiograms was performed as described in section 2.2.1. 
Data Analysis 
The equilibrium dissociation rate constant (KD) was calculated by Scatchard Analysis 
according to the theory detailed in section 2.2, with levels of Total, Non-specific and 
Specific binding expressed as nmoles per g for each region of interest. 
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2.2.3 Effect Of Heptylphysostigmine On (R, S) and (R, R) [1251]_' 
QNB Binding In Vitro: Displacement Analysis ' 
Experimental Protocol 
20pm coronal sections of rat brain at the level of the caudate nucleus, dorsolateral 
hippocampus and cerebellum were prepared as described in section 2.2.1. 
Sections were placed in binding trays before 130, ul 10-6M heptylphysostigmine was 
applied directly onto each section with a Iml adjustable pipette. Sections were 
incubated in heptylphysostigmine for 30 mins to allow complete inhibition of any of 
the acetylcholinesterase enzyme present. For (RS)-[125I1-QNB experiments, a further 
270, u l of incubate medium containing 0.1nM (RS)-[125I]-QNB and 10-5M, 10-4 M, 
10-3M or 10-2M ACh was applied onto each section to determine Total binding. For 
(R, R)-[ 1251] -QNB experiments 270, u 1 of incubate medium containing 0.2 nM (R, R) 
[125I]-QNB and 10-6M, 104M or 10-3M ACh was applied onto each section to 
determine Total binding. Sections were therefore incubated with a final volume of 
400p1 of medium covering each section. Non-specific binding was determined as for 
Total with the presence of 1 pM and 2 pM atropine in the incubation medium 
respectively for (R, S) and (R, R) experiments . After initiation of the assay the cover of 
the binding tray was fitted to prevent loss of incubate medium from sections through 
evaporation. Triplicate sections from each region were assayed to determine both Total 
and Non-specific binding. 
After 60 mins, the binding tray cover was removed and the incubation medium was 
poured off the sections before they were briefly dipped in distilled water. Sections 
were then placed in slide racks and washed in PBS (pH 7.4) for 30 mins at 250C. 
Preparation of Autoradiograms 
Autoradiograms were prepared as described in section 2.1.1. 
Quantification Of Autoradiograms 
Analysis of autoradiograms was performed as described in section 2.2.1. 
Data Analysis . 
Levels of Total, Non-specific and Specific binding were expressed as nmoles per g for 
each region of interest. 
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2.3 ASSESSMENT OF REGIONAL CEREBRAL BLOOD FLOW 
(rCBF) BY [14C]-IODOANTIPYRINE AUTORADIOGRAPHY 
2.3.1 Theory Of Quantitative Auotradiographic Determination of rCBF 
Quantitative determination of regional cerebral blood flow was first reported by Kety 
and associates using radioactive tracer trifluoroiodoethane ([ 1311] CF3I) (Landau et 
al., 1955) . The method is based upon the principles of inert gas exchange between 
blood and tissues, and the following equation developed by Kety (1951): 
JTt C1(T) = ?K CA C. K(T t) dt 0 
Where 
Ci(7)= tissue concentration of the chemically inert diffusible tracer at a given time T 
2, = the tissue: blood partition coefficient 
CA= the concentration of the tracer in the arterial blood 
t= the variable time 
K= a constant that incorporates within it the rate of blood flow in the tissue 
K is defined as follows: 
K= mF/W? 
where 
F/W= the rate of blood flow per unit mass of tissue 
m= a constant between 0 and 1 that represents the extent to which diffusion 
equilibrium between blood and tissue is achieved during passage from arterial to 
venous end of the capillary. 
In the brain , due to the absence of arteriovenous shunts, m= 1 and K becomes solely 
dependent upon the perfusion rate of the tissue. 
The method developed by Kety depended upon the ability of the radioactive tracer to 
diffuse unrestricted across the blood brain barrier, hence the use of the radioactive gas 
[131I]-CF3I. However using [131I]-CF3I had several disadvantages. The tracer has a 
relatively short half-life (8 days) , was difficult to obtain commercially and the assay of 
tracer concentration in the blood was difficult. 
The use of this tracer for the determination of blood flow was superseded by the 
development of [14C] labelled antipyrine, which has in turn been superseded by [14C] 
iodoantipyrine (IAP). The use of IAP as a tracer for the determination of blood flow 
has a number of advantages. It is a freely diffusible tracer thus blood flow 
measurement is limited only by the level of blood flow to a region. It produces 
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excellent spatial resolution with autoradiography, is inert and non-metabolised and 
allows determination of blood flow in multiple regions. In addition TAP has a higher 
lipid/water partition coefficient than antipyrine and produces blood flow measurements 
similar to these obtained with CF3I (Sakurada et al., 1978). 
One of the main disadvantages of the TAP is the complex nature of the 
methodology. Accurate measurement of time of blood sample collection and the 
duration of the experiment is necessary. Any inaccuracies in these parameters can 
result in marked errors in the value of cerebral blood flow obtained (Patlak et al., 
1984). With the use of freely diffusible radioactive tracers such as TAP there is also the 
problem of back-flux from the tissue into blood (Patlak et al., 1984). This source of 
error can be minimised however, using a short experimental schedule (30 - 60 sec) and 
the use of a ramped infusion of isotope (Patlak et al., 1984). 
2.3.2 Measurement of rCBF In The Conscious Rat Following 
Heptylphysostigmine Administration 
There are a number of methods of assessing rCBF with [14C]-IAP, two of which are 
the Indicator Fractionation technique (Goldman and Sapirstein, 1973) and the Tissue 
Equilibration technique (Sakurada et al., 1978). In this study the latter technique was 
performed. 
This procedure assumes the tracer is in equilibrium between the tissue and blood after 
iv administration. The tracer is injected as a ramped infusion over 60 sec during which 
timed arterial blood samples are collected from a free flowing catheter. The technique 
is based upon a model of blood-tissue exchange which assumes equilibration between 
plasma, red blood cells and a single tissue compartment. 
Surgical Preparation 
Male sprague dawley rats (335-356g) were placed in a perspex chamber with 5% 
halothane in a gas mixture of nitrous oxide (70%) and oxygen(30%). Anaesthesia was 
subsequently maintained by administration of 0.5-1% halothane in the gas mixture via 
a face mask. A rectal temperature probe was inserted to allow monitoring of core 
temperature. Both left and right femoral vessels were exposed by blunt dissection 
through a small incision made in the groin of the rat. Polyethylene catheters (Portex, 
exterior diameter 0.96 mm, interior diameter 0.58 mm) were then inserted 
approximately 2 cm into the femoral artery and vein on both left and right sides and 
tied in place with surgical silk. The incisions were then infiltrated with antiseptic 
xylocaine gel (2%) and sutured closed with surgical silk (4/0). Catheterisation of 
femoral vessels allows continuous monitoring of arterial blood pressure, intermittent 
arterial blood sampling and administration of drugs and radioisotope tracer. The 
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animals were then lightly restrained in plaster casts fitting loosely around the abdomen 
and hind legs. The weight of the rat was then supported by means of taping the plaster 
cast to a lead brick placed under the animal. 
Anaesthesia was discontinued and animals were allowed a minimum period of 1 hour 
recovery before any further procedures were performed. I 
Administration Of Drugs 
Following recovery from anaesthesia each animal received heptylphysostigmine 
tartrate 2 mg/kg (0.7 mis 0.9% saline) or vehicle (0.7 mis 0.9% saline) as an 
intravenous infusion at a constant rate over 30 mins. 
Measurement of Cerebral Blood Flow 
Local cerebral blood flow was determined 120 mins after cessation of drug/vehicle 
infusion according to minor modification of the method of Sakurada et al., 1978 (see 
Nehls et al., 1990). Animals received a ramped infusion of 50p. Ci of [14C]- 
Iodoantipyrine radioisotope in 1.5 mis of 0.9% saline over 60 seconds. During the 
infusion 15-18 timed samples of arterial blood were collected onto pre-weighed filter 
discs. Animals were killed by decapitation approximately 1 minute following the start 
of the isotope infusion. the brain was quickly removed and frozen in isopentane at 
-420C for later processing. The filter discs were then re-weighed and placed in 
scintillation vials. A 30% solution of hydrogen peroxide was then added to bleach the 
blood from the discs. Commercial scintillant was then added to the vials and [14C] 
radioactivity was determined by liquid scintillation counting. In addition to those blood 
samples collected during the experimental protocol, further blood samples were taken 
immediately prior to initiation of drug/vehicle infusion and blood flow measurement to 
allow plasma glucose and blood gas status determination. 
Preparation of [14C]. IAP Autoradiograms 
The frozen brains were mounted onto swivel headed microtome chucks with plastic 
embedding matrix (Lipshaw) over solid C02. Three 20µm coronal sections were 
collected serially onto glass coverslips at 200µm intervals throughout the brain and 
rapidly dried on a hotplate at 600C. the coverslips were then glued onto thin card. 
Autoradiograms were generated by apposing the sections along with pre-calibrated 
[14C] standards (44-2500 nCi/g, tissue equivalents) to Kodak Biomax MR film in 
light-tight cassettes for 3 days. 
Quantification Of Autoradiograms 
The autoradiograms were analysed densitometrically for radioisotope content by grey 
level comparison with the pre-calibrated standards in a similar manner to that described 
in section 2.1.1 for 125I-autoradiograms. Twelve bilateral readings were taken from 
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33 pre-determined anatomical loci, where the region of interest could be identified 
from the rat brain atlas of Paxinos and Watson (1986). 
Calculation Of Cerebral Blood Flow 
The local cerebral blood flow was calculated for each region of interest from the 
equation of Sakurada et al., 1978, with the knowledge of the time course history of the 
[14C]-IAP in the arterial blood, the [14C] concentration in each region and the 
tissue: blood partition coefficient (0.79) for the rat (see above). 
Data Analysis 
The data from the two experimental groups, heptylphysostigmine and vehicle were 
analysed using a two tailed Student's unpaired t-test. The data were expressed as mean 
± S. E. M. ml/100g/min for each region of interest. 
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2.4 ACETYLCHOLINESTERASE HISTOCHEMISTRY 
2.4.1 Theory 
The primary function of acetylcholinesterase in animal tissue is to catalyse the 
hydrolysis of acetylcholine to choline and acetic acid. To understand how the 
hydrolysis of ACh occurs it is necessary to have knowledge of the active centre of 
enzyme. The active centre of acetylcholinesterase has two subsites consisting of a 
negatively charged anionic site and an esteratic site (Wilson, 1951). The esteratic 
site contains both an acidic (electrophillic) and basic (nucleophillic) group. 
Hydrolysis is initiated when the positively charged quaternary nitrogen of an ACh 
molecule binds to the negatively charged anionic site on the enzyme. This causes the 
ACh molecule to orientate such that its carbonyl group is presented to the esteratic site. 
An enzyme -substrate complex is then formed. The acetyl group of the ACh molecule 
then transfers to the hydroxyl group of the esteratic site and a molecule of choline is 
liberated. Spontaneous and rapid hydrolysis of the acetyl group then occurs, 
producing acetic acid, and the esteratic site returns to its original state (See Fig. 9). 
Histochemical staining procedures make use of this reaction by providing a 
substrate other than acetylcholine that may be hydrolysed by the enzyme. The 
hydrolysis product is then reacted with another component to from an insoluble 
precipitate at the site of enzyme activity. The precipitate may then be coloured by a 
further reaction to visualise distribution of enzyme activity. The first demonstration of 
histochemical staining of AChE in this manner used higher fatty acid esters of choline 
as substrates . The most common substrates in use however, are thiocholine esters as 
these show high specificity for acetylcholinesterase over other esterases that may be 
present in the tissue. Thiocholine esters were originally shown to be suitable 
histochemical substrates for acetylcholinesterase by Koelle and Friedenwald in 1949. 
Their technique involves incubation of the tissue to be stained in a medium containing 
acetylthiocholine as a substrate for the enzyme, copper in the form of copper sulphate 
(CuSO4) as the capture agent and glycine which chelates the copper to reduce its 
inhibitory action on enzyme activity. The reactions which occur in the tissue during 
incubation in the staining medium not entirely understood, however the following 
reaction has been proposed (Bergner and Bayliss, 1952). 
Acetylthiocholine and copper glycinate react with the AChE producing copper 
thiocholine, glycine and acetic acid, as shown below. 
2 CH3000H2CH2(CH3)30H + (NH2CH2000)2Cu + H2O 
Acetylthiocholine Copper Glycinate 
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Mechanism of Hydrolysis of ACh by AChE 
Acetate 
Ac-serine 
hydrolysed 
(fast) 
0 
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Hý V OH 
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Fig 9: Schematic representation of ACh hydrolyisis by Acetylcholinesterase. 
ACh molecule binds to anionic site on the enzyme initiating hydrolyisis, whereby the 
acetyl group of ACh is transferred to the serine -OH of the esteratic site producing an 
acetylated enzyme form and liberation of a molecule of choline. Spontaneous hydrolysis of 
the serine-acetyl group occurs rapidly thereafter regenerating the enzyme and producing a 
molecule of acetic acid. , 
HO 
Choline 
Cu [SCH2CHN(CH3)30H]2 +2 NH2CH2COOH +2 CH3COOH 
Coppertbiocholine Glycine Acetic Acid 
White copperthiocholine is then precipitated in the region of enzyme activity. The 
copper in the incubate immediately precipitates the newly released thiocholine 
produced by the enzyme reaction. This prevents it from diffusing away from the 
reaction site ensuring accurate identification of enzyme distribution. The white copper 
thiocholine can then be "developed" to produce a characteristic dark stain by incubating 
tissue in a sodium or ammonium sulphide solution. This replaces copperthiocholine 
with brown copper sulphide in the following reaction: 
Cu [SCH2CHN(CH3)30H]2 + (NH4)2S 
CuS +2 NH4SCH2CH2N(CH3)30H 
The histochemical staining procedure for acetylcholinesterase used in this thesis is that 
described by Silver (1974) for fresh-frozen or unfixed tissue, and is based upon the 
technique of Lewis (1961). It is a modification of the thiocholine method of Koelle and 
Friedenwald (1949). 
2.4.2 Experimental Procedure 
Preparation Of Acetylthiocholine iodide incubate 
100mg of acetylthiocholine iodide (ACThI) was dissolved in 4mls of distilled H2O in a 
centrifuge tube. 7mls of 0.1M copper sulphate(CuSO4) solution was then added to the 
centrifuge tube. The initial2-3mis of CuSO4 being added dropwise. 
The tube was then left to stand for 10 mins before being centrifuged at 2000 rpm for 
20 mins. Following centrifugation, 10 mis of supernatant was pipetted off and 62 mg 
of glycine dissolved in it. The pH of the resulting solution was adjusted to 5.5 by 
addition of 1M sodium acetate solution. The incubate solution was then made up to a 
final volume of SOmis with dH2O and filtered using Whatmans No. 1 filter paper. 
This solution may be made up to one week in advance of use if stored in a refrigerator. 
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For the studies performed in this thesis, the incubate medium was used no more than 
24 hrs after preparation. 
Preparation Of Developer 
lg of sodium sulphide was dissolved in 45 mis of 0.2N acetic acid. The pH of 
the solution was then adjusted to 5.5 by addition of IM sodium acetate, before filtering 
through Whatmans No.! filter paper folded fanwise. The entire preparation of the 
developing solution was performed in fume hood, as the addition of acetic acid to 
crystals of sodium sulphide releases toxic hydrogen sulphide gas. 
The shelf-life of this soultion is very short, therefore, a fresh solution was prepared 
daily and refrigerated until use. 
Protocol 
201im coronal sections of rat brain mounted on subbed glass microscope slides were 
incubated in 0.2M sodium acetate solution containing 10-4M ethopropazine, at 250C 
for 30mins. Sections were then removed from the sodium acetate solution and 
incubated in ACThI solution containing 104M ethopropazine for 4 hrs at 250C. 
Ethopropazine is an inhibitor of butrylcholinesterase. The presence of this compound 
in the incubation medium ensures that only acetylcholinesterase enzyme activity is 
stained. Following incubation, sections underwent 3x1 min washes in dH2O. 
Sections were then immersed in sodium sulphide developer for 2mins, before 
undergoing 2x2 min washes in dHZO and were then allowed to dry. 
Dehydration of sections was produced by 3 sequential incubations of 1 min in 100% 
alcohol. Sections were then cleared by dipping in xylene and mounted with coverslips 
using DPX. 
Although great care was taken to standardise the staining procedure, 
histochemistry is intrinsically variable and small differences in incubation time, 
temperature or pH which affect the intensity of stain are unavoidable in the 
performance of the technique. To reduce the effect of such variations on staining 
intensity, sections were simultaneously stained in batches. In addition, control 
sections from an untreated animal were stained along with experimental tissue to 
provide an internal control for each batch.. - 
Semi-quantitative analysis of AChE stained sections 
In this thesis enzyme activity in histochemically stained sections was determined by a 
semi-quantitative densitometric technique using a computer based image analysis 
system. Absolute quantitative analysis of acetylcholinesterase activity in 
histochemically stained sections is possible when tissue standards containing known 
amounts of purified enzyme are prepared and incubated along with the experimental 
sections (Biegon and Wollf, 1986). Due to the constraints of time and unavailability of 
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a purified enzyme source, preparation of standards as described above was 
impractical. The image analyser was instead calibrated against as set of optical density 
standards. Enzyme activity in analysed sections was therefore converted to units of 
optical density, with areas of greater enzyme activity(i. e. greater stain intensity) 
scoring a higher optical density. 
Histochemically stained sections were analysed using a computer based image 
analysis system (M4 MCD, Imaging Research Inc. ). Sections were analysed 
densitometrically for enzyme activity in discrete brain regions by grey level 
comparison with pre-calibrated optical density standards. The image analyser was 
calibrated against optical density standards (Kodak Wratten gelatin filters) in the range 
of 0 -1.0, with the zero value taken as the background level when no filter was present 
in the image field. Measurements were made by placing a measuring frame over each 
anatomical region of interest. The size of the measuring frame was variable but was 
kept constant for anatomical regions of interest between individual studies. Bilateral 
readings were taken from individual sections for each region of interest. Background 
readings were taken from each slide and subtracted from the O. D. value measured for 
each region of interest. This was done to reduce the effect slight differences the 
mounting procedure produces in the density of the staining. 
Structures in the rat brain were defined anatomically by reference to the stereotaxic 
atlas of Paxinos and Watson (1986). 
Data Analysis 
To reduce measurement variability, sections from a single batch of staining were 
analysed on the same day. Similarly, direct comparisons in the level of staining were 
made only between sections stained in the same batch. Data from heptylphysostigmine 
and vehicle treated sections were analysed using a two tailed Student's unpaired t- 
test. Data are expressed as mean ± S. E. M optical density, as a semi-quantitative 
measure of enzyme function. A higher O. D. representing greater enzyme activity. 
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CHAPTER 3 
RESULTS 
3.1 IN VIVO AUTO RADIOGRAPHIC STUDIES 
3.1.1 Uptake and Retention of (R, S)-[125I]. QNB in Rat Brain 
The uptake and retention of (R, S)-[125I]-QNB in the brain of conscious rat between 2 
and 24 hours following intravenous administration of tracer was determined by in vivo 
autoradiography. Quantitative densitometric analysis of autoradiograms was performed 
to determine (R, S)-[1251]-QNB levels in 33 anatomically distinct brain regions with 
tracer level in each region expressed as a ratio relative to uptake in the caudate nucleus 
(Table 5). 
General Observations 
Physiologic variables were measured prior to and at various time points after 
administration of (R, S)-[1251_QNB. No significant differences were observed in any of 
the variables measured following administration at any of the time points. Tables of 
physiologic variables are presented in Appendix B. 
Regional Uptake and Retention of (R, S). [1251]-QNB 
(R, S)-[1251]-QNB shows a heterogeneous pattern of distribution within the brain. 
Autoradiographic images of (R, S)-[125I]-QNB distribution in the brain are shown in Fig 
10. Notable differences in regional tracer retention can be seen between the 2 hour and 
24 hour images. High levels of activity were observed in the cortex, caudate nucleus and 
hippocampus at 2 hours which persisted up to 24 hours. In the thalamus, (R, S)-[1251]- 
QNB levels were initially high at 2 hours, but activity was then observed to decrease 
significantly over the next few hours with a 40% reduction in activity observable by 24 
hours. In comparison a reduction in activity of 10% is observed in the frontal cortex over 
the same time period. In contrast (R, S)-[1251]-QNB activity in the cerebellum was 
initially low at 2 hours (less than 10% of that in frontal cortex) and remained at this low 
level up to 24 hours. Regional activity-time profiles of normalised data for (R, S)-[1251]_ 
QNB are shown in Fig 11 for frontal cortex, CAI of the hippocampus, mediodorsal 
thalamus and the cerebellum. 
The regional distribution of (R, S)-[125q: QNB in rat brain in vivo generally 
corresponds to the rank order of mAChR concentration as determined in vitro . Highest 
levels of (R, S)-[1251]-QNB are observed in the caudate and cortex, with low levels 
observed in the cerebellum and intermediate levels observed in the thalamus. 
Correlation of non-normalised regional activity (tCi/g) for (R, S)-[ 
125I]-QNB with 
mAChR concentration is displayed in Fig 12. An overall correlation coefficient of 
r=0.87 indicates a high degree of association between regional (R, S)-[1251]-QNB 
distribution and mAChR concentration. 
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Plasma Clearance of (R, S)-[125I]. QNB 
The concentration-time profile of (R, S)-[1251]-QNB in plasma following intravenous 
injection is presented in Fig 13. Radioactivity is detectable in the plasma of rat up to 24 
hours following administration, albeit at a low level. This data is uncorrected for the 
presence of metabolites however and therefore the proportion of radioactivity in plasma 
representing authentic ligand cannot be determined. 
Normalisation of Data to the Caudate Nucleus 
Raw data (lCi per g brain) for regional (R, S)- [ 1251]-QNB activity in rat brain were 
expressed as a ratio of percent of the injected dose relative the level in the caudate 
nucleus to reduce the impact of interanimal variability on the data. Normalisation to this 
region was performed as tracer levels in this region are reproducible from animal to 
animal and are relatively unchanged over the experimental time period. Raw data (µCi/g) 
for (R, S)-[125rj-QNB in caudate nucleus between 2 and 24 hours is shown in Fig 14. 
Complete regional tables of non-normalised time-activity data for (R, S)-[1251]-QNB are 
displayed in Appendix A. 
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Table 5 
(R, S). [1251]. QNB in the Brain of Conscious Rat 
Region 
Cerebellum 
Cerebellar Cortex 
Medulla/Pons 
Pontine Grey 
Nucleus of the Lateral Lemniscus 
Lateral Dorsal Tegmental nucleus 
Mesencephalon 
Inferior Colliculus 
Superior Colliculus 
Substantia Nigra (pars compacts) 
Substantia Nigra (pars reticulata) 
Diencepahlon 
TIME FOLLOWING ADMINISTRATION OF TRACER 
2 Hours 6 Hours 12 Hours 24 Hours 
0.108 ± 0.021 0.147 ± 0.029 0.092 ± 0.043 0.073 ± 0.036 
0.907 t 0.247 0.799 ±0.081 0.377 ± 0.093 0.411 ± 0.178 
0.322 ± 0.089 0.302 ± 0.029 0.220 ± 0.031 0.101 ± 0.075 
0.451 ± 0.127 0.409 ±0.066 0.415 ±0.178 0.266 ± 0.137 
0.471 ± 0.121 0.480 ±0.106 0.276 ± 0.060 0.273 ± 0.121 
0.725 ±0.068 0.464 ±0.021 0.279 ± 0.074 0.172 ± 0.100 
0.504 ± 0.064 0.476 ± 0.007 0.328 ± 0.098 0.206 ± 0.079 
0.495 ± 0.074 0.418 ± 0.029 0.275 ± 0.080 0.179 ± 0.073 
Hippocampus CAl 0.659 ± 0.082 0.816 ± 0.040 0.741 ± 0.263 0.831 ± 0.038 
Hippocampus CA2 0.869 ± 0.061 0.971 ± 0.075 0.805 ± 0.288 0.837 ± 0.019 
Hippocampus CA3 0.762 ± 0.059 0.871 ± 0.075 0.747 ± 0.245 0.797 ± 0.023 
Medial Geniculate Body 0.841 ± 0.061 0.763 ± 0.022 0.540 ± 0.193 0.435 ± 0.087 
Sub Thalamic Nucleus 0.596 ± 0.064 0.410 ± 0.026 0.376 ± 0.103 0.240 ± 0.118 
Lateral Geniculate Nucleus 0.713 ± 0.082 0.687 ± 0.070 0.533 ± 0.182 0.341 ± 0.131 
Hypothalamus 0.471 ± 0.108 0.544 ± 0.037 0.383 ± 0.146 0.309 ± 0.097 
Mediodorsal Thalamic Nucleus 0.762 ± 0.083 0.750 ± 0.074 0.584 ± 0.020 0.465 ± 0.011 
Ventrolateral Thalamic Nucleus 0.642 ± 0.093 0.643 ± 0.051 0.464 ± 0.147 0.327 ± 0.109 
Telencephalon 
Visual Cortex (layer IV) 0.751 ± 0.345 0.971 ±0.022 0.910 ± 0.279 1.057 ± 0.165 
Dentate Gyms 0.837 ± 0.060 0.927± 0.062 0.782 ± 0.263 0.749 ± 0.058 
Auditory Cortex (layer IV) 1.365 ± 0.081 1.279 ± 0.095 1.140 ± 0.414 1.204 ± 0.086 
Hippocampus Molecular Layer 0.897 ± 0.046 0.956 ±0.071 0.893 ± 0.314 0.805 ± 0.065 
Amygdala 0.698 ± 0.054 0.693 ± 0.055 0.607 ± 0.211 0.562 ± 0.025 
Globus Pallidus 0.365 ± 0.085 0.368 ± 0.043 0.275 ± 0.097 0.266 ± 0.093 
Caudate Nucleus 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000 
Septal Nuclei 0.682 ± 0.055 0.664 ± 0.056 0.576 ± 0.178 0.486 ± 0.086 
Nucleus Basalis Magnocellularis 0.383 ± 0.083 0.409 ± 0.042 0.326 ± 0.128 0.292 ± 0.074 
Nucleus Accumbens 1.03 t 0.069 1.094 ± 0.037 1.016 ± 0.040 1.085 ± 0.055 
Sensory Motor Cortex (layer IV) 1.275 t 0.042 1.114 ± 0.084 1.112 ± 0.041 1.09 t 0.044 
Anterior Cingulate Cortex 1.067 t 0.064 1.111 ± 0.049 1.004 t 0.04 1.078 f 0.054 
Frontal Cortex 1.181 t 0.050 1.128 ± 0.049 1.035 t 0.041 1.072 t 0.065 
Parietal Cortex 0.926 t 0.145 1.091 ± 0.093 1.021 ± 0.038 1.028 t 0.035 
Myelinated Fibre Tracts 
Internal Capsule 0.351 ± 0.071 0.287 ± 0.039 0.222 ± 0.056 0.220 ± 0.075 
Genu 0.338 ± 0.046 0.344 ± 0.035 0.270 ± 0.109 0.281 ± 0.056 
Table shows (R, S)-[125I]-QNB in discrete brain regions of the conscious rat 2,6,12 
and 24 hours following iv administration of 200gCi of tracer. Data are expressed as 
mean ± S. E. M % dose per g brain normalised to the caudate nucleus, n= 3-5 animals for 
each time point. 
90 
(R, S)-[125I]-QNB In Brain Of Conscious Rat 
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Fig 10: (R, S)-[125I]-QNB in the brain of conscious rat at 2,6,12 and 24 hours. 
Illustrative autoradiograms show tracer uptake at the level of the caudate nucleus (A), 
dorsolateral hippocampus (B) and cerebellum (C) of rat brain. Tracer uptake shows a 
heterogeneous distribution within the brain corresponding to regional mAChR density. High 
levels of activity are observed in the caudate and cortex, intermediate levels in the thalamus 
and low levels in the cerebellum. Washout of tracer from thalamus and cerebellum is 
considerably faster than in the caudate and cortex, with neglible amounts of activity observed 
in the cerbellum by 6 hours. Each brain section represents a digitised video image taken 
directly from individual autoradiograms at the relevant time point. 
Regional Distribution of (RS)-[125I]-QNB in Rat Brain 
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Fig 11: Uptake and retention of (R, S)-[125I]_QNB in the frontal cortex, hippocampus CAI, 
mediodorsal thalamus and cerebellum between 2 and 24 hours following tracer administration, 
note loss of (R, S)-[125I]-QNB from mediodorsal thalamus with time. Data are expressed as 
mean ± S. E. M. % dose per g brain normalised to caudate nucleus. n= number of animals in each 
group. 
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Correlation of Regional (R, S)-[1251]-QNB Activity and mAChR Concentration 
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Fig 12: Figure shows a plot of raw data for (R. S)-[125I]-QNB at 2 hours at the level of the 
caudate nucleus, frontal cortex, hippocampus, mediodorsal thalamus, and cerebellum 
against regional mAChR concentration. Correlation coefficient of r2=0.87 indicates a high 
degree of association between regional levels of (R, S)-[125I]-QNB and mAChR 
concentration. (R, S)-[ 125I]-QNB for each region is expressed as mean ± S. E. M iCi per g 
of Brain, n= 5 animals per region. mAChR concentration is expressed as the average 
concentration of receptors in nmoles for each region as adapted from Boulay et al., (1996). 
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Fig 13: Timecourse of radioactivity in plasma up to 24 hours following intravenous 
administration of 200gCi (R, S)-[1251]-QNB. Data is uncorrected for metabolites and 
therefore the proportion of radioactivity representing authentic tracer cannot be 
determined. Data is expressed as mean ± S. E. M % dose per ml plasma of 5-16 samples. 
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Fig 14: Uptake and retention of (R, S)-[125I]-QNB in the caudate nucleus of conscious rat 
from 2 to 24 hours following intravenous administration of tracer. Data are expressed as 
mean ± S. E. M. jCi per g brain , n=3-5 animals per time point. 
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3.1.2 'Uptake and Retention of (R, R)-[1251]-QNB in Rat Brain 
The uptake and retention of (R, R)-[1251]-QNB in the brain of conscious rat between 30 
mins and 6 hours following intravenous administration of tracer was determined by in 
vivo autoradiography. Quantitative densitometric analysis of autoradiograms was 
performed to determine (R, R)-[1251]-QNB levels in 33 anatomically distinct brain 
regions with tracer level in each region expressed as a ratio relative to uptake in the 
caudate nucleus (Table 6). Regional uptake and retention data for (R, R)-[1251]-QNB 
was compared to that determined for (RS)-[1251]-QNB. 
General Observations 
Physiologic variables were measured prior to and at various time points after 
administration of (R, R)-[1251]-QNB. No significant differences were observed in any of 
the variables measured following administration at any of the time points. Tables of 
physiologic variables are presented in Appendix B. 
Comparison of (R, R). [125I]. QNB and (R, S). [125I]. QNB Uptake and 
Retention 
Autoradiographic images of (R, R)-[1251]-QNB distribution in the brain are shown in 
Fig 15. (R, R)-[125I]-QNB shows a heterogeneous pattern of distribution in the brain 
over 6 hours analogous to that observed for (R, S)-[1251]-QNB over 24 hours. A 
comparison of regional activity-time profiles of normalised data for (R, R)-[1251]-QNB 
and (R, S)-[125I]-QNB are shown in Fig 16 for frontal cortex, CAI of the hippocampus 
and the cerebellum. 
In the cortex comparable levels of activity are observable with (R, S)- and (R, R)-(125I]- 
QNB with little or no washout of activity observed over the time course of the 
experiments. In the CAI of the hippocampus activity levels for the two tracers are also 
generally comparable, although (R, R)-[ 1251]-QN 3 levels are observed to increase with 
time and are highest at 6 hours. In the cerebellum (R, R)-[ 1251]-QNB levels are initially 
higher than those for (R, S)-[ 1251]-QNB but washout of activity is observed with time 
such that levels are comparable by 2 hours. 
Although the in vivo distribution and behaviour of (R, S)- and (R, R)-[1251]-QNB is 
qualitatively similar in the above regions, an important difference between the tracers is 
the time course over which these observations are made. (R, S)-[125U_QNB essentially 
shows no washout from regions of high mAChR concentration such as the cortex and 
hippocampus over 24 hours. In contrast this is only true for (R, R)-(1251]-QNB over 6 
hours. Analysis of regional levels of (R, R)-[125I]-QNB in a single animal at 12 hours 
(data not shown) indicates that a significant loss of activity is observed from all regions 
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with the exception of the cortex, to the extent that no activity is observable in the 
cerebellum at this time. (R, S)- and (R, R)-[125I]-QNB therefore display considerable 
differences in kinetic behaviour in vivo. 
This is exemplified by analysis of regions of intermediate mAChR concentration which 
display moderate uptake of tracer. Fig 17 shows comparison of time activity data for 
(R, S)- and (R, R)-[1251]-QNB in the mediodorsal thalamus, ventrolateral thalamus and 
the lateral geniculate nucleus. The above regions display a significant washout of activity 
over time for both tracers. However, a greater loss of (R, R)-[12511-QNB activity is 
observed from these regions over a shorter period of time. In each region levels of 
(R, R)-[1251]-QNB are initially higher at 30 mins than those of (R, S)-[I251]-QNB at 2 
hours, but are significantly lower than those of (R, S)-[1251]-QNB by 6 hours. 
Mediodorsal thalamus, ventrolateral thalamus and lateral geniculate nucleus respectively 
show a 70%, 72% and 70% reduction in (R, R)-[125I]-QNB activity from 30 mins to 6 
hours. In comparison, for the same regions a 40%, 50% and 53% reduction in (R, S)- 
[1251-QNB activity was observed between 2 and 24 hours. These observations indicate 
that although (R, S)- and (R, R)-[1251]-QNB display qualitatively similar distribution the 
time course of their uptake and retention in the brain is considerably different. 
Differences in their in vivo kinetics for association and dissociation and in their affinity 
for mAChRs is likely to be responsible for this. 
Plasma Clearance of (R, R)-[1251]. QNB 
The concentration-time profile of (R, R)-[125I]-QNB in plasma following intravenous 
injection is presented in Fig 18. Radioactivity is detectable in the plasma of rat up to 6 
hours following administration, albeit at a low level. This data is uncorrected for the 
presence of metabolites however and therefore the proportion of radioactivity in plasma 
representing authentic ligand cannot be determined. 
Normalisation of Data to the Caudate Nucleus 
As with (R, S)-[1251]-QNB raw data (gCi per g brain) for regional (R, R)-[1251]-QNB 
activity in rat brain were expressed as a ratio of percent of the injected dose relative the 
level in the caudate nucleus to reduce the impact of interanimal variability on the data. 
Complete regional tables of non-normalised time-activity data for (R, R)-[1251]-QNB are 
displayed in Appendix A. 
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Table 6 
(R, R)-[125I]. QNB in the Brain of Conscious Rat 
Region 
Cerebellum 
Cerebellar Cortex 
Medulla/Pons 
Pontine Grey 
Nucleus of the Lateral Lemniscus 
Lateral Dorsal Tegmental nucleus 
Mesencephalon 
Inferior Colliculus 
Superior Colliculus 
SubstantiaNigra (pars compacta) 
Substantia Nigra (pars reticulata) 
TIME FOLLOWING ADMINISTRATION OF TRACER 
0.5 Hours 1 Hours 2 Hours 6 Hours 
0.388 ± 0.056 0.288 ± 0.012 0.102 ± 0.029 0.160 ± 0.047 
1.097 ± 0.053 0.936 ± 0.060 0.534 ± 0.097 0.487 ± 0.130 
0.732 ± 0.096 0.541 ± 0.046 0.457 ± 0.095 0.363 t 0.101 
0.818±0.061 0.56410.048 0.328±0.081 0.329±0.099 
0.744 ± 0.036 0.593 ± 0.034 0.346 ± 0.098 0.239 ± 0.067 
0.780 ± 0.044 0.650 ± 0.056 0.334 ± 0.096 0.286 ± 0.107 
0.622 ± 0.035 0.533 ± 0.032 0.368 ± 0.091 0.305 ± 0.094 
0.525±0.039 0.485±0.029 0.309±0.074 0.247±0.079 
Diencepahlon 
Hippocampus CA1 0.664 ± 0.015 0.817 ± 0.090 0.902 ± 0.067 1.276 ± 0.135 
Hippocampus CA2 0.896 ± 0.059 0.902 ± 0.044 0.804 ± 0.190 0.954 ± 0.096 
Hippocampus CA3 0.816 ± 0.016 0.854 ± 0.019 0.898 ± 0.067 1.131 ± 0.110 
Medial Geniculate Body 0.862 ± 0.032 0.823 ± 0.019 0.549 ± 0.130 0.379 ± 0.080 
Sub Thalamic Nucleus 0.795 ± 0.064 0.632 ± 0.077 0.428 t 0.057 0.365 t 0.067 
Lateral Geniculate Nucleus 0.858 ± 0.062 0.752 ± 0.026 0.512 ± 0.052 0.257 ± 0.083 
Hypothalamus 0.639 ± 0.030 0.518 ± 0.033 0.370 ± 0.056 0.189 ± 0.058 
Mediodorsal Thalamic Nucleus 0.846 ± 0.079 0.751 ± 0.034 0.544 ± 0.050 0.254 ± 0.760 
Ventrolateral Thalamic Nucleus 0.617 ± 0.026 0.480 ± 0.035 0.343 ± 0.053 0.175 ± 0.059 
Telencephalon 
Visual Cortex (layer IV) 1.133 ± 0.011 0.944 ± 0.095 1.052 ± 0.078 1.164 ± 0.280 
Dentate Gyrus 0.949 ± 0.051 0.924 ± 0.055 0.969 ± 0.087 1.028 ± 0.227 
Auditory Cortex (layer IV) 1.460 ± 0.900 1.341 ± 0.074 1.400 ± 0.094 1.350 ± 0.258 
Hippocampus Molecular Layer 0.949 ± 0.046 1.004 ± 0.044 0.911 ± 0.097 1.070 ± 0.232 
Amygdala 
, 
0.732 ± 0.059 0.721 ± 0.021 0.644 ± 0.064 0.624 ± 0.034 
Globus Pallidus 0.513 ± 0.047 0.398 ± 0.036 0.394 ± 0.059 0.267 ± 0.052 
Caudate Nucleus 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000 
Septal Nuclei 0.667 ± 0.047 0.743 ± 0.032 0.630 ± 0.017 0.461 ± 0.037 
Nucleus Basalis Magnocellularis 0.551 ± 0.037 0.497 ± 0.029 0.471 ± 0.028 0.331 ± 0.052 
Nucleus Accumbens 1.086 ± 0.012 1.102 ± 0.052 1.074 ± 0.078 1.189 ± 0.105 
Sensory Motor Cortex (layer IV) 1.272 ± 0.064 1.203 ± 0.022 1.272 ± 0.060 1.106 t 0.090 
Anterior Cingulate Cortex 1.173 ± 0.079 1.163 ± 0.006 1.176 ± 0.054 1.219 ± 0.072 
Frontal Cortex 1.144 ± 0.036 1.176 ± 0.027 1.192 ± 0.070 1.134 t 0.078 
Parietal Cortex 1.141 10.047 1.100 ± 0.034 1.108 ± 0.066 1.061 t 0.099 
Myelinated Fibre Tracts 
Internal Capsule 0.252 i 0.039 0.366 t 0.020 0.196 ± 0.056 0.069 ± 0.041 
Genu 0.270 ± 0.060 0.324 t 0.025 0.210 ± 0.053 0.223 ± 0.063 
Table shows (R, R)-(125I]-QNB in discrete brain regions of the conscious rat 0.5,1,2 
and 6 hours following iv administration of 200gCi of tracer. Data are expressed as mean 
± S. E. M % dose per g brain normalised to the caudate nucleus, n= 5 animals for each 
time point. 
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Fig 15: (R, R)-['2 l j-QNB in the brain of conscious rat at 30 minn, 1,2 and 6 hours. 
Illustrative autoradiograms show tracer uptake at the level of the caudate nucleus (A), 
dorsolateral hippocampus (B) and cerebellum (C) of rat brain. Tracer uptake shows a 
heterogeneous distribution within the brain corresponding to regional mAChR density. 
High levels of activity are observed in the caudate and cortex, intermediate levels in the 
thalamus and low levels in the cerebellum. Washout of tracer from thalamus and 
cerebellum is considerably faster than in the caudate and cortex, with negligible amounts 
of activity observed in the cerebellum by 6 hours. 
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Fig 16: Time activity profiles of (R, S)- and (R, R)-[1251]-QNB uptake and retention in the 
brain of conscious rat at the level of the frontal cortex (A), CAI of the hippocampus (B) 
and cerebellum (C). Regional levels of (R, R)-[I25n-QNB activity over 6 hours are 
comparable to those of (R, S)-[125I]-QNB over 24 hours. Different time-activity profiles 
for (R, S)- and (R, R)-[125I]-QNB should be noted. Data are expressed as mean ± S. E. M. % 
dose per g brain normalised to caudate nucleus. n= number of animals in each group. 
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Fig 17: Time activity profiles of (R, S)- and (R, R)-[125I]-QNB in rat brain at the level of 
the mediodorsal thalamus (A), ventrolateral thalamus (B) and the lateral geniculate nucleus 
(C) between 30 mins and 24 hours after tracer administration. Each region shows loss of 
(R, S)- and (R, R)-[125I]-QNB activity over time. Regional loss of (R, R)-[125I]-QNB is 
greater than that of (R, S)-[125I]-QNB and occurs on a shorter timescale. Data are 
expressed as mean ± S. E. M. % dose per g brain normalised to the caudate nucleus. n= 
number of animals in each group. 
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Fig 18: Timecourse of radioactivity in plasma up to 6 hours following intravenous 
administration of 200µCi (R, R)-[125n_QNB. Data is uncorrected for metabolites and 
therefore the proportion of radioactivity representing authentic tracer cannot be 
determined. Data is expressed as mean ± S. E. M % dose per ml plasma of 5-20 samples. 
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3.1.3 Metabolic Fate of (R, S). and (R, R). [125I]-QNB in the Conscious 
Rat 
Plasma and brain homogenate samples were taken from rats injected with (R, S)- and 
(R, R)-[1251]-QNB and analysed by high performance liquid chromatography (HPLC) 
for the presence of authentic Iigand and radioactive metabolites. 
Stability Of (R, S)- and (R, R). [1251]. QNB Upon Reconstitution 
Before in vivo investigation of the metabolism of (R, S)- and (R, R)-[125I]-QNB samples 
of both ligands reconstituted in 0.9 % saline representing injectate were analysed by 
HPLC for authentic ligand and metabolite content. 
For both (R, S)- and (R, R)-[125I]-QNB samples of injectate were found to consist 
almost entirely of authentic ligand. Fig 19 shows illustrative HPLC traces from analysis 
of injectate samples of (R, S)- and (R, R)-[125I]-QNB. The major peaks visible on both 
traces eluted with retention times of 6.6 and 8.2 mins, represent authentic (R, S)- and 
(R, R)-[1251]-QNB respectively. Both traces show a minor species eluted at 
approximately 3 mins which represents the presence of free iodide in the sample. The 
HPLC trace for (R, S)-[1251]-QNB also shows two other minor peaks at 7.7 and 12.0 
mins. These peaks represent unidentified radioactive species that may be breakdown 
products of the parent compound that have evolved upon reconstitution. 
Metabolism of (R, S)- and (R, R)-[1251]. QNB in the Conscious Rat 
The fraction of radioactivity representing parent (R, S)- and (R, R)-[125n. QNB in brain 
tissue and plasma at various time intervals after intravenous injection of each ligand was 
determined by radio-HPLC analysis. The HPLC column performs reverse phase 
chromatography, separating radioactive species by polarity, with the most highly charged 
species eluted first. 
(R, S) -[125I]-QNB-Plasma Analysis 
Plasma samples were analysed for the presence of parent (R, S)-[1251]-QNB and 
metabolites at time intervals from 1 min to 12 hours after ligand administration. 
Fig 20 shows illustrative HPLC traces from plasma samples taken at 1,5,15, and 45 
minn and 1 and 12 hours following intravenous administration of (R, S) [1251J-QNB. 
From HPLC analysis of plasma samples authentic (R, S)-[ 1251]-QNB is observed to be 
present in plasma up to 12 hours following intravenous administration. The plasma 
content of ligand decreases slowly with time as free iodide concentration increases. Two 
unidentified metabolite species are also observable in plasma. 
One minute following tracer administration a significant degree of tracer metabolism has 
already occurred (Fig 20: A). Parent compound remains present as a major component in 
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plasma represented by the peak eluted at 8.7 mins. Two major radioactive species 
constituting unidentified metabolites of (R, S) [125I]-QNB are present in the sample 
represented by the peaks observed at 12.9 and 15.5 mins. A significant amount of free 
iodide is also present and is represented by the large peak observed at 3.0 mins. 
By 15 mins the slower eluting metabolite with a retention time of 153 mins has been 
cleared from plasma. Authentic ligand remains present along with free iodide and 'a 
remaining metabolite species (Fig20: C). At 12 hours following administration authentic 
(R, S)-[125I]-QNB remains detectable in plasma (Fig 20: F). Whether any radioactive 
metabolites are present in plasma at this time cannot be determined, although it is possible 
that peaks representative of such species are hidden by the background noise apparent on 
this trace. The small volume of plasma collected combined with the low level of 
radioactivity contained within the samples is responsible for the high level of noise 
observable on later traces. Under these conditions subtraction of the background noise 
from each trace is usually carried out to highlight the signal. This however was not 
possible for all samples, as the signal to noise ratio on some traces was extremely low 
and would result in the loss of the desired signal. This results in poor resolution of the 
traces and accounts for the high degree of "noise" observed. 
(R, S)-[125I]-QNB-Brain homogenate Analysis 
HPLC analysis indicates that authentic tracer constitutes the only major radioactive 
species present in rat brain up to 24 hours following intravenous administration of (R, S)- 
[1251]-QNB. Fig 21 shows illustrative HPLC traces from brain homogenate samples 
taken at 2,6,12 and 24 hours after (RS)-[125I1-QNB administration. 
A single large peak representing parent ligand was observed at approximately 7.0 mins 
on HPLC traces from brain homogenate samples at all time points . The smaller peaks 
observed at approximately 8.0 and 12.0 mins on some traces represent unidentified 
radioactive species that may be metabolites of the parent compound. Corresponding 
peaks are observed at similar times on traces of injectate analysed (Figl9) and in this case 
may represent metabolites generated upon reconstitution of the tracer. It should be noted 
that these peaks are not present on traces from quality control samples of radiotracer 
analysed following completion of synthesis (not shown). The small single peak 
observed at approximately 3.0 mins on injectate and on some brain homogenate traces 
constitutes a highly polar compound eluted with the void volume of the column. It is 
highly likely that this first metabolite represents free iodide species produced by de- 
iodination of the tracer. The presence of these small amounts of metabolites in some brain 
homogenate samples may be the result of plasma metabolite contamination of brain tissue 
samples due to incomplete removal of blood from the brain before analysis. 
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(R, R). [ 125I]-QNB-Plasma Analysis 
Plasma samples were analysed for the presence of parent (R, R)-[1251]-QNB and 
metabolites at time intervals from 1 min to 6 hours after ligand administration. 
Fig 22A-E show illustrative HPLC traces from plasma samples taken at 1,5,15, and 30 
mins and 1, and 6 hours following intravenous administration of (R, R)-[1251. QNB. 
From HPLC analysis of plasma samples authentic (R, R)-[ 125I]-QNB is observed to be 
present in plasma up to 6 hours following intravenous administration. The plasma 
content of ligand decreases slowly with time as free iodide concentration increases. No 
major radioactive metabolite species are observable in plasma at any of the time points 
analysed. 
In all samples analysed the peak observed at approximately 3.0 minn is very likely to 
represent a free iodide species . This indicates that the de-iodination of the tracer occurs 
as the major step in the metabolism of this tracer. However, a broad low level peak is 
observed at approximately 13.0 mins on all plasma traces from 5 mins onwards (Fig 
22B). This is possibly due to the presence of one or more radioactive metabolites in 
plasma which are present at a very low level. It is possible that they are formed and 
cleared rapidly with no accumulation in the plasma. Fig 23 represents a plot of the "Free 
Pool" of authentic (R, R)-[1251]-QNB (i. e. tracer available for uptake from plasma into 
the brain) in plasma following intravenous injection. This indicates that authentic tracer 
is available for uptake into the brain, albeit at a low level, up to 6 hours following 
administration. 
(R, R)-[125I]-QNB-Brain Homogenate Analysis 
HPLC analysis indicates that authentic tracer constitutes the only major radioactive 
species present in rat brain up to 6 hours following intravenous administration of (R, R)- 
[125I]-QNB. Fig 24 shows illustrative HPLC traces from brain homogenate samples 
taken at 30 min, 1,2, and 6 hours after (R, R)-[125I1-QNB administration. 
A single large peak representing parent ligand is observed at approximately 8.0 mins on 
HPLC traces from brain homogenate samples at all time points. A corresponding peak is 
observed at a similar time on traces of injectate analysed (Fig 19) indicating that this 
represents authentic tracer. 
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Iodide 
Fig 19: Stability of reconstituted (RS)- and (R, R)-[1251]-QNB. 
Figure shows representative HPLC traces for injectate samples of (RS)- and (R, R)-['251]-QNB 
reconstituted in 0.9% saline. Authentic ligand represented by the peaks at 6.6 and 8.0 mins 
respectively for (RS)- and (R, R)-['251]-QNB constitutes the major species present in injectate. 
A free iodide species identified by the peak at approximately 3.0 mins is present on both 
traces. Two unidentified species likely to be breakdown products are present at 7.7 and 12.0 
mins on the trace for (R, S)-['251]_QNB 
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Fig 20: Metabolism of (R, S)-[125I]-QNB in the rat: Plasma 
Representative HPLC traces from plasma samples taken at 1,5,15, and 45 mins and I and 12 
hours (traces A-F respectively) after administration of tracer. Authentic (R, S)-[1251]-QNB 
(represented by peak at approximately 8.0 minn on each trace) is present in the plasma up to 
12 hours. A free iodide species (earliest eluted peak) and two unidentified radioactive 
metabolites less polar than (R, S)-[1251]-QNB (peaks appearing at approximately 13.0 and 15.0 
mins) are also present in plasma. 
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Fig 21: Metabolism of (R, S)-[1251]-QNB in the rat: Brain 
Representative HPLC traces of brain homogenate samples from animals sacrificed at 2,6,12 
and 24 hours (traces A-D respectively)after administration of tracer. Authentic (R, S)-['251]- 
QNB represents the only major radioactive species present in brain. Two additional peaks 
present on traces for 6 and 24 hours are likely to represent contamination from blood present 
in the sample and do not represent a major component of brain activity. 
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Fig 22: Metabolism of (PR)-['25I]-QNB in rat: Plasma 
Representative HPLC traces from plasma samples taken at 1,5,15 and 45 mins and 1 and 6 
hours (traces A-F respectively) after administration. Authentic (R, R)-[1251]-QNB (represented 
by peak at approximately 7.0 mins on each trace) is present in the plasma up to 6 hours. In all 
plasma samples a free iodide species (peak at approximately 3.0 mins) represents the only 
metabolite detected. 
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Fig 23: Timecourse of free (R, R)-[125I]-QNB in plasma following intravenous injection in 
rat. Data points represent levels of authentic non-plasma protein bound ligand available 
for uptake into brain in plasma of conscious rat between I. min and 6 hours after 
administration. Note that significant levels of authentic ligand are still present in plasma at 
6 hours. Data are expressed as mean ± S. E. M % of injected dose (n= 2-3). 
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Fig 24: Metabolism of (RR)-[1251]-QNB in rat: Brain 
Representative HPLC traces of brain homogenate samples from animals sacrificed at 0.5,1,2 
and 6 hours (traces A-D respectively)after administration of tracer. Authentic (R, R)-['251]- 
QNB represents the only radioactive species present in brain. 
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3.1.4 Effect of Heptylphysostigmine on (RS). and (R, R). [1251]-QNB 
Levels in the Brain of Conscious Rat 
Levels of (RS)- and (R, R)-[1251]-QNB in rat brain over 24 hours and 6 hours 
respectively was determined by in vivo autoradiography following intravenous 
administration of heptylphysostigmine (2mg/kg). 
General Observations 
Administration of heptylphysostigmine produced a number of overt behavioural changes 
in rats symptomatic of acute cholinergic toxicity which were not observed in vehicle 
(saline) treated animals. 
Symptoms included salivation, urination, muscle tremor and fasciculation, hind limb 
splay and an increased sensitivity to noise. In addition, animals exhibited reduced 
locomotor activity and absence of the normal grooming and exploratory behaviour 
associated with rats. There was however no sedative effect and all animals remained 
conscious throughout. 
These symptoms were observed in all animals receiving heptylphysostigmine, with mild 
effects first appearing approximately 10 rains after initiation of drug infusion. The 
symptoms gradually increased in severity peaking approximately 1 hour after cessation of 
the drug infusion. Thereafter symptoms subsided over the next few hours, with no signs 
of toxicity observable by 4 hours. In animals receiving a second drug infusion similar 
symptomology was observed. Drug effects peaked approximately 1 hour after end of 
infusion, with no symptoms observable 4 hours later. 
Physiologic variables were measured prior to and 30 mins after heptylphysostigmine 
administration. Thereafter physiologic variables were measured prior to and at various 
time points after administration of (R, S)- or (RR)-[125I]-QNB. Tables of physiologic 
variables are presented in Appendix B. 
Heptylphysostigmine administration generally had a minor effect on physiologic 
variables. Elevations in mean arterial blood pressure and in plasma glucose levels were 
measured in some experimental groups, however no consistent pattern of changes was 
observable (see Appendix B) 
Effect of Heptylphysostigmine on Uptake and Retention of (R, S). [125I]- 
QNB 
Quantitative densitometric analysis of autoradiograms was performed to determine (R, S)- 
[1251]-QNB levels in 33 anatomically distinct brain regions at 2 and 24 hours following 
tracer administration in heptylphysostigmine (2mg/kg) and vehicle (0.9% saline) treated 
animals. Tracer level in each region was expressed as a ratio relative to uptake in the 
caudate nucleus (Tables 7 and 8). 
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Table 7 
Effect of Heptylphysostigmine on (R, S)-[125I]-QNB 
in Brain of Conscious Rat at 2 Hours 
Region 
Cerebellum Vehicle Heptyiphysostigmine t 
Cerebellar Cortex 0.155 ± 0.020 0.186 t 0.029 0.894 
Medulla/ Pons 
Nucleus of the Lateral Lemniscus 0.465 t 0.014 0.504 t 0.095 0.411 
Lateral Dorsal Tegmental Nucleus 0.493 t 0.132 0.691 t 0.121 0.451 
Pontine grey matter 1.127 t 0,069 1.221 t 0.175 0.503 
Mesencepahlon 
Inferior Colliculus 0.738 ± 0.055 0.770 ± 0.128 0.23 
Superior Colliculus 0.689 ± 0.039 0.943 t 0.065* 3.32 
Substantia Nigra (pars compacts) 0560 t 0.029 0.620 ± 0.020 1.69 
Substantia Nigra (pars reticulata) 0.512 ± 0.028 0.547 ± 0.026 0.92 
Diencephalon 
Medial Geniculate Body 0.881 t 0.057 1.037 t 0.052 2.02 
Subthalamic nucleus 0.708: t 0.029 0.837 t 0.050 2.21 
Lateral Geniculate Nucleus 0.783 t 0.076 0.888 t 0.042 1.21 
Hippocampus CAI 0.768 t 0.025 0.801 t 0.012 0.13 
Hippocampus CA2 1.007 t 0.024 1.066 t 0.033 1.42 
Hippocampus CA3 0.822 t 0.018 0.917 t 0.029* 2.77 
Hypothalamus 0.637 t 0.068 0.616: t 0.025 0.28 
Mediodorsal Thalamic Nucleus 0.860 f 0.050 0.920 t 0.032 1.01 
Ventrolateral ThalamicNucleus 0.670 t 0.042 0.705 t 0.036 0.64 
Telencephalon 
Visual Cortex (layer IV) 1.113 t 0.041 1.104 t 0.118 0.07 
Hippocampus (Molecular Layer) 0.968 t 0.051 1.033 t 0.010 1.26 
Dentate gyrus 0.948 t 0.040 1.042 t 0.032 1.85 
Auditory Cortex (Layer IV) 1.401 t 0.072 2.314: t 0.201 ** 4.47 
Amygdala 0.637 t 0.069 0.735 t 0.027 1.32 
Septal nuclei 0.746 t 0.035 0.751 t 0.035 0.09 
Nucleus Basalis Magnocellularis 0527 t 0.018 0.565 t 0.0 18 1.47 
Globus pallidus 0.443 t 0.022 0.473 t 0.026 0.90 
Caudate Nucleus 1.000 t 0.000 1.000 t 0.000 
Sensory Motor Cortex (Layer IV) 1.200 ± 0.072 1.505 t 0.061* 3.23 
Nucleus Accumbens 1.127 ± 0.019 1.220 t 0.043 1.97 
Anterior Cingulate Cortex 1.221 ± 0.029 1.237 t 0.025 0.42 
Frontal Cortex 1.140 ± 0.089 1.463 t 0.056* 3.07 
Parietal Cortex 1.150 ± 0.036 1.423 t 0.101* 2.54 
Myelinated Fibre Tracts 
Internal Capsule 0.256 t 0.0 17 0.277 t 0.024 0.71 
Genu 0.269* 0.019 0.316: t 0.029 1.36 
Table shows effect of heptylphysosigmine(2mg /kg) on (R, S)-[125I]-QNB in brain of 
conscious rat at 2 hours. *P <0.05 and **P <0.01 for the comparison between vehicle 
and heptylphysostigmine unpaired Student's t-test; critical value t= 2.306 (8 df) for P< 
0.05. Data are expressed as meant S. E. M % dose per g brain normalised to caudate 
nucleus. 
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Table 8 
Effect of Heptyiphysostigmine on (R, S)"[1251]. QNB 
in Brain of Conscious Rat at 24 Hours 
Region 
Cerebellum Vehicle Heptylphysostigmine t 
Cerebellar Cortex 0.025 ± 0.013 0.018 ± 0.014 0.38 
Medulla/ Pons 
Nucleus of the Lateral Lemniscus 0.068 ± 0.026 0.055 ± 0.019 0.42 
Lateral Dorsal Tegmental Nucleus 0.097 ± 0.042 0.080 ± 0.040 0.28 
Pontine grey matter 0.257 ± 0.030 0.143 ± 0.050 1.97 
Mesencepahlon 
Inferior Colliculus 0.128 ± 0.029 0.111 ± 0.045 0.31 
Superior Colliculus 0.098 ± 0.016 0.114 ± 0.020 0.65 
Substantia Nigra (pars compacta) 0.091 ± 0.024 0.149 ± 0.013 2.08 
Substantia Nigra (pars reticulata) '0.091 ± 0.023 0.118 ± 0.015 0.97 
Diencephalon 
Medial Geniculate Body 0.444 ± 0.048 1.74 t 1.313 0.98 
Subthalamic nucleus 0.135 ± 0.038 0.201 t 0.076 0.78 
Lateral Geniculate Nucleus 
Hippocampus CAI 0.322 ± 0.028 0.343 t 0.017 1.18 
Hippocampus CA2 0.957 ± 0.035 1.004 t 0.019 1.84 
Hippocampus CA3 0.926 ± 0.028 1.013 ± 0.038* 2.64 
Hypothalamus 0.153 ± 0.047 0.149 ± 0.018 0.07 
Mediodorsal Thalamic Nucleus 0.361 ± 0.037 0.365 ± 0.022 0.09 
Ventrolateral ThalamicNucleus 0.193 ± 0.038 0.195 ± 0.016 0.04 
Telencephalon 
Visual Cortex (layer IV) 1.23 ± 0.078 0.884 ± 0.30 1.12 
Hippocampus (Molecular Layer) 1.07 ± 0.037 1.023 ± 0.034 1.01 
Dentate gyrus 1.00 ± 0.033 1.047 ± 0.056 0.75 
Auditory Cortex (Layer IV) 1.44 ± 0.088 1.733 ± 0.070* 2.61 
Amygdala 0.543 ± 0.030 0.525 ± 0.017 0.05 
Septal nuclei 0.422 ± 0.040 0.479 ± 0.028 1.16 
Nucleus Basalis Magnocellularis 0.217 ± 0.028 0.200 ± 0.012 0.55 
Globus pallidus 0.153 ± 0.047 0.147 ± 0.012 0.11 
Caudate Nucleus 1.000 ± 0.000 1.000 ± 0.000 NA 
Sensory Motor Cortex 1.26 t 0.058 1.261 ± 0.040 0.05 
(Layer IV) 
Nucleus Accumbens 1.221 t 0.034 1.227 ± 0.032 0.12 
Anterior Cingulate Cortex 1.209 t 0.020 1.271 ± 0.064 0.48 
Frontal Cortex 1.225 t 0.060 1.266 ± 0.030 0.44 
Parietal Cortex 1.283 t 0.041 1.316 ± 0.053 0.50 
Myelinated Fibre Tracts 
Internal Capsule 0.073 t 0.011 0.093 ± 0.009 1.47 
Genu 0.182 t 0.130 0.139 ± 0.041 0.99 
Table shows effect of heptylphysosigmine (2mg /kg) on (R, S)-[ 125I]-QNB in brain of 
conscious rat at 24 hours. *P <0.05 for the comparison between vehicle and 
heptylphysostigmine unpaired Student's t-test; critical value t= 2.306 (8 df) for P <0.05. 
Data are expressed as mean ± S. E. M % dose per g brain normalised to caudate nucleus. 
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Statistically significant increases in (R, S)-[125 ]-QNB levels were observed in 6 out of 
33 regions analysed at 2 hours following heptylphysostigmine administration (Fig 25). 
Regions showing increased levels of (R, S)-[125j]"QNB at 2 hours were frontal cortex 
(28%), sensory motor cortex (25%), auditory cortex (6%), parietal cortex (24%), 
superior colliculus (37%) and CA3 region of the hippocampus (24%). 
At 24 hours heptylphysostigmine administration produced significant increase in (R, S)- 
[1251-QNB levels in the auditory cortex (20%) and in the CA3 region of the 
hippocampus (9%). Illustrative autoradiograms showing regions of increased activity at 
2 and 24 hours are displayed in Fig 26 and 27 respectively. 
Effect of Heptylphysostigmine on Uptake and Retention of (R, R)-[1251]. 
QNB 
Quantitative densitometric analysis of autoradiograms was performed to determine 
(R, R)-[125I]-QNB levels in 33 anatomically distinct brain regions at 05 hours, Ihour, 2 
hours and 6 hours following tracer administration in heptylphysostigmine (2m/kg) and 
vehicle (0.9% saline) treated animals. Tracer level in each region was expressed as a ratio 
relative to uptake in the caudate nucleus (Tables 9 and 10). 
Statistically significant increases in brain levels of (R, R)-[125n-QNB were observed in 
20 out of 33 regions analysed between 30 mins and 20 hours following 
heptylphysostigmine administration. At 6 hours following heptylphysostigmine 
administration no significant increases in (R, R)-[125U.. QNB were observed in any of the 
regions analysed. 
Heptylphysostigmine administration produced significant increases in (R, R)-[12511. 
QNB levels in the parietal cortex (29%), sensory motor cortex (33%), auditory cortex 
(76%) and in the superior colliculus (38%) at 30 mins after, tracer administration. At 1 
hour 15 out of the 33 regions analysed showed significant increases in (R, R)-[125n- 
QNB levels Regions include CA3 of hippocampus (16%), auditory cortex (46%), 
sensory motor cortex (19%), parietal cortex (20%), globus pallidus (40%), 
ventrolateral thalamic nucleus (34%), amygdala (12%), lateral geniculate nucleus (17%), 
nucleus basalis magnocellularis (27%), CA2 of hippocampus (19%), substantia nigra 
pars compacta (35%), mediodorsal thalamic nucleus (15%), substantia nigra pars 
reticulata (31%), hypothalamus (21%) and inferior colliculus (17%). 
Significant increases in (R, R)-[1251]-QNB levels were also observed at 2 hours 
following heptylphysostigmine in the auditory cortex (53%), pontine grey matter (62%), 
septal nuclei (10%), superior colliculus (88%), molecular layer of the hippocampus 
(28%) and in the visual cortex (28%). Illustrative autoradiograms of regions displaying 
increased activity at 30 mins, 1 hour and 2 hours are presented in Figs 28-30. 
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(R, S)-['251J-QNB In Rat Brain at 21-lours 
Following Heptylphysostigmine Administration 
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Fig 26: (R, S)-['25I]-QNB levels in brain of vehicle and heptylphysostigmine treated animals 
at 2 hours. Autoradiograms show (R, S)-[I25, I-QNB in brain at the level of the frontal 
cortex (A), dorsolateral hippocampus (B) and auditory cortex (C). Heptylphysostigmine 
significantly increases (R, S)-[1251]-QNB in the frontal cortex (Fr), parietal cortex (Par), 
sensory motor cortex (Sens. Mot. ), auditory cortex (Aud), the CA3 region of the 
hippocampus (CA3) and the superior colliculus (SC). The auditory cortex is notably darker 
in the heptylphysostigmine image. 
(R, S)-['2511-QNB In Rat Brain at 24 Hours 
Following Heptyphysostigmine Administration 
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Fig 27: (R, S)-['25I]-QNB in rat brain at 24 hours following heptylphysostigmine 
administration. Autoradiograms show (R, S)-['25I]-QNB at the level of the dorsolateral 
hippocampus (A) and auditory cortex (B). Heptylphysostigmine significantly increases 
(R, S)-[ 1`5ý5 II-QNB in the CA3 region of the hippocampus (CA3) and auditory cortex 
(Aud). 
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Table 9 
Effect of Heptylphysostigmine on 
(R, R)-[1251]-QNB in the Brain of Conscious Rat: 
VEHICLE TREATED ANIMALS 
Region 
Cerebellum 
Cerebellar Cortex 
Medulla/Pons 
Pontine Grey 
Nucleus of the Lateral Lemniscus 
Lateral Dorsal Tegmental nucleus 
Mesencephalon 
Inferior Colliculus 
Superior Colliculus 
Substantia Nigra (pars compacts) 
Substantia Nigra (pars reticulata) 
Diencepahlon 
TIME FOLLOWING TRACER ADMINISTRATION 
30 mins 1 Hour 2 Hours 6 Hours 
0.388 ± 0.056 0.288 ± 0.012 0.102 ± 0.029 0.160 ± 0.047 
1.097 ± 0.053 0.936 ± 0.060 0.534 ± 0.097 0.487 ± 0.130 
0.732±0.096 0.541±0.046 0.457±0.095 0.363±0.101 
0.818±0.061 0.564±0.048 0.328±0.081 0.329±0.099 
0.744±0.036 0.593: t0.034 0.346±0.098 0.239: t0.067 
0.780 ± 0.044 0.650 ± 0.056 0.334 ± 0.096 0.286 ± 0.107 
0.622±0.035 0.533±0.032 0.368±0.091 0.30510,094 
0.525±0.039 0.485±0.029 0.309±0.074 0.247 ± 0.079 
Hippocampus CAI 0.664 ± 0.015 0.817 ± 0.090 0.902 ± 0.067 1.276 ± 0.135 
Hippocampus CA2 0.896 ± 0.059 0.902 ± 0.044 0.804 ± 0.190 0.954 ± 0.096 
Hippocampus CA3 0.816 ± 0.016 0.854 ± 0.019 0.898 ± 0.067 1.131 ± 0.110 
Medial Geniculate Body 0.862 ± 0.032 0.823 ± 0.019 0.549 ± 0.130 0.379 ± 0.080 
Sub Thalamic Nucleus 0.795 ± 0.064 0.632 ± 0.077 0.428 ± 0.057 0.365 ± 0.067 
Lateral Geniculate Nucleus 0.858 ± 0.062 0.752 ± 0.026 0.512 ± 0.052 0.257 ± 0.083 
Hypothalamus 0.639 ± 0.030 0.518 ± 0.033 0.370 ± 0.056 0.189 ± 0.058 
Mediodorsal Thalamic Nucleus 0.846 ± 0.079 0.751 ± 0.034 0.544 ± 0.050 0.254 ± 0.760 
Ventrolateral Thalamic Nucleus 0.617 ± 0.026 0.480 ± 0.035 0.343 ± 0.053 0.175 ± 0.059 
Teleneephalon 
Visual Cortex (layer IV) 1.133 ± 0.011 0.944 ± 0.095 1.052 ± 0.078 1.164 ± 0.280 
Dentate Gyrus 0.949 ± 0.051 0.924 ± 0.055 0.969 ± 0.087 1.028 ± 0.227 
Auditory Cortex (layer IV) 1.460 ± 0.900 1.341 ± 0.074 1.400 ± 0.094 1.350 ± 0.258 
Hippocampus Molecular Layer 0.949 ± 0.046 1.004 ± 0.044 0.911 ± 0.097 1.070 ± 0.232 
Amygdala 0.732 ± 0.059 0.721 ± 0.021 0.644 ± 0.064 0.624 ± 0.034 
Globus Pallidus 0.513 ± 0.047 0.398 ± 0.036 0.394 ± 0.059 0.267 ± 0.052 
Caudate Nucleus 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000 
Septal Nuclei 0.667 ± 0.047 0.743 ± 0.032 0.630 ± 0.017 0.461 ± 0.037 
Nucleus Basalis Magnocellularis 0.551 ± 0.037 0.497 ± 0.029 0.471 ± 0.028 0.331 ± 0.052 
Nucleus Accumbens 1.086 ± 0.012 1.102 ± 0.052 1.074 ± 0.078 1.189 ± 0.105 
Sensory Motor Cortex (layer IV) 1.272 ± 0.064 1.203 ± 0.022 1.272 ± 0.060 1.106 ± 0.090 
Anterior Cingulate Cortex 1.173 ± 0.079 1.163 ± 0.006 1.176 ± 0.054 1.219 ± 0.072 
Frontal Cortex 1.144t 0.036 1.176 ± 0.027 1.192 ± 0.070 1.134 ± 0.078 
Parietal Cortex 1.141 ± 0.047 1.100 ± 0.034 1.108 ± 0.066 1.061 ± 0.099 
Myelinated Fibre Tracts 
Internal Capsule 0.252 ± 0.039 0.366 ± 0.020 0.196 ± 0.056 0.069 ± 0.041 
Genu 0.270 ± 0.060 0.324 ± 0.025 0.210 ± 0.053 0.223 ± 0.063 
Table shows (R, R)-[1251]-QNB in discrete brain regions of the conscious rat in vehicle 
(0.7 mis 0.9% saline) treated animals 0.5 hours, 1,2 and 6 hours following iv 
administration of 200pCi of tracer. Data are expressed as mean ± S. E. M % Dose per g 
brain normalised to the caudate nucleus, n= 5 animals for each time point. 
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Table 10 
Effect of ý Heptylphysostigmine on 
(R, R)-[125I]-QNB in the Brain of Conscious Rat: 
HEPTYLPHYSOSTIGMINE TREATED ANIMALS 
TIME FOLLOWING TRACER ADMINISTRATION 
30 mins 1 Hour 2 Hours 6 Hours 
Region 
Cerebellum 
Cerebellar Cortex 0.488 ± 0.098 0.392 ± 0.086 0.194 ± 0.056 0.253 ± 0.117 
Medulla/Pons 
Pontine Grey 1.270 ± 0.134 1.030 ± 0.093 0.863 ± 0.053 0.458 ± 0.137 
Nucleus of the Lateral Lemniscus 0.792 ± 0.103 0.737 ± 0.105 0.603 ± 0.083 0.507 ± 0.248 
Lateral Dorsal Tegmental nucleus 0.921 ± 0.150 0.607 ± 0.046 0.491 ± 0.049 0.359 ± 0.134 
Mesencephalon 
Inferior Colliculus 0.364 ± 0.100 0.696 ± 0.028 0.529 ± 0.069 0.357 ± 0,122 
Superior Colliculus 1.082 ± 0.087 0.872 ± 0.079 0.628 ± 0.044 0.351 ± 0.080 
Substantia Nigra (pars compacts) 0.661 ± 0.045 0.720 ± 0.059 0.580 ± 0.039 0.373 ± 0.077 
Substantia Nigra (pars redculata) 0.565 ± 0.045 0.637 ± 0.050 0.501 ± 0.053 0.326 ± 0.058 
Diencepahlon 
Hippocampus CA1 0.717 ± 0.070 0.915 t 0.046 0.858 # 0.058 0.939 t 0.276 
Hippocampus CA2 0.996 t 0.068 1.072 t 0.041 1.010 t 0.054 0.832 t 0.117 
Hippocampus CA3 0.878 t 0.052 0.990 f 0.008 0.871 t 0.038 0.919 t 0.122 
Medial Geniculate Body 1.119 ± 0.116 0.956 ± 0.052 0.808 t 0.024 0.482 ± 0.065 
Sub Thalamic Nucleus 0.920 ± 0.085 0.782 ± 0.028 0.549 ± 0.066 0.222 ± 0.067 
Lateral Geniculate Nucleus 0.874 ± 0.065 0.878 ± 0.031 0.576 ± 0.026 0.223 ± 0.072 
Hypothalamus 0.661 ± 0.055 0.626 ± 0.032 0.405 ± 0.040 0.365 ± 0.156 
Mediodorsal Thalamic Nucleus 0.865 ± 0.053 0.865 ± 0.024 0.625 ± 0.027 0.252 ± 0.076 
Ventrolateral Thalamic Nucleus 0.651 ± 0.086 0.645 ± 0.031 0.432 ± 0.040 0.186 ± 0.050 
Telencephalon 
Visual Cortex (layer IV) 1.374 t 0.124 1.183±0.084 1.351±0.087 1.307±0.196 
Dentate Gyrus 1.146 ± 0.133 1.007 ± 0.089 1.177 ± 0.043 1.084 ± 0.116 
Auditory Cortex (layer IV) 2.565 ± 0.336 1.955 ± 0.063 2.139 ± 0.104 2.005 ± 0.225 
Hippocampus Molecular Layer 1.065 t 0.102 0.983 ± 0.092 1.171 ± 0.024 1.098 ± 0.099 
Amygdala 0.790 ± 0.074 0.811 ± 0.019 0.684 ± 0.046 0.387 ± 0.134 
Globus Pallidus 0.526 ± 0.051 0.562 ± 0.025 0.408 ± 0.015 0.191 ± 0.050 
Caudate Nucleus 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000 
Septal Nuclei 0.744 ± 0.080 0.795 ± 0.041 0.692 ± 0.014 0.427 ± 0.095 
Nucleus Basalis Magnocellularis 0.601 ± 0.047 0.630 ± 0.034 0.497 ± 0.026 0.258 ± 0.079 
Nucleus Accumbens 1.113 + 0.100 1.184 ± 0.063 1.195 ± 0.031 1.025 ± 0.188 
Sensory Motor Cortex (layer IV) 1.689 ± 0.063 1.434 ± 0.044 1.399 ± 0.080 0.988 ± 0.185 
Anterior Ciugulate Cortex 1.332 t 0.055 1.253 ± 0.055 1.329 ± 0.095 1.037 ± 0.101 
Frontal Cortex 1.625 0.074 1.277 ± 0.117 1.446 ± 0.103 1.202 ± 0.056 
Parietal Cortex 1.475 t 0.030 1.317 ± 0.045 1.444 ± 0.152 1.153 ± 0.172 
Myelinated Fibre Tracts 
Internal Capsule 0.295 ± 0.043 0.359 ± 0.024 0.253 ± 0.063 0.163 ± 0.066 
Genu 0.258 ± 0.067 0.363 ± 0.031 0.321 ± 0.045 0.282 ± 0.076 
Table shows (R, R)-[ 1251]-QNB in discrete brain regions of the conscious rat in 
heptylphysostigmine (2 mg/kg) treated animals 30 mins, 1,2 and 6 hours following iv 
administration of 200gCi of tracer. Data are expressed as mean ± S. E. M % dose per g 
brain normalised to the caudate nucleus, n= 5 animals for each time point. 
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(R, R)-[1251j-QNB In Rat Brain at 30 rains 
Following Heptylphysostigmine Administration 
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Fig 28: (R, R)-[1225l]-QNB in rat brain at 30 minn following heptylphysostigmine 
administration. Autoradiograms show activity at the level of the caudate nucleus (A), 
dorsolateral hippocampus (B), auditory cortex (C) and inferior colliculus (D). 
Heptylphysostigmine (2mg/kg) increased (R, R)-[1'`51]-QNB in a number of regions 
including the superior colliculus (SC), auditory cortex (Aud) and lateral lemniscus (LL). 
Profound increases in tracer levels were observed in the parietal cortex (Par) and sensory 
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(R, R)-[1251J-QNB In Rat Brain at 1 Hour 
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Fig 29: (R, R)-['25I]-QNB in rat brain at I hour following heptylphysostigmine 
administration. Autoradiograms show activity at the level of the caudate nucleus (A), 
dorsolateral hippocampus (B), auditory cortex (C) and inferior colliculus (D). 
Heptylphysostigmine increased in (R, R)-[1251-QNB in a number of regions including 
inferior colliculus (IC), lateral lemniscus (LL), CA2 region of hippocampus (CA2), 
parietal cortex (Par), mediodorsal thalamus (MD), ventrolateral thalamus (VL) and sensory 
motor cortex (Sens. Mot. ) Profound increases in tracer levels were observed in the auditory 
cortex (Aud) and CA3 region of the hippocampus (CA3). 
(R, R)-(12-51 I-QNB In Rat Brain at 2 Hours 
Following Heptylphysostigmine Administration 
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Fig 30: (R, R)-['251]-QNB in rat brain at 2 hours following heptylphysostigmine 
administration. Autoradiograms show activity at level of the caudate nucleus (A), auditory 
cortex (B) and visual cortex (C). Heptylphysostigmine increased (R, R)-[1251]-QNB levels 
in a number of regions including the septa) nucleus (Sep), auditory cortex (Aud), 
molecular layer of the hippocampus (Hipp. Mol. ) and in the visual cortex (Vis). 
Tables 11-14 display regions of increased (R, R)-[1251J-QNB in heptylphysostigmine 
treated animals rank ordered by t-value for Student's unpaired t-test for the comparison 
with vehicle treated animals at 0.5 hours, Ihour, 2 hours and 6 hours. 
From these tables it can be seen that cortical regions show the greatest and most 
consistent increases in (R, R)-[125I]-QNB level following heptylphysostigmine 
administration. 
Parietal cortex, sensory motor cortex, auditory cortex and visual cortex all show 
significant increases in (R, R)-[125IJ-QNB at one or more time points. Of these regions 
the auditory cortex is most clearly affected with significant increases greater than 46% of 
those in vehicle treated animals observed a 30 mins, 1 hour and 2 hours. Additionally, 
auditory cortex is ranked highest by t-value at 6 hours falling just short of significance. 
Similarly, increases in (R, R)-[1251]-QNB observed in both visual and parietal cortex fall 
just short of significance at 30 mins and 2 hours respectively. Increases in (R, R)-[1251]. 
QNB level in cortical regions between 30 mins and 6 hours following 
heptylphysostigmine administration are. displayed in Fig 31. 
A number of non-cortical regions also show significant increases in (R, R)-[1251J-QNB 
at multiple time points following heptylphysostigmine administration. The most notable 
of these is the superior colliculus, which displays significant increases in (R, R)-[1251)- 
QNB at 30 mins and 2 hours but not at 1 hour. At 1 hour t= 2.293 for superior colliculus 
indicating that the increases in tracer observed at this time are extremely close to reaching 
significance with a critical t value of 2.306 for P< 0.05 for the comparison with vehicle 
treated animals. 
Normalisation of Data to the Caudate Nucleus 
As previously described raw data (iCi per g brain) for regional (R, S)- and (R, R)- 
[125I]-QNB activity in rat brain were expressed as a ratio of percent of the injected dose 
relative the level in the caudate nucleus to reduce the impact of interanimal variability on 
the data. Normalisation to this region was performed as tracer levels in this region are 
reproducible from animal to animal and are relatively unchanged over the experimental 
time period. 
Fig 32 shows raw data (µCi/g) for (R, S)- and (R, R)-[125I]-QNB in caudate nucleus of 
vehicle and heptylphysostigmine treated animals. Heptylphysostigmine administration 
had no significant effect on tracer levels in the caudate nucleus indicating that 
normalisation of data to this region therefore remains valid for experiments utilising 
heptylphysostigmine. 
Complete regional tables of un-normalised time-activity data for (R, S)- and (R, R)- 
[1251]-QNB for heptylphysostigmine experiments are displayed in Appendix A. 
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Hierarchy of Regional Increases in (R, R)-[125I]-QNB at 0.5 hours: 
Rank Order By t-value 
Parietal Cortex t= 5.990 ***P<0.001 
Sensory Motor Cortex 
--------- 
t= 4.643 **P< 0.01 
------- - ------------ 
Auditory Cortex 
------- --- -- --- ------------------- --- ---- -- --------------------- 
t= 3.177 *P< 0.05 
Superior Colliculus t= 3.098 
Visual Cortex t= 1.936 P> 0.05 
Pontine Grey t= 1.201 
Hippocampus CA3 t=1.14 
Inferior Colliculus t= 1.129 
Hippocampus CAI t=1.111 
Molecular Layer 
of Hippocampus t= 1.037 
Septal Nuclei t= 0.822 
SNc t= 0.684 
SNr t=0.672 
Amygdala t= 0.613 
NBM t= 0.427 
Nucleus of the Lateral 
Lemniscus t= 0.426 
VL Thalamus t= 0.378 
Hypothalamus t=0.351 
MD Thalamus t=0.199 
Globus Pallidus t=0.187 
Lateral Genculate 
Nucleus t= 0.178 
Table 11: Rank order by t-value of regions showing increases in (R, R)-[1251]-QNB 
levels in heptylphysosdgmine treated animals at 30 mins ***P<0.001, **P<0.01 and 
*P< 0.05 indicate a statistcally significant increase in (R, R)-[ 125I]-QNB level 
(Student'ts unpaired t-test) for comparison with vehicle treated animals. 
SNc= substantia nigra pars compacta, SNr= substantia nigra pars reticulata, NBM= 
nucleus basalis magnocellularis, VL= ventrolateral, MD= mediodorsal. 
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Hierarchy of Regional Increases in (R, R)-(1251]-QNB at 1 Hour: 
Rank Order By t-value 
Hippocampus CA3 t= 6.597 ***P<0.001 
Auditory Cortex t=6.318 
------------------------------------ 
Sensory Motor Cortex 
-------------------------------------------------------------------- 
t= 4.696 **P< 0.01 
Parietal Cortex t= 3.847 
Globus Pallidus t= 3.742 
VL Thalamus t= 3.529 
----------------------------------- 
Amygdala 
---------------------------------------------------------------- 
t= 3.178 *P< 0.05 
Lateral Geniculate 
Nucleus t= 3.114 
NBM t= 2.976 
Hippocampus CA2 t= 2.827 
SNc t= 2.786 
MD Thalamus t= 2.739 
SNr t= 2.630 
Hypothalamus t= 2.349 
Inferior Colliculus t= 2.338 
Superior Colliculus t= 2.293 P>0.05 
Nucleus of the Lateral 
Lemniscus t= 1.710 
Visual Cortex t= 1.490 
Pontine Grey t= 0.849 
Molecular Layer 
of Hippocampus t= 0.206 
Septal Nuclei t= 0.100 
Table 12: Rank order by t-value of regions showing increases in (R, R)-[ 1251]-QNB 
levels in heptylphysostigmine treated animals at 1 hour ***P< 0.001, **P< 0.01 and 
*P< 0.05 indicate a statistcally significant increase in (R, R)-[ 1251]-QNB level 
(Student'ts unpaired t-test) for comparison with vehicle treated animals. 
See Table 11 for a list of abbreviations. 
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Hierarchy of Regional Increases in (R, R). [1251]. QNB at 2 Hours: 
Rank Order By t-value 
Auditory Cortex t= 5.285 **P< 0.01 
-------------- - --------------- 
Pontine Grey 
----------- --- ------------------------- --- ------------- - ---- - ----- 
t= 2.990 **P< 0.05 
Septal Nuclei t= 2.851 
Superior Colliculus t= 2.755 
Molecular Layer 
of Hippocampus t= 2.594 
Visual Cortex t= 2.565 
--------------------------- 
SNc 
------------------------------------------------------------------- 
t= 2.138 P>0.05 
SNr t= 2.105 
Parietal Cortex t= 2.025 
Inferior Colliculus t= 1.525 
MD Thalamus t= 1.427 
VL Thalamus t= 1.343 
Sensory Motor Cortex t= 1.277 
Nucleus of the Lateral 
Lemniscus t= 1.159 
Lateral Geniculate 
Nucleus t= 1.103 
Hippocampus CA2 t= 1.040 
NBM t= 0.684 
Hypothalamus t= 0.514 
Amygdala t= 0.509 
Hippocampus CA3 t= 0.343 
Globus Pallidus t= 0.228 
Table 13: Rank order by t-value of regions showing increases in (R, R)-[ 125I]-QNB 
levels in heptylphysostigmine treated animals at 2 hours ***P< 0.001, **P< 0.01 and 
*P< 0.05 indicate a statistcally significant increase in (R, R)-[125I]-QNB level 
(Student'ts unpaired t-test) for comparison with vehicle treated animals. 
See Table 11 for a list of abbreviations. 
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Hierarchy of Regional Increases in (R, R). [1251]. QNB at 6 Hours: 
Rank Order By t-value 
Auditory Cortex t=1.917 P>0.05 
Amygdala t= 1.767 
Hippocampus CA2 t= 1.290 
Hypothalamus t= 1.058 
Globus Pallidus t= 1.054 
Inferior Colliculus t= 0.850 
Hippocampus CA2 t= 0.805 
SNr t= 0.805 
NBM t= 0.770 
Septal Nuclei t= 0.747 
Sensory Motor Cortex t= 0.572 
SNc 
, t= 
0.559 
Nucleus of the Lateral 
Lemniscus t= 0.538 
Superior Colliculus t= 0.486 
Parietal Cortex t= 0.463 
Visual Cortex t= 0.419 
Lateral Geniculate 
Nucleus t= 0.308 
VL Thalamus t= 0.142 
Molecular Layer 
of Hippocampus t= 0.111 
Pontine Grey t= 0.106 
MD Thalamus t= 0.018 
Table 14: Rank order by t-value of regions showing increases in (R, R)-[125I]-QNB 
levels in heptylphysostigmine treated animals at 6 hours t-values calculated for Student's 
unpaired t-test for comparison with vehicle treated animals. 
See Table 11 for a list of abbreviations. 
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Heptylphysostigmine Increases (R, R)-[125I]-QNB 
In Cortex of Conscious Rat 
Vehicle 
Heptyl. 
n- 5 
.ýz 
bAý 
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oU 
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I 
3 
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Fig 31 Level of (R, R)-[125I]-QNB in cortical brain regions in vehicle and 
heptylphysostigmine treated animals at 0.5,1,2 and 6 hours. In drug treated animals 
auditory cortex shows the greatest and most consistent increase in tracer retention with 
levels signifcantly higher compared to vehicle between 0.5 and 2 hours. *P< 0.05, **P 
<0.01 and ***P <0.001 for comparison between vehicle and heptylphysostigmine treated 
animals. Studen'ts unpaired t-Test. Data are expressed as mean ± S. E. M % Dose per g 
Brain normalised to the caudate nucleus, n= 5 for each time point. 
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Fig 32: Uptake and retention of (R, S)-[1251]-QNB (top) and (R, R)-[125I]-QNB (bottom) 
in the caudate nucleus of conscious rat in vehicle and heptylphysostigmine (2mg/kg) 
treated animals. Heptylphysostigmine administration had no significant effect on levels of 
either ligand in caudate nucleus. Expression of data as a ratio of the level in the caudate 
nucleus is therefore a valid means of normalisation in experiments with 
heptylphysostigmine. Data are expressed as mean ± S. E. M iCi per g Brain, n= 5. 
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3.1.5 Acetylcholinesterase Activity in Rat brain Sections Following 
Heptyiphysostigmine Administration 
Effect of Heptylphysostigmine on AChE Activity in Vivo 
AChE activity in sections of rat brain taken from heptylphysostigmine and vehicle treated 
animals was determined by semi-quantitative histochemistry. Figure 33 shows 
illustrative sections stained for AChE activity taken from drug and vehicle treated animals 
from (R, S)- and (R, R)-[125I]-QNB studies. Heptylphysostigmine (2mg/kg) produced a 
prolonged inhibition of AChE activity in the brain. 
AChE Activity in Sections from Studies with (R, S)-j1251I. QNB 
Statistically significant reductions in enzyme activity were measured in the parietal cortex 
and CAI of the hippocampus at 2 hours and in the parietal cortex at 24 hours. 
Heptylphysostigmine administration (2mglkg) reduced AChE activity in all regions at 
both 2 and 24 hours with the exception of the cerebellum. Enzyme activity in this region 
was not reduced following heptylphysostigmine administration and was apparently 
greater at 24 hours (Fig 34). The intrinsically low levels of enzyme present in the 
cerebellum and the limited sensitivity of the assay to accurately determine low levels of 
staining are likely to account for this apparent anomaly. Complete tables of measured 
AChE activity in sections from vehicle and heptylphysostigmine treated animals are 
displayed in Appendix C. 
AChE Activity in Sections from Studies with (R, R)-[125I]-QNB 
At 30 mins heptylphysostigmine (2mg/kg) significantly inhibits AChE activity in all 
regions analysed. At 1 hour AChE activity is significantly inhibited in frontal cortex, 
parietal cortex and CAI of hippocampus. At 2 hours AChE activity is significantly 
inhibited in the parietal cortex and CAI of hippocampus and at 6 hours AChE activity is 
significantly inhibited in the CAI of hippocampus. AChE activity in the cerebellum 
appeared to be least sensitive to inhibition, again this may be due to the limited sensitivity 
of the assay combined with the intrinsically low level of enzyme present in this region. 
Fig 35 shows AChE activity in the parietal cortex, CAI of hippocampus and cerebellum 
between 30 mins and 6 hours. As in studies with (R, S)-['25I]-QNB 
heptylphysostigmine (2mg/kg) produced a prolonged inhibition of AChE activity in the 
majority of brain regions analysed. Complete tables of measured AChE activity in 
sections from vehicle and heptylphysostigmine treated animals are displayed in Appendix 
C. 
These observations indicate that heptylphysostigmine is effective in producing a 
significant inhibition of AChE activity in vivo for a prolonged period of time particularly 
in cortex and hippocampus. 
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Fig 33: Figure shows AChE histochemical staining in rat brain sections at the level of the 
caudate nucleus, dorsolateral hippocampus and cerebellum taken from vehicle treated 
animals and from heptylphysostigmine treated animals at 30 minn, 6 hours and 24 hours 
following drug administration. Heptylphysostigmine (2 mg/kg) produced a prolonged 
inhibition of AChE activity. It should be noted that animals in the 24 hour group received a 
second infusion of heptylphysostigmine 8 hours after the first. 
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Fig 34: AChE activity measured by semi-quantitative histochemistry in rat brain sections - 
at the level of parietal cortex (A), CAI of hippocampus (B) and cerebellum(C) from 
vehicle and heptylphysostigmine treated animals in studies with (R, S)-[1251J-QNB at 2 
and 24 hours. Heptylphysotigmine produced significant reductions in AChE activity in 
parietal cortex and CAI of hippocampus at 2 hours and in parietal cortex at 24 hours. Data 
are expressed as mean ± S. E. M Optical Density as a measure of staining intensity. *P 
<0.05, **P <0.01 and ***P <0.001 Student's unpaired t-Test (n= 5). 
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Fig 35: AChE activity measured by semi-quantitative histochemistry in rat brain sections 
at the level of parietal cortex (A), CAI of hippocampus (B) and cerebellum(C) from 
vehicle and heptylphysostigmine treated animals in studies with (R, R)-[125I]-QNB at 0.5, 
1,2 and 6hours. Heptylphysotigmine produced significant reductions in AChE activity in 
parietal cortex and CAI of hippocampus at 2 hours and in parietal cortex at 6 hours. *P 
<0.05, **P <0.01 and ***P <0.001 Student's unpaired two-tailed t-Test. Data are 
expressed as mean ± S. E. M optical density as a measure of staining intensity [n= 5]. 
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3.2 REGIONAL CEREBRAL BLOOD FLOW IN THE CONSCIOUS 
RAT FOLLOWING HEPTYLPHYSOSTIGMINE ADMINISTRATION 
Regional cerebral blood flow was measured by [14C]-IAP autoradiography 2 hours 
following vehicle or heptylphysostigmine (2mg/kg) administration in the conscious rat. 
General Observations 
Animals receiving heptylphysostigmine (2mg/kg) were observed to display overt 
behavioural changes identical to those previously observed following administration of 
this drug. Symptoms included salivation, urination, muscle tremor and fasciculation and 
an increased sensitivity to noise. In addition, animals exhibited reduced locomotor 
activity and absence of the normal grooming behaviour associated with rats. The 
majority of animals displayed mild symptoms by 2 hours when CBF was measured. 
Animals receiving saline displayed none of these symptoms and exhibited normal 
behaviour. 
Physiologic variables were measured prior to vehicle / heptylphysostigmine infusion and 
before measurement of CBF (i. e. 2 hours after initiation of vehicle / heptylphysostigmine 
infusion). 
Heptylphysostigmine was observed to significantly increase mean arterial blood 
pressure and plasma glucose and to significantly reduce body temperature compared to 
vehicle treated animals when measured pre-CBF. Additionally, plasma glucose levels 
were significantly higher in heptylphysostigmine treated animals pre-CBF when 
compared levels measured pre-infusion (Appendix B). 
Effect of Heptylphysostigmine on Cerebral Blood Flow in the Conscious 
Rat 
Quantitative densitometric analysis was performed to determine regional cerebral blood 
flow in 33 anatomically distinct brain regions at 2 hours following a cholinergic 
challenge produced by the administration of the cholinesterase inhibitor 
heptylphysostigmine(2mg/kg). 
Heptylphysostigmine produced highly circumscribed alterations in regional cerebral 
blood flow at 2 hours after administration. Table 15 shows rCBF in vehicle and 
heptylphysostigmine treated animals. Significant increases in CBF were measured in 
parietal cortex, visual cortex, sensory motor cortex, auditory cortex and frontal cortex in 
heptylphysostigmine treated animals (Fig 36). Illustrative autoradiograms of (14C]-IAP 
levels in vehicle and heptylphysostigmine treated animals are presented in Fig 37. 
Cortical regions in heptylphysostigmine treated animals are notably darker than those in 
vehicle treated animals. It should be noted that the cortical regions displaying increased 
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Table 15. 
Effect Of Heptylphysostigmine On 
Local Cerebral Blood Flow In The Conscious Rat 
Region Vehicle Heptylphysostigmi 
ne 
Cerebellum 
Cerebellar Cortex 101 t 10 87 ±9 1.041 
Medulla/ Pons 
Nucleus of the Lateral Lemniscus 154 t8 138 ± 11 1.176 
Lateral Dorsal Tegmental Nucleus 122 ± 14 135 ± 11 0.730 
Pontine grey matter 130 ±7 149 ± 10 1.557 
Mesencepahlon 
Inferior Colliculus 177 ± 17 181 ± 16 0.171 
Superior Colliculus 116 ± 12 147 ± 94 0.327 
Substantia Nigra (pars compacta) 110± 17 94 ±6 0.887 
Substantia Nigra (pars reticulata) 78 f 17 73 ±4 0.286 
Diencephalon 
Medial Geniculate Body 155 t 12 183 ± 16 1.4 
Subthalamic nucleus 149 ± 23 127 t9 0.891 
Lateral Geniculate Nucleus 128 ± 16 135 t 17 0.299 
Hippocampus CAI 67 ±7 65 t7 0.202 
Hippocampus CA2 77 ±5 77 t9 0 
Hippocampus CA3 84 ± 14 91 f 11 0.393 
Hypothalamus 81 ± 10 76 t4 0.464 
Mediodorsal Thalamic Nucleus 135 ± 13 131 t 15 0.201 
Ventrolateral ThalamicNucleus 97 ±8 100 t 11 0.220 
Telencephalon 
Visual Cortex (layer IV) 119 ± 15 172 t 14* 2.583 
Hippocampus (Molecular Layer) 98 t 11 102 t 10 0.269 
Dentate gyrus 105 t 32 119 ±9 0.421 
Auditory Cortex (Layer IV) 215 t 24 291 t 22* 2.334 
Amygdala 86 t6 82 t5 0.512 
Septal nuclei 79 t 10 74 ±8 0.390 
Nucleus Basalis Magnocellularis 79 t5 74 ±5 0.707 
Globus pallidus 77 t 15 66 ±5 0.696 
Caudate nucleus 113 t 14 95 ±9 1.082 
Sensory Motor Cortex (Layer IV) 143 t 11 211 t 26* 2.409 
Nucleus Accumbens 131: t 11 138 ± 19 0.318 
Anterior Cingulate Cortex 140± 24 161 ± 23 0.631 
Frontal Cortex 122± 18 190 t 23* 2.328 
Parietal Cortex 151 ± 20 244 t 28* 2.703 
Myelinated Fibre Tracts 
Internal Capsule 53 ± 15 53 ±2 0 
Genu 35±3 41±4 1.2 
Local cerebral blood flow was measured in the conscious rat at 2 hours following 
vehicle/heptylphysostigmine infusion. Significant increases in blood flow are observed 
in cortical regions in heptylphysostigmine treated animals. *P<0.05 for the comparison 
between vehicle and heptylphysostigmine unpaired Student's t-test; critical value t= 
2.306 (8 df) . Data are expressed as mean ± S. E. M. ml/100g/min (n =5 
in each group). 
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Heptylphysostigmine Increases Cerebral Blood Flow In The Conscious Rat 
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Fig 37: ['°C]-IAP levels in rat brain at 2 hours following heptylphysostigmine 
administration. Autoradiograms show ["C]-IAP at the level of the caudate nucleus (A), 
dorsolateral hippocampus (B), auditory cortex (C) and cerebellum (D). 
Heptylphysostigmine significantly increased in cerebral blood flow in a number of cortical 
regions including the frontal cortex (Fr), sensory motor cortex (Sens. Mot. ), auditory cortex 
(Aud) and parietal cortex (Par). ["C]-IAP levels in cortical regions of heptylphysostigmine 
treated animals are notably higher. 
blood flow correspond to those regions observed to have increased levels of (R, S)- and 
(R, R)-[ l25I]-QNB following heptylphysostigmine administration. 
Increases in blood flow produced by heptylphysostigmine appear to be restricted to the 
cortex, with no general pattern of altered blood flow obvious throughout the rest of the 
brain. However, the superior colliculus shows a substantial but non-significant increase 
in blood flow following heptylphysostigmine administration (Table 15). It is interesting 
to note that this region also displayed significant increases in (PR)-[125I]-QNB 
following heptylphysostigmine administration (Table 11-14). 
III 
3.3 IN VITRO AUTORADIOGRAPHIC RESULTS 
General Observations 
Fig 38 shows illustrative autoradiograms of (R, S)- and (R. R)-[1251]-QNB binding to rat 
brain sections in vitro. Regional distribution of ligand in vitro is generally similar to that 
observed in vivo . 
High levels of activity are observed in the caudate, with uniformly high 
levels observed in the cortex and high to intermediate levels observed in the hippocampal 
formation. Activity levels in the thalamus and cerebellum although lower than those 
observed in cortex and caudate are however relatively high compared to levels observed in 
vivo. In addition levels of non-specific binding are very high for both ligands, constituting 
a minimum of approximately 50 % of total binding in the majority of studies performed 
despite extensive post incubation washing. The calculated in vitro association rate and 
equilibrium dissociation constants for (R, S)- and (R, R)-[1251]-QNB are presented in Table 
16. 
3.3.1 In Vitro Determination of the Association Rate Constant 
for (RS). and (R, R). [1251]-QNB 
The observed association rate (kobs, mins-1) was determined for (R, S)- and (R, R)-[125I]- 
QNB by in vitro autoradiographic analysis of 20µm coronal rat brain sections following 
incubation for 2 hours with 0.1 nM and 0.2 nM (R, S)- and (R, R)-[ 125I]-QNB 
respectively. Complete tables for total, non-specific and specific binding of (R, S)- and 
(R, R)-[125I]-QNB to frontal cortex, parietal cortex, caudate nucleus and cerebellum are 
displayed in Appendix D. 
(RAS)-[ 125I]-QNB 
The time course of (R, S)-[125I]-QNB binding to mAChRs in vitro from 1-120 mins is 
presented in Fig 39. The association rate constant for frontal cortex (kobs= 0.0156 min-1), 
parietal cortex (kobs= 0.0303 min-1) and caudate nucleus (kobs= 0.0105 min-) were 
calculated according to the theory described in section 2.3.2 from a linear transformation 
of binding data (Fig 40). The association rate constant for cerebellum could not be 
determined as the binding data from this region did not transform well to a linear plot, 
possibly due to the high levels of non-specific binding observed in this region. 
Comparison of regional association rates indicates that (R, S)-[125I]-QNB displays more 
rapid binding to cortex than caudate, with the rate of association approximately 3 fold 
faster in the parietal cortex than in the caudate nucleus 
(RAR)-[125I]-QNB 
Association rate constants for (R, R)-[125I]-QNB in frontal cortex (kobs= 0.0 185 min-1), 
parietal cortex (kobs= 0.0203 min-1) and caudate nucleus (kobs= 0.0462 min -1) were 
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determined in an identical manner to those for (R, S)-[125I]-QNB. Time course of (R, R)- 
[1251]-QNB binding to mAChRs and linear transformation of this data to yield association 
rate constants are displayed in Figs 41 and 42. As with (R, S)-[1251]-QNB the association 
rate constant for cerebellum could not be determined due to the non-linearity of 
transformed data. Comparison of regional association rates indicates that (R, R)-[125n- 
QNB displays most rapid association kinetics in the caudate nucleus, with the rate of 
association 2.5 fold faster than in the frontal cortex 
Comparison of association rates for (R, S)- and (R, R)-[125I]. QNB 
The in vitro association kinetics for (R, S)- and (R, R)-[125I]-QNB display some subtle 
differences. In cortical regions kobs is broadly similar between the two ligands, with the 
rate of association of (R, R)-[1251]-QNB less than twofold faster i. e. (R, S) kobs= 0.0 156 
min-1 and 0.0303 min-' and (R, R) kobs= 0.0185 min-I and 0.0203 min-1 for frontal and 
parietal cortices respectively. 
In the caudate nucleus however, kobs of (R, R)-[12511-QNB is more than four fold faster 
than that of (R, S)-[125I]-QNB i. e. kobs= 0.0 105 mins-1 and 0.0462 mins-1 for (R, S)- and 
- (R, R) respectively. 
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Table 16 
Association Rate Constants and Equilibrium Dissociation Constants 
for (RS)- and (R, R)-[125I]. QNB Determined by In Vitro Autoradiography 
Region (R, S)-[1251]. QNB (R, R)-[125I -QNB 
Frontal Cortex kobs (mins'1) 0.0156 0.0185 
KD (nit) 0.036 0.226 
Parietal Cortex kobs 0.0303 0.0203 
KD 0.050 0.115 
Caudate Nucleus kobs 0.0105 0.0462 
KD 0.028 0.206 
Tables show association rate constant (kobs) and equilibrium dissociation rate constant 
(KD) for (R, S)- and (R, R)-[125I]-QNB binding to mAChRs in rat brain sections as 
determined by in vitro autoradiography in this thesis Rate constant values determined by 
in vitro autoradiography in this thesis are consistent with literature values determined by 
binding to transfected cell membranes. 
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Fig 38: (R, S)- and (R, R)-['2 1)-QNB in rat brain sections in vitro. 
Autoradiograms show (R, S)- and (R, R)-['2'1]-QNB at the level of the caudate nucleus (A), 
dorsolateral hippocampus (B) and cerebellum (C). Regional distribution of ligand in vitro 
corresponds to that observed in vivo and to regional mAChR distribution. High levels of 
activity are observed in the cortex and caudate and intermediate levels are observed in the 
thalamus. Activity levels in the cerebellum although lower than in cortex are higher than 
would be expected considering the relatively low mAChR density of this region. 
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Fig 39: Time course of of (R, S)-[125 I]-QNB(0.1 nM) binding to mAChRS showing 
total (" ), non-specific (o) and specific ( ) binding in frontal cortex (A), parietal 
cortex (B) and caudate nucleus (C) of 20 pm coronal rat brain sections as 
determined by in vitro autoradiography. Binding is expressed as mean nmols per g 
of Brain from 3 individual experiments. Values for S. E. M are not shown as they 
would obscure the data points. 
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Fig 40: Linear transformation of association specific binding of (R. S)-[IUI]-QNB to 
frontal cortex (A), parietal cortex (B) and cauate nucleus (C) mAChRs in 20 µm corornal 
rat brain sections in vitro. Association assays were performed with 0.1 nM (R, S)-Eu 
IJ-QNB over 120 mins, with kobs calculated for each region from the mean of 3 
individual assays as described in section 2.3.2. kobs= 0.0156 mins-1,0.0303 mins-1 and 
0.0105 mins-lfor frontal cortex, parietal cortex and caudate nucleus respectively. 
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Fig 41: Time course of of (R, R)-[125I]-QNB(0.2 nM)binding to mAChRS showing 
total (0), non-specific (a) and specific ( ) binding in frontal cortex (A), parietal 
cortex (B) and caudate nucleus (C) of 20 pm coronal rat brain sections as 
determined by in vitro autoradiography. Binding is expressed as mean nmols per g 
of Brain from 3 individual experiments. Values for S. E. M are not shown as they 
would obscure the data points. 
B: Parietal Cortex 
C: Caudate Nucleus 
0 20 40 60 80 100 120 140 
0 20 40 60 
a., 
80 
. 
100 120 140 
Graphical Determination of Observed Association 
Rate Constant for (R, R)-[1uI]-QNB in vitro 
E0 
Ra 
aý 
C 
3.0- 
2. S- 
2.0- 
Ls- 
1.0. 
0S 
0.0 
0 
A! Frnnt: A CnrteY 
U. pn-: a#nl Cnrfnv 
Kobs= 0.0185 m3n1 
Kobs= 0.0203 mfnl 
Time (Mips) 
Kobs= 0.0462 mitii 
Fig 42: Linear transformation of association specific binding of (R. R)-[lam IJ-QNB to 
frontal cortex (A), parietal cortex (B) and cauate nucleus (C) mAChRs in 20 µm corornal 
rat brain sections in vitro. Association assays were performed with 0.2 nM (R, R)-[125 
I]-QNB over 120 mins, with kobs calculated for each region fromthe mean of 3 individual 
assays as described in section 2.3.2. kobs= 0.0185 mins-10.0203 mins-land 0.0462 mins 
for frontal cortex, parietal cortex and caudate nucleus respectively. 
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3.3.2 In Vitro Determination of the Equilibrium Dissociation Constant 
for (R, S). and (R, R)-[1251]-QNB. 
The equilibrium dissociation constant (KD nM) was determined for (R, S)- and (R, R)- 
[1251]-QNB by in vitro autoradiographic analysis of 20µm coronal rat brain sections 
following incubation for 1 hour with 0.007nM-0.1 nM (R, S)- and (R, R)-[1251]-QNB. 
Tables of total, non-specific and specific binding for (R, S)- and (R, R)-[ 1251)-QNB are 
presented in Appendix D. 
(R, S)-[1251]-QNB 
Saturation analysis of (R, S)- [1251J-QNB binding to frontal cortex, parietal cortex and 
caudate nucleus of rat brain sections is shown in Fig 43. 
The equilibrium dissociation constant (KD) was calculated as a single line according to 
Scatchard analysis for each region (Fig 44). Scatchard analysis indicates that (R, S)-[125I]- 
QNB binds with high affinity (KD in the sub-nanomolar range) to mAChRs in frontal 
cortex (KD= 0.036 nM), parietal cortex (KD= 0.050 nM) and caudate nucleus (KD= 0.028 
nM). KD determination for cerebellum was not possible as binding data from this region 
was unsuitable for Scatchard analysis. KD values indicate that (R, S)-[125I]-QNB displays 
similar affinity for receptors in each region with less than a2 fold difference in affinity 
observed between frontal cortex , parietal cortex and caudate nucleus 
(R, R)-[125I]-QNB 
Equilibrium dissociation rate constants for frontal cortex (KD= 0.266 nM), parietal cortex 
(KD=0.115nM) and caudate nucleus (Kp=0.206 nM) were determined for (R, R)-[1251]- 
QNB in an identical manner to those for (R, S)-[1251]-QNB. KD values for (R, R)-[125I]_ 
QNB indicate that this ligand also binds to mAChRs with high affinity and displays less 
than 2 fold difference in affinity for receptors between regions As with (R, S)-[ 1251]-QNB 
KD for cerebellum could not be determined. Saturation binding of (R, R)-[ 125I]-QNB to 
frontal cortex, parietal cortex and caudate nucleus and Scatchard transformation of this 
data to allow calculation of KD is displayed in Fig 45 and 46 respectively. 
Comparison of equilibrium dissociation rates for (11, S). and (R, R)-[1251]. QNB 
Scatchard analysis indicates that both ligand's display high affinity for mAChRs in frontal 
cortex, parietal cortex and caudate nucleus. However, (R, S)-[125I]-QNB displays a 2.3 to 
7.4 fold greater affinity for mAChRs than (R, R)-[ 1251]-QNB across the regions, with 
greatest difference in affinity observed in the caudate nucleus i. e. KD=0.028 nM and 0.206 
nM for (R, S) and (R, R) respectively. 
115 
In Vitro Saturation Binding of (R, S)-[125I]-QNB 
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Fig43: Saturation curves showing total (o ), non-specific (o ) and specific (a) 
binding of (R, S)-[125 I]-QNB to mAChRs in frontal cortex (A), parietal cortex (B) 
and caudate nucleus (C) of 20 µm coronal rat brain sections as determined by in 
vitro autoradiography. Binding is expressed as mean nmols per g of Brain from 3-4 
individual experiments. Values for S. E. M are not shown as they would obscure the 
data points. 
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Fig 44: Representitative Scatchard plots of (R, S)-[125I]-QNB binding to frontal cortex 
(A) 
, parietal cortex (B) and caudate nucleus (C) from a single experiment. The 
saturation binding experiments were carried out with (R, S)-[1251]-QNB concentrations 
ranging from 0.007 to 0.1 nM with a1 hour incubation period followed by Scatchard 
analysis. KD= 0.036nM, 0.050 nM and 0.028 nM for frontal cortex, pariteal cortex and 
caudate nucleus respectivley. KD values for each region were calculated from the mean 
data of 3-4 individual experiments. 
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Fig 45: Saturation curves showing total (" ), non-specific (0) and specific (n ) 
binding of (R, R)-[125I]-QNB to mAChRs in frontal cortex (A), parietal cortex (B) 
and caudate nucleus (C) of 20 µm coronal rat brain sections as determined by in 
vitro autoradiography. Binding is expressed as mean nmols per g of Brain from 3 
individual experiments. Values for S. E. M are not shown as they would obscure the 
data points. 
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Fig 46: Representitative Scatchard plots of (R, R)-[125 I]-QNB binding to frontal cortex 
(A) , parietal cortex (B) and caudate nucleus (C) from a singlgxperiment. The saturation binding experiments were carried out with (R, R)-[ I]-QNB concentrations 
ranging from 0.007 to 0.1 nM with a1 hour incubation period followed by Scatchard 
analysis. KD= 0.226nM, 0.115 nM and 0.206 nM for frontal cortex. parietal cortex and 
caudate nucleus respectivley. KD values for each region were calculated from the mean 
data of 3 individual experiments. 
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3.3.3 Effect Of Acetylcholine on Binding of (R, S). and (R, R)-[1251]-QNB to Rat 
Brain Sections In Vitro in the Presence of Heptylphysostigmine 
The effect of ACh (10-6 to 10-2M) on the binding of (R, S)- and (R, R)-[1251]-QNB 
(0.1nM and 0.2 nM respectively) to 20µm coronal rat brain sections was determined by in 
vitro autoradiography in the presence of heptylphysostigmine (10-6M). Tables of total. 
non-specific and specific binding for (R, S)- and (R, R)-[ 125I]-QNB displacement studies 
are presented in Appendix D. 
Effect of Heptylphysostigmine on (R, R)-[125I]. QNB binding In Vitro 
Before investigation of the ability of ACh to displace (R, S)- and (R, R)-[1251]-QNB 
binding in vitro, the effects of a range of concentrations of heptylphysostigmine (10-3M, 
10-4M and 10-6M) on the binding of (R, R)-[ 125I]-QNB to rat brain sections in vitro was 
determined by autoradiography (Fig 47). 
10-3M heptylphysostigmine significantly reduced specific binding of (R, R)-[ 125I]-QNB in 
rat brain sections at the level of the frontal cortex, parietal cortex and cerebellum. 
Reductions in specific binding of (R, R)-[1251]-QNB were also observed with 10-4 M 
heptylphysostigmine but did not reach statistically significant levels. 10-6 M 
heptylphysostigmine had no effect on (R, R)-[125I]-QNI binding, this concentration was 
therefore used in all subsequent in vitro displacement studies with (R, S)- and (R, R)-[125I]- 
QNB. 
Effect of Acetylcholine on (RS)- and (R, R)-[1251]-QNB Binding in vitro 
ACh (10-5M to 10-2M) had no effect on (R, S)-[1251]-QNB binding to rat rain sections at 
the level of the frontal cortex, parietal cortex and cerebellum (Fig 48). Similarly, ACh (10- 
6M to 10-3M) had no effect on (R, R)-[125I]-QNB binding to rat brain sections at the level 
of the frontal cortex, parietal cortex and cerebellum (Fig 49). 
3.3.4 Acetylcholinesterase Activity in Rat Brain Sections In Vitro Following 
Heptylphysostigmine Administration 
Effect of Heptylphysostigmine (10-6M) on AChE activity in Vitro 
AChE activity in heptylphysostigmine treated sections and control sections taken from in 
vitro displacement studies with (R, S)- and (R, R)-[1251]-QNB was determined by semi- 
quantitative histochemistry. Sections were processed for acetylcholinesterase activity to 
determine that inhibition of the enzyme was maintained throughout the duration of the 
assay. 
10-6 M heptylphysostigmine significantly inhibited AChE activity in frontal cortex, 
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parietal cortex and cerebellum in sections taken from displacement studies with (R, S)- 
[1251]-QNB and in frontal and parietal cortex in sections taken from displacement studies 
with (R, R)-[1251]-QNB (Fig 50). Illustrative sections stained for AChE are displayed in 
Fig 51. Inhibition of AChE activity is apparent by the residual level of staining observable 
in heptylphysostigmine treated sections compared to that in control sections. 
Tables of regional AChE activity for (R, S)- and (R, R)-[1251]-QNB displacement studies 
are presented in Appendix C. 
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Heptylphysostigmine Displaces (R, R)-[1251]-QNB from Rat 
Brain Sections In Vitro at High Concentrations 
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Fig 47: Specific binding of (RR)-[1251]-QNB (0.2 nM) to 20 pm coronal rat brain 
sections in vitro. Heptylphysostigmine (10-3 M) reduces (R, R)-[125I]-QNB in frontal 
cortex (A), parietal cortex (B) and cerebellum (C) of rat brain sections. *P <0.05 for 
statistical comparison between control and each concentration of heptylphysostigmine (ANOVA, Student's t-Test with Bonferroni Correction). Data are expressed as mean t S. E. M nM per g brain of specifically bound ligand of 3 individual experiments. 
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Fig 48: Specific binding of (R, S)-[12511-QNB(0.1 nM) to 20 µm coronal rat brain sections 
in vitro. ACh (10-5 to 10-2 M) fails to displace (R, S)-[1251]-QNB from frontal cortex 
(A), parietal cortex (B) and cerebellar cortex (C) of rat brain sections in the presence of 
heptylphysostigmine (10-6M). Data are expressed as mean t S. E. M nM per g brain of 
specifically bound ligand of 4 individual experiments. 
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Fig 49: Specific binding of (R, R)-[1251]-QNB(0.2 nM) to 20 µm coronal rat brain sections 
in vitro. ACh (10-6 to 10-3 M) fails to displace (R. R)-[125I]-QNB from frontal cortex 
(A), parietal cortex (B) and cerebellum (C) of rat brain sections in the presence of 
heptylphysostigmine (10-6M). Data are expressed as mean ± S. E. M nM per g brain of 
specifically bound ligand of 3 individual experiments. 
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Fig 50: AChE enzyme activity measured by semi-quantitative histochemistry in untreated 
(control) and heptylphysostigmine (10-6M) treated sections of rat brain taken from in vitro 
displacement studies with (RS)- and (RR)-[125I]-QNB (Figs A and B respectively). 
Heptylphysostigmine inhibits enzyme activity in all regions analysed, with profound 
reductions observed in all regions in sections from (RS)-[125I]-QNB studies and in the 
frontal and parietal cortices in sections from (R, R)-[1251]-QNB studies. *P <0.05, **P <0.01 
and ***p <0.001 for the statistical comparison between control and heptylphysostigmine 
treated sections (Student's unpaired t-test). Data are expressed as mean ± S. E. M. optical 
density as a measure of staining intensity, n= number of sections analysed per region. 
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Fig 51: Figure shows AChE histochernical staining in rat brain sections at the level of the 
caudate nucleus (A), dorsolateral hippocampus (B) and cerebellum (C) taken from in vitro 
displacement experiments with (R, S)- and (R, R)-['2`1]-QNB. Heptylphysostigmine (10'M) 
significantly inhibits AChE activity. 
fleptylphysostlg nlnt 
r 
r, ý ýtl, * 
ý{. 
,. >ý ,. 
t' 
CHAPTER 4 
DISCUSSION 
4.1 (R, S)- AND (R, R)-[125I]. QNB ARE SUITABLE LIGANDS FOR MAPPING 
MUSCARINIC CNS RECEPTORS IN VIVO 
Ligand Distribution in vivo 
In vivo analysis of (R, S)- and (R, R)-[1251]-QNB in the conscious rat confirms the utility of 
these ligands as in vivo agents for the imaging of mAChRs. Autoradiographs indicate that 
following intravenous administration both ligands display effective uptake from the 
plasma into the brain; with metabolite analysis of brain homogenates identifying (R, S)- 
and (R, R)-[125I]-QNB as the sole constituents of brain radioactivity. Furthermore, 
regional localisation of (R, S)- and (R, R)-[1251]-QNB activity in the brain is consistent 
with the known distribution of mAChRS. High levels of activity are observed in the cortex 
and caudate, moderate levels are observed in the thalamus and low levels are observed in 
the cerebellum. This distribution is consistent with the observations of a number of in vivo 
studies with these ligands (Gibson, et al., 1989, Gibson et al., 1991, Gibson et al., 1992, 
Gitler et al., 1995, McRee et al., 1995, Boulay et al, 1996a, 1996b, Sood et al., 1997). This 
pattern of in vivo distribution correlates with the rank order of mAChR concentration in the 
brain of caudate > cortex > thalamus > cerebellum as determined by in vitro analysis and 
also with the rank order of regional binding potential for (R)-[125I]-QNB as determined in 
vivo by Sawada et al., (1990b). (Table 17). 
It is possible however, that the regional uptake and distribution of iodo-QNB is dependent 
upon cerebral blood flow rather than mAChR concentration, as regions of high blood flow 
such as the cortex also display highest activity levels. This is not thought to be the case 
however, as there is significant dissociation of blood flow and tracer activity in the 
cerebellum. The low level of activity observed in this region is consistent with its low 
density of mAChRs but is in contrast to the relatively high blood flow for this region. 
Furthermore, regional cerebral blood flow rates, measured in vehicle treated animals in this 
thesis (section 3.2), show a poor degree of correlation with regional levels of (R, S)-[125I]- 
QNB (Fig 52). It is therefore reasonable to assume that differences in regional activity 
levels reflect differences in mAChR binding. This view is supported by the observation 
that co-injection of unlabelled mAChR ligands displaces iodo-QNB activity from the brain 
in a non-region specific manner indicating that binding to receptors other than mAChRs 
does not contribute to the signal observed (Gitler et al., 1995, McRee et al., 1995, Lee et 
al., 1995). 
In Vitro Distribution and Binding Kinetics 
Examination of the in vitro autoradiographs of (R, S)- and (R, R)-[125I]-QNB binding to rat 
brain sections reveals that both ligands display regional distribution appropriate for CNS 
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In Vivo Distribution of (R, S)- and (R, R)-[125I]-QNB is 
Consistent with Regional mAChR Concentration 
Region mAChR 
Concentration 
(nM) 
Binding 
Potential 
(k3/k4) 
(R, S). QNB 
ROI/Caudate 
(R, R)-QNB 
ROI/Caudate 
Caudate 
Nucleus 
57 1116 1.0 1.0 
Frontal Cortex 45 1171 1.181 1.108 
Hi ocam us 37 NA 0.763 0.868 
Thalamus 18 247 0.762 0.544 
Cerebellum 5 51 0.108 0.102 
Table 17: Comparison of mAChR concentration, binding potential for R-IQNB and 
(R, S)- and (R, R)-[125I]-QNB level in caudate nucleus, frontal cortex, hippocampus, 
thalamus and cerebellum in rat brain. Regional distribution of (R, S)- and (R, R)-[1251]- 
QNB as measured in vivo is generally consistent with mAChR concentration as determined 
in vitro and with the regional binding potential of R-IQNB as determined in vivo by 
Sawada et al., 1990b). In vitro mAChR concentration is expressed as the average 
concentration of ml, m2, m3 and m4 receptors in nM adapted from Table 2 in Boulay et al., 
(1996). ' 
Regional binding potential for R-IQNB is equal to the ratio of the in vivo association rate 
constant (k3) and dissociation rate (k4) constant as determined by Sawada et al., (1990b) 
for R-IQNB in rat. Regional concentrations of (R, S)- and (R, R)-[125I]-QNB are expressed 
as mean % Dose per g Brain normalised to the caudate nucleus (n= 5) measured at 2 hours 
after intravenous administration as measured in this thesis. 
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Correlation Of Regional (R, S)-[1251]-QNB Activity And 
Regional Cerebral Blood Flow 
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Fig 52: Figure shows a plot of (R, S)-[1251]-QNB levels in 33 discrete'rat brain regions at 
2 hours against local cerebral blood flow rates for the same regions. A correlation 
coefficient of r2=0.162 indicates that there is a low degree of association between regional 
cerebral blood flow and regional levels of (R, S)-[125I]-QNB in the brain of the conscious 
rat. Data are expressed as mean % dose per g Brain, n= 5 for (R, S)-[1251]-QNB and mean 
ml/l00g/min n= 5 for CBF. Regional cerebral blood flow data was measured by [14C]- 
IAP autoradiography in saline treated animals as described in section 3.2 in this thesis. 
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mAChRs, similar to that observed in vivo. Ligand distribution is heterogeneous, with high 
levels of binding observed in the cortex, caudate and the hippocampal formation with 
lower levels observed in the thalamus and cerebellum. The binding pattern is consistent 
with that of with [3H]-QNB described by Nonaka and Moroji (1984) and with the 
distribution of the putative "M1 sites" described by Mash and Potter (1986). These 
observations support the view that the pattern of (R, S)- and (R, R-[125I]-QNB distribution 
observed in vivo reflects mAChR binding. However, the level of binding observed in vitro 
in the cerebellum in studies performed in this thesis is relatively high for the low mAChR 
concentration in this region. A high degree of non-specific binding is observed in all 
assays [see Appendix D] and is likely to be due to the high lipophilicity afforded to the 
ligand by iodination of the molecule. Post-incubation washing of sections is usually 
employed to reduce non-specific binding to increase signal to noise ratio. However, despite 
extended periods of post-incubation washing (30 mins) levels of non-specific binding 
remain high in assays with both (R, S)- and (R, R)-[12511-QNB. It is likely that this 
accounts in part for the unexpectedly high level of activity observed in the cerebellum. 
Estimated equilibrium dissociation constants (KD) for both ligands are in the sub- 
nanomolar range in all regions analysed (0.036nM - 0.226 nM) indicating that both ligands 
display high affinity for mAChRs. Additionally, the association kinetics of the ligands are 
rapid enough to support their use in vivo, with kobs ranging from 0.0 105 mins-1 to 0.0462 
mins-1 between regions. The values for KD and kobs determined by in vitro 
autoradiography for (R, S)- and (R, R)-[125I]-QNB are intended only as an approximation 
and it is recognised that the autoradiographic methodology employed in this thesis suffers 
from a number of disadvantages compared to homogenate binding which is accepted to 
produce more accurate data when characterising ligand binding in vitro. 
Nevertheless, the in vitro binding kinetics of (R, S)- and (R, R)-[ 1251]-QNB presented in 
this thesis are in general agreement with the data from homogenate binding assays 
performed in a number of tissue preparations [Table 18 and 19] (Gibson, et al., 1984a, 
Gibson et al., 1989, Zeeberg et al., 1991, Gibson et al., 1992). The binding parameters 
calculated indicate high affinity and specificity of (R, S)- and (R, R)-[1251]-QNB for 
mAChRs. 
In Vivo Selectivity for mAChR Subtypes 
Investigation of (R, S)- and (R, R)-[125I]-QNB binding to transfected cell 
membranes expressing a single cloned mAChR subtype indicates ml selectivity for these 
ligands in, vitro (Zeeberg et al., 1991). This is supported by the observation that the 
dissociation rate 
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Table 18 
Association Rate Constants and Equilibrium Dissociation Constants 
for (R, S)- and (R, R)-[12511-QNB Determined by In Vitro Autoradiography 
Region (RAS)-[12511-QNB (RAR)-[125I]-QNB 
Frontal Cortex kobs (mins-1) 0.0156 0.0185 
KD (nM) 0.036 0.226 
Parietal Cortex kobs 0.0303 0.0203 
KD 0.050 0.115 
Caudate Nucleus kobs 0.0105 0.0462 
KD 0.028 0.206 
Table 19 
Association and Dissociation Rate Constants and Equilibrium 
Dissociation Constants for (R, S)- and (R, R)-[1251J. QNB Determined by In Vitro 
Binding to Transfected Cell Membranes Expressing Muscarinic Receptors 
Radioli and Subtype kass (nins-1) kdis (mins-1) KD (nM) 
(R, S) ml 0.0158 0.00276 0.0116 
m2 0.1787 0.10362 0.0482 
m3 0.0144 0.00431 0.0470 
(R, R) ml 0.0681 008134 0.490 
m3 0.0724 0.05564 1.268 
Tables show association rate constant (kobs) and equilibrium dissociation rate constant 
(KD) for (R, S)- and (R, R)-[1251]-QNB binding to mAChRs in rat brain sections as 
determined by in vitro autoradiography in this thesis [Table 18] and the association rate 
constant (kass), dissociation rate constant (kdis) and equilibrium dissociation rate constant 
(KD) for (R, S)- and (R, R)-[125I]-QNB binding to transfected cell membranes expressing 
ml, m2 and m3 mAChRs as determined by Zeeberg et al., (1991)[Table 19]. Rate constant 
values determined by in vitro autoradiography in this thesis are consistent with literature 
values determined by binding to transfected cell membranes. 
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of (R, S)-[125I]-QNB from M2 receptors in vitro was 20 fold faster than from M1, M3 or 
M4 receptors and was reflected by in vivo washout of ligand which was predominantly 
faster in regions of high M2 density (Sawada et al., 1990b, Gibson et al., 1992). 
In contrast, [3H]-QNB displays M2 selectivity in vitro (Boulay et al., 1996b). A relatively 
low homogeneous distribution of [3H]-QNB is observed in vivo in accordance with m2 
distribution and suggests a significant population of m2 receptors is present in the 
cerebellum. In contrast the in vivo distribution of (R, S)- and (RR)-[125I]-QNB is more 
highly circumscribed with (R, S)-[125I]-QNB distributed in accordance with total mAChR 
concentration and (RR)-[125I]-QNB distributed in accordance with ml/m4 concentration 
(Boulay et al., 1996b). That is, levels of (R, S)- and (RR)-[125I]-QNB were high in the 
cortex, caudate and hippocampus but were extremely low in the cerebellum, consisting 
almost entirely of non-specific binding. 
The in vivo distribution of (R, S)- and (RR)-[125I]-QNB observed in this thesis is in 
general agreement with observations from the above studies. High levels of activity 
observed in the cortex, caudate and hippocampus compared with very low levels in the 
cerebellum indicate that (R, S)- and (RR)-[125I]-QNB display predominantly ml or "ml 
like" selectivity in vivo. 
4.1.1 Uptake and Retention of (RS)- and (RR)-[125j]-QNB 
Although regional uptake and distribution of (R, S)- and (RR)-[125I]-QNB are 
qualitatively similar (corresponding to mAChR concentration) the ligands display 
considerable differences in regional retention and washout in vivo. 
Comparison of regional time-activity profiles of (R, S)- and (RR)-[125I]-QNB in rat brain 
highlight these differences. (R, S)-[125I]-QNB displays essentially no washout from cortex 
between 2 and 24 hours after administration. In thalamus however, a considerable loss of 
activity is observed over this time. These observations are in general agreement with those 
of Sawada et al., (1990b) for R-IQNB in rat brain. Graphical analysis (Patlak Plot) 
indicated that uptake of R-IQNB into cortex and caudate was essentially irreversible over 
the first 6 hours following intravenous administration, with a slow loss of activity 
observable when the plot was extended to 26 hours. Similar analysis of time-activity data 
for the thalamus indicated that uptake in this region was irreversible only for the first 2 
hours following administration and that loss of activity could be observed after this time. 
These observations are qualitatively similar to regional time-activity profiles for (R, S)- 
[1251]-QNB presented in this thesis and provides a degree of validation of the 
methodology employed here. 
In contrast, regional time activity data for (RR)-[125I]-QNB is considerably different from 
that of (R, S)-[1251]-QNB and R-IQNB, although some comparisons can be made. 
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Washout of (R, R)-[1251]-QNB from brain follows a similar regional pattern to that of 
(R, S)-[125I]-QNB, with little loss of activity observed in cortex and considerable loss of 
activity observed in thalamic regions. However this occurs over a much shorter time-scale 
i. e. 6 hours as opposed to 24 hours. Washout of (R, S)- and (R, R)-[ 1251]-QNB from 
regions such as mediodorsal thalamus, ventrolateral thalamus and lateral geniculate 
nucleus best demonstrate the differences in vivo kinetic behaviour of these ligands. 
Although washout of activity from each of these regions is observed with time, a much 
greater loss of (R, R)-[125I]-QNB activity occurs over a shorter time i. e.. 70%, 72% and 
70% for (R, R) over 6 hours compared to 39%, 49% and 53% over 24 hours for (R, S), 
respectively for each region. 
Initially, for studies with (R, R)-[1251]-QNB the same temporal profile as that for (R, S)- 
[1251]-QNB was to be used to allow direct comparison of tracers over 24 hours. However 
preliminary analysis of (R, R)-[125I]-QNB indicated that by 12 hours although tracer levels 
in cortex were comparable with those of (R, S)-[125I]-QNB at this time, activity in the 
thalamus was significantly lower and was undetectable in the cerebellum. and by 24 hours 
after administration radioactivity was undetectable in the brain. Fig 53 shows a comparison 
of time-activity profiles of (R, S)- and (R, R)-[ 125I]-QNB in frontal cortex, mediodorsal 
thalamus and cerebellum over 24 hours. 
From these observations it is reasonable to assume that (R, S)- and (R, R)-[ 1251] _QNB 
display considerable differences in their in vivo binding kinetics with mAChRS. 
The differences in the regional washout rates of (R, S)- and (R, R)-[1251]-QNB described 
above are consistent with their in vitro binding kinetics. The dissociation rate for (R, R)- 
[1251]-QNB from mAChRS is 13-20 fold faster than that for (R, S)-[125I]-QNB (Gibson et 
al., 1989, Gibson et al., 1992). The increased washout of (R, R)-[1251]-QNB observed in 
this thesis is also consistent with previous reports indicating that this ligand clears more 
rapidly from all brain regions than (R, S)-[125I]-QNB in vivo (Gibson, et al., 1989, Zeeberg 
et al., 1996). The more rapid clearance of (R, R)-IQNB activity from brain promotes its 
greater suitability over (R, S)-IQNB as an in vivo agent for use in man. (R, S)-[1231]-QNB 
has been successfully used in man to image mAChRS but suffers from slow washout 
kinetics in that it takes longer than 20 hours to reach optimal specific to non-specific 
binding ratios (Fig 54) (Wyper et al., 1993). The in vivo rat data presented here suggests 
that (R, R)-[123I]-QNB would reach optimal binding conditions more rapidly than (R, S)- 
[123I]-QNB indicating its greater utility as an in vivo imaging agent in man. Similarly, 
these observations suggest that (R, R)-[1251]-QNB would be more sensitive to changes in 
ACh function than (R, S)-[1251]-QNB. 
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(R, 5)- and (R, R)-[ 125I]-QNB in Rat Brain over 24 hours 
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Fig 53: Figure shows (R, S)- and (R, R)-[125I]-QNB in rat brain at the level of the frontal cortex, mediodorsal thalamus (MD) and cerebellum at 30 mins to 24 hours after intravenous administration. (R, R)-[ 1251]-QNB is washed out of brain more quickly than (R, S)-[125I]-QNB. Data are expressed as mean t S. E. M % Dose per g Brain normalised to caudate nucleus. n=3-5 for (R, S)-[ 125I]-QNB and n= 5 for (R, R)-[1251]-QNB, with the exception of data points at 12 and 24 hours where n= 1. 
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4.2 METABOLISM OF (R, S)- AND (R, R)-[1251]-QNB IN VIVO 
Brain Radioactivity 
Analysis of rat brain homogenate samples indicates that authentic (R, S)- and (R, R)-[125n- 
QNB represent the only major radioactive species present in brain following intravenous 
administration of tracer. It can thus be assumed that radioactivity measured in 
autoradiograms is entirely due to authentic ligand. This observation is consistent with other 
reports in which iodo-QNB was observed to represent greater than 90% of the radioactivity 
present in brain following intravenous administration (Blasberg et al., 1986, Gibson et al., 
1989, Sawada et al., 1990b). 
Plasma Radioactivity 
Analysis of arterial plasma samples taken from animals receiving (R, S)-[125I]-QNB and 
(R, R)-[ 1251]-QNB indicate that authentic ligand is present in plasma up to 12 and 6 hours 
respectively following intravenous administration. Blasberg et al., (1986) estimated that 
15-30% of total R-IQNB in plasma is exchangeable during a single capillary pass in the 
brain, thus it can be assumed that (R, S)- and (R, R)-[12511-QNB may be transported into 
the brain for a 'period equal to the time they are present in plasma. 
The reverse phase chromatography technique employed in this thesis in the analysis of 
plasma samples separates radioactive species by polarity with the most polar species eluted 
first. Analysis of (R, S)-[12511-QNB plasma samples identified the presence of 3 
radioactive species in addition to the parent ligand. The fastest eluting (i. e. most polar) of 
these with a retention time of approximately 3 mins is likely to represent free iodide, 
produced by de-iodination of parent ligand and for its radioactive metabolites. Two 
unidentified radioactive metabolite species are also observed in plasma following 
intravenous administration. It is of interest that both metabolite species are of higher 
lipophilicity (i. e. less polar) than authentic tracer as evinced by their longer retention times 
of approximately 13 mins and 15 mins. This is unusual in that metabolic processes usually 
result in the formation of more polar/less lipophillic compounds to aid clearance from the 
body and is in opposition to the observations of Blasberg et al., (1986) and Sawada et al., 
(1990b) who identify two metabolites of greater polarity than parent compound in the 
plasma following intravenous administration of (R)-[125I]-QNB. A possible explanation 
for this apparent anomaly may be that the metabolic process leading to clearance of (R, S)- 
[1251]-QNB consists of a number of steps, one of which involves the formation of 
compounds of greater lipophilicity than parent ligand. This would correlate with the 
relatively rapid clearance (i. e. by 15 mins) of the more lipophilic metabolite from plasma, 
in that this metabolite may be formed first and then converted to the second less lipophilic 
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metabolite species. The second metabolite may then undergo further processing probably 
involving de-iodination as evinced by the increase in free iodide observed with time. This 
would also account for the lack of polar radioactive metabolite species on HPLC traces. 
Neither of the metabolite species observed in plasma were identified, but their lack of 
presence in the brain indicates that they possess no affinity for mAChR or other brain 
receptors. 
In contrast to (R, S)-[1251]-QNB, analysis of plasma samples following administration of 
(R, R)-[1251]-QNB indicates that free iodide constitutes the major radioactive metabolite 
species present in plasma This observation suggests that de-iodination represents the 
major metabolic event in the clearance of (R, R)-[1251]-QNB from the body. However, the 
broad low level peak with a retention time of 13.0 mins on a number of traces is possibly 
due to the presence of one or more radioactive metabolites in plasma which are present at a 
very low level. It is possible that metabolites are formed and cleared with sufficient 
rapidity that no significant accumulation in the plasma occurs. As (R, R)-[125I]-QNB 
represents the sole radioactive species in brain it is likely that any radioactive metabolites 
formed display no affinity for mACh or other brain receptors. 
Fig 55 shows the percentage of authentic (R, R)-[125I]-QNB bound to plasma protein up to 
6 hours following tracer administration. Plasma protein bound activity peaks at 
approximately 22% 2 hours after administration. This is in contrast to previous 
observations which estimate greater than 90% of authentic ligand in plasma is bound to 
plasma proteins at any one time following intravenous administration (Blasberg et al., 
1986). These observations indicate that a significant proportion of the authentic ligand 
detectable in plasma constitutes a "free pool" which is available for uptake into the brain. 
This theory is supported by the increases in brain (R, R)-[1251]-QNB activity observed 
between 30 mins to 2 hours after administration of tracer. 
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Fig 55: Timecourse of protein bound (R, R)-[1251}-QNB in plasma following intravenous 
injection in rat. Data points represent levels of authentic ligand bound to protein in plasma 
of conscious rat between 1 min and 6 hours after administration. Protein bound ligand 
constitutes no more than 25 % of authentic ligand present in plasma at any one time. Data 
are expressed as mean ± S. E. M % of injected dose (n= 2-3). 
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4.3 KINETIC MODELLING 
A3 compartment model [Fig 56] was used to examine the hypothetical brain 
concentrations arising from intravenous administration of tracer with an input function like 
that of (R, S)- [1251]-QNB where tracer is cleared slowly from plasma. 
A number of specifications of this model require discussion. The model is set up to reflect 
the situation where a tracer moves from the plasma into a second compartment within the 
brain which describes free and non-specifically bound tracer. 
K1 kin 
Specific 
Plasma Free and NS 
(Brain) (Brain) 
K2 troff 
A third compartment describes tracer bound specifically to receptors within the brain. The 
factors influencing the movement of tracer between these three compartments are 
described below. 
1) K1 is an input constant describing the amount of tracer delivered to the brain which is 
determined by the plasma concentration of tracer, the free fraction of tracer within the 
plasma, cerebral blood flow, and the extraction fraction. 
" Plasma concentration is described by a plasma time-activity graph based upon the 
plasma clearance of (R, S)-[125I]QNB as observed in in vivo studies (Fig 12). 
" The free fraction of tracer in plasma was set 0.086, as estimated by Sawada et al., 
(1990b) for R-IQNB. 
" Cerebral blood flow (ml/g/min) was variable with values of 0.8 mu g/min set for cortex 
and cerebellum and 0.4 ml/g/min set for caudate nucleus and thalamus to represent 
the differences in blood flow between these regions. 
" The extraction fraction is dependent on the capillary surface area S, the capillary 
permeability P and perfusion (flow) F. The dependence on blood flow reflects the fact 
that at higher flows, the tracer spends less time within the capillary. The extraction 
fraction itself may vary with time as the concentration of tracer in plasma changes, but 
is set at 0.431 as determined by Sawada et al., (1990a) for R-IQNB. 
2) K2 is the elimination rate constant describing the amount of tracer flowing out of the 
brain into plasma. K2 can be expressed as K1/(V2*fl) where K1 is the association rate 
constant, V2 is the volume of distribution of the free and non-specifically bound 
compartment and fl is the free fraction of tracer within the blood. K2 is dependent 
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upon the concentration of tracer within the brain, the partition coefficient or volume of 
distribution of the tracer, the extraction fraction and cerebral blood flow. 
The volume of distribution of specifically bound tracer varies between brain regions 
and was therefore set at 24,16,6 and 0.6 for cortex, caudate nucleus, thalamus and 
cerebellum based upon the values estimated Sawada et al., (1990b) for R-IQNB. 
3) Unbound ligand reversibly binds to receptors at a rate dependent upon the concentration 
of the 2 reactants. The rate constant for this reaction is known as the association rate 
constant kon. The value of kon is variable for the uptake of tracer into different brain 
regions and was set at 2.04,2.10,0.78 and 1.10 for cortex, caudate nucleus, thalamus 
and cerebellum respectively based on parameters estimated by Sawada et al., (1990b) 
for R-IQNB. Bmax equals the concentration of receptors available for binding which is 
also variable from region to region and was set at 0.19,0.24,0.08 and 0.02 based upon 
the relative concentrations of mAChRs in cortex, caudate nucleus, thalamus and 
cerebellum respectively. 
4) The rate of dissociation of the tracer from the receptor is determined by the dissociation 
rate constant koff and the concentration of tracer within the specifically bound 
compartment. As with kon and Bmax the value of koff varies between regions and was 
set at 0.00 17,0.0018,0.0032 and 0.045 for cortex, caudate nucleus , thalamus and 
cerebellum respectively based on parameters estimated by Sawada et al., (1990b) for 
R-IQNB. 
Comparison of hypothetical concentrations of radioactivity arising from the input curve for 
(R, S)-[125I]-QNB and actual tracer uptake (tCi/g) in the frontal cortex, caudate nucleus, 
thalamus and cerebellum is displayed in Fig 57. In general, simulated regional uptake of 
tracer is consistent with actual uptake. Highest levels of activity are observed in the cortex 
and caudate with no washout of tracer observed to occur from these regions over 24 hours. 
A lower level of uptake is observed in the thalamus with washout of activity observed 
from this region with time. Uptake and retention of tracer in the cerebellum is negligible. 
A number of inconsistencies are evident however. The time course of modelled uptake is 
slower than that of actual uptake. Activity in the thalamus takes in excess of 5 hours to 
reach peak levels with washout of activity observed thereafter. In contrast, actual 
radioactivity in the thalamus in vivo is at its highest measured level at 2 hours, with 
washout of activity observed thereafter. Similarly, modelled levels of activity in the cortex 
and caudate are estimated to increase steadily over 24 hours in contrast to the steady state 
levels measured in vivo. 
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Fig 57: Comparison of Actual and Hypothetical uptake and retention of (R, S)- 
[1251]-QNB in rat brain-raw and normalised data. 
A3 compartment model was used to model the hypothetical uptake and retention of 
(R, S)-[1251]-QNB in frontal cortex, caudate nucleus, thalamus and cerebellum of 
conscious rat using the plasma input curve for (R, S)-[125I]-QNB. All model 
parameters were identical to those described in section 4.3. 
Hypothetical concentrations of un-normalised tracer (top right graph) in brain are 
generally consistent with actual un-normalised concentrations (top left graph) of 
tracer measured in vivo, although differences in the time course of uptake and 
retention of radioactivity are evident. Comparison of hypothetical and actual 
concentrations of tracer in the brain normalised to the concentration in the caudate 
nucleus (bottom right and bottom left graphs respectively) show greater consistency 
than un-normalised data sets. The time course of uptake and retention is comparable 
as are levels of tracer in each brain region. 
The 3 compartment model described in section 4.2 therefore adequately describes 
the uptake and retention of (R, S)-[1251]-QNB in brain and provides validation of the 
normalisation procedure employed. 
Data are expressed as mean ± S. E. M [tCi per g Brain for Actual data: Un- 
normalised (n= 5), RCi per g Brain for Modelled Data: Un-normalised , mean f 
S. E. M % Dose per g Brain normalised to the caudate nucleus (n= 5) for Actual Data: 
Normalised 
, and 
% Dose per g Brain normalised to the caudate nucleus for 
Modelled Data: Normalised. 
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The inconsistencies observed between modelled data and actual data may be due to the use 
in the model of the transport and binding parameters estimated by Sawada et at., (1990b) 
for R-IQNB. Although these values are likely to be a realistic approximation of actual 
values for (R, S)-[1251]-QNB, differences in the input function, and in blood flow between 
the model used here and the model of Sawada et al., (1990b) will effect the values for K1 
and K2 which will have consequent impact upon the uptake and washout of tracer from the 
brain. For example K1 as estimated by Sawada et al., (1990b) for frontal cortex was 0.320 
mu g/min. In the model above Kl can be calculated as 0.345 ml/g/min from K1= FE 
(where F is blood flow and E= extraction fraction) and is consistent with the literature 
value. Similarly, from the model K2 can be calculated as 0.167 min-1from K2= 
Kl/(V2*fl) (where V2 is volume of distribution of tracer and fl= free fraction in blood). 
In contrast, K2= 1.58 min-1 as estimated by Sawada et al., (1990b). Therefore, K2 as 
calculated in the model is approximately 10 fold lower than that estimated by Sawada et 
al., (1990b) and would result in slower elimination of tracer from the brain. It is possible 
that this accounts for the time differences observed between modelled and actual washout 
of tracer from the thalamus. 
Comparison of hypothetical concentrations of radioactivity "normalised" to the 
concentration in the caudate nucleus for frontal cortex, caudate nucleus, thalamus and 
cerebellum with actual normalised data is also displayed in Fig 57. Expressing modelled 
data as a ratio relative to the caudate nucleus is consistent with actual raw (. tCi/g) and 
normalised data for each region. The time course of modelled uptake is comparable to 
actual uptake, with peak brain activity levels achieved at approximately 2 hours in all brain 
regions. Washout of activity from thalamus is then observed between 2 and 24 hours, 
while activity levels in cortex and caudate nucleus remain constant up to 24 hours. This is 
consistent with regional activity levels measured in vivo and with the observations of 
Sawada et al., (1990b) with R-IQNB. It is therefore proposed that the 3 compartment 
model described above adequately describes the uptake and retention of (R, S)-[125I]-QNB 
in the brain of conscious rat and additionally provides validation of the in vivo 
methodology and normalisation procedure employed in this thesis. 
Modelling of (R, R)-[125I-QNB uptake and retention in the brain was not performed due 
to the lack of transport and binding parameters in the literature adequately describing the in 
vivo behaviour of this radioligand. 
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4.4. NORMALISATION OF DATA 
Data from in vivo experiments with iodo-QNB is routinely normalised to a control region 
(caudate nucleus) in which activity levels have been shown to be highly reproducible from 
animal to animal (Gitler et al., 1995, Boulay et al., 1996, Sood et al., 1997, Zeeberg et al., 
1997). In accordance with this, all in vivo data in this thesis has been expressed as a ratio 
of % injected dose per g brain to caudate nucleus. Normalisation of data in this manner is 
particularly important where the data set is inherently variable as in this thesis where time- 
activity data for the uptake and retention of tracer is obtained from multiple animals for 
each time point analysed. The benefit of data normalisation can be appreciated by 
comparing raw and normalised data sets for the uptake and retention of (R, S)-[1251j-QNB 
activity in the frontal cortex between 2 and 24 hours . The average standard 
deviation of 
binding was 10% of the mean for normalised data (% dose per g brain /caudate) and 47 % 
of the mean for un-normalised data (% dose per g brain) respectively. This observation is 
roughly consistent with those of previous investigations where the standard deviations of 
binding were 8% and 30% of the mean for data normalised to the caudate nucleus and un- 
normalised data respectively (Gitler et al., 1995) and confirms the utility of normalisation 
of data by this means. 
Although normalisation of data to the caudate nucleus is well accepted, alternative means 
of data normalisation were considered in this thesis. These included normalisation of data 
to the cerebellum and to the concentration of tracer in plasma. 
Comparison of regional activity levels with those observed in the cerebellum has been 
proposed as a means of accounting for the degree of non-specific binding apparent with a 
number of tracers including those specific for glutamate and dopamine receptors (Farde et 
al., 1990, McCulloch et al., 1992). The validity of this comparison is based upon the theory 
that cerebellar uptake and retention of tracer acts as a measure of non-specific binding due 
to the relative paucity of receptors in this region compared to target regions. On the basis 
that mAChR density in the cerebellum is similarly low, activity levels in this region should 
be relatively reproducible from animal to animal and expression of data as cerebellar ratio 
should thus provide a means to normalise data and account for inter-animal variation in 
activity levels. 
Expression of regional brain activity as a ratio of tracer concentration in plasma, as 
described by the 5 minute plasma integral, is based upon the theory that differences in 
individual animals uptake of tracer into the brain or in its metabolism and clearance of 
tracer will be accurately reflected by the level of tracer present in the plasma. The choice 
of the 5 minute plasma integral for normalisation should allow sufficient time for tracer 
levels to fall from their peak immediately following injection (thus avoiding variations in 
activity resulting from differences in injected dose), while also allowing time for tissue 
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uptake and metabolism of tracer. Additionally, activity levels in plasma at 5 mins are high 
enough to allow accurate determination by liquid scintillation analysis. 
However, normalisation of the same data from frontal cortex for (R, S)-[125I]-QNB to 
cerebellum and to 5 min plasma integral indicates that they offer no improvement over 
normalisation to the caudate nucleus. Fig 58 shows (R, S)-[125I]-QNB activity levels in the 
frontal cortex of conscious rat between 2 and 24 hours as raw data (% dose per g brain), 
and data normalised to caudate nucleus, cerebellum and to the 5 minute plasma integral. 
The average standard deviation of the binding was 93 % and 45% of the mean for 
normalisation to cerebellum and to plasma respectively. These normalisation procedures 
therefore produce either a significant increase or little improvement in data variation over 
un-normalised data and profound increases in data variation compared to normalisation to 
caudate . The unworthiness of normalisation either to the cerebellum or to plasma is likely 
to reside in some inherent flaws in the respective data sets used. The extremely low levels 
of tracer observed in the cerebellum at all time points make accurate quantification of 
autoradiograms difficult. The image analysis system used in this thesis is most accurate 
when working in the middle of its calibrated range, therefore the low levels of isotope 
combined with the limitations of the detection system can produce both overestimation and 
underestimation of activity in the cerebellum. Therefore any small change in the level 
cerebellar activity measured can have enormous impact on the ratio calculated, particularly 
when the numerator is from a region of high activity such as the frontal cortex. 
This "instability" in the ratios formed when normalising to the cerebellum is likely to be 
responsible for the significant increase in the data variability observed. In addition, the 
identification of a small but significant population of mAChRs in the cerebellum suggests 
that this region is less suitable as a reference region for cholinergic ligands than it is for 
other neurotransmitter ligands. 
Normalisation of data to the 5 minute plasma integral is no improvement in data variation 
on raw data. Plasma activity is assumed to consist entirely of authentic ligand with no 
correction for radioactive metabolites or for the proportion of tracer that is plasma protein 
bound. Therefore whole plasma radioactivity does not accurately reflect the level of 
authentic tracer in plasma or the relative uptake of tracer for each animal. These 
inaccuracies may therefore account for the poor efficacy of this normalisation technique. 
The viability of normalisation of data to the caudate nucleus is confirmed by the 
reproducibility of tracer uptake and retention observed between animals, the lack of effect 
of heptylphysostigmine on tracer level in this region and the significant reduction in 
standard deviation produced by normalisation of data to this region. Therefore 
normalisation of data to the caudate nucleus is an effective means of correcting for data 
variability. 
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Fig 58: Figure shows (R, S)-[125I}-QNB activity at the level of the frontal cortex as un- 
normalised data (A), data normalised to caudate nucleus (B), to cerebellum (C) and to 5 
minute plasma integral (D) between 2 and 24 hours. Expression data as a ratio of 
ROUcaudate provides the best means of correction for inter-animal variation. Data are 
expressed a mean ± S. D. % Dose per g Brain, n= 3-5 for each time point. 
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4.5 EFFECT OF HEPTYLPHYSOSTIGMINE ON UPTAKE AND RETENTION OF 
(R, S)- AND (R, R)-1125I]-QNB 
It has been established that the localisation of (R, S)- and (RR)-[125I]-QNB in the brain 
following intravenous administration generally reflect mAChR distribution. It was 
therefore postulated that these stereoisomers may be suited to detect changes in cholinergic 
function in vivo. Quantification of postsynaptic receptor occupancy of either radioligand 
following a pharmacologically induced release of ACh would provide an indirect measure 
of synaptic ACh concentration and thus the ability to assess cholinergic function in vivo in 
a given brain region. To this end the sensitivity of (R, S)- and (R, R)-[125I]-QNB to detect 
increases in endogenous ACh produced by administration of the AChE inhibitor 
heptylphysostigmine was assessed. In theory, inhibition of AChE the catabolic enzyme for 
ACh, will increase synaptic ACh concentration . ACh will then compete with radioligand 
for mAChR sites producing a reduction in measured radioligand concentration in the brain. 
Of the two ligands it was postulated that (RR)-[125I]-QNB was more likely to be 
displaced from mAChRs by ACh. The more rapid washout from brain in vivo and the 
lower affinity and faster dissociation rate for mAChRs of this ligand in vitro and in vivo 
compared to (RS)-[125I]-QNB, suggest its greater sensitivity to displacement by ACh in 
vivo. 
Analysis of (R, S)- and (RR)-[1251]-QNB levels in brain following heptylphysostigmine 
administration indicate that no significant reduction in radioactivity was observed in any of 
the regions analysed. Similarly, a range of concentrations of ACh (10-6M to 10-2M) failed 
to displace (R, S)- and (RR)-[ 1251]-QNB from rat brain sections in vitro in the presence of 
heptylphysostigmine. On the contrary, administration of heptylphysostigmine was 
observed to produce significant increases in (R, S)- and (RR)-[125I]-QNB levels in vivo, 
most notably in cortical regions. Average increases in activity of 30 % and 39% 
respectively for (R, S)- and (RR)-[1251]-QNB were observed in cortical regions of 
heptylphysostigmine treated animals over vehicle treated animals. Of the cortical regions 
showing increases in activity the auditory cortex displayed the greatest and most consistent 
increases at all time points analysed. At 2 hours increases in (R, S)- and (RR)-[125I]-QNB 
activity are almost identical in this region with levels measured at 52% and 53% greater 
than vehicle respectively. 
4.5.1 Heptylphysostigmine increases cortical cerebral blood flow 
It is possible that the increases in regional brain activity of (R, 5)- and (RA)-[ 1251]-QNB 
observed following heptylphysostigmine administration are the result, of dynamic changes 
in cerebral blood flow. The initial uptake of a lipophilic molecule into the brain with no 
diffusion restriction is determined by its rate of delivery to the tissue (Rapoport, 1976). 
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Therefore, an increase in cerebral blood flow, particularly during the period immediately 
following (R, S)- or (R, R)-[125I]-QNB administration would result in increased tracer 
delivery to the brain and increased tracer uptake into specific regions. The distribution of 
capillaries within the brain is heterogeneous with capillary density greatest in grey matter 
regions such as the cortex (Zeman and Innes, 1963). Brain regions of high capillary 
density also have greater rates of glucose use and higher blood flow with capillary density 
in sensory and correlative regions of the cortex greater than that of motor regions 
(Edvinsson et al., 1993). It is therefore reasonable to hypothesise that an increase in 
cerebral blood flow produced by heptylphysostigmine administration could account for the 
increases in (R, S)- and (R, R)-[12511-QNB observed in cortical regions and in particular the 
striking increases observed in the auditory cortex. 
To this end regional cerebral blood flow was measured in the conscious rat after 
heptylphysostigmine administration. Significant increases in blood flow were measured in 
a number of cortical regions in the conscious rat, including those regions displaying 
increased levels of iodo-QNB following heptylphysostigmine administration. Previous 
investigations into the effect of heptylphysostigmine on cerebral blood flow confirm the 
observations made in this thesis, with increases in blood flow observed in the cortex 
(Linville at al., 1992, Scremin et al., 1993). A peak increase in cortical blood flow of 80% 
was observed at 40 mins after drug administration, with increased levels of blood flow 
observed up to 360 mins after administration (Scremin et al., 1993). The increases in 
cortical blood flow of between 20% and 53% measured at 2 hours after 
heptylphysostigmine administration in this thesis are therefore consistent with the above 
results. As measured blood flow is increased 2 hours following drug administration it is 
reasonable to assume that it is also elevated at earlier time points. If this is the case then it 
is extremely likely that tracer delivery to the brain will be enhanced for a crucial period 
immediately following administration when plasma levels of ligand are high. It is therefore 
likely that increased cerebral blood flow is responsible for the increased levels of (R, S)- 
and (R, R)-[1251]-QNB observed in brain following heptylphysostigmine administration. 
The increases in blood flow produced by heptylphysostigmine are characteristic of AChE 
inhibitor administration. The vasodilatory effects of AChE inhibitors are well known., with 
physostigmine inducing a significant increase in cerebral blood flow without concomitant 
metabolic activation (Scremin et al, 1982). Increases in cerebral blood flow produced by 
AChE inhibitors result from the action of excess ACh on mAChRs in the 
cerebrovasculature (Taylor, 1990). It is therefore assumed that the effects of 
heptylphysostigmine on cerebral blood flow observed in this thesis are produced by 
increased levels of endogenous ACh. It is possible however, that the blood flow effects 
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observed are at least in part the result of direct action of heptylphysostigmine on mAChRs 
in the cerebrovasculature. Heptylphysostigmine is known to bind to both mAChRs and 
nAChRs in vitro, showing greater affinity for mAChRs (De Sarno et al., 1989). It 
displaces [3H]-QNB binding in vitro with an IC50=1.9 x 10-5 M and has greater affinity 
for mAChRs than physostigmine (Ki= 4.4 x 10-6 M and 3.8 x 10-5M respectively). The 
ability of 10-3M heptylphysostigmine to displace (R, R)-[1251]-QNB binding to rat brain 
sections observed in this thesis is consistent with the data presented above. 
Regional differences in the degree of AChE inhibition may account for the pattern of 
altered blood flow observed following heptylphysostigmine administration. 
Heptylphysostigmine (5mg/kg im) produced an 80% inhibition of AChE activity in the 
cortex while only inhibiting cerebellar AChE activity by 40% (De Sarno et al., 1989). A 
similar reduction in AChE inhibition in the cerebellum of heptylphysostigmine treated 
animals was identified by AChE histochemical analysis of rat brain sections in this thesis. 
This may account for the unaltered blood flow measured and the lack of change in QNB 
levels observed in the cerebellum following heptylphysostigmine administration. A lower 
level of enzyme inhibition will result in a smaller increase in ACh concentration and 
reduced effects on cerebral blood flow with consequent effects on tracer delivery and 
uptake in this region.. In support of this theory is the observation that increases in ACh 
following heptylphysostigmine vary from region to region (De Sarno et al., 1989). 
Additionally, the cholinergic input to the cerebrovasculature in this region is low compared 
to that in the cortex, thus raised levels of ACh are likely to have a comparatively smaller 
vasodilatory effect with subsequent effects on the rate of blood flow and level of QNB 
accumulation (Arneric et al., 1988). 
Kinetic Modelling 
The effects of increased cortical blood flow on uptake and retention of (R, S)-[ 125I]-QNB 
in the frontal cortex of conscious rat were modelled using the 3 compartment model 
described in section 4.3. All model parameters effecting tracer uptake and elimination from 
brain were unchanged with the exception of blood flow which was set at 0.8,1.0 and 1.2 
ml/g/min to represent "normal" blood flow, a 25% increase in blood flow and a 50% 
increase in blood flow, respectively. Fig 59 shows hypothetical levels of (R, S)-[125I]- 
QNB in the frontal cortex for the 3 blood flow rates. According to this model higher blood 
flow rates increase tracer uptake and retention with no concomitant increase in washout. 
Modelled increases in tracer concentration in the frontal cortex resulting from increased 
blood flow are consistent with measured increases in tracer level in the frontal cortex of 
conscious rats following heptylphysostigmine administration (Fig 60). These observations 
confirm the hypothesis that the increases in tracer concentration observed in cortex of rats 
are the result of heptylphysostigmine induced increases in cerebral blood flow. 
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Increasing Cerebral Blood Flow Increases Hypothetical 
Tracer Uptake and Retention 
öJD 
c4 aý a 
U 
Time (Hours) 
Fig 59 Hypothetical concentrations of (R, S)-[1251]-QNB in frontal cortex as determined by a 
3 compartment model with blood flow of 0.8.1.0 and 1.2 ml/g/min. Increasing blood flow 
increases uptake and retention of tracer in brain. Data is expressed as jCi per g brain as 
calculated by the 3 comparment model described in section 4.3. With the exception of blood 
flow all parameters effecting tracer uptake and elimination from the brain were identical. 
06 12 18 24 30 
Fig 60: Comparison of actual concentration of (R, S)-[125I]-QNB in frontal cortex in 
vehicle and heptylphysostigmine treated animals (left hand graph) as measured in 
vivo, with hypothetical brain concentrations in frontal cortex for "normal" blood 
flow (0.8 ml/g/min) and for blood flow increases of 50% (1.2 mu g/min) (right hand 
graph). 
A3 compartment model was used to simulate the effect of increased cerebral blood 
flow on the hypothetical uptake and retention of (R, S)-[1251]-QNB in frontal cortex 
of conscious rat using the plasma input curve for (R, S)-[125I]-QNB. All model 
parameters were identical to those described in section 4.3 with the exception of 
blood flow which was set at 0.8 mu g/min representing normal blood flow or 1.2 
mu g/min to simulate a 50% increase in cortical blood flow. 
Increasing blood flow to 1.2 mu g/min produces approximately a 7% increase in 
hypothetical (RS)-[125I]-QNB concentration in the frontal cortex (right hand 
graph). This is consistent with the increase in (R, S)-[ 125I]-QNB measured in frontal 
cortex of conscious rats following heptylphysostigmine administration (left hand 
graph). According to this model the increases in tracer levels observed in the cortex 
of heptylphysostigmine treated animals can be explained as a result of increased 
cerebral blood flow. 
Data are expressed as mean ± S. E. M % Dose per g Brain normalised to the caudate 
nucleus (n= 5) for Actual Data, and % Dose per g Brain normalised to the caudate 
nucleus for Modelled Data. *P <0.05 Student's unpaired t"test for the comparison 
between vehicle and heptylphysostigmine treated animals. 
0 U 
.r 
In N 
. 9C 
ts, 
0 m 
ii 
Pý 
aý 
cý 
aý w 
v 
C 
r"ý 
0 
W 
cl 4.6 
'C 
O 
z 
A 
cý 
U 
dý 
(snapnN a; npntD 01 pasiI*WJoN) 
ultlsg ä . iad asou off, 
b 
C -d 
1, o 
N .., u., 
op 
ý" o 
eö 
.C0 bC 
cd = 
O 
C0 
0aý 
o 
UU 
OO 
u OO 
a° 
Ný 
u 
U^ 
^0u 
12 CA Ab 
OU 
CU) 
O OA 
E- Ö 'o UÄ 
NC 
.Obv ý 
oÖ 
b_A Lu u 
= -12 
ýy rr O 
N r-4 
(snapnu alupn1D o; pasijuuiaoN) 
u! uag 3 aad asoQ o1, 
4.5.2 AChE inhibition and synaptic ACh concentration 
Data from in vivo experiments indicates that heptylphysostigmine administration does not 
displace (R, S)- or (R, R)-[125I]-QNB from rat brain in vivo by increasing synaptic levels of 
endogenous ACh. It is possible that heptylphysostigmine (2mg/kg) did not inhibit AChE 
activity effectively or for a long enough period to raise synaptic ACh concentration to a 
level where it could displace iodo-QNB from mAChRs. However, a number of lines of 
evidence suggest that this is not the case. Histochemical analysis of brain AChE performed 
in this thesis indicates that enzyme activity is significantly reduced for a prolonged period. 
Secondly, the elevated cerebral blood flow rates measured in vivo and the overt behaviour 
displayed by the animals following heptylphysostigmine administration are indicative of 
raised levels of ACh. Finally, the efficacy of the dosing regime utilised in this thesis to 
inhibit AChE activity for extended periods and to increase synaptic ACh concentration is 
vindicated by the literature (De Sarno et at., 1989, Messamore et at., 1993, Cuadra et al., 
1994). 
Semi-quantitative analysis of AChE histochemical staining of rat brain sections taken from 
in vivo studies appears to validate the dosing regime used in this thesis. Significant 
reductions in AChE enzyme activity were observed in a number of brain regions including 
frontal cortex, parietal cortex, hippocampus CAI and cerebellum between 30 mins and 24 
hours after heptylphysostigmine administration. Furthermore, a number of in vivo 
microdialysis studies support these results indicating that heptylphysostigmine 
significantly inhibits brain AChE activity for prolonged periods. Following intramuscular 
administration heptylphysostigmine (5mg/kg) was observed to produce greater than 80% 
inhibition of AChE activity in the frontal cortex of rat for up to 6 hours (De Sarno et al., 
1989, Cuadra et al., 1994). Additionally, heptylphysostigmine (5mg/kg ip) was observed to 
produce a significant level of inhibition (approximately 20%) of cortical AChE activity up 
to 24 hours after administration (Messamore et al., 1993). 
In most studies maximal inhibition of AChE activity is observed approximately 1-1.5 
hours after administration a time co-inciding with the administration of radiotracers in this 
thesis (De Sarno et al., 1989, Messamore et al., 1993, Cuadra et al., 1994). 
Pharmacokinetic analysis of heptylphysostigmine in rat provides further evidence for the 
use of this compound. After a single administration (2mg/kg iv -the same dose and route of 
administration used in this thesis) heptylphysostigmine displays a prolonged plasma half- 
life of approximately 12 hours and preferential accumulation in the brain with levels as 
high as 22 times those found in plasma (Segre et al., 1992). 
These observations all support the utility of heptylphysostigmine in the dosing regime used 
in this thesis to produce a sustained and effective inhibition of brain AChE. 
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However, magnitude of AChE inhibition is not a predictive determinant of extracellular 
ACh levels. Heptylphysostigmine and physostigmine have both been observed to produce 
increases of 1000% in extracellular ACh concentration while inhibiting AChE activity by 
90% and 54 % respectively (Messamore at al., 1993). Inconsistencies between duration of 
AChE inhibition and the time course of increases in extracellular ACh are also apparent. 
Heptylphysostigmine (5mg/k ip)produces a peak increase in ACh of 1000% of baseline 
1.5 hours following administration, with significant increases in ACh levels observed up to 
9.5 hours after administration. However, in the period between 2 and 6 hours following 
drug administration however there is a drop in ACh levels of 700% during which time 
AChE inhibition falls by only 10% (Messamore et al., 1993). Indeed AChE activity is 
significantly inhibited long after (up to 24 hours) ACh levels have returned to normal. 
Therefore, although AChE activity appears to have been significantly inhibited for 
prolonged periods during the studies performed in this thesis, as evinced by AChE 
histochemistry, there is no evidence to indicate the magnitude or duration of increase in 
ACh concentration, or indeed whether ACh levels were raised at all. 
A number of factors however suggest that extracellular levels of ACh were increased for a 
significant period following heptylphysostigmine administration. 
The behaviour of animals receiving heptylphysostigmine was characteristic of cholinergic 
toxicity and lasted up to 4 hours after drug administration, indicating that extracellular 
concentration of ACh was raised for a prolonged period in the periphery at least. The 
increases in cerebral blood flow measured following heptylphysostigmine administration 
are characteristic of AChE inhibitor administration and are acknowledged to result from 
the action of excess ACh on mAChRs in the cerebrovasculature (Taylor, 1990). This 
observation indicates raised ACh concentration in the brain. Further evidence for increased 
ACh concentration in the brain comes from the observation that blood pressure was 
increased in a number of animals following hetylphysostigmine administration. Centrally 
administered physostigmine has been observed to produce dose dependent increases in 
heart rate and blood pressure in rats through the 
action of ACh on central M2 receptors (Ally et al., 1995). The central basis of this action is 
likely as it is in opposition to the characteristic inhibitory effects of peripherally 
administered cholinomimetics on heart rate. 
Additionally, microdialysis studies of brain extracellular ACh concentration following 
heptylphysostigmine administration indicate significant increases in extracellular ACh are 
measurable for more than 6 hours after administration (De Sarno et al., 1989, Messamore 
et al., 1993, Cuadra et al., 1994). Furthermore, maximal levels of extracellular ACh are 
reached approximately 1 to 1.5 hours following administration. This correlates well with 
the increases in cerebral blood flow measured at 2 hours. These observations suggest that 
the dosing regime used in this thesis was successful in raising extracellular ACh levels to a 
significant degree for a period greater than 3 hours although no measurement of ACh was 
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made. Continuous infusion of heptylphysostigmine or physostigmine was considered as an 
alternative to the bolus administration employed in this thesis, but was decided to be 
impractical due to the prolonged experimental period necessary with some animals. 
Therefore administration of heptylphysostigmine a AChE inhibitor with prolonged 
duration of action was preferred. 
4.5.3 Displacement of (R, S)- and (R, R)-[12511-QNB by endogenous ACh 
Assuming that levels of extracellular ACh were raised for a significant period following 
heptylphysostigmine administration there may be several reasons why no displacement of 
(R, S)- or (R, R)-[125I]-QNB from brain is observed. One possibility is that (R, S)- and 
(R, R)-[1251]-QNB accumulation in brain does not reflect binding to mAChRs. Increasing 
ACh would therefore have little effect on brain levels of radioactivity. Previously 
described evidence suggests that brain accumulation of both tracers is receptor mediated. 
However, an in vivo displacement study with co-administration of either cold tracer or 
another mAChR antagonist would need to be performed to confirm mAChR occupancy by 
(R, S)- and (R, R)-[12511-QNB. Displacement of iodo-QNB in such a manner has been 
described in a number of studies with (R, S)-[125I]-QNB (Gitler et al., 1995, McRee et al., 
1995, Lee et al., 1995). 
Additionally, it is possible that a small amount of radioligand is displaced from receptors 
by ACh but that this is masked by the effects of elevated blood flow increasing tracer 
delivery and uptake into the brain. Increased blood flow is also likely to increase washout 
of the tracer from the brain once it is dissociated from receptors. However, metabolism and 
clearance of both (R, S)- and (R, R)-[125I]-QNB from plasma is slow with measurable 
levels of authentic ligand present in plasma for significant periods after administration (> 6 
hours), albeit at a low concentration. Ligand washed out of brain which is not immediately 
metabolised and cleared may feasibly contribute to the pool of authentic ligand in plasma 
and may thus be available for re-uptake into brain. Furthermore, authentic ligand is present 
in plasma for a period exceeding that in which there will be significant competition from 
raised levels of endogenous ACh. 
It is perhaps more likely therefore that extracellular ACh levels do not reach a 
concentration great enough to effect displacement of ligand from receptors. This theory is 
supported by evidence from displacement of D2 receptor ligands in vivo by 
pharmacologically induced increases in endogenous dopamine. The magnitude of 
dopamine increase produced is usually several fold greater than the ligand displacement 
observed (Brier et al., 1997, Laruelle et al., 1997). Amphetamine induced displacement of 
[11C]-raclopride combined with in vivo microdialysis in monkeys reported a mean 
dopamine increase to [11C1-raclopride binding reduction ratio of 44 to 1, indicating that 
relatively small changes in ligand binding reflect large changes in transmitter outflow 
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raclopride(Endres et al., 1990). Therefore, significant increases in synaptic concentration 
of endogenous neurotransmitter are no indication of magnitude of ligand displacement 
occurring. 
If a similar linear relationship exists between cortical ACh levels and iodo-QNB and 
assuming that heptylphysostigmine (2 mg/kg) produces an increase of 1000% in 
extracellular ACh concentration (based on the data of Messamore et al., 1993) a reduction 
of approximately 20% in cortical radioactivity would be observed following 
heptylphysostigmine administration. This however is obviously a gross oversimplification 
of the situation as evinced by the complete absence of QNB displacement observed in the 
studies presented in this thesis. Even if the relationship between ACh concentration and 
radioligand displacement is linear the kinetics of binding and affinity of raclopride and 
dopamine for D2 receptors are considerably different to those of (R, S)- and (R, R)-[125I]_ 
QNB and ACh for mAChRs. 
Differences in the relative affinity of ligands are an extremely important factor in their 
ability to reflect changes in endogenous ligand concentration, e. g. binding of [11C]- 
raclopride is affected to a much greater extent than [18F]-N-methylspiroperidol following 
amphetamine induced increases in dopamine due its larger KD value (i. e. lOnM and 
0.25nM respectively) for D2 receptors (Logan et al., 1991). 
Raclopride is a highly selective but a relatively low affinity ligand for D2 receptors, with a 
KD value of approximately lOnM (Farde et al., 1989). In contrast, (R, S)- and (R, R)-[ 125I]- 
QNB are high affinity mAChR antagonists and assuming relative mI selectivity KD values 
equal 0.0116 nM and 0.490 nM respectively (Zeeberg et al., 1991). Therefore the affinity 
of iodo-QNB for mAChRs is approximately 20 to 1000 fold greater than that of raclopride 
for D2 receptors. Furthermore, the affinity of the endogenous neurotransmitters for their 
target receptors must be taken into account when considering their ability to displace 
radioligand binding. The KD of dopamine for D2 receptors has been estimated at 5 nM to 
50 nM (Seeman et al., 1990, Ross et al., 1991). In contrast the KD of ACh for high affinity 
mAChR sites has be estimated at 3.3pM (Berstein et al., 1988). Therefore, at best 
dopamine displays 66 fold higher affinity for D2 receptors than ACh for mAChRs. These 
observations suggest that displacement of iodo-QNB by endogenous ACh is likely to be 
very modest even when synaptic concentrations of ACh are significantly increased. 
Therefore, the synaptic concentration of ACh in cortex under normal conditions has a 
significant impact on the likelihood of radioligand displacement occurring under 
conditions where synaptic ACh concentrations are increased. The synaptic concentration of 
ACh in the cortex of the conscious rat as determined by in vivo microdialysis is estimated 
at 3-6 nM under normal conditions (Messamore et al., 1993, Cuadra et al., 1994 , Cuadra et 
al., 1995). An increase of ACh levels of 1000% following heptylphysostigmine 
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Cuadra et at., 1995). An increase of ACh levels of 1000% following heptylphysostigmine 
administration would give a synaptic concentration of 60nM, a value significantly lower 
than the KD of ACh for mAChRs. 
The observations above suggest that although heptylphysostigmine can be predicted to 
produce a significant increase in cortical ACh concentration this may not be sufficient to 
displace (R, S)- or (R, R)-[125I]-QNB binding from mAChRs due to the relative affinity of 
the radioligands and ACh for receptors and the basal synaptic concentration of ACh in the 
cortex. Furthermore, the dissociation evident between synaptic increases in dopamine and 
the observed displacement of [11C]-raclopride binding-where the in vivo conditions are 
considerably more conducive to producing radioligand displacement -indicates that it may 
be impossible to raise synaptic ACh levels to a sufficient concentration to displace iodo- 
QNB binding with the use of heptylphysostigmine. 
4.5.4 Sensitivity of radiotracers to dynamic neurotransmitter changes 
A recent study has modelled radiotracer characteristics that confer maximum sensitivity to 
neurotransmitter release in vivo (Endres and Carson, 1998). 
Using an extended compartmental model, the effect of a pharmacologically induced 
increase in endogenous neurotransmitter was modelled to calculate the percent reduction in 
distribution volume (AV) of tracer in the brain. The magnitude of AV detected was found 
to be dependent upon a number of factors including the integral of the neurotransmitter 
pulse, clearance rate (k2) of tracer from brain and binding potential of the tracer as well as 
on the free tracer concentration in the brain. In general the value of AV increases with the 
integral of neurotransmitter pulse i. e. the reduction in volume of distribution of ligand is 
dependent upon the overall increase in transmitter concentration and not just upon the peak 
level of neurotransmitter produced. Furthermore, the time at which the increase in 
neurotransmitter is induced has significant impact upon the magnitude of AV. 
Simultaneous release of neurotransmitter with tracer delivery was found to maximise AV, 
with stimulation of neurotransmitter release before or after tracer administration producing 
suboptimal values of AV. This has significant relevance to the studies performed in this 
thesis where increased levels of neurotransmitter were produced before administration of 
tracer. Therefore, optimal conditions for tracer displacement may not have been achieved 
in the studies presented in this thesis. 
The clearance rate (k2) of tracer from brain is also important in defining AV-with a higher 
k2 producing a larger AV. 
However, the binding potential of a tracer for receptors was identified as being the most 
useful parameter to describe the sensitivity of a tracer to neurotransmitter changes. 
Simulations revealed that tracers with smaller binding potentials generally produced the 
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biggest values of AV, with a binding potential of 3-10 optimal for tracer sensitivity to 
neurotransmitter changes (Endres and Carson, 1998). Use of the binding parameters k3 
(association rate of specific binding), k4 (dissociation rate of specific binding) as 
determined by Sawada et al., (1990b) for R-IQNB allows estimation of the binding 
potential for iodo-QNB which is defined by these rate constants as k3/k4. The smallest 
binding potential values for frontal cortex, parietal cortex, caudate nucleus, thalamus and 
cerebellum were estimated as 1171,977,1116,247 and 51 for each region respectively. 
Each value is significantly outwith the optimum range proposed by Endres and Carsson 
(1998), indicating that iodo-QNB is likely to be insensitive to changes in neurotransmitter 
levels due to its high binding potential. 
4.5.5 Competition studies with AChE inhibitors and muscarinic radioligands 
It has been established that (R, S)- and (R, R)-[125I]-QNB are unsuitable ligands for the 
detection of dynamic changes in ACh levels in vivo. The viability of using AChE 
inhibitors such as heptylphysostigmine to increase ACh concentrations to levels sufficient 
to produce ligand displacement is also in question. Several factors are likely to restrict the 
extracellular ACh concentration following AChE administration. Accumulation of ACh at 
cholinergic synapses may have inhibitory actions on pre-synaptic autoreceptors resulting 
in reduced release of ACh from neurons. Recent evidence suggests that auto-inhibition 
such as this is an important factor governing extracellular ACh concentration at higher 
levels of AChE inhibition (Moor et al., 1998). In addition to increasing synaptic ACh 
concentration administration of AChE inhibitors elicit simultaneous increases in 
noradrenaline and dopamine in the cortex of rat (Cuadra et al., 1994). Interactions between 
noradrenergic and cholinergic systems are known to exist with noradrenaline inhibiting the 
release of cortical ACh through direct action on pre-synaptic a-adrenoceptors present on 
ACh terminals and indirectly through modulation of GABA release (Moroni et al., 1993, 
Beani et al., 1986). Increases in noradrenaline may therefore also have an impact upon 
extracellular levels of ACh. The preferential inhibition of cytosolic (intracellular) AChE 
over molecular (extracellular) AChE by heptylphysostigmine may also play a role in the 
dissociation between synaptic ACh levels and the degree of inhibition of AChE observed 
and serve to limit synaptic ACh concentration (Ogane et al., 1992). 
These observations suggest that AChE inhibitors may not be suitable for use in 
displacement studies with mAChR ligands. However, continuous infusion of 
physostigmine was observed to produce a 35% reduction in specific binding of the novel 
M2 selective (i. e. Ki= 2.2 nM for M2 and 7.4 nM for M1 receptors) PET ligand [18F]FP- 
TZTP in monkeys (Carson et al., 1998). A significantly smaller reduction in binding of 
12% was observed in the basal ganglia, consistent with the markedly higher AChE activity 
in this region. These results confirm the viability of using AChE inhibitors to displace 
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radioligands and indicate that ACh function can be measured in vivo with the use of 
mAChR ligands. 
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APPENDIX A 
Table Al 
(R, S)-[1251]-QNB in the CNS of Conscious Rat 
Region 
Cerebellum 
Cerebellar Cortex 
Medulla/Pons 
Pontine Grey 
Nucleus of the Lateral Lemniscus 
Lateral Dorsal Tegmental nucleus 
Mesencephalon 
Inferior Colliculus 
Superior Colliculus 
Substantia Nigra (pars compacta) 
Substantia nigra (pars reticulata) 
Diencepahlon 
TIME FOLLOWING ADMINISTRATION OF TRACER 
2 Hours 6 Hours 12 Hours 24 Hours 
0.036±0.012 0.03±0.011 0.027 ± 0.027 0.018±0.013 
0.250 t 0.086 0.240 t 0.055 0.095 t 0.038 0.065 t 0.017 
0.12310.025 0.090±0.015 0.050±0.015 0.009±0.009 
0.173±0.059 0.12010.019 0.119±0.024 0.03910.026 
0.180±0.045 0.140±0.031 0.072±0.012 0.04210.018 
0.235±0.074 0.140±0.029 0.075±0-009 0.021±0,011 
0.160 ± 0.047 0.140 ± 0.025 0.083 ± 0.007 0.039 t 0.016 
0.153±0.042 0.130±0.029 0.070±0.005 0.035 t 0,018 
Hippocampus CA1 0.215 ± 0.070 0.240 ± 0.034 0.213 ± 0.041 0.254 ± 0.031 
Hippocampus CA2 0.275 ± 0.080 0.281 ± 0.035 0.234 ± 0.051 0.246 ± 0.027 
Hippocampus CA3 0.239 ± 0.067 0.250 ± 0.028 0.212 ± 0.039 0.235 ± 0.023 
Medial Geniculate Body 0.260 ± 0.069 0.231 ± 0.035 0.147 ± 0.015 0.104 ± 0.015 
Sub Thalamic Nucleus 0.183 ± 0.048 0.350± 0.201 0.102 ± 0.012 0.038 ± 0.014 
Lateral Geniculate Nucleus 0.225 ± 0.065 0.203 ± 0.034 0.148 ± 0.020 0.071 ± 0.025 
Hypothalamus 0.153 ± 0.053 0.167 ± 0.023 0.113 ± 0.021 0.069 ± 0.024 
Mediodorsal Thalamic Nucleus 0.240 ± 0.069 0.224 ± 0.031 0.166 ± 0.029 0.105 ± 0.014 
Ventrolateral Thalamic Nucleus 0.206 ± 0.063 0.195 ± 0.028 0.131 ± 0.024 0.067 ± 0.019 
Telencephalon 
Visual Cortex (layer IV) 0.349 ± 0.113 0.292 ± 0.055 0.254 ± 0.041 0.308 ± 0.026 
Dentate Gyrus 0.267 ± 0.079 0.280 ± 0.060 0.223 ± 0.042 0.219 t 0.007 
Auditory Cortex (layer N) 0.400 ± 0.085 0.370 ± 0.048 0.333 ± 0.074 0.350 ± 0.017 
Hippocampus Molecular Layer 0.280 ± 0.077 0.290± 0.059 0.256 ± 0.049 0.236 ± 0.020 
Amygdala 0.213 ± 0.055 0.207 ± 0.026 0.177 ± 0.040 0.161 * 0.016 
Globus Pallidus 0.117 ± 0.038 0.111 ± 0.026 0.082 ± 0.023 0.062 ± 0.026 
Caudate Nucleus 0.301 ± 0.072 0.300 ± 0.053 0.291 ± 0.064 0.298 ± 0.037 
Septal Nuclei 0.209 ± 0.054 0.19 t 0.023 0.163 ± 0.030 0.125 ± 0.023 
Nucleus Basalis Magnocellularis 0.124 ± 0.041 0.121 t 0.025 0.102 ± 0.040 0.074 ± 0.021 
Nucleus Accumbens 0.319 t 0.089 0.322 t 0.054 0.307 ± 0.086 0.328 t 0.051 
Sensory Motor Cortex (layer IV) 0.377 t 0.085 0.302 t 0.043 0.324 ± 0.070 0.315 t 0.038 
Anterior Cingulate Cortex 0.329 ± 0,090 0.333 t 0.048 0.305 ± 0.090 0.311 t 0.033 
Frontal Cortex 0.362 ± 0.096 0.332 t 0.049 0.316 ± 0.099 0.302 t 0.030 
Parietal Cortex 0.306 ± 0.103 0.323 t 0.036 0.298 ± 0.066 0.305 t 0.036 
Myelinated Fibre Tracts 
Internal Capsule 0.107 t 0.033 0.090±0.022 0.060±0.011 0.043 t 0.010 
Genu 0.104±0.029 0.111±0.026 0.085±0.035 0.071±0.015 
Table shows (R, S)-[125I]-QNB in discrete brain regions of the conscious rat 2,6,12 and 24 hi 
following iv administration of 200yCi of tracer. Data are expressed as mean t S. E. M j Ci per g brain 
, n= 3-5 animals for each time point. 
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Table A2 
Effect of Heptylphysostigmine on (R, S)-[125I]-QNB 
in Brain of Conscious Rat 
Region 
Cerebellum 
Cerebellar Cortex 
Medulla/Pons 
Pontine Grey 
Nucleus of the Lateral Lemniscus 
Lateral Dorsal Tegmental nucleus 
Mesencephalon 
Inferior Colliculus 
Superior Colliculus 
Substantia Nigra (pars compacta) 
Substantia nigra (pars reticulata) 
TIME FOLLOWING ADMINISTRATION OF TRACER 
2 Hours 24 Hours 
Vehicle Heptyl. Vehicle Heptyl. 
0.080 ± 0.018 0.074 ± 0.009 0.007 ± 0.004 0.001 ± 0.001 
0.584 t 0.023 0.593 t 0.018 0.077 ± 0.012 0.045 ± 0.023 
0.232 ± 0.024 0.218 t 0.030 0.012 t 0.006 0.018 ± 0.009 
0.197 ± 0.108 0.274 t 0.034 0.039 ± 0.023 0.029 ± 0.019 
0.389 ± 0.021 0.321 ± 0.049 0.038 ± 0.009 0.043 ±0.022 
0.351 ± 0.031 0.392 ± 0.098 0.030 t 0.009 0.038 ± 0.011 
0.283 ±0.021 0.286±0.102 0.028±0.014 0.049±0.011 
0.259 ± 0.011 0.241 ± 0.075 0.031 ± 0.016 0.040 ± 0.007 
Diencepahlon 
Hippocampus CAI 0.379 t 0.045 0.350 t 0.130 0.311 t 0.086 0.302 t 0.045 
Hippocampus CA2 0.486 t 0.058 0.456 t 0.142 0.295 t 0.075 0.311 t 0.052 
Hippocampus CA3 0.395 t 0.041 0.393 t 0.137 0.308 t 0.069 0.316 t 0.046 
Medial Geniculate Body 0.453 t 0.055 0.428 t 0.122 0.126 t 0.011 0.139 t 0.034 
Sub Thalamic Nucleus 0.355 t 0.048 0.369 t 0.104 0.039 t 0.009 0.077 t 0.035 
Lateral Geniculate Nucleus 0.357 ± 0.048 0.393 ± 0.122 0.100 t 0.013 0.108 ± 0.020 
Hypothalamus 0.274 ± 0.027 0.276 ± 0.091 0.054 ± 0.007 0.051 ± 0.007 
Mediodorsal Thalamic Nucleus 0.440 ± 0.046 0.403 ± 0.127 0.112 ± 0.010 0.113 ± 0.019 
Ventrolateral Thalamic Nucleus 0.344 ± 0.043 0.328 ± 0.116 0.067 ± 0.008 0.064 ± 0.010 
Telencephalon 
Visual Cortex (layer IV) 0.536 ± 0.032 0.495 ± 0.149 0.365 ± 0.087 0.281 ± 0.141 
Dentate Gyrus 0.479 ± 0.050 0.443 ± 0.146 0.321 ± 0.080 0.317 ± 0.058 
Auditory Cortex (layer IV) 0.722 ± 0.071 0.925 ± 0.217 0.430 ± 0.085 0.521 ± 0.094 
Hippocampus Molecular Layer 0.491 ± 0.042 0.451 ± 0.160 0.344 ± 0.089 0.303 ± 0.042 
Amygdala 0.296 ± 0.075 0.324 ± 0.105 0.185 ± 0.041 0.165 ± 0.026 
Globus Pallidus 0.215 ± 0.016 0.213 ± 0.079 0.053 ± 0.008 0.048 ± 0.008 
Caudate Nucleus 0.478 ± 0.037 0.445 ± 0.164 0.331 ± 0.082 0.307 ± 0.048 
Septal Nuclei 0.340 ± 0.040 0.311 ± 0.117 0.140 ± 0.018 0.147 ± 0.027 
Nucleus Basalis Magnocellularis 0.262 ± 0.029 0.257 ± 0.095 0.071 ± 0.006 0.064 ± 0.009 
Nucleus Accumbens 0.529 ± 0.048 0.528 ± 0.167 0.407 ± 0.105 0.376 ± 0.057 
Sensory Motor Cortex (layer IV) 0.535 ± 0.019 0.628 ± 0.187 0.401 ± 0.076 0.381 ± 0.045 
Anterior Cingulate Cortex 0.564 ± 0.030 0.532 ± 0.175 0.369 ± 0.104 0.392 ± 0.065 
Frontal Cortex 0.593 ± 0.062 0.609 ± 0.182 0.382 ± 0.085 0.382 ± 0.053 
Parietal Cortex 0.534 ± 0.053 0.606 ± 0.157 0.400 ± 0.092 0.394 ± 0.069 
Myelinated Fibre Tracts 
Internal Capsule 0.113 t 0.014 0.119 t 0.043 0.020 t 0.002 0.031 t 0.006 
Genu 0.115±0.010 0.137±0.061 0.056±0.014 0.038±0.018 
Table shows effect of heptylphysosigmine(2mg /kg) on (R, S)-[125I]-QNB in brain of consci( 
rat at 2 and 24 hours following iv administration of 200yiCi of tracer. Data are expressed as mea 
S. E. M p Ci per g brain, n= 5 animals for each time point. 
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Table A3 
Effect of Heptylphysostigmine on 
(R, R)-[1251]-QNB in the Brain of Conscious Rat: 
VEHICLE TREATED ANIMALS 
Region 
Cerebellum 
Cerebellar Cortex 
Medulla/Pons 
Pontine Grey 
Nucleus of the Lateral Lemniscus 
Lateral Dorsal Tegmental nucleus 
Mesencephalon 
Inferior Colliculus 
Superior Colliculus 
Substantia Nigra (pars compacta) 
Substantia nigra (pars reticulata) 
Diencepahion 
TIME FOLLOWING TRACER ADMINISTRATION 
30 mins 1 Hour 2 Hours 6 Hours 
0.050 ± 0.005 0.024 ± 0.003 0.023 ± 0.007 0.009 ± 0.002 
0.14210.015 0.101±0.015 0.114 ± 0.023 0.026 ± 0.007 
0.090 ± 0.009 0.057 ± 0.006 0.095 ± 0.021 0.019 ± 0.005 
0.101 ± 0.006 0.059 ± 0.007 0.072 ± 0.020 0.018 ± 0.006 
0.097 ± 0.010 0.064 ± 0.009 0.077 ± 0.022 0.013 ± 0.003 
0.099 ± 0.008 0.068 ± 0.008 0.075 ± 0.022 0.017 ± 0.007 
0.080 ± 0.008 0.056 ± 0.006 0.080 ± 0.021 0.018 ± 0.007 
0.069 ± 0.007 0.051 ± 0.006 0.069 ± 0.018 0.014 ± 0.005 
Hippocampus CAl 0.084 ± 0.010 0.085 ± 0.011 0.186 ± 0.021 0.077 ± 0.008 
Hippocampus CA2 0.117 ± 0.018 0.096 ± 0.011 0.181 ± 0.048 0.058 ± 0.008 
Hippocampus CA3 0.109 ± 0.017 0.090 ± 0.008 0.185 ± 0.021 0.068 ± 0.007 
Medial Geniculate Body 0.113 ± 0.013 0.087 ± 0.009 0.114 ± 0.031 0.022 ± 0.005 
Sub Thalamic Nucleus 0.103 ± 0.015 0.067 ± 0.009 0.086 ± 0.011 0.025 ± 0.008 
Lateral Geniculate Nucleus 0.110 ± 0.015 0.079 ± 0.008 0.107 ± 0.017 0.014 ± 0.005 
Hypothalamus 0.080 ± 0.008 0.054 ± 0.006 0.079 ± 0.018 0.011 ± 0.004 
Mediodorsal Thalamic Nucleus 0.109 ± 0.015 0.079 ± 0.008 0.113 ± 0.017 0.014: t 0.005 
Ventrolateral Thalamic Nucleus 0.079 ± 0.009 0.051 ± 0.05 0.073 ± 0.016 0.010 ± 0.004 
Telencephalon 
Visual Cortex (layer IV) 0.145 ± 0.016 0.106 ± 0.016 0.224 ± 0.031 0.065 ± 0.016 
Dentate Gyrus 0.125 ± 0.014 0.099 ± 0.014 0.205 ± 0.033 0.059 ± 0.015 
Auditory Cortex (layer IV) 0.183 ± 0.017 0.142 ± 0.016 0.289 ± 0.032 0.077 ± 0.014 
Hippocampus Molecular Layer 0.161 ± 0.047 0.107 ± 0.012 0.195 ± 0.036 0.60 t 0.012 
Amygdala 0.092 ± 0.008 0.076 ± 0.006 0.132 ± 0.017 0.040 t 0.007 
Globus Pallidus 0.065 ± 0.006 0.043 ± 0.006 0.086 ± 0.022 0.018 f 0.006 
Caudate Nucleus 0.127 ± 0.014 0.106 ± 0.010 0.209 ± 0.024 0.064 t 0.011 
Septal Nuclei 0.092 ± 0.013 0.079 ± 0.009 0.132 ± 0.024 0.031 t 0.008 
Nucleus Basalis Magnocellularis 0.070 ± 0.007 0.053 ± 0.007 0.098 ± 0.013 0.023 t 0.007 
Nucleus Accumbens 0.136 ± 0.014 0.118 ± 0.015 0.224 ± 0.030 0.072 t 0.007 
Sensory Motor Cortex (layer IV) 0.169 ± 0.022 0.127 ± 0.013 0.261 ± 0.024 0.070 t 0.012 
Anterior Cingulate Cortex 0.147 ± 0.017 0.123 ± 0.012 0.243 ± 0.027 0.075 t 0.009 
Frontal Cortex 0.152 ± 0.019 0.125 ± 0.013 0.244 ± 0.023 0.070 t 0.010 
Parietal Cortex 0.155 ± 0.022 0.116 ± 0.012 0.231 ± 0.030 0.064 t 0.007 
Myelinated Fibre Tracts 
Internal Capsule 0.036 t 0.008 0.035 t 0.002 0.044 ± 0.015 0.003 ± 0.002 
Genu 0.038 ± 0.006 0.033 ± 0.002 0.046 ± 0.013 0.012 ± 0.003 
Table shows (RR)-[125I]-QNB in discrete brain regions of the conscious rat in vehicle (0.7 m: 
0.9% saline) treated animals 30 mins, 1,2 and 6 hours following iv administration of 200yß Ci 
tracer. Data are expressed as meant S. E. M pCi per g brain , n= 5 animals 
for each time point. 
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Table A4 
Effect of Heptylphysostigmine on 
(R, R)-[1251]-QNB in the Brain of Conscious Rat: 
HEPTYLPHYSOSTIGMINE TREATED ANIMALS 
Region 
Cerebellum 
Cerebellar Cortex 
Medulla/Pons 
Pontine Grey 
Nucleus of the Lateral Lemniscus 
Lateral Dorsal Tegmental nucleus 
Mesencephalon 
Inferior Colliculus 
Superior Colliculus 
Substantia Nigra (pars compacta) 
Substantia nigra (pars reticulata) 
TIME FOLLOWING TRACER ADMINISTRATION 
30 mins 1 Hour 2 Hours 6 Hours 
0.047 ± 0.006 0.046 ± 0.012 0.026 ± 0.009 0.016 ± 0.005 
0.123 ± 0.007 0.114 ± 0.008 0.106 ± 0.005 0.032 ± 0.006 
0.077 ± 0.007 0.087 ± 0.019 0.077 ± 0.015 0.033 ± 0.012 
0.089±0.009 0.070±0.010 0.064±0.012 0.024±0.006 
0.085±0.007 0.080±0.010 0.069±0.014 0.024±0.005 
0.108 ± 0.010 0.097 ± 0.007 0.079 ± 0.011 0.025 ± 0.004 
0.069 ± 0.012 0.080 ± 0.006 0.074 ± 0.011 0.027 ± 0.003 
0.058 ± 0.010 0.073 ± 0.009 0.065 ± 0.012 0.024 ± 0.002 
Diencepahlon 
Hippocampus CA1 0.072 ± 0.010 0.104 ± 0.011 0.108 t 0.014 0.071 t 0.022 
Hippocampus CA2 0.102± 0.014 0.123 ± 0.016 0.126 t 0.013 0.065 ± 0.011 
Hippocampus CA3 0.090 ± 0.012 0.114 ± 0.015 0.110 t 0.012 0.070 t 0.011 
Medial Geniculate Body 0.112 ± 0.014 0.109 ± 0.012 0.101 t 0.009 0.036 ± 0.004 
Sub Thalamic Nucleus 0.095 ± 0.015 0.088 ± 0.008 0.068 t 0.010 0.018 ± 0.006 
Lateral Geniculate Nucleus 0.089 ± 0.013 0.102 ± 0.016 0.073 ± 0.009 0.018 ± 0.005 
Hypothalamus 0.066 ± 0.009 0.073 ± 0.012 0.051 ± 0.008 0.032 ± 0.015 
Mediodorsal Thalamic Nucleus 0.088 ± 0.012 0.099 ± 0.011 0.078 ± 0.008 0.020 ± 0.006 
Ventrolateral Thalamic Nucleus 0.065 ± 0.011 0.076 ± 0.014 0.055 ± 0.009 0.015 ± 0.004 
Telencephalon 
Visual Cortex (layer IV) 0.136 ± 0.013 0.133 ± 0.012 0.166 ± 0.010 0.099 ± 0.019 
Dentate Gyrus 0.113 ± 0.013 0.112 ± 0.009 0.146 ± 0.010 0.080 ± 0.008 
Auditory Cortex (layer IV) 0.254 ± 0.035 0.223 ± 0.026 0.146 ± 0.012 0.147 ± 0.011 
Hippocampus Molecular Layer 0.107 ± 0.014 0.109 ± 0.008 0.265 ± 0.017 0.081 ± 0.006 
Amygdala 0.078 ± 0.008 0.094 ± 0.014 0.086 ± 0.010 0.030 ± 0.010 
Globus Pallidus 0.055 ± 0.010 0.066 ± 0.011 0.052 ± 0.007 0.016 ± 0.005 
Caudate Nucleus 0.104 ± 0.016 0.115 ± 0.015 0.126 ± 0.012 0.076 ± 0.008 
Septal Nuclei 0.079 ± 0.016 0.091 ± 0.013 0.088 ± 0.010 0.035 ± 0.010 
Nucleus Basalis Magnocellularis 0.063 ± 0.011 0.074 ± 0.012 0.063 ± 0.008 0.022 ± 0.008 
Nucleus Accumbens 0.113 ± 0.015 0.133 ± 0.012 0.149 t 0.11 0.076 ± 0.016 
Sensory Motor Cortex (layer IV) 0.174 ± 0.256 0.166 ± 0.024 0.173 t 0.013 0.071 ± 0.014 
Anterior Cingulate Cortex 0.137 ± 0.018 0.142 ± 0.016 0.164 t 0.011 0.080 ± 0.012 
Frontal Cortex 0.171 ± 0.030 0.149 ± 0.025 0.178 t 0.012 0.090 ± 0.007 
Parietal Cortex 0.154 ± 0.025 0.152 ± 0.022 0.176 t 0.014 0.088 ± 0.017 
Myelinated Fibre Tracts 
Internal Capsule 0.030 ± 0.006 0.042 ± 0.008 0.034 ± 0.011 0.014 ± 0.006 
Genu 0.020 ± 0.006 0.043 ± 0.008 0.042 ± 0.009 0.023 ± 0.007 
Table shows (RR)-[1251]-QNB in discrete brain regions of the conscious rat in 
heptylphysostigmine (2 mg/kg) treated animals 30 mins, 1,2 and 6 hours following iv 
administration of 200pCi of tracer. Data are expressed as meant SE. M pCi per g brain, n= 
5 
animals for each time point. 
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ýENDIX B 
(R, S)-[125I]-QNB in Rat Brain 
Table Bi 
Physiologic Variables-2 Hour Animals 
Sample Time (Hours) 
0 1 2 
pH 7.1±0.02 7.42±0.01 7.43±0.01 
pCO2 (mmHg) 42.3 ± 1.9 38.6 f 4.7 38.6 t 2.1 
P02 (mmHg) 90.8 ± 5.4 90.8 t 5.5 94.0 t 6.2 
Temp. (°C) 37.5 ± 0.3 37.7 t 0.2 37.6 t 0.2 
MABP (mmHg) 121 ±4 122 t5 124 t3 
Plasma 
Glucose (mM) 4.7 ± 0.2 5.3 ± 0.3 5.6 ± 0.4 
n 5 5 5 
Table B2 
Physiologic Variables-6 Hour Animals 
Sample Time (Hours) 
0 2 4 6 
H 7.4±0.1 7.4±0.1 7.4±0.1 7.4±0.1 
pCO2(mmHg) 37.0 ± 5.1 37.7 ± 0.3 36.7 t 0.7 36.0 t 2.0 
p02 (mmHg) 97.7 t 3.1 99.3 t 3.9 111.3 t 17.1 103.7 t 2.2 
Tem . (°C) 37.1 ± 0.1 37.1 t 0.1 37.0 t 0.1 37.2 t 0.3 
MABP 
(mmHg) 
122±4 108±7 115±5 115±3 
Plasma 
Glucose(mM) 
6.3 ± 0.3 6.0 ± 0.5 6.2±0.5 6.1 ± 0.1 
n 3 3 3 3 
Tables show physiologic variables measured in 2 and 6 hour animals following intravenous 
administration of 200 ytCi (R, S)-[1251]-QNB. Samples were taken immediately prior to (0), 1, 
and 6 hours following (R, S)-[1251]-QNB administration. Brains were removed and processed f 
autoradiography at 2 and 6 hours post-administration of tracer. There were no statistically 
significant differences in any of the variables measured at any of the time points between animal, 
the 2,6,12 and 24 hour groups (ANOVA). Data are presented as mean ± S. E. M. 
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(R, S)-[125IJ-QNB in Rat Brain 
Table B3 
Physiologic Variables-12 Hours 
Ssm le Time (Hours) 
0 2 4 8 12 
H 7.4±0.1 7.4±0.1 7.4±0.1 7.4±0.1 7.5 ± 0.02 
pC02(mmHg) 40.9 t 1.8 42.2 ý- 0.5 41.3 ± 0.9 42.7 t 1.8 41.7 t 0.3 
p02 (mmHg) 101.1 ± 3.8 93.9 ± 6.6 99.7 t 2.7 107.0 t 6.2 105.3 t 4.1 
Tem. (°C) 37.5 t 0.2 37.5 t 0.2 37.5 t 0.1 37.6 t 0.2 37.1 t 0.2 
MABP 
(mmHg) 
11512 120±4 121 t3 119±4 115±4 
Plasma 
Glucose(mM) 
6.9 ± 1.3 5.5 ± 0.8 5.3±0.9 6.4 ± 0.4 7.2 ± 0.1 
n 3 3 3 3 3 
Table B4 
Physiologic Variables-24 Hour Animals 
Sample Time (Hours) 
0 2 4 8 12 24 
H 7.4±0.1 7.4±0.1 7.4±0.1 7.4±0.1 7.4 ± 0.1 7.5 ± 0.1 
pCO2(mmHg) 36.9 t 3.4 39.8 f 2.4 41.4 t 1.5 40.8 t 0.8 41.3 ±3.0 41.5 ±2.4 
p02 (mmHg) 95.7 f 4.2 96.8 ± 5.6 92.6 ± 45 96.5 t 4.3 103.5±7.8 102.8±6.7 
Tem. (°C) 37.3±0.2 37.4 0.2 37.7 ± 0.3 37.6±0.3 37.4±0.2 37.5±0.4 
MABP 
(mmHg), 
111±6 129±9 112±4 108±8 107±8 114±5 
Plasma 
Glucose(mM) 
5.3 ± 0.5 7.2 ± 0.1 6.5 ± 0.2 44. ± 0.6 6.1 ± 0.2 5.7 ± 0.7 
n 5 5 5 5 5 5 
Tables show physiologic variables measured in 12 and 24 hour animals following intravenous 
administration of 200 pCi (RS)-[125I]-QNB. Samples were taken immediately prior to (0) and 
4,8 
, 12 and 24 hours following (R, S)-[1251]-QNB administration. Brains were removed and 
processed for autoradiography at 12 and 24 hours post-administration of tracer. There were no 
statistically significant differences in any of the variables measured at any of the time points 
between animals in the 2,6,12 and 24 hour groups (ANOVA). Data are presented as mean t 
S. E. M. 
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(R, R)-[1251]-QNB in Rat Brain 
Table B5 
Physiologic Variables-30 min Animals 
Sample Time (Mins) 
0 30 
pH 7.4 t 0.1 7.4 t 0.1 
pCO2 (mmHg) 33.5 t 3.5 31.0 t 2.7 
p02 (mmHg) 123.0 t 13.2 113.7 t 6.8 
Temp. (°C) 37.4±0.1 37.4 ± 0.1 
MABP (mmHg) 118 t4 126 t4 
Plasma 
Glucose (mM) 
4.6 ± 0.5 5.1 ± 0.3 
n 5 5 
Table B6 
Physiologic Variables-1 Hour Animals 
Sample Time (Hours) 
0 1 
H 7.410.1 7.39±0.1 
pCO2 (mmHg) 37.6 t 4.7 39.6 t 2.5 
P02 (mmHg) 115.6: t 8.0 116.8 t 3.3 
Temp. (°C) 37.2 t 0.1 37.3: ± 0.1 
MABP (mmHg) 123 t7 131 t7 
Plasma 
Glucose (mM) 
8.2±0.9 8.2±0.3 
n 5 5 
Tables show physiologic variables measured in 30 mins and 1 hour animals following intravenc 
administration of (RR)-[125I]-QNB. Samples were taken immediately prior to (0), 30 mins an( 
hour following (RR)-[125I]-QNB administration. Brains were removed and processed for 
autoradiography 30 mins and 1 hour post-administration of tracer. There were no statistically 
significant differences in any of the variables measured at any of the time points between animal, 
the 30 min , 1,2 and 6 hour groups. Data are presented as mean ± S. E. M. 
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(R, R)-[125I]-QNB in Rat Brain 
Table B7 
Physiologic Variables-2 Hour Animals 
Sam le Time (Hours) 
0 1 2 
pH 7.43 t0.1 7.40 ± 0.1 7.43 ± 0.1 
pCO2 (mmHg) 36.4 t 4.2 33.8 ± 3.3 34.8 ± 2.3 
P02 (mmHg) 136.0 t 6.0 140.2 f 4.8 133.4 t 8.6 
Temp. (°C) 37.3 t 0.1 37.3 t 0.1 37.3 t 0.1 
MABP (mmHg) 124 ± 1.3 121 t2 132 t6 
Plasma 
Glucose (mM) 5.1 t 0.5 5.9 ± 0.3 5.5 ± 0.8 
n 5 5 5 
Table B8 
Physiologic Variables-6 Hour Animals 
Sample Time (Hours) 
0 2 4 6 
H 7.43 ± 0.1 7.41 ± 0.1 7.43 ± 0.1 7.4 t 0.1 
pCO2(mmHg) 34.4 ± 3.2 33.4 ± 3.7 36.0 ± 3.0 38.2 t 2.6 
P02 (mmHg) 122.6 ± 10.2 117.2 t 7.8 128.2 t 3.1 132.8 t 10.4 
Temp. (°C) 37.3 ± 0.1 37.3±0.1 37.3±0.1 37.4±0.1 
MABP 
(mmHg) 
120±5 122±8.4 120±3.9 120±2.8 
Plasma 
Glucose 
(mM) 
6.0± 1.1 5.2±0.4 5.6±0.7 5.1 ±0.3 
n 5 5 5 5 
Tables show physiologic variables measured in 2 and 6 hour animals following intravenous 
administration of (RR)-[125I]-QNB. Samples were taken immediately prior to (0) , 1,2,4 and 
hours following (RR)-[125I]-QNB administration. Brains were removed and processed for 
autoradiography at 2 and 6 hours post-administration of tracer. There were no statistically 
significant differences in any of the variables measured at any of the time points between animal. 
the 0.5,1,2 and 6 hour groups (ANOVA). Data are presented as mean ± S. E. M. 
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Table B9 
(R, S)-[125I]-QNB in Rat Brain 
Following Heptylphysostigmine (2mg/kg) Administration 
Physiologic Variables-2 Hour Animals 
Sam le Time (Hours) 
Pre 0 1 2 
Infusion 
pH Veh 7.5 ± 0.1 7.5 ± 0.1 7.5 ± 0.1 7.5 ± 0.1 
HEP 7.5 ± 0.1 7.4 ± 0.1 7.4 ± 0.1 7.4 ± 0.1 
pCO2 Veh 37.0 ± 1.7 38.7 ± 1.5 37.0 ± 1.4 38.7 t 1.2 
(mmHg) HEP 41.7 ± 1.2 37.7 ± 1.4 37.7 ± 1.7 45.7 t 10 
P02 (mmHg) Veh 85.0 ± 3.7 89.7 ± 1.7 97.7 ± 1.9 96.7 t 1.8 
HEP 86.0 ± 0.8 95.7 ± 4.5 109 ± 2.1 99.3 1.5 
Temp. (°C) Veh 37.0 ± 0.1 37.1 ± 0.2 37.1 ± 0.1 37.2 ± 0.2 
HEP 37.0 ± 0.1 37.0 ± 0.2 37.1 ± 0.2 37.0 ± 0.1 
MABP Veh 110±1 110±1 108±8 112±2 
(mmHg) HEP 113±2 120± 1.3 128±1 ** 127±2 
Plasma Veh 4.8 ± 0.7 4.9 ± 0.9 5.2 ± 1.1 5.7 ± 0.9 
Glucose HEP 5.2 ± 0.5 6.1 ± 0.8 7.3 ± 0.3 5.5 ± 0.6 
(mM) 
n 5 5 5 5 
Samples were taken before vehicle/heptylphysostigmine administration (Pre-Infusion), immedia 
prior to (0) and I and 2 hours following (RS)-[125I]-QNB administration. Brains were remove 
and processed for autoradiography at 2 hours post-administration of tracer. **P <0.01 denotes 
significant difference for statistical comparison between variables for vehicle and 
heptylphysostigmine treated animals (ANOVA, Student's t-test with Bonferroni correction). Dat,, 
are presented as mean ± S. E. M. 
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Table 1311 
(R,, R)-[1251]-QNB in Rat Brain 
Following Heptylphysostigmine (2mg/kg) Administration 
Physiologic Variables-30min Animals 
Sam le Time (Mins) 
Pre 0 30 
Infusion 
pH Veh 7.42 1 0.1 7.42 ± 0.1 7.42 1 0.1 
HEP 7.43 10.1 7.42±0.1 7.41 10.1 
pCO2 (mmHg) Veh 33.5 ± 3.5 40.7 ± 4.3 31.0 ± 2.7 
HEP 39.2 ± 1.9 32.0 ± 3.1 34.6 ± 3.5 
P02 (mmHg) Veh 123.0 ± 13.2 113 ± 8.1 113.7 ± 6.8 
HEP 131.0 ± 10.0 126.0±3.6 139.8 ± 8.2 
Temp. (°C) Veh 37.4 ± 4.7 37.4 t 0.1 37.4 ± 0.1 
HEP 37.4 ± 0.1 37.4±0.1 37.3 10.1 
MABP (mmHg) Veh 118 ±1 115 ± 4.8 126 ±4 
HEP 121±6 132±3.4 138±3.9 
Plasma Veh 4.6 ± 0.5 6.1 ± 0.7 5.1 t 0.3 
Glucose (mM) HEP 5.7 ± 0.9 8.9 ± 1.8 8.6 t 1.1 
n 5 5 5 
Samples were taken before vehicle/ heptylphysostigmine administration (Pre-Infusion), 
immediately prior to (0) and 30 mins following (RR)-[125I]-QNB administration. Brains were 
removed and processed for autoradiography at 30 mins post-administration of tracer. There were 
statisitcally significant differences between vehicle and heptylphyostigmine treated animals in the 
variables measured at any of the time points (ANOVA, Student's t-test with Bonferroni 
correction). Data are presented as mean ± S. E. M(n=5). 
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Table B12 
(R, R)-[1251]-QNB in Rat Brain 
Following Heptylphysostigmine (2mg/kg) Administration 
Physiologic Variables-i Hour Animals 
Sample Time (Hours) 
Pre 0 1 
Infusion 
pH Veh 7.40 ± 0.1 7.40 ± 0.1 7.39 ± 0.1 
HEP 7.41 ± 0.1 7.41 ± 0.1 7.42 ± 0.1 
pCO2 (mmHg) Veh 45.0 ± 3.0 37.6 ± 4.7 39.6 ± 2.5 
HEP 34.2 ± 5.0 34.4 ± 1.7 35.4 ± 1.2 
P02 (mmHg) Veh 118.0 ± 7.5 115.6 ± 8.1 116.8 ± 3.3 
HEP 120.4±5.8 117.4±2.5 131.8 ±8.5 
Temp. (°C) Veh 37.2 ± 0.1 37.2 ± 0.1 37.3 ± 0.1 
HEP 37.2 ± 0.1 37.2 ± 0.1 37.2 ± 0.1 
MABP (mmHg) Veh 124 ±6 123 ±7 131 ±7 
HEP 107±5 117±3.7 126±4 
Plasma Veh 5.8 ± 0.8 8.2 ± 0.9 8.2 ± 0.3 
Glucose (mM) HEP 4.2 ± 0.3 7.6 ± 1.1 * 8.1 ± 0.4 
n 5 5 5 
Samples were taken before vehicle/ heptylphysostigmine administration (Pre-Infusion), 
immediately prior to (0) and 1 hour following (RR)-[125I]-QNB administration. Brains were 
removed and processed for autoradiography at 1 hour post-administration of tracer. 
*P < 0.05, **P <0.01 denotes significant difference for statistical comparison between pre- an( 
post drug variables and comparision of pre-drug variables and variables measured 1 hour after 
tracer administration in heptylphysotigmine treated animals (ANOVA, Student's t-test with 
Bonferroni correction). Data are presented as mean ± S. E. M(n=5). 
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Table B13 
(R, R)-[1251]-QNB in Rat Brain 
Following Heptylphysostigmine (2mg/kg) Administration 
Physiologic Variables-2 Hour Animals 
ample Time (Hours) 
Pre 0 1 2 
Infusion 
pH Veh 7.44 7.43 7.44 ± 0.1 7.43 ± 0.1 
HEP 7.45 10.1 7.43 10.1 7.42±0.1 7.42 ± 0.1 
pCO2 Veh 43.0 ± 3.0 36.4 ± 4.2 33.8 ± 3.3 39.0±2,3 
(mmHg) HEP 37.0 ± 4.2 29.0 ± 1.6 36.6 ± 2.1 29.8 ± 3.3 
P02 (mmHg) Veh 183.0 ± 9.0 136.0 ± 6.0 140.0 ± 4.8 147.0 ± 8.6 
HEP 128.0 ± 8.4 136.8 ±11.6 127.4 ± 7.4 128.4 ± 7.4 
Temp. (°C) Veh 37.3 ± 0.1 37.3 ± 0.1 37.3 ± 0.1 37.2 ± 0.1 
HEP 37.2 ± 0.1 37.3 10.1 37.2 ± 0.1 37.2 ± 0.1 
MABP Veh 120±3 124±1.3 124±1.3 132±5.6 
(mmHg) HEP 116±7 124±2 126±1.8 117±5 
Plasma Veh 5.9±0.4 5.9±1.1 5.9±0.3 5.5±0.8 
Glucose HEP 5.7 ± 0.7 9.0 ±1 7.3 ± 1.3 7.8 ± 1.3 
(mM) 
n 5 5 5 5 
Samples were taken before vehicle/ heptylphysostigmine administration (Pre-Infusion), 
immediately prior to (0), 1 and 2 hours following (RR)-[125I]-QNB administration. Brains we 
removed and processed for autoradiography at 2 hours post-administration of tracer. There were 
statistically significant differences between vehicle and heptylphyostigmine treated animals in thf 
variables measured at any of the time points (ANOVA, Student's t-test with Bonferroni 
correction). Data are presented as mean ± S. E. M(n=5). 
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Table BiS 
Regional Cerebral Blood Flow In The Conscious Rat 
Following Heptylphysostigmine Administration 
Physiologic Variables 
Pre-Infusion Pre-CBF 
Vehicle He t 1. Vehicle He t 1. 
H 7.43 t 0.10 7.41 ± 0.023 7.47 f 0.02 7.42 ± 0.1 
CO2 (mmHg) 44.7 t 1.4 47.6 ± 1.0 37.8 t 1.2 43.8 ± 1.9 
p02 (mmHg) 85.0 ± 2.8 88.8 ± 5.8 94.8 ± 4.6 109.8 ± 6.1 
Temp. (OC) 36.7±0.1 36.6±0.2 37.0±0.1 35.4±0.6* 
MABP(mmHg) 121 t2 124± 1 129±2 146t6* 11 
Plasma Glucose 
(mM) 
8.1 ± 0.5 10.0 t 1.6 7.8 ±0.3 20.2 t 1.2*** 
ttt 
n 5 5 5 5 
Samples were taken before vehicle/heptylphysostigmine administration (Pre-Infusion), and 
immediately prior to blood flow measurement (Pre-CBF). Brains were removed and processed 
for autoradiography at 2 hours post-administration of vehicle/heptylphysostigmine. 
Heptylphysostigmine produced a moderate fall in body temperature as well as significant 
increases in both mean artereial blood pressure and plasma glucose levels. *P <0.05, ***P 
<0.001 for statistical comaprison between heptylphysostigmine and vehicle treated animals. tf 
P <0.01, tttP <0.001 for statistical comparison between Pre-Infusion and Pre-CBF 
measurements in heptylphysostigmine treated animals. (ANOVA, Student's t-test with 
Bonferroni correction). Data are presented as mean ± S. E. M(n=5). 
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APPENDI D 
Table D1 
(R, $)_[1251]-QNB In Vitro Association Data 
Total Binding (nM/g) Non-specific Binding 
nM/ 
Specific Binding 
nM/ 
Frontal Cortex 
I min 10.58 ± 0.94 7.50±0.76 3.00 ± 0.25 
2 mins 12.08 ± 1.73 10.00 ± 2.18 2.80 ± 0.98 
5 mins 14.75 ± 2.27 13.42 ± 1.58 1.33 ± 0.96 
lOmins 21.33±1.17 18.33±1.39 2.85±1.43 
20 mins 39.40 ± 3.82 25.58 ± 2.97 13.83 ± 1.21 
40 mins 66.08 ± 14.01 33.30 ± 1.31 31.92± 12.72 
60 mins 85.58 ± 18.28 43.58 ± 6.01 42.00 ± 12.34 
90 mins 109.00 t 5.94 38.58 ± 8.30 70.50 ± 10.49 
120 mins 96.58 t 1.71 36.75 ± 1.28 59.83 ± 1.76 
Parietal Cortex 
1 min 7.33 ± 0.08 4.09 ± 0.52 1.09 ± 0.46 
2mins 10.25±1.38 6.83±1.08 0.67±0.30 
5 mins 14.33 ± 2.34 9.67 ± 1.97 0.75 ± 0.38 
10mins 23.42±0.71 12.33±3.31 5.08±2.60 
20 mins 40.25 ± 6.39 20.67 ± 4.55 14.58 t 2.90 
40mins 71.00±18.90 38.33±7.32 38.50±12.13 
60 mins 87.43 ± 23.91 41.77 ± 6.39 47.37 t 17.9 
90 mins 96.33 = 17.00 39.67 ± 6.67 57.5 ± 12.06 
120 mins 90.42 ± 6.68 42.08 ± 6.45 53.33 ± 0.83 
Caudate Nucleus 
1min 6.92±0.46 4.08±0.79 0.83±0.83 
2 mins 9.33 ± 0.96 5.84 ± 0.68 1.18 ± 0.91 
5minn 13.33±1.40 9.17±1.170 1.42±0.51 
10 mins 17.88 ± 0.68 10.83 t 0.22 1.75 t 0.630 
20mins 24.25±1.46 14.34±1.160 4.33±0.51 
40 mins 34.08 ± 4.08 20.170 t 1.30 8.92 t 2.87 
60 mins 45.42 ± 6.57 26.25 t 3.11 11.17 ± 3.48 
90 mins 58.25 ± 4.63 26.75 t 5.67 24.02 ± 1.90 
120 mins 59.83 ± 4.21 32.75 t 3.67 21.25 ± 2.32 
Cerebellar Cortex 
1 min 9.17 t 1.42 4.17 ± 1.80 1.50 ± 0.52 
2 mins 11.08 t 1.76 3.17 ± 2.68 5.50± 2.65 
5mins 19.15±2.08 12.42±1.12 3.92±2.65 
10mins 20.17±3.47 7.58±4.8 2.37±1.30 
20 mins 34.75 t 9.72 30.42 ± 6.02 13.33 ± 7.7 
40 minn 78.92 ± 22.96 51.17 ± 16.76 25.25 ± 13.65 
60 mins 92.33 ± 23.49 36.85 ± 14.23 41.42 ± 15.31 
90 mins 94.85 ± 28.49 44.17 ± 23.25 27.35 ± 5.55 
120mins 94.33±16.61 46.75±6.16 53.42±10.67 
n 3 3 3 
In vitro association data for 0.1 nM (R, S)-[ 125I]-QNB binding to rat brain sections over 
120 mins. Table shows total, non-specific and specific binding to frontal cortex, parietal 
cortex, caudate nucleus and cerbellar cortex. Data are expressed as mean + S. E. M. nmols 
per g Brain. n= number of experiments. 
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Table D2 
(R, R)-[125IJ-QNB In Vitro Association Data 
Total Binding (nM/g) Non-specific Binding 
nM/ 
Specific Binding 
(nM/g) 
Frontal Cortex 
1min 1.79±130 1.58: t 1.07 0.21±0.21 
2 mins 2.96 ± 1.08 2.33 ± 0.77 0.63 ± 0.34 
5mins 4.65±0.80 3.45±0.57 1.20±0.36 
10 mins 6.65 ± 0.50 5.74 ± 0.72 0.91 ± 0.28 
20 mins 11.53 ± 1.55 7.07 ± 0.63 4.46 t 1.88 
40 mins 15.07 ± 7.54 7.69 t 4.02 7.38 t 3.91 
60mins 28.14±3.04 11.91 ±0.40 16.22±3.17 
90mins 32.48±4.59 12.88±1.52 19.60t 5.77 
120 mins 35.40 ± 2.85 13.83 ± 1.24 21.57 ± 4.00 
Parietal Cortex 
1min 1.58±1.02 14.5±0.91 0.13±0.12 
2 mins 2.84 ± 0.07 2.40±0.50 0.44 ± 0.18 
5 mins 4.63 ± 0.88 3.54 ± 0.60 1.08 ± 0.28 
10 mins 7.02 ± 0.68 5.15 ± 0.07 1.87 ± 0.64 
20 mins 8.99 ±4.54 4.96 ± 2.49 4.03 ± 2.20 
40mins 15.46±7.77 7.31±3.67 8.14±4.10 
60 mins 27.61 ± 1.74 9.21 ± 1.00 18.40 ± 2.02 
90 mina 34.96 ± 5.81 11.05 ± 1.78 23.9 ± 6.37 
120mins 38.38±5.61 13.10±2.53 25.28±6.66 
Caudate Nucleus 
1min 1.55±1.10 1.40±. 92 0.15±0.09 
trains 2.77±1.10 2.47±0.72 0.29±0.15 
5mins 4.74±0.86 4.22±0.68 0.51±0.24 
lOmins 6.94±0.88 6.18±0.95 0.75±0.33 
20mins 9.98±0.82 7.01 ±0.67 2.97± 1.03 
40 mins 9.50 ± 1.70 6.51 ± 3.29 2.99 ± 1.49 
60 rains 16.53 ± 4.78 10.07 ± 0.17 6.47 ± 1.45 
90 rains 20.80±1.41 12.00±1.58 8.83±1.56 
120 mins 23.40 ± 1.05 13.16 ± 1.45 10.24 ± 0.43 
Cerebellar Cortex 
lmin 1.57±0.95 1.43±0.84 0.14±0.12 
2mins 2.88±0.95 2.44±0.84 0.44±0.12 
5 mins 4.52 ± 0.44 3.56 ± 0.40 0.66 ± 0.08 
10 mins 5.99 ± 0.64 4.86 ± 0.31 1.13±0.40 
20 rains 6.54 ± 0.36 4.65 ± 0.19 1.89 ± 0.18 
40 mins 12.64 ± 3.30 7.98 ± 2.36 4.66 ± 0.95 
60 mins 16.78 ± 6.42 10.52 ± 4.00 6.27 ± 2.49 
90 minn 16.55±0.44 10.54±0.57 6.00±0.86 
120mins 21.52±0.92 12.28±0.27 9.24± 1.04 
n 3 3 3 
In vitro association data for 0.2 nM (RR)-[125I]-QNB binding to rat brain sections over 
120 mins. Table shows total, non-specific and specific binding to frontal cortex, parietal 
cortex, caudate nucleus and cerebellar cortex. Data are expressed as mean + S. E. M. nmols 
per g Brain. n= number of experiments. 
190 
Table D3 
(R$)_[1251]-QNB In Vitro Saturation Data 
Total Binding (nM/g) Non-specific Binding 
nM/ 
Specific Binding 
nM/ 
Frontal Cortex 
0.007 nM NB 1.08 ± 0.20 0.82 ± 0.02 026 t 0.06 
0.01nM QNB 1.93±0.17 1.33 ±0.18 0.60±0.28 
0.03 nM QNB 4.39 ± 0.39 2.56 ± 0.19 1.84±0.29 
0.05 nM NB 5.89 ± 0.54 3.48 ± 0.21 2.41 t 0.56 
0.07nM NB 5.71±0.97 3.37±0.24 2.3±0.95 
0.1 nM NB 6.47 ± 1.07 4.69 ± 0.84 1.78 t 0.55 
Parietal Cortex 
0.007 nM QNB 1.50±0.29 0.79 ± 0.03 0.74±0.27 
0.01 nM NB 2.16 ± 0.14 1.30±0.21 0.86±0.17 
0.03 nM QNB 4.19 ± 0.36 2.25 ± 0.21 1.94 ± 0.42 
0.05 nM QNB 5.98 ± 0.49 3.32 ± 0.13 2.66 ± 0.25 
0.07nM NB 7.34±2.74 3.34±0.34 1.00± 1.2 
0.1 nM QNB 7.50 ± 2.15 4.80 ± 1.37 2.70 ± 0.92 
Caudate Nucleus 
0.007nM QNB 1.00±0.12 0.73±0.05 0.27 ± 0.09 
0.01nM QNB 1.45±0.10 0.88±0.09 0.57±0.11 
0.03 nM QNB 2.83 ± 0.36 1.86 t 0.20 0.97± 0.16 
0.05nM NB 4.58±0.23 3.05±0.16 1.53±0.12 
0.07 nM QNB 5.03 ± 0.35 3.02 ± 0.03 2.00 ± 0.36 
0.1 nM QNB 5.08 ± 0.46 3.65 ± 0.27 1.43 ± 0.47 
Cerebellar Cortex 
0.007nM QNB 0.88 ± 0.014 0.66 ± 0.15 0.22 ± 0.06 
0.01 nM QNB 1.29±0.13 0.91 ±0.08 0.39±0.06 
0.03 nM QNB 2.82 ± 0.59 2.06 ± 0.27 0.77 ± 0.45 
0.05 nM QNB 4.29 ± 0.24 2.98±0.17 1.31±0.12 
0.07 nM QNB 4.77 ± 0.28 3.32 ± 0.25 1.45 ± 0.46 
0.1 nM QNB 6.36 ± 1.28 4.00 ± 0.79 2.66 ± 0.58 
n 3-4 3-4 3-4 
In vitro saturation data for 0.007 nM to 0.1 nM (R, S)-[1251]-QNB binding to rat brain 
sections. Table shows total, non-specific and specific binding to frontal cortex, parietal 
cortex, caudate nucleus and cerebellar cortex. Data are expressed as mean + S. E. M. nmols 
per g Brain. n= number of experiments. 
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Table D4 
(R, R)_[1251j-QNB In Vitro Saturation Data 
Total Binding (nM/g) Non-specific Binding 
nM/ 
Specific Binding 
nM/ 
Frontal Cortex 
0.007 nM NB 1.21 ± 0.11 0.50±0.04 0.55 ± 0.05 
0.01 nM QNB 2.38 ± 0.22 0.92 ± 0.14 1.61 ± 0.36 
0.03 nM QNB 3.84 ±1.13 2.23 ± 0.29 2.36 ± 0.91 
0.05 nM QNB 8.70 ± 1.63 2.93 ± 0.31 6.80 ± 1.50 
0.07 nM QNB 8.19 ± 0.74 4.04±0.23 4.86 ± 0.15 
0.1 nM QNB 13.21 ± 2.45 6.91 ± 0.12 9.00 ± 1.27 
Parietal Cortex 
0.007 nM NB 1.05 ± 0.01 0.51 ±0.02 0.54: t 0.02 
0.01nM NB 2.27 ± 0.15 0.71 ± 0.17 1.56 ± 0.32 
0.03 nM NB 5.32 ± 0.33 2.39 ± 0.33 2.92 ± 0.01 
0.05 nM QNB 6.91 ± 0.76 4.78 ± 0.77 2.13 ± 1.53 
0.07 nM QNB 10.43 ± 1.40 4.41 ± 0.69 6.01 ± 0.71 
0.1 nM QNB 15.02 ± 0.70 6.70 ± 0.60 8.33 ± 1.29 
Caudate Nucleus 
0.007 nM QNB 0.453 ± 0.03 0.39 ± 0.01 0.14 ± 0.04 
0.01 nM QNB 0.96 ± 0.04 0.45 ± 0.07 0.51 ± 0.03 
0.03 nM QNB 3.37 ± 0.43 2.10 ± 0.08 1.27 ± 0.35 
0.05 nM NB 6.25 ± 0.58 2.60 ± 0.01 3.65 ± 0.60 
0.07nM QNB 5.11 ± 0.38 2.92±0.29 2.18±0.09 
0.1 nM NB 10.45 ± 1.34 5.00 ± 0.36 5.45 ± 1.70 
Cerebellar Cortex 
0.007nM QNB 0.74 ± 0.02 0.59±0.01 0.59±0.01 
0.01 nM QNB 0.80 ± 0.03 0.57 ± 0.03 0.57 t 0.03 
0.03nM NB 2.84±0.32 2.61±0.26 2.61±0.26 
0.05 nM QNB 4.86 ± 0.47 3.28 ± 0.64 3.28 ± 0.64 
0.07 nM QNB 5.03 ± 1.25 3.61 = 0.63 3.61 ± 0.63 
0.1 nM QNB 8.76 ± 1.60 5.67 t 1.85 5.67 * 1.85 
n 3 3 3 
In vitro saturation data for 0.007 nM to 0.1 nM (RR)-[125I]-QNB binding to rat brain 
sections. Table shows total, non-specific and specific binding to frontal cortex, parietal 
cortex, caudate nucleus and cerbellar cortex. Data are expressed as mean + S. E. M. nmols 
per g Brain. n= number of experiments. 
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Table D5 
(R$)-[1251]-QNB In Vitro Displacement Data 
Effect of Acetyl choline On Binding to Rat Brain Sections 
In The Presence Of Heptylphysostigmine 
Total Binding 
(nM/g) 
Non-specific 
Binding (nM/g) 
Specific Binding 
(nM/ ) 
Frontal Cortex 
Control 120.6 t 12.9 76.33 ± 21.88 50.0 ± 16.2 
10-5M Ach 115.6 ± 12.66 6.3.1 ± 8.77 58.8 ± 13.3 
104M Ach 106.3 t 20.3 5.1.3: t 13.22 55.0 ± 11.9 
10-3MACh 109.4±15.0 61.3±7.5 48.1±7.7 
10-21VIACh 14.4±21.1 70.0± 14.0 45.6± 10.5 
Parietal Cortex 
Control 91.3±11.4 5.2.5±5.9 38.8±16.5 
10-5M Ach 92.5 ± 17.3 5.13 ± 10.7 41.3 ± 7.4 
104M Ach 93.1 ± 10.8 61.3 ± 11.0 21.3 ± 8.6 
10-3M ACh 96.9 t 12.8 53.1 ± 4.3 33.8 t 9.9 
10-21VIACh 107.5±15.0 51.3 ± 3.9 56.3±11.7 
Cerebellar Cortex 
Control 108.8 t 22.3 78.8 ± 11.6 30.0 ± 11.9 
10-5M Ach 157.5±10.5 91.9±16.9 64.4±11.1 
10-4M Ach 113.1+11.4 73.8+9.9 39.4+9.4 
10-3M ACh 139.4 t 15.1 90.0 ± 13.7 49.4 ± 12.6 
10-2M ACh 126.3 t 9.4 93.1 ± 15.8 35.0 ± 11.7 
n 4 4 4 
Effect of 10-5 to 10-2 M Acetylcholine on the binding of (R, S)-[ 1251]-QNB to 20pm 
coronal rat brain sections in vitro, in the presence of 10-6M heptylphysostigmine. Table 
shows Total, Non-specific and Specific binding for frontal, parietal and cerebellar cortices. 
Acetylcholine failed to displace specicifc binding over this concentration range in any of 
the regions analysed. Data are expressed as mean t S. E. M. nM per g brain, n= number of 
experiments performed. 
193 
Table D6 
(R, R)-[125I]-QNB In Vitro Displacement Data 
Effect of Acetyl choline On Binding to Rat Brain Sections 
In The Presence Of Heptylphysostigmine 
Total Binding 
(nM/g) 
Non-specific 
Binding (nM/g) 
Specific Binding 
(nM/g) 
Frontal Cortex 
Control 83.54 ± 25.89 48.68 ± 17.41 34.86 ± 11.35 
10-6M Ach 102.86: t 44.43 58.96 ± 21.21 43.90 ± 23.95 
10-4M Ach 102.66 ± 44.61 50.44 ± 18.69 52.22 ± 25.97 
10-3M ACh 88.07 ± 31.75 54.74 ± 18.78 33.33 ± 13.25 
Parietal Cortex 
Control 74.22 ± 20.71 33.11 ± 14.91 41.11 ± 14.99 
10-6M Ach 78.62 ± 26.06 47.92 t 16.15 30.70 t 11.11 
10-4M Ach 103.91 ± 8.93 64.84 t 1.91 39.07 t 7.02 
10-3M ACh 72.37 f 24.77 42.81 ± 15.39 29.56 ± 9.72 
Cerebellar Cortex 
Control 105.91 t 42.56 85.70 ± 43.81 20.21 ± 9.58 
10-6M Ach 128.21 ± 43.41 97.60 ± 41.78 30.61 t 7.78 
10-4M Ach 124.58 ± 46.90 57.97 ± 22.80 66.61 t 24.19 
10-3M ACh 94.64 ± 30.49 52.24 ± 18.07 42.40 ± 14.18 
n 3 3 3 
Effect of 10-6 to 10-3 M Acetylcholine on the binding of (RR)-[ 125I]-QNB(0.2 nM) to 
20pm coronal rat brain sections in vitro, in the presence of 10-6M heptylphysostigmine. 
Table shows Total, Non-specific and Specific binding for frontal, parietal and cerebellar 
cortices. Acetylcholine failed to displace specific binding over this concentration range in 
any of the regions analysed. Data are expressed as mean ± S. E. M. nM per g brain, n= 
number of experiments performed. 
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Table D7 
(R, R)-[125IJ-QNB In Vitro Displacement Data 
Effect of Heptylphysostigmine On Binding to Rat Brain Sections 
Total Binding 
(nM/g) 
Non-specific 
Binding (nM/g) 
Specific Binding 
(nM/g) 
Frontal Cortex 
Control 83.54: t 25.89 48.68 ± 17.41 34.86 t 11.35 
10-6M HEP 89.22 ± 22.31 50.89 ± 16.60 38.33 f 7.21 
104MHEP 64.48± 18.11 48.59± 15.28 15.89±2.86 
10-3M HEP 26.98 ± 10.15 25.68 ± 9.34 1.30: t 1.01* 
Parietal Cortex 
Control 74.22 ± 20.71 33.11 ± 14.91 41.11 ± 14.99 
10-6M HEP 69.92 ± 17.71 40.34 ± 10.47 29.58 ±7.77 
10-4M HEP 50.42 ± 13.91 35.55 ± 10.02 14.87 ± 3.91 
10-3MHEP 24.06±8.19 23.03±8.19 1.03±0.51* 
Cerebellar Cortex 
Control 105.91 ± 42.56 85.70 ± 43.81 20.21 ± 9.58 
10-6M HEP 75.82 ± 16.05 40.40 ± 13.72 35.42 ± 9.27 
10-4M HEP 55.84: t 18.98 48.62 ± 21.89 7.22 ± 3.88 
10-3M HEP 23.34 ± 9.52 21.46 ± 7.86 1.88 ± 1.79 
n 3 3 3 
Effect of 10-6 to 10-3 M Heptylphysostigmine on the binding of (RR)-[ 125I]-QNB (0.2 
nM) to 20pm coronal rat brain sections in vitro. Table shows Total, Non-specific and 
Specific binding for frontal, parietal and cerebellar cortices. Heptylphysostigmine produces 
profound reductions in (RR)-[ 1251]-QNB binding at 10-3 M. *P <0.05 for the statisitcal 
comparison between specific binding in control and heptylphysostigmine treated sections 
(ANOVA, Student's unpaired t-test with Bonferroni correction). Data are expressed as 
mean ± S. E. M. nM per g brain, n= number of experiments performed. 
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